

03/15/00
 3c784 U.S. PTO

03-16-00

A
 Box 5eq

Certificate of Mailing	
Date of Deposit <u>March 15, 2000</u>	Label Number: <u>EL488650049US</u>
I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
Luis A. Cruz Printed name of person mailing correspondence	 Signature of person mailing correspondence

3c530 U.S. PTO

09/526193

03/15/00

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 CFR §1.53(b)	
Attorney Docket Number	50110/002005
Applicant	Michael R. Hayden et al.
Title	METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS
PRIORITY INFORMATION:	
This application claims priority from U.S. Provisional Application No. 60/124,702, filed March 15, 1999, U.S. Provisional Application No. 60/138,048, filed June 8, 1999, U.S. Provisional Application No. 60/139,600, filed June 17, 1999, and U.S. Provisional Application No. 60/151,977, filed September 1, 1999.	
APPLICATION ELEMENTS:	
Cover sheet	1 pages
Specification	84 pages
Claims	15 pages
Abstract	1 pages
Drawing	68 pages
Combined Declaration and POA, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application ["**SERIAL NUMBER**"] and the entire disclosure of the prior application is considered as being part of the disclosure of this new application and is hereby incorporated by reference therein.	3 pages
Statement Deleting Inventors	["**"] pages
Sequence Statement	2 pages
Sequence Listing on Paper	84 pages
Sequence Listing on Diskette	1 diskette

03/15/00

Small Entity Statement, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application [**SERIAL NUMBER**] and such small entity status is still proper and desired.	2 pages
Preliminary Amendment	[**] pages
IDS	[**] pages
Form PTO 1449	[**] pages
Cited References	[**] pages
Recordation Form Cover Sheet and Assignment	[**] pages
Assignee's Statement	[**] pages
English Translation	[**] pages
Certified Copy of Priority Document	[**] pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$345	\$345.00
Excess Claims Fee: $127-20=107 \times \$9 =$	\$963.00
Excess Independent Claims Fee: $43-3=40 \times \$39=$	\$1,560.00
Multiple Dependent Claims Fee: \$130	\$130.00
Total Fees:	\$2998.00
<input checked="" type="checkbox"/> Enclosed is a check for \$2,998.00 to cover the total fees. <input type="checkbox"/> Charge [**AMOUNT**] to Deposit Account No. 03-2095 to cover the total fees. <input type="checkbox"/> The filing fee is not being paid at this time. <input checked="" type="checkbox"/> Please apply any other charges, or any credits, to Deposit Account No. 03-2095.	
CORRESPONDENCE ADDRESS:	
Paul T. Clark Reg. No. 30,162 Clark & Elbing LLP 176 Federal Street Boston, MA 02110	
Telephone: 617-428-0200 Facsimile: 617-428-7045	
Signature: <u>Mary Rox Kyppava Reg. No. 36,268</u>	
Date: <u>March 15, 2000</u>	

Applicant or Patentee : Michael R. Hayden et al.
 Serial or Patent No. :
 Filed or Issued : March 15, 2000
 Title : METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
 (37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: The University of British Columbia
 Address of Organization: 2329 West Mall, Vancouver, British Columbia, V6T 1Z4 Canada
 Type of Organization:

- ☒ University or Other Institution of Higher Education
☐ Tax Exempt under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3))
☐ Nonprofit Scientific or Educational under Statute of State of the United States of America
 Name of State:
 Citation of Statute:
☐ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3)) If Located in the United States of America
☐ Would Qualify as Nonprofit Scientific or Educational under Statute of State of the United States of America If Located in the United States of America
 Name of State:
 Citation of Statute:

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS by inventors Michael R. Hayden, Angela R. Wilson, and Simon N. Pimstone described in

- ☒ the specification filed herewith.
☐ application serial No. , filed
☐ patent no. [**PATENT NUMBER**], issued [**ISSUE DATE**].

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Full Name: Xenon Bioresearch, Inc.
 Address: 3250 East Mall, Vancouver, British Columbia, V6T 1W5 Canada
☐ INDIVIDUAL ☒ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name: Angus Livingstone

Title: Managing Director

Address: The University of British Columbia, 2329 West Mall, Vancouver, B.C. CANADA V6T 1Z4

Signature: _____ Date: _____

Applicant or Patentee : Michael R. Hayden et al.
 Serial or Patent No. :
 Filed or Issued : March 15, 2000
 Title : METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
 (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: Xenon Bioresearch Inc.,

Address of Small Business Concern: 3250 East Mall, Vancouver, B.C. V6T 1W5 Canada

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS by inventors Michael R. Hayden, Angela R. Wilson, and Simon N. Pimstone described in

- ☒ the specification filed herewith.
☐ application serial no. , filed
☐ patent no. [**PATENT NUMBER**], issued [**ISSUE DATE**].

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Assignee Name:

Assignee Address:

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.

Name: Michael R. Hayden, M.D. Ph.D.

Title: Chief Scientific Officer

Address: Xenon Bioresearch, Inc., NRC Innovation Centre, 3250 East Mall, Vancouver, BC V6T 1W5

Signature: _____ **Date:** _____

Certificate of Mailing

Date of Deposit March 15, 2000

Label Number: EL488650049US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner of Patents, Washington, D.C. 20231.

Luis A. Cruz
Printed name of person mailing correspondence


Signature of person mailing correspondence

APPLICATION
FOR
UNITED STATES LETTERS PATENT

APPLICANT : MICHAEL R. HAYDEN, ANGELA R. WILSON,
SIMON N. PIMSTONE

TITLE : METHODS AND REAGENTS FOR MODULATING
CHOLESTEROL LEVELS

METHODS AND REAGENTS FOR MODULATING
CHOLESTEROL LEVELS

Cross-Reference to Related Applications

This application claims priority from U.S. Provisional Application No. 60/124,702, filed March 15, 1999, U.S. Provisional Application No. 60/138,048, filed June 8, 1999, U.S. Provisional Application No. 60/139,600, filed June 17, 1999, and U.S. Provisional Application No. 60/151,977, filed September 1, 1999.

Background of the Invention

Low HDL cholesterol (HDL-C), or hypoalphalipoproteinemia, is a blood lipid abnormality which correlates with a high risk of cardiovascular disease (CVD), in particular coronary artery disease (CAD), but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. HDL, or 'good cholesterol' levels are influenced by both environmental and genetic factors.

Epidemiological studies have consistently demonstrated that plasma HDL-C concentration is inversely related to the incidence of CAD. HDL-C levels are a strong graded and independent cardiovascular risk factor. Protective effects of an elevated HDL-C persist until 80 years of age. A low HDL-C is associated with an increased CAD risk even with normal (<5.2 mmol/l) total plasma cholesterol levels. Coronary disease risk is increased by 2% in men and 3% in women for every 1 mg/dL (0.026 mmol/l) reduction in HDL-C and in the majority of studies this relationship is statistically significant even after adjustment for other lipid and non-lipid risk factors. Decreased HDL-C levels are the most common lipoprotein abnormality seen in patients with premature CAD. Four percent of patients with

premature CAD with have an isolated form of decreased HDL-C levels with no other lipoprotein abnormalities while 25% have low HDL levels with accompanying hypertriglyceridemia.

Even in the face of other dyslipidemias or secondary factors, HDL-C levels are important predictors of CAD. In a cohort of diabetics, those with isolated low HDL cholesterol had a 65% increased death rate compared to diabetics with normal HDL cholesterol levels (>0.9 mmol/l). Furthermore, it has been shown that even within high risk populations, such as those with familial hypercholesterolemia, HDL cholesterol level is an important predictor of CAD. Low HDL cholesterol levels thus constitute a major, independent, risk for CAD.

These findings have led to increased attention to HDL cholesterol levels as a focus for treatment, following the recommendations of the National Cholesterol Education Program. These guidelines suggest that HDL cholesterol values below 0.9 mmol/l confer a significant risk for men and women. As such, nearly half of patients with CAD would have low HDL cholesterol. It is therefore crucial that we obtain a better understanding of factors which contribute to this phenotype. In view of the fact that pharmacological intervention of low HDL cholesterol levels has so far proven unsatisfactory, it is also important to understand the factors that regulate these levels in the circulation as this understanding may reveal new therapeutic targets.

Absolute levels of HDL cholesterol may not always predict risk of CAD. In the case of CETP deficiency, individuals display an increased risk of developing CAD, despite increased HDL cholesterol levels. What seems to be important in this case is the functional activity of the reverse cholesterol transport pathway, the process by which intracellular cholesterol is trafficked out of the cell to acceptor proteins such as ApoAI or HDL. Other important genetic determinants of HDL

cholesterol levels, and its inverse relation with CAD, may reside in the processes leading to HDL formation and intracellular cholesterol trafficking and efflux. To date, this process is poorly understood, however, and clearly not all of the components of this pathway have been identified. Thus, defects preventing proper HDL-mediated cholesterol efflux may be important predictors of CAD. Therefore it is critical to identify and understand novel genes involved in the intracellular cholesterol trafficking and efflux pathways.

HDL particles are central to the process of reverse cholesterol transport and thus to the maintenance of tissue cholesterol homeostasis. This process has multiple steps which include the binding of HDL to cell surface components, the acquisition of cholesterol by passive absorption, the esterification of this cholesterol by LCAT and the subsequent transfer of esterified cholesterol by CETP, to VLDL and chylomicron remnants for liver uptake. Each of these steps is known to impact the plasma concentration of HDL.

Changes in genes for ApoAI-CIII, lipoprotein lipase, CETP, hepatic lipase, and LCAT all contribute to determination of HDL-C levels in humans. One rare form of genetic HDL deficiency is Tangier disease (TD), diagnosed in approximately 40 patients world-wide, and associated with almost complete absence of HDL cholesterol (HDL-C) levels (listed in OMIM as an autosomal recessive trait (OMIM 205400)). These patients have very low HDL cholesterol and ApoAI levels, which have been ascribed to hypercatabolism of nascent HDL and ApoAI, due to a delayed acquisition of lipid and resulting failure of conversion to mature HDL. TD patients accumulate cholesterol esters in several tissues, resulting in characteristic features, such as enlarged yellow tonsils, hepatosplenomegaly, peripheral neuropathy, and cholesterol ester deposition in the rectal mucosa. Defective removal of cellular cholesterol and phospholipids by

ApoAI as well as a marked deficiency in HDL mediated efflux of intracellular cholesterol has been demonstrated in TD fibroblasts. Even though this is a rare disorder, defining its molecular basis could identify pathways relevant for cholesterol regulation in the general population. The decreased availability of free cholesterol for efflux in the surface membranes of cells in Tangier Disease patients appears to be due to a defect in cellular lipid metabolism or trafficking.

Approximately 45% of Tangier patients have signs of premature CAD, suggesting a strong link between decreased cholesterol efflux, low HDL cholesterol and CAD. As increased cholesterol is observed in the rectal mucosa of persons with TD, the molecular mechanism responsible for TD may also regulate cholesterol adsorption from the gastrointestinal (GI) tract.

A more common form of genetic HDL deficiency occurs in patients who have low plasma HDL cholesterol usually below the 5th percentile for age and sex (OMIM 10768), but an absence of clinical manifestations specific to Tangier disease (Marcil et al., *Arterioscler. Thromb. Vasc. Biol.* 19:159-169, 1999; Marcil et al., *Arterioscler. Thromb. Vasc. Biol.* 15:1015-1024, 1995). These patients have no obvious environmental factors associated with this lipid phenotype, and do not have severe hypertriglyceridemia nor have known causes of severe HDL deficiency (mutations in ApoAI, LCAT, or LPL deficiency) and are not diabetic. The pattern of inheritance of this condition is most consistent with a Mendelian dominant trait (OMIM 10768).

The development of drugs that regulate cholesterol metabolism has so far progressed slowly. Thus, there is a need for a better understanding of the genetic components of the cholesterol efflux pathway. Newly-discovered components can then serve as targets for drug design.

Low HDL levels are likely to be due to multiple genetic factors. The use of

pharmacogenomics in the aid of designing treatment tailored to the patient makes it desirable to identify polymorphisms in components of the cholesterol efflux pathway. An understanding of the effect of these polymorphisms on protein function would allow for the design of a therapy that is optimal for the patient.

5

Summary of the Invention

In a first aspect, the invention features a substantially pure ABC1 polypeptide having ABC1 biological activity. Preferably, the ABC1 polypeptide is human ABC1 (e.g., one that includes amino acids 1 to 60 or amino acids 61 to 2261 of SEQ ID NO: 1). In one preferred embodiment, the ABC1 polypeptide includes amino acids 1 to 2261 of SEQ ID NO: 1.

Specifically excluded from the polypeptides of the invention are the polypeptide having the exact amino acid sequence as GenBank accession number CAA10005.1 and the nucleic acid having the exact sequence as AJ012376.1. Also excluded is protein having the exact amino acid sequence as GenBank accession number X75926.

In a related aspect, the invention features a substantially pure ABC1 polypeptide that includes amino acids 1 to 2261 of SEQ ID NO: 1.

In another aspect, the invention features a substantially pure nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity (e.g., a nucleic acid molecule that includes nucleotides 75 to 254 or nucleotides 255 to 6858 of SEQ ID NO: 2). In one preferred embodiment, the nucleic acid molecule includes nucleotides 75 to 6858 of SEQ ID NO: 2.

In a related aspect, the invention features an expression vector, a cell, or a non-human mammal that includes the nucleic acid molecule of the invention.

In yet another aspect, the invention features a substantially pure nucleic acid

molecule that includes nucleotides 75 to 254 of SEQ ID NO: 2, nucleotides 255 to 6858 of SEQ ID NO: 2, or nucleotides 75 to 6858 of SEQ ID NO: 2.

In still another aspect, the invention features a substantially pure nucleic acid molecule that includes at least fifteen nucleotides corresponding to the 5' or 3' untranslated region from a human ABC1 gene. Preferably, the 3' untranslated region includes nucleotides 7015-7860 of SEQ ID NO: 2.

In a related aspect, the invention features a substantially pure nucleic acid molecule that hybridizes at high stringency to a probe comprising nucleotides 7015-7860 of SEQ ID NO: 2.

In another aspect, the invention features a method of treating a human having low HDL cholesterol or a cardiovascular disease, including administering to the human an ABC1 polypeptide, or cholesterol-regulating fragment thereof, or a nucleic acid molecule encoding an ABC1 polypeptide, or cholesterol-regulating fragment thereof. In a preferred embodiment, the human has a low HDL cholesterol level relative to normal. Preferably, the ABC1 polypeptide is wild-type ABC1, or has a mutation increases its stability or its biological activity. A preferred biological activity is regulation of cholesterol.

In a related aspect, the invention features a method of preventing or treating cardiovascular disease, including introducing into a human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter and encoding an ABC1 polypeptide having ABC1 biological activity.

In another related aspect, the invention features a method of preventing or ameliorating the effects of a disease-causing mutation in an *ABC1* gene, including introducing into a human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter and encoding an ABC1 polypeptide having ABC1 biological activity.

In still another aspect, the invention features a method of treating or preventing cardiovascular disease, including administering to an animal (e.g., a human) a compound that mimics the activity of wild-type ABC1 or modulates the biological activity of ABC1.

5 One preferred cardiovascular disease that can be treated using the methods of the invention is coronary artery disease. Others include cerebrovascular disease and peripheral vascular disease.

10 The discovery that the ABC1 gene and protein are involved in cholesterol transport that affects serum HDL levels allows the ABC1 protein and gene to be used in a variety of diagnostic tests and assays for identification of HDL-increasing or CVD-inhibiting drugs. In one family of such assays, the ability of domains of the ABC1 protein to bind ATP is utilized; compounds that enhance this binding are potential HDL-increasing drugs. Similarly, the anion transport capabilities and membrane pore-forming functions in cell membranes can be used
15 for drug screening.

ABC1 expression can also serve as a diagnostic tool for low HDL or CVD; determination of the genetic subtyping of the *ABC1* gene sequence can be used to subtype low HDL individuals or families to determine whether the low HDL phenotype is related to ABC1 function. This diagnostic process can lead to the
20 tailoring of drug treatments according to patient genotype (referred to as pharmacogenomics), including prediction of the patient's response (e.g., increased or decreased efficacy or undesired side effects upon administration of a compound or drug.

25 Antibodies to an ABC1 polypeptide can be used both as therapeutics and diagnostics. Antibodies are produced by immunologically challenging a B-cell-containing biological system, e.g., an animal such as a mouse, with an ABC1

polypeptide to stimulate production of anti-ABC1 protein by the B-cells, followed by isolation of the antibody from the biological system. Such antibodies can be used to measure ABC1 polypeptide in a biological sample such as serum, by contacting the sample with the antibody and then measuring immune complexes as a measure of the ABC1 polypeptide in the sample. Antibodies to ABC1 can also be used as therapeutics for the modulation of ABC1 biological activity.

Thus, in another aspect, the invention features a purified antibody that specifically binds to ABC1.

In yet another aspect, the invention features a method for determining whether a candidate compound modulates ABC1 biological activity, comprising: (a) providing an ABC1 polypeptide; (b) contacting the ABC1 polypeptide with the candidate compound; and (c) measuring ABC1 biological activity, wherein altered ABC1 biological activity, relative to an ABC1 polypeptide not contacted with the compound, indicates that the candidate compound modulates ABC1 biological activity. Preferably, the ABC1 polypeptide is in a cell or is in a cell-free assay system.

In still another aspect, the invention features a method for determining whether a candidate compound modulates ABC1 expression. The method includes (a) providing a nucleic acid molecule comprising an ABC1 promoter operably linked to a reporter gene; (b) contacting the nucleic acid molecule with the candidate compound; and (c) measuring reporter gene expression, wherein altered reporter gene expression, relative to a nucleic acid molecule not contacted with the compound, indicates that the candidate compound modulates ABC1 expression.

In another aspect, the invention features a method for determining whether candidate compound is useful for modulating cholesterol levels, the method including the steps of: (a) providing an ABC1 polypeptide; (b) contacting the

polypeptide with the candidate compound; and (c) measuring binding of the ABC1 polypeptide, wherein binding of the ABC1 polypeptide indicates that the candidate compound is useful for modulating cholesterol levels.

In a related aspect, the invention features method for determining whether a candidate compound mimics ABC1 biological activity. The method includes (a) providing a cell that is not expressing an ABC1 polypeptide; (b) contacting the cell with the candidate compound; and (c) measuring ABC1 biological activity of the cell, wherein altered ABC1 biological activity, relative to a cell not contacted with the compound, indicates that the candidate compound modulates ABC1 biological activity. Preferably, the cell has an *ABC1* null mutation. In one preferred embodiment, the cell is in a mouse or a chicken (e.g., a WHAM chicken) in which its *ABC1* gene has been mutated.

In still another aspect, the invention features a method for determining whether a candidate compound is useful for the treatment of low HDL cholesterol. The method includes (a) providing an ABC transporter (e.g., ABC1); (b) contacting the transporter with the candidate compound; and (c) measuring ABC transporter biological activity, wherein increased ABC transporter biological activity, relative to a transporter not contacted with the compound, indicates that the candidate compound is useful for the treatment of low HDL cholesterol.

Preferably the ABC transporter is in a cell or a cell free assay system.

In yet another aspect, the invention features a method for determining whether candidate compound is useful for modulating cholesterol levels. The method includes (a) providing a nucleic acid molecule comprising an ABC transporter promoter operably linked to a reporter gene; (b) contacting the nucleic acid molecule with the candidate compound; and (c) measuring expression of the reporter gene, wherein increased expression of the reporter gene, relative to a

nucleic acid molecule not contacted with the compound, indicates that the candidate compound is useful for modulating cholesterol levels.

In still another aspect, the invention features a method for determining whether a candidate compound increases the stability or decreases the regulated catabolism of an ABC transporter polypeptide. The method includes (a) providing an ABC transporter polypeptide; (b) contacting the transporter with the candidate compound; and (c) measuring the half-life of the ABC transporter polypeptide, wherein an increase in the half-life, relative to a transporter not contacted with the compound, indicates that the candidate compound increases the stability or decreases the regulated catabolism of an ABC transporter polypeptide. Preferably the ABC transporter is in a cell or a cell free assay system.

In a preferred embodiment of the screening methods of the present invention, the cell is in an animal. The preferred ABC transporters are ABC1, ABC2, ABCR, and ABC8, and the preferred biological activity is transport of cholesterol (e.g., HDL cholesterol or LDL cholesterol) or interleukin-1, or is binding or hydrolysis of ATP by the ABC1 polypeptide.

Preferably, the ABC1 polypeptide used in the screening methods includes amino acids 1-60 of SEQ ID NO: 1. Alternatively, the ABC1 polypeptide can include a region encoded by a nucleotide sequence that hybridizes under high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2.

In another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes determining whether an *ABC1* gene of the patient has a mutation, wherein a mutation indicates that the patient has an increased risk for cardiovascular disease.

In related aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes

determining whether an *ABC1* gene of the patient has a polymorphism, wherein a polymorphism indicates that the patient has an increased risk for cardiovascular disease.

5 In another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes measuring ABC1 biological activity in the patient, wherein increased or decreased levels in the ABC1 biological activity, relative to normal levels, indicates that the patient has an increased risk for cardiovascular disease.

10 In still another aspect, the invention features a method for determining whether a patient has an increased risk for cardiovascular disease. The method includes measuring ABC1 expression in the patient, wherein decreased levels in the ABC1 expression relative to normal levels, indicates that the patient has an increased risk for cardiovascular disease. Preferably, the ABC1 expression is determined by measuring levels of ABC1 polypeptide or *ABC1* RNA.

15 In another aspect, the invention features a non-human mammal having a transgene comprising a nucleic acid molecule encoding a mutated ABC1 polypeptide. In one embodiment, the mutation is a dominant-negative mutation.

20 In a related aspect, the invention features a non-human mammal, having a transgene that includes a nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

In another related aspect, the invention features a cell from a non-human mammal having a transgene that includes a nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

25 In still another aspect, the invention features a method for determining whether a candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide. The method includes (a) providing a cell expressing a

dominant-negative ABC1 polypeptide; (b) contacting the cell with the candidate compound; and (c) measuring ABC1 biological activity of the cell, wherein an increase in the ABC1 biological activity, relative to a cell not contacted with the compound, indicates that the candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide.

By “polypeptide” is meant any chain of more than two amino acids, regardless of post-translational modification such as glycosylation or phosphorylation.

By “substantially identical” is meant a polypeptide or nucleic acid exhibiting at least 50%, preferably 85%, more preferably 90%, and most preferably 95% identity to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). This software program matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

By “high stringency conditions” is meant hybridization in 2X SSC at 40°C with a DNA probe length of at least 40 nucleotides. For other definitions of high stringency conditions, see F. Ausubel et al., *Current Protocols in Molecular Biology*, pp. 6.3.1-6.3.6, John Wiley & Sons, New York, NY, 1994, hereby
5 incorporated by reference.

By “substantially pure polypeptide” is meant a polypeptide that has been separated from the components that naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally
10 associated. Preferably, the polypeptide is an ABC1 polypeptide that is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, pure. A substantially pure ABC1 polypeptide may be obtained, for example, by extraction from a natural source (e.g., a pancreatic cell), by expression of a recombinant nucleic acid encoding a ABC1 polypeptide, or by chemically
15 synthesizing the protein. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

A polypeptide is substantially free of naturally associated components when it is separated from those contaminants that accompany it in its natural state. Thus,
20 a polypeptide which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those which naturally occur in eukaryotic organisms but are synthesized in *E. coli* or other prokaryotes.

By “substantially pure nucleic acid” is meant nucleic acid that is free of the
25 genes which, in the naturally-occurring genome of the organism from which the

nucleic acid of the invention is derived, flank the nucleic acid. The term therefore includes, for example, a recombinant nucleic acid that is incorporated into a vector; into an autonomously replicating plasmid or virus; into the genomic nucleic acid of a prokaryote or a eukaryote cell; or that exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant nucleic acid that is part of a hybrid gene encoding additional polypeptide sequence.

By “modulates” is meant increase or decrease. Preferably, a compound that modulates cholesterol levels (e.g., HDL-cholesterol levels, LDL-cholesterol levels, or total cholesterol levels), or ABC1 biological activity, expression, stability, or degradation does so by at least 10%, more preferably by at least 25%, and most preferably by at least 50%.

By “purified antibody” is meant antibody which is at least 60%, by weight, free from proteins and naturally occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody. A purified antibody may be obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.

By “specifically binds” is meant an antibody that recognizes and binds to, for example, a human ABC1 polypeptide but does not substantially recognize and bind to other non-ABC1 molecules in a sample, e.g., a biological sample, that naturally includes protein. A preferred antibody binds to the ABC1 polypeptide sequence of Fig. 9A (SEQ ID NO: 1).

By “polymorphism” is meant that a nucleotide or nucleotide region is characterized as occurring in several different forms. A “mutation” is a form of a

polymorphism in which the expression level, stability, function, or biological activity of the encoded protein is substantially altered.

By “ABC transporter” or “ABC polypeptide” is meant any transporter that hydrolyzes ATP and transports a substance across a membrane. Preferably, an ABC transporter polypeptide includes an ATP Binding Cassette and a transmembrane region. Examples of ABC transporters include, but are not limited to, ABC1, ABC2, ABCR, and ABC8.

By “ABC1 polypeptide” is meant a polypeptide having substantial identity to an ABC1 polypeptide having the amino acid sequence of SEQ ID NO: 1.

By “ABC biological activity” or “ABC1 biological activity” is meant hydrolysis or binding of ATP, transport of a compound (e.g., cholesterol, interleukin-1) or ion across a membrane, or regulation of cholesterol or phospholipid levels (e.g., either by increasing or decreasing HDL-cholesterol or LDL-cholesterol levels).

The invention provides screening procedures for identifying therapeutic compounds (cholesterol-modulating or anti-CVD pharmaceuticals) which can be used in human patients. Compounds that modulate ABC biological activity (e.g., ABC1 biological activity) are considered useful in the invention, as are compounds that modulate ABC concentration, protein stability, regulated catabolism, or its ability to bind other proteins or factors. In general, the screening methods of the invention involve screening any number of compounds for therapeutically active agents by employing any number of *in vitro* or *in vivo* experimental systems. Exemplary methods useful for the identification of such compounds are detailed below.

The methods of the invention simplify the evaluation, identification and development of active agents for the treatment and prevention of low HDL and

CVD. In general, the screening methods provide a facile means for selecting natural product extracts or compounds of interest from a large population which are further evaluated and condensed to a few active and selective materials. Constitutes of this pool are then purified and evaluated in the methods of the invention to determine their HDL-raising or anti-CVD activities or both.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Drawings

Figs. 1A and 1B are schematic illustrations showing two pedigrees with Tangier Disease, (TD-1 and TD-2). Square and circle symbols represent males and females, respectively. Diagonal lines are placed through the symbols of all deceased individuals. A shaded symbol on both alleles indicates the probands with Tangier Disease. Individuals with half shaded symbols have HDL-C levels at or below the 10th percentile for age and sex, while those with quarter shaded symbols have HDL-C between the 11th and 20th percentiles.

Each individual's ID number, age at the time of lipid measurement, triglyceride level and HDL cholesterol level followed by their percentile ranking for age and sex are listed below the pedigree symbol. Markers spanning the 9q31.1 region are displayed to the left of the pedigree. The affected allele is represented by the darkened bars which illustrate the mapping of the limits of the shared haplotype region as seen in Fig. 3. Parentheses connote inferred marker data, questions marks indicate unknown genotypes, and large arrows show the probands.

Fig. 1C shows ApoAI (10 μ g/mL) -mediated cellular cholesterol efflux in control fibroblasts (n=5, normalized to 100%) and two subjects with Tangier

disease (TD). Cells were ^3H -cholesterol (0.2 $\mu\text{Ci/mL}$) labeled during growth and cholesterol (20 $\mu\text{g/mL}$) loaded in growth arrest. Cholesterol efflux is determined as ^3H medium/(^3H cell + ^3H medium)

Fig. 2A - 2D are schematic illustrations showing four French Canadian pedigrees with FHA (FHA-1 to -4). The notations are as in Fig. 1. Exclamation points on either side of a genotype (as noted in Families FHA-3 and FHA-4) are used when the marker data appears to be inconsistent due to potential microsatellite repeat expansions. A bar that becomes a single thin line suggests that the haplotype is indeterminate at that marker.

Figs. 3A - 3E are a schematic illustration showing a genetic and physical map of 9q31 spanning 35 cM. Fig. 3A: YACs from the region of 9q22-34 were identified and a YAC contig spanning this region was constructed. Fig. 3B: A total of 22 polymorphic CA microsatellite markers were mapped to the contig and used in haplotype analysis in TD-1 and TD-2. Fig 3C: The mutant haplotypes for probands in TD-1 and -2 indicate a significant region of homozygosity in TD-2, while the proband in TD-1 has 2 different mutant haplotypes. The candidate region can be narrowed to the region of homozygosity for CA markers in proband 2. A critical crossover at D9S1690 in TD-1 (A)* also provides a centromeric boundary for the region containing the gene. Three candidate genes in this region (*ABCI*, *LPA-R* and *RGS-3*) are shown. Fig. 3D: Meiotic recombinations in the FHA families (A-H) refine the minimal critical region to 1.2 cM between D9S277 and D9S1866. The heterozygosity of the TD-2 proband at D9S127, which ends a continuous region of homozygosity in TD-2, further refines the region to less than 1 cM. This is the region to which *ABCI* has been mapped. Fig. 3E: Isolated YAC DNA and selected markers from the region were used to probe high-density BAC grid filters, selecting BACs which via STS-content mapping produced an 800 Kb

contig. Four BACs containing *ABC1* were sequenced using high-throughput methods.

Fig. 4A shows sequence of one mutation in family TD-1. Patient III-01 is heterozygous for a T to C transition at nucleotide 4503 of the cDNA; the control is homozygous for T at this position. This mutation corresponds to a cysteine to arginine substitution in the ABC1 protein (C1477R).

Fig 4B shows the amino acid sequence conservation of residue 1477 in mouse and human, but not a related *C. elegans* gene. A change from cysteine to arginine likely has an important effect on the protein secondary and tertiary structure, as noted by its negative scores in most substitution matrices (Schuler et al., A Practical Guide to the Analysis of Genes and Proteins, eds. Baxevanis, A.D. & Ouellette, B.F.F. 145:171, 1998). The DNA sequences of the normal and mutant genes are shown above and below the amino acid sequences, respectively.

Fig. 4C shows the segregation of the T4503C mutation in TD-1. The presence of the T4503C mutation (+) was assayed by restriction enzyme digestion with *HgaI*, which cuts only the mutant (C) allele (↓). Thus, in the absence of the mutation, only the 194 bp PCR product (amplified between → and ←) is observed, while in its presence the PCR product is cleaved into fragments of 134 bp and 60 bp. The proband (individual III.01) was observed to be heterozygous for this mutation (as indicated by both the 194 bp and 134 bp bands), as were his daughter, father, and three paternal cousins. A fourth cousin and three of the father's siblings were not carriers of this mutation.

Fig. 4D shows Northern blot analysis with probes spanning the complete ABC1 gene reveal the expected ~8 Kb transcript and, in addition, a ~3.5 kb truncated transcript only seen in the proband TD-1 and not in TD-2 or control. This was detected by probes spanning exons 1-49 (a), 1-41 (b), 1-22 (c), and 23-29

(d), but not with probes spanning exons 30-41 (e) or 42-49 (f).

Fig. 5A shows the sequence of the mutation in family TD-2. Patient IV-10 is homozygous for an A to G transition at nucleotide 1864 of the cDNA (SEQ ID NO: 2); the control is homozygous for A at this position. This mutation corresponds to a glutamine to arginine substitution in the ABC1 protein (Q597R).

Fig. 5B shows that the glutamine amino acid, which is mutated in the TD-2 proband, is conserved in human and mouse ABC1 as well as in an ABC orthologue from *C. elegans*, revealing the specific importance of this residue in the structure/function of this ABC protein in both worms and mammals. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 5C shows the segregation of the A1864G mutation in TD-2. The presence of the A1864G mutation (indicated by +) was assayed by restriction enzyme digestion with *AciI*. The 360 bp PCR product has one invariant *AciI* recognition site (↓), and a second one is created by the A1864G mutation. The wild-type allele is thus cleaved to fragments of 215 bp and 145 bp, while the mutant allele (G-allele) is cleaved to fragments of 185 bp, 145 bp and 30 bp. The proband (individual IV-10), the product of a consanguineous mating, was homozygous for the A1864G mutation (+/+), as evidenced by the presence of only the 185 bp and 145 bp bands, while four other family members for whom DNA was tested are heterozygous carriers of this mutation (both the 215 bp and 185 bp fragments were present). Two unaffected individuals (-/-), with only the 215 bp and 145 bp bands are shown for comparison.

Fig. 6A shows a sequence of the mutation in family FHA-1. Patient III-01 is heterozygous for a deletion of nucleotides 2151-2153 of the cDNA (SEQ ID NO: 2). This deletion was detected as a superimposed sequence starting at the first

nucleotide after the deletion. This corresponds to deletion of leucine 693 in the ABC1 protein (SEQ ID NO: 1).

Fig. 6B is an alignment of the human and mouse wild-type amino acid sequences, showing that the human and mouse sequences are identical in the vicinity of Δ L693. L693 is also conserved in *C. elegans*. This highly conserved residue lies within a predicted transmembrane domain. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 6C shows segregation of the Δ L693 mutation in FHA-1, as assayed by *Eco*RI restriction digestion. Two invariant *Eco*RI restriction sites (indicated by \downarrow) are present within the 297 bp PCR product located between the horizontal arrows ($\rightarrow\leftarrow$) while a third site is present in the wild-type allele only. The presence of the mutant allele is thus distinguished by the presence of a 210 bp fragment (+), while the normal allele produces a 151 bp fragment (-). The proband of this family (III.01) is heterozygous for this mutation, as indicated by the presence of both the 210 and 151 bp bands.

Fig. 6D shows a sequence of the mutation in family FHA-3. Patient III-01 is heterozygous for a deletion of nucleotides 5752-5757 of the cDNA (SEQ ID NO: 2). This deletion was detected as a superimposed sequence starting at the first nucleotide after the deletion. This corresponds to deletion of glutamic acid 1893 and aspartic acid 1894 in the ABC1 protein (SEQ ID NO: 1).

Fig. 6E is an alignment of the human and mouse wild-type amino acid sequences, showing that the human and mouse sequences are identical in the vicinity of Δ 5752-5757. This region is highly conserved in *C. elegans*. The DNA sequences of the normal and mutant proteins are shown above and below the amino acid sequences, respectively.

Fig. 6F shows a sequence of the mutation in family FHA-2. Patient III-01 is heterozygous for a C to T transition at nucleotide 6504 of the cDNA (SEQ ID NO: 2). This alteration converts an arginine at position 2144 of SEQ ID NO: 1 to a STOP codon, causing truncation of the last 118 amino acids of the ABC1 protein.

Figs. 7A and 7B show cholesterol efflux from human skin fibroblasts treated with ABC1 antisense oligonucleotides. Fibroblasts from a control subject were labeled with ³H cholesterol (0.2 μCi/mL) during growth for 48 hours and transfected with 500 nM *ABC1* antisense AN-1 (5'-GCA GAG GGC ATG GCT TTA TTT G-3'; SEQ ID NO: 3) with 7.5 μg lipofectin for 4 hours. Following transfection, cells were cholesterol loaded (20 μg/mL) for 12 hours and allowed to equilibrate for 6 hours. Cells were either then harvested for total RNA and 10 μg was used for Northern blot analysis. Cholesterol efflux experiments were carried out as described herein. Fig. 7A: AN-1 was the oligonucleotide that resulted in a predictable decrease in *ABC1* RNA transcript levels. Fig. 7B: A double antisense transfection method was used. In this method, cells were labeled and transfected with AN-1 as above, allowed to recover for 20 hours, cholesterol loaded for 24 hours, and then re-transfected with AN-1. Twenty hours after the second transfection, the cholesterol efflux as measured. A ~50% decrease in *ABC1* transcript levels was associated with a significant decrease in cholesterol efflux intermediate between that seen in wild-type and TD fibroblasts.

Fig. 7C shows show cholesterol efflux from human skin fibroblasts treated with antisense oligonucleotides directed to the region encoding the amino-terminal 60 amino acids. Note that the antisense oligonucleotide AN-6, which is directed to the previously unrecognized translation start site, produces a substantial decrease in cellular cholesterol efflux.

Fig. 8 is a schematic illustration showing predicted topology, mutations, and polymorphisms of ABC1 in Tangier disease and FHA. The two transmembrane and ATP binding domains are indicated. The locations of mutations are indicated by the arrows with the amino acid changes, which are predicted from the human *ABC1* cDNA sequence. These mutations occur in different regions of the ABC1 protein.

Fig. 9A shows the amino acid sequence of the human ABC1 protein (SEQ ID NO: 1).

Figs. 9B - 9E show the nucleotide sequence of the human *ABC1* cDNA (SEQ ID NO: 2).

Fig. 10 shows the 5' and 3' nucleotide sequences suitable for use as 5' and 3' PCR primers, respectively, for the amplification of the indicated ABC1 exon.

Fig. 11 shows a summary of alterations found in ABC1, including sequencing errors, mutations, and polymorphisms.

Fig. 12 shows a series of genomic contigs (SEQ ID NOS. 14-29) containing the ABC1 promoter (SEQ ID NO: 14), as well as exons 1-49 (and flanking intronic sequence) of ABC1. The exons (capitalized letters) are found in the contigs as follows: SEQ ID NO: 14--exon 1; SEQ ID NO: 15--exon 2; SEQ ID NO: 16--exon 3; SEQ ID NO: 17--exon 4; SEQ ID NO: 18--exon 5; SEQ ID NO: 19--exon 6; SEQ ID NO: 20--exons 7 and 8; SEQ ID NO: 21--exons 9 through 22; SEQ ID NO: 22--exons 23 through 28; SEQ ID NO: 23--exon 29; SEQ ID NO: 24--exons 30 and 31; SEQ ID NO: 25--exon 32; SEQ ID NO: 26--exons 33 through 36; SEQ ID NO: 27--exons 37 through 41; SEQ ID NO: 28--exons 42-45; SEQ ID NO: 29--exons 46-49.

Fig. 13 is a series of illustrations showing that the amino-terminal 60 amino acid region of ABC1 is protein-coding. Lysates of normal human fibroblasts were

immunoblotted in parallel with a rabbit polyclonal antibody to amino acids 1-20 of human ABC1 (1); a rabbit polyclonal antibody to amino acids 1430-1449 of human ABC1 (2); and a mouse monoclonal antibody to amino acids 2236-2259 of human ABC1. The additional bands detected in lane 2 may be due to a lack of specificity of that antibody or the presence of degradation products of ABC1.

Fig. 14 is a schematic illustration showing that the WHAM chicken contains a non-conservative substitution (G265A) resulting in an amino acid change (E89K).

Fig. 15 is a schematic illustration showing that the mutation in the WHAM chicken is at an amino acid that is conserved among human, mouse, and chicken.

Fig. 16 show a summary of locations of consensus transcription factor binding sites in the human ABC1 promoter (nucleotides 1-8238 of SEQ ID NO: 14). The abbreviations are as follows: PPRE=peroxisome proliferator-activated receptor. SRE=steroid response element-binding protein site. ROR=RAR-related orphan receptor.

Detailed Description

Genes play a significant role influencing HDL levels. Tangier disease (TD) was the first reported genetic HDL deficiency. The molecular basis for TD is unknown, but has been mapped to 9q31 in three families. We have identified two additional probands and their families, and confirmed linkage and refined the locus to a limited genomic region. Mutations in the *ABC1* gene accounting for all four alleles in these two families were detected. A more frequent cause of low HDL levels is a distinct disorder, familial HDL deficiency (FHA). On the basis of independent linkage, meiotic recombinants and disease associated haplotypes, FHA was localized to a small genomic region encompassing the *ABC1* gene. A

mutation in a conserved residue in ABC1 segregated with FHA. Antisense reduction of the *ABC1* transcript in fibroblasts was associated with a significant decrease in cholesterol efflux.

Cholesterol is normally assembled with intracellular lipids and secreted, but in TD the process is diverted and cholesterol is degraded in lysosomes. This disturbance in intracellular trafficking of cholesterol results in an increase in intracellular cholesterol ester accumulation associated with morphological changes of lysosomes and the Golgi apparatus and cholesteryl ester storage in histiocytes, Schwann cells, smooth muscle cells, mast cells and fibroblasts.

The clinical and biochemical heterogeneity in patients with TD has led to the possibility that genetic heterogeneity may also underlie this disorder. Considering this, we initially performed linkage analysis on these two families of different ancestries (TD-1 is Dutch, TD-2 is British; Frohlich et al., Clin. Invest. Med. 10:377-382, 1987) and confirmed that the genetic mutations underlying TD in these families were localized to the same 9q31 region, to which a large family with TD had been assigned (Rust et al., Nature Genetics 20:96-98, 1998). Detailed haplotype analysis, together with the construction of a physical map, refined the localization of this gene. Mutations in the ABC1 gene were found in TD.

FHA is much more common than TD, although its precise frequency is not known. While TD has been described to date in only 40 families, we have identified more than 40 FHA families in the Netherlands and Quebec alone. After initial suggestions of linkage to 9q31, thirteen polymorphic markers spanning approximately 10 cM in this region were typed and demonstrated the highest LOD score at D9S277. Analysis of the homozygosity of markers in the TD-2 proband, who was expected to be homozygous for markers close to TD due to his parents' consanguinity, placed the TD gene distal to D9S127. Combined genetic data from

TD and FHA families pointed to the same genomic segment spanning approximately 1,000 kb between D9S127 and D9S1866. The *ABC1* transporter gene was contained within the minimal genomic region. RT-PCR analysis in one family demonstrated a deletion of leucine at residue 693 ($\Delta 693$) in the first transmembrane domain of ABC1, which segregated with the phenotype of HDL deficiency in this family.

ABC1 is part of the ATP-binding cassette (ABC transporter) superfamily, which is involved in energy-dependent transport of a wide variety of substrates across membranes (Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). These proteins have characteristic motifs conserved throughout evolution which distinguish this class of proteins from other ATP binding proteins. In humans these genes essentially encode two ATP binding segments and two transmembrane domains (Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). We have now shown that the ABC1 transporter is crucial for intracellular cholesterol transport.

We have demonstrated that reduction of the *ABC1* transcript using oligonucleotide antisense approaches results in decreased efflux, clearly demonstrating the link between alterations in this gene and its functional effects. TD and FHA now join the growing list of genetic diseases due to defects in the ABC group of proteins including cystic fibrosis (Zielenski, et al., Annu. Rev. Genet. 29:777-807, 1995), adrenoleukodystrophy (Mosser et al., Nature 361: 726-730, 1993), Zellweger syndrome (Gärtner et al., Nat. Genet. 1:23, 1992), progressive familial intrahepatic cholestasis (Bull et al., Nat. Genet. 18:219-224, 1998), and different eye disorders including Stargardt disease (Allikmets et al., Nat. Genet. 15:236-246, 1997), autosomal recessive retinitis pigmentosa (Allikmets et al., Science 277:1805-1807, 1997), and cone-rod dystrophy (Cremers et al., Hum. Mol. Genet. 7:355-362, 1998).

Patients with TD have been distinguished from patients with FHA on the basis that Tangier disease was an autosomal recessive disorder (OMIM 20540) while FHA is inherited as an autosomal dominant trait (OMIM 10768). Furthermore, patients with TD have obvious evidence for intracellular cholesterol accumulation which is not seen in FHA patients. It is now evident that heterozygotes for TD do have reduced HDL levels and that the same mechanisms underlie the HDL deficiency and cholesterol efflux defects seen in heterozygotes for TD as well as FHA. Furthermore, the more severe phenotype in TD represents loss of function from both alleles of the *ABC1* gene.

ABC1 is activated by protein kinases, presumably via phosphorylation, which also provides one explanation for the essential role of activation of protein kinase C in promoting cholesterol efflux (Drobnick et al., Arterioscler. Thromb. Vasc. Biol. 15: 1369-1377, 1995). Brefeldin, which inhibits trafficking between the endoplasmic reticulum and the Golgi, significantly inhibits cholesterol efflux, essentially reproducing the effect of mutations in *ABC1*, presumably through the inhibition of *ABC1* biological activity. This finding has significance for the understanding of mechanisms leading to premature atherosclerosis. TD homozygotes develop premature coronary artery disease, as seen in the proband of TD-1 (III-01) who had evidence for coronary artery disease at 38 years. This is particular noteworthy as TD patients, in addition to exhibiting significantly reduced HDL, also have low LDL cholesterol, and yet they develop atherosclerosis despite this. This highlights the importance of HDL intracellular transport as an important mechanism in atherogenesis. There is significant evidence that heterozygotes for TD are also at increased risk for premature vascular disease (Schaefer et al., Ann. Int. Med. 93:261-266, 1980; Serfaty-Lacrosniere et al., Atherosclerosis 107:85-98, 1994). There is also preliminary evidence for

premature atherosclerosis in some probands with FHA (Fig. 2B), *e.g.*, the proband in FHA-2 (III-01) had a coronary artery bypass graft at 46 years while the proband in FHA-3 (Fig. 2C) had evidence for CAD around 50 years of age. The TD-1 proband had more severe efflux deficiency than the TD-2 proband (Fig. 1C).

5 Interestingly, the TD-2 proband had no evidence for CAD by 62 when he died of unrelated causes, providing preliminary evidence for a relationship between the degree of cholesterol efflux (mediated in part by the nature of the mutation) and the likelihood of atherosclerosis.

The *ABCI* gene plays a crucial role in cholesterol transport and, in particular, intracellular cholesterol trafficking in monocytes and fibroblasts. It also appears to play a significant role in other tissues such as the nervous system, GI tract, and the cornea. Completely defective intracellular cholesterol transport results in peripheral neuropathy, corneal opacities, and deposition of cholesterol esters in the rectal mucosa.

15 HDL deficiency is heterogeneous in nature. The delineation of the genetic basis of TD and FHA underlies the importance of this particular pathway in intracellular cholesterol transport, and its role in the pathogenesis of atherosclerosis. Unraveling of the molecular basis for TD and FHA defines a key step in a poorly defined pathway of cholesterol efflux from cells and could lead to new approaches to treatment of patients with HDL deficiency in the general population.

20 HDL has been implicated in numerous other biological processes, including but not limited to: prevention of lipoprotein oxidation; absorption of endotoxins; protection against *Trypanosoma brucei* infection; modulation of endothelial cells; and prevention of platelet aggregation (see Genest et al., J. Invest. Med. 47: 31-42, 1999, hereby incorporated by reference). Any compound that modulates HDL

levels may be useful in modulating one or more of the foregoing processes. The present discovery that ABC1 functions to regulate HDL levels links, for the first time, ABC1 with the foregoing processes.

The following examples are to illustrate the invention. They are not meant to limit the invention in any way.

Analysis of TD Families

Studies of cholesterol efflux

Both probands had evidence of marked deficiency of cholesterol efflux similar to that previously demonstrated in TD patients (Fig. 1C). TD-1 is of Dutch descent while TD-2 is of British descent.

Linkage analysis and establishment of a physical map

Multiple DNA markers were genotyped in the region of 9q31 to which linkage to TD had been described (Rust et al., Nat. Genet. 20, 96-98, 1998). Two point linkage analysis gave a maximal peak LOD score of 6.49 at D9S1832 (Table 1) with significant evidence of linkage to all markers in a ~10 cM interval. Recombination with the most proximal marker, D9S1690 was seen in II-09 in Family TD-1 (A* in Fig. 3D) providing a centromeric boundary for the disease gene. Multipoint linkage analysis of these data did not increase the precision of the positioning of the disease trait locus.

A physical map spanning approximately 10 cM in this region was established with the development of a YAC contig (Fig. 3A). In addition, 22 other polymorphic multi-allelic markers which spanned this particular region were mapped to the contig (Fig. 3B) and a subset of these were used in construction of a

TABLE 1

Two Point Linkage Analysis of TD-1 and TD-2

Marker Locus	LOD Score at recombination fraction						
	0	0.01	0.05	0.10	0.20	0.30	0.40
<i>D9S1690</i>	-infini	4.25	4.52	4.26	3.39	2.30	1.07
<i>D9S277</i>	6.22	6.11	5.67	5.10	3.90	2.60	1.17
<i>D9S1866</i>	4.97	4.87	4.49	4.00	2.96	1.85	0.70
<i>D9S1784</i>	5.50	5.40	5.00	4.47	3.36	2.17	0.92
<i>D9S1832</i>	6.49	6.37	5.91	5.31	4.05	2.69	1.21
<i>D9S1677</i>	4.60	4.51	4.18	3.76	2.88	1.93	0.93

Results of pairwise linkage analysis using MLINK. Values correspond to the LOD score for linkage between the disease locus and a marker locus for specified values of the recombination fraction.

TABLE 2. Microsatellite markers used in this study

Genetic Markers	Type	Heterozygosity	Number of alleles	Allele frequency [*] size.bp (proportion)
D9S283	CA	0.80	10	179(0.04); 181(0.34); 183(0.19); 185(0.20); 189(0.05); 193(0.04); 197(0.07); 199(0.02); 201(0.04); 203(0.04)
D9S176	CA	0.82	9	129(0.03); 131(0.16); 133(0.24); 135(0.12); 137(0.25); 139(0.03); 141(0.01); 143(0.05); 147(0.05)
D9S1690	CA	0.79	8	225(0.38); 227(0.14); 229(0.04); 231(0.12); 233(0.05); 235(0.16); 237(0.05); 239(0.05)
D9S277	CA	0.89	15	167(0.07); 171(0.02); 173(0.15); 175(0.11); 177(0.07); 179(0.04); 181(0.17); 183(0.06); 185(0.02); 187(0.02); 189(0.13); 191(0.13); 193(0.02); 197(0.00); 199(0.00)
D9S127	CA	0.72	6	149(0.11); 151(0.07); 153(0.23); 155(0.03); 157(0.45); 159(0.06)
D9S306	CA	0.87	13	102(0.06); 104(0.01); 110(0.03); 112(0.08); 114(0.16); 116(0.15); 118(0.11); 120(0.23); 122(0.06); 124(0.06); 126(0.03); 134(0.02); 136(0.01)
D9S1866	CA	0.62	11	248(0.06); 252(0.04); 254(0.01); 256(0.58); 258(0.03); 260(0.06); 262(0.02); 264(0.12); 266(0.06); 268(0.03); 270(0.01)
D9S1784	CA	0.86	15	174(0.10); 176(0.02); 178(0.06); 180(0.08); 182(0.11); 184(0.22); 186(0.15); 188(0.06); 190(0.04); 192(0.07); 194(0.03); 196(0.07); 198(0.01); 200(0.01); 202(0.01)
AFMa107xf9	CA	n.a.	n.a.	n.a.
D9S2170	CA	n.a.	n.a.	n.a.
D9S2171	CA	n.a.	n.a.	n.a.
D9S2107	CA	0.63	5	n.a.
D9S172	CA	0.54	5	291(0.00); 297(0.05); 299(0.32); 303(0.62); 305(0.02)
D9S2109	CA	0.51	3	1(0.42); 2(0.56); 3(0.02)
D9S1832	CA	0.88	12	161(0.04); 163(0.02); 167(0.02); 169(0.04); 171(0.10); 173(0.09); 175(0.15); 177(0.28); 179(0.19); 181(0.04); 183(0.01); 185(0.01)
D9S1835	CA	0.48	4	110(0.02); 112(0.23); 116(0.58); 118(0.07)
D9S1801	CA	0.77	10	166(0.10); 172(0.04); 174(0.02); 182(0.02); 184(0.19); 186(0.40); 188(0.15); 190(0.04); 192(0.02); 194(0.02)
D9S261	CA	0.63	7	90(0.02); 92(0.52); 94(0.02); 98(0.02); 100(0.29); 102(0.04); 104(0.08)
D9S160	CA	0.62	6	136(0.25); 138(0.53); 140(0.01); 142(0.12); 144(0.00); 146(0.07)
D9S1677	CA	0.81	10	251(0.27); 257(0.27); 259(0.07); 261(0.09); 263(0.27); 265(0.14); 267(0.02); 269(0.02); 271(0.04); 273(0.02)
D9S279	CA	0.78	6	244(0.09); 246(0.18); 248(0.29); 250(0.29); 252(0.07); 254(0.09)
D9S275	CA	0.62	4	190(0.31); 196(0.07); 198(0.52); 200(0.09)

* In a Caucasian population of French Canadian or French descent (J. Weissenbach, Personal Communication 1993).
n.a. = not assessed.

These polymorphic microsatellite markers were used for DNA typing in the region of 9q31 seen in Fig.3. The majority come from the last version of the Génethon human linkage map⁵³. The frequency of heterozygosity, the number of alleles as well as the allele frequency of each marker are presented.

haplotype for further analysis (Figs. 1A and 1B; Table 2). The condensed
haplotype in these families is shown in Figs. 1A and 1B.

While the family of Dutch decent did not demonstrate any consanguinity,
the proband in TD-2 was the offspring of a first-cousin consanguineous marriage
(Fig. 1B). We postulated, therefore, that it was most likely that this proband would
be homozygous for the mutation while the proband in the Dutch family was likely
to be a compound heterozygote. The Dutch proband shows completely different
mutation bearing haplotypes, supporting this hypothesis (Fig. 3C).

The TD-2 proband was homozygous for all markers tested (Fig. 1B) distal
to D9S127 but was heterozygous at D9S127 and DNA markers centromeric to it
(Fig. 3C). This suggested that the gene for TD was likely located to the genomic
region telomeric of D9S127 and encompassed by the markers demonstrating
homozygosity (Fig. 3B).

Mutation detection

Based on the defect in intracellular cholesterol transport in patients with
TD, we reviewed the EST database for genes in this region which might be
relevant to playing a role in this process. One gene that we reviewed as a
candidate was the lysophosphatidic acid (LPA) receptor (*EDG2*) which mapped
near D9S1801 (Fig. 3C). This receptor binds LPA and stimulates phospholipase-C
(PLC), and is expressed in fibroblasts. It has previously been shown that the
coordinate regulation of PLC that is necessary for normal HDL3 mediated
cholesterol efflux is impaired in TD (Walter et al., J. Clin. Invest. 98:2315-2323,
1996). Therefore this gene represented an excellent candidate for the TD gene.
Detailed assessment of this gene, using Northern blot and RT-PCR and sequencing
analysis, revealed no changes segregating with the mutant phenotype in this

family, in all likelihood excluding this gene as the cause for TD. Polymorphisms were detected, however, in the RT-PCR product, indicating expression of transcripts from both alleles.

The second candidate gene (*RGS3*) encodes a member of a family regulating G protein signaling which could also be involved in influencing cholesterol efflux (Mendez et al., Trans. Assoc. Amer. Phys. 104:48-53, 1991). This gene mapped 0.7 cM telomeric to the LPA-receptor (Fig. 3C), and is expressed in fibroblasts. It was assessed by exon-specific amplification, as its genomic organization was published (Chatterjee et al., Genomics 45:429-433, 1997). No significant sequence changes were detected.

The *ABCI* transporter gene had previously been mapped to 9q31, but its precise physical location had not been determined (Luciani et al., Genomics 21:150-159, 1994). The *ABCI* gene is a member of the ATP binding cassette transporters which represents a super family of highly conserved proteins involved in membrane transport of diverse substrates including amino acids, peptides, vitamins and steroid hormones (Luciani et al., Genomics 21:150-159, 1994; Dean et al., Curr. Opin. Gen. Dev. 5:779-785, 1995). Primers to the 3' UTR of this gene mapped to YACs spanning D9S306 (887-B2 and 930-D3) compatible with it being a strong candidate for TD. We initiated large scale genomic sequencing of BACs spanning approximately 800 kb around marker D9S306 (BACs 269, 274, 279 and 291) (Fig 3E). The *ABCI* gene was revealed encompassing 49 exons and a minimum of 75 Kb of genomic sequence. In view of the potential function of a gene in this family as a cholesterol transporter, its expression in fibroblasts and localization to the minimal genomic segment underlying TD, we formally assessed *ABCI* as a candidate.

Patient and control total fibroblast RNA was used in Northern blot analysis

and RT-PCR and sequence analyses. RT-PCR and sequence analysis of TD-1 revealed a heterozygous T to C substitution (Fig. 4A) in the TD-1 proband, which would result in a substitution of arginine for cysteine at a conserved residue between mouse and man (Fig. 4B). This mutation, confirmed by sequencing exon 30 of the ABC1 gene, exhibited complete segregation with the phenotype on one side of this family (Fig. 4C). This substitution creates a *Hga*I site, allowing for RFLP analysis of amplified genomic DNA and confirmation of the mutation (Fig. 4C). The point mutation in exon 30 was not seen on over 200 normal chromosomes from unaffected persons of Dutch decent, and 250 chromosomes of Western European decent, indicating it is unlikely to be a polymorphism. Northern blot analysis of fibroblast RNA from this patient, using a cDNA encompassing exons 1 to 49 of the gene, revealed a normal sized ~8 Kb transcript and a truncated mutant transcript which was not visible in control RNA or in RNA from other patients with HDL deficiency (Fig. 4D). Additionally, Northern blot analysis using clones encompassing discrete regions of the cDNA revealed that the mutant transcript was detected with a cDNA compassing exons 1 to 49 (a), 1 to 41 (b), 1 to 22 (c), much more faintly with a probe spanning exon 23 to 29 (d) and not seen with probes encompassing exons 30 to 42 (e), but not seen with cDNA fragment spanning exons 30 to 49 (f). This was repeated on multiple filters with control RNA, RNA from other patients with HDL deficiency and the other TD proband, and only in TD-1 was the truncated transcript observed. Sequence analysis of the coding region did not reveal an alteration in sequence that could account for this finding. Furthermore, DNA analysis by Southern blot did not reveal any major rearrangements. Completion of exon sequencing in genomic DNA showed that this mutation was a G to C transversion at position (+1) of intron 24, (Fig. 11) affecting a splice donor site and causing aberrant splicing.

RT-PCR analysis of fibroblast RNA encoding the *ABCI* gene from the proband in TD-2 (Fig. 1B) revealed a homozygous nucleotide change of A to G at nucleotide 1864 of SEQ ID NO: 2 in exon 13 (Fig. 5A), resulting in a substitution of arginine for glutamine at residue 597 of SEQ ID NO: 1 (Fig. 5B), occurring just proximal to the first predicted transmembrane domain of ABC1 (Fig. 8) at a residue conserved in mouse and as well as a *C. elegans* homolog. This mutation creates a second *Acil* site within exon 13. Segregation analysis of the mutation in this family revealed complete concordance between the mutation and the low HDL phenotype as predicted (Fig 5C). The proband in TD-2 is homozygous for this mutation, consistent with our expectation of a disease causing mutation in this consanguineous family.

Analysis of FHA families

Linkage analysis and refinement of the minimal genomic region containing the gene for FHA

Data from microsatellite typing of individual family members from the four pedigrees of French Canadian origin were analyzed (Fig. 2). A maximum LOD score of 9.67 at a recombination fraction of 0.0 was detected at D9S277 on chromosome 9q31 (Fig. 3; Table 3). Thereafter, 22 markers were typed in a region spanning 10 cM around this locus in these families (Figs. 2 and 3). The frequency for these markers were estimated from a sample of unrelated and unaffected subjects of French ancestry (Table 2).

TD and FHA have thus far been deemed distinct with separate clinical and biochemical characteristics. Even though the genes for these disorders mapped to the same region, it was uncertain whether FHA and TD were due to mutations in the same gene or, alternatively, due to mutations in genes in a similar region.

TABLE 3
Two Point Linkage Analysis in FHA

Marker Locus	LOD Score at recombination fraction						
	0	0.01	0.05	0.10	0.20	0.30	0.40
<i>D9S253</i>	-infini	-2.57	0.51	1.48	1.84	1.48	0.76
<i>D9S176</i>	-infini	1.42	3.07	3.39	3.05	2.22	1.12
<i>D9S1630</i>	-infini	3.11	4.04	4.04	3.33	2.24	0.96
<i>D9S277</i>	9.67	9.51	8.89	8.06	6.29	4.30	2.10
<i>D9S306</i>	5.60	5.51	5.13	4.62	3.55	2.36	1.11
<i>D9S1666</i>	-infini	7.24	7.35	6.87	5.50	3.82	1.91
<i>D9S1784</i>	-infini	9.85	9.76	9.03	7.09	4.78	2.25
<i>D9S172</i>	-infini	2.63	3.00	2.87	2.26	1.50	0.67
<i>D9S1632</i>	-infini	5.20	5.97	5.75	4.59	3.02	1.30
<i>D9S1801</i>	0.14	0.13	0.11	0.09	0.06	0.03	0.01
<i>D9S1677</i>	-infini	7.83	7.90	7.38	5.90	4.08	2.01
<i>D9S279</i>	-infini	3.43	3.80	3.66	3.01	2.12	1.05
<i>D9S275</i>	-infini	2.57	2.98	2.91	2.41	1.69	0.81

Results of pairwise linkage analysis using MLINK. Values correspond to the LOD score for linkage between the disease locus and a marker locus for specified values of the recombination fraction.

Refinement of the region containing the gene for FHA was possible by examining haplotype sharing and identification of critical recombination events (Fig. 2). Seven separate meiotic recombination events were seen in these families (“A” through “G” in Figs. 2 and 3), clearly indicating that the minimal genomic region containing the potential disease gene was a region of approximately 4.4 cM genomic DNA spanned by marker D9S1690 and D9S1866 (Figs. 2 and 3). This region is consistent with the results of two point linkage analysis which revealed maximal LOD scores with markers D9S277 and D9S306 and essentially excluded the region centromeric to D9S1690 or telomeric to D9S1866. An 8th meiotic recombination event (“H” in Fig. 3) further refined the FHA region to distal to D9S277.

As described herein, the *ABCI* gene mapped within this interval. The overlapping genetic data strongly suggested that FHA may in fact be allelic to TD. Utilization of sets of genetic data from FHA and TD provided a telomeric boundary at D9S1866 (meiotic recombinant) (Fig. 3D) and a centromeric marker at D9S127 based on the homozygosity data of TD-2. This refined the locus to approximately 1 Mb between D9S127 and D9S1866. The *ABCI* gene mapped within this minimal region (Fig. 3E).

Mutation detection in FHA

Mutation assessment of the *ABCI* gene was undertaken in FHA-1 (Fig. 2A). Using primers that spanned overlapping segments of the mRNA we performed RT-PCR analysis and subjected these fragments to mutational analysis. A deletion of three nucleotides is evident in the RT-PCR sequence of FHA-1 III.01 (Fig. 6A), resulting in a loss of nucleotides 2151-2153 of SEQ ID NO: 2 and deletion of a leucine (Δ L693) at amino acid position 693 of SEQ ID NO: 1 (Fig. 6A). This

leucine is conserved in mouse and *C. elegans* (Fig. 6B). The alteration was detected in the RT-PCR products as well as in genomic sequence from exon 14 specific amplification. This mutation results in a loss of an *EarI* restriction site. Analysis of genomic DNA from the family indicated that the mutation segregated completely with the phenotype of HDL deficiency. The loss of the *EarI* site results in a larger fragment being remaining in persons heterozygous for this mutation (Fig. 6C). This mutation maps to the first putative transmembrane domain of ABC1 (Fig. 8) and was not seen in 130 chromosomes from persons of French Canadian descent nor seen in over 400 chromosomes from persons of other Western European ancestry.

A mutation has also been found in patient genomic DNA in pedigree FHA-3 from Quebec. The alteration, a 6 bp deletion of nucleotides 5752-5757 of SEQ ID NO: 2 within exon 41, results in a deletion of amino acids 1893 (Glu) and 1894 (Asp) of SEQ ID NO: 1. The deletion was detected as a double, superimposed, sequence starting from the point of the deletion (Fig. 6D), and was detected in sequence reads in both directions. The deletion can be detected on 3% agarose or 10% polyacrylamide gels, and segregates with disease in FHA-3. It was not seen in 128 normal chromosomes of French-Canadian origin or in 434 other control chromosomes. Amino acids 1893 and 1894 are in a region of the ABC1 protein that is conserved between human, mouse, and *C. elegans* (Fig. 6E), implying that it is of functional importance.

An additional mutation has been found in patient genomic DNA in pedigree FHA-2 from Quebec (Fig. 6F). The alteration, a C to T transition at position 6504 of SEQ ID NO: 2, converts an arginine at position 2144 of SEQ ID NO: 1 to a STOP codon, causing truncation of the last 118 amino acids of the ABC1 protein. This alteration segregates with disease in family FHA-2.

A summary of all mutations and polymorphisms found in ABC1 is shown in Fig. 11. Each variant indicated as a mutation segregates with low HDL in its family, and was not seen in several hundred control chromosomes.

Functional relationship between changes in ABC1 transcript levels and cholesterol efflux

Antisense approaches were undertaken to decrease the ABC1 transcript and assess the effect of alteration of the transcript on intracellular cholesterol transport. The use of antisense primers to the 5' end of ABC1 clearly resulted in a decrease to approximately 50% of normal RNA levels (Fig. 7A). This would be expected to mimic in part the loss of function due to mutations on one allele, similar to that seen in heterozygotes for TD and patients with FHA. Importantly, reduction in the mRNA for the ABC1 gene resulted in a significant reduction in cellular cholesterol efflux (Fig. 7B), further establishing the role of this protein in reverse cholesterol transport and providing evidence that the mutations detected are likely to constitute loss of function mutations. Furthermore, these data support the functional importance of the first 60 amino acids of the protein. Antisense oligonucleotide AN-6 is directed to the novel start codon 5' to the one indicated in AJ012376.1; this antisense oligonucleotide effectively suppresses efflux.

The above-described results were obtained using the following materials and methods.

Patient selection

The probands in TD families had previously been diagnosed as suffering from TD based on clinical and biochemical data. Study subjects with FHA were selected from the Cardiology Clinic of the Clinical Research Institute of Montréal.

The main criterion was an HDL-C level <5th percentile for age and gender, with a plasma concentration of triglycerides <95th percentile in the proband and a first-degree relative with the same lipid abnormality. In addition, the patients did not have diabetes.

5

Biochemical studies

Blood was withdrawn in EDTA-containing tubes for plasma lipid, lipoprotein cholesterol, ApoAI, and triglyceride analyses, as well as storage at -80°C. Leukocytes were isolated from the buffy coat for DNA extraction.

10 Lipoprotein measurement was performed on fresh plasma as described elsewhere (Rogler et al., Arterioscler. Thromb. Vasc. Biol. 15:683-690, 1995). The laboratory participates and meets the criteria of the Lipid Research Program Standardization Program. Lipids, cholesterol and triglyceride levels were determined in total plasma and plasma at density $d < 1.006$ g/mL (obtained after preparative ultracentrifugation) before and after precipitation with dextran 15 manganese. Apolipoprotein measurement was performed by nephelometry for ApoB and ApoAI.

Linkage analysis

20 Linkage between the trait locus and microsatellite loci was analyzed using the FASTLINK version (4.0 P). FASTLINK/MLINK was used for two-point linkage analysis assuming an autosomal dominant trait with complete penetrance. In FHA and TD heterozygotes, the phenotype was HDL deficiency <5th percentile for age and sex. The disease allele frequency was estimated to be 0.005. Marker 25 allele frequencies were estimated from the genotypes of the founders in the pedigrees using NEWPREP. Multipoint linkage analysis was carried out using

FASTLINK/LINKMAP.

Genomic clone assembly and physical map construction of the 9q31 region

Using the Whitehead Institute/MIT Center for Genome Research map as a
5 reference, the genetic markers of interest at 9q31 were identified within YAC
contigs. Additional markers that mapped to the approximate 9q31 interval from
public databases and the literature were then assayed against the YAC clones by
PCR and hybridization analysis. The order of markers was based on their presence
or absence in the anchored YAC contigs and later in the BAC contig. Based on
10 the haplotype analysis, the region between D9S277 and D9S306 was targeted for
higher resolution physical mapping studies using bacterial artificial chromosomes
(BACs). BACs within the region of interest were isolated by hybridization of
DNA marker probes and whole YACs to high-density filters containing clones
from the RPCI-11 human BAC library (Fig. 3).

Sequence retrieval and alignment

The human *ABCI* mRNA sequence was retrieved from GenBank using the
Entrez nucleotide query (Baxevanis et al., A Practical Guide to the Analysis of
Genes and Proteins, eds. Baxevanis, A.D. & Ouellette, B.F.F. 98:120, 1998) as
20 GenBank accession number AJ012376.1. The version of the protein sequence we
used as wild-type (normal) was CAA10005.1.

We identified an additional 60 amino acids in-frame with the previously-
believed start methionine (Fig. 9A). Bioinformatic analysis of the additional
amino acids indicates the presence of a short stretch of basic amino acid residues,
25 followed by a hydrophobic stretch, then several polar residues. This may represent
a leader sequence, or another transmembrane or membrane-associated region of

the ABC1 protein. In order to differentiate among the foregoing possibilities, antibodies directed to the region of amino acids 1-60 are raised against and used to determine the physical relationship of amino acids 1-60 in relation to the cell membrane. Other standard methods can also be employed, including, for example, expression of fusion proteins and cell fractionation.

We also identified six errors in the previously-reported nucleotide sequence (at positions 839, 4738, 5017, 5995, 6557, and 6899 of SEQ ID NO: 2; Fig. 11). Hence, the sequence of the ABC1 polypeptide of Fig. 9A differs from CAA10005.1 as follows: Thr⇒Ile at position 1554; Pro⇒Leu at position 1642; Arg⇒Lys at position 1973; and Pro⇒Leu at position 2167. We also identified 5' and 3' UTR sequence (Figs. 9B - 9E).

The mouse *ABC1* sequence used has accession number X75926. It is very likely that this mouse sequence is incomplete, as it lacks the additional 60 amino acids described herein for human ABC1.

Version 1.7 of ClustalW was used for multiple sequence alignments with BOXSHADE for graphical enhancement (http://www.isrec.isb-sib.ch:8080/software/BOX_form.html) with the default parameter. A *Caenorhabditis elegans* ABC1 orthologue was identified with BLAST (version 2.08) using CAA1005.1 (see above) as a query, with the default parameter except for doing an organism filter for *C. elegans*. The selected protein sequence has accession version number AAC69223.1 with a score of 375, and an E value of 103.

Genomic DNA sequencing

BAC DNA was extracted from bacterial cultures using NucleoBond Plasmid Maxi Kits (Clontech, Palo Alto, CA). For DNA sequencing, a sublibrary was first constructed from each of the BAC DNAs (Rowen et al., Automated DNA

Sequencing and Analysis, eds. Adams, M.D., Fields, C. & Venter, J.C., 1994). In brief, the BAC DNA was isolated and randomly sheared by nebulization. The sheared DNA was then size fractionated by agarose gel electrophoresis and fragments above 2 kb were collected, treated with Mung Bean nuclease followed by T4 DNA polymerase and klenow enzyme to ensure blunt-ends, and cloned into *Sma*I-cut M13mp19. Random clones were sequenced with an ABI373 or 377 sequencer and fluorescently labeled primers (Applied BioSystems, Foster City, CA). DNASTar software was used for gel trace analysis and contig assembly. All DNA sequences were examined against available public databases primarily using BLASTn with RepeatMasker (University of Washington).

Reverse transcription (RT)-PCR amplification and sequence analysis

Total RNA was isolated from the cultured fibroblasts of TD and FHA patients, and reverse transcribed with a CDS primer containing oligo d(T)18 using 250 units of SuperScript II reverse transcriptase (Life Technologies, Inc., Rockville, MD) as described (Zhang et al., J. Biol. Chem. 27:1776-1783, 1996). cDNA was amplified with Taq DNA polymerase using primers derived from the published human *ABCI* cDNA sequence (Luciani et al., Genomics 21:150-159, 1994). Six sets of primer pairs were designed to amplify each cDNA sample, generating six DNA fragments which are sequentially overlapped covering 135 to 7014 bp of the full-length human *ABCI* cDNA. The nucleotides are numbered according to the order of the published human cDNA sequence (AJ012376.1). Primer pairs (1): 135-158 (f) and 1183-1199 (r); (2): 1080-1107 (f) and 2247-2273 (r); (3): 2171-2197 (f) and 3376-3404 (r); (4): 3323-3353 (f) and 4587-4617 (r); (5) 4515-4539 (f) and 5782-5811 (r); (6): 5742-5769 (f) and 6985-7014 (r). RT-PCR products were purified by Qiagen spin columns. Sequencing was carried out

in a Model 373A Automated DNA sequencer (Applied Biosystems) using Taq di-deoxy terminator cycle sequencing and Big Dye Kits according to the manufacturer's protocol.

5 *Northern blot analysis*

Northern transfer and hybridizations were performed essentially as described (Zhang et al., J. Biol. Chem. 27:1776-1783, 1996). Briefly, 20 µg of total fibroblast RNA samples were resolved by electrophoresis in a denaturing agarose (1.2%; w/v) gel in the presence of 7% formaldehyde, and transferred to
10 nylon membranes. The filters were probed with ³²P-labeled human ABC1 cDNA as indicated. Pre-hybridization and hybridizations were carried out in an ExpressHyb solution (ClonTech) at 68°C according to the manufacturer's protocol.

15 *Detection of the mutations in TD*

Genotyping for the T4503C and A1864G variants was performed by PCR amplification of exon 30 followed by restriction digestion with *Hga*I and amplification of exon 13 followed by digestion with *Acl*I, respectively. PCR was carried out in a total volume of 50 µL with 1.5 mM MgCl₂, 187.5 nM of each
20 dNTP, 2.5U Taq polymerase and 15 pmol of each primer (forward primer in exon 30: 5'-CTG CCA GGC AGG GGA GGA AGA GTG-3' (SEQ ID NO: 4); reverse primer spanning the junction of exon 30 and intron 30: 5'-GAA AGT GAC TCA CTT GTG GAG GA-3' (SEQ ID NO: 5); forward primer in intron 12: 5'-AAA GGG GCT TGG TAA GGG TA-3' (SEQ ID NO: 6); reverse in intron 13: 5'-CAT
25 GCA CAT GCA CAC ACA TA -3' (SEQ ID NO: 7)). Following an initial denaturation of 3 minutes at 95°C, 35 cycles consisting of 95°C 10 seconds, 58°C

30 seconds, 72°C 30 seconds were performed, with a final extension of 10 minutes at 72°C. For detection of the T4503C mutation, 15 µL of exon 30 PCR product was incubated with 4 U *HgaI* in a total volume of 25 µL, for 2 hours at 37°C, and the resulting fragments were separated on a 1.5% agarose gel. The presence of the T4503C mutation creates a restriction site for *HgaI*, and thus the 194 bp PCR product will be cut into fragments of 134 and 60 bp in the presence of the T4503C variant, but not in its absence. For detection of the A1864G mutation, 15 µL of exon 13 PCR products were digested with 8 U *AciI* for three hours at 37°C. Products were separated on 2% agarose gels. The presence of the A1864G mutation creates a second *AciI* site within the PCR product. Thus, the 360 bp PCR product is cleaved into fragments of 215 bp and 145 bp on the wild-type allele, but 185 bp, 145 bp and 30 bp on the mutant allele.

Detection of mutation in FHA

Genotyping for the Δ693 variant was performed by PCR amplification of exon 14 followed by restriction enzyme digestion with *EaeI*. PCR was carried out in a total volume of 80 µL with 1.5 mM MgCl₂, 187.5 nM of each dNTP, 2.5 U Taq polymerase and 20 pmol of each primer (forward primer in exon 14: 5'- CTT TCT GCG GGT GAT GAG CCG GTC AAT-3' (SEQ ID NO: 8); reverse primer in intron 14: 5'-CCT TAG CCC GTG TTG AGC TA-3' (SEQ ID NO: 9)).

Following an initial denaturation of 3 minutes at 95°C, 35 cycles consisting of 95°C 10 seconds, 55°C 30 seconds, 72°C 30 seconds were performed, with a final extension of 10 minutes at 72°C. Twenty microliters of PCR product was incubated with 4 U *EaeI* in a total volume of 25 µL, for two hours at 37°C, and the fragments were separated on a 2 % agarose gel. The presence of the Δ693 mutation destroys a restriction site for *EaeI*, and thus the 297 bp PCR product will

be cut into fragments of 151 bp, 59 bp, 48 bp and 39 bp in the presence of a wild-type allele, but only fragments of 210 bp, 48 bp and 39 bp in the presence of the deletion.

A 6 bp deletion encompassing nucleotides 5752-5757 (inclusive), was detected in exon 41 in the proband of family FHA-3 by genomic sequencing using primers located within the introns flanking this exon. Genotyping of this mutation in family FHA-3 and controls was carried out by PCR with forward (5'-CCT GTA AAT GCA AAG CTA TCT CCT CT- 3' (SEQ ID NO: 10)) and reverse primers (5'-CGT CAA CTC CTT GAT TTC TAA GAT GT (SEQ ID NO: 11)) located near the 5' and 3' ends of exon 41, respectively. Each PCR was carried out as for the genotyping of the 693 variant, but with annealing temperature of 58°C. Twenty microliters of PCR product was resolved on 3% agarose or 10% acrylamide gels. The wild type allele was detected as a 117 bp band and the mutant allele as a 111 bp band upon staining with ethidium bromide.

A C to T transition was detected at nucleotide 6504 in genomic DNA of the proband of family FHA-2. It was detectable as a double C and T peak in the genomic sequence of exon 48 of this individual, who is heterozygous for the alteration. This mutation, which creates a STOP codon that results in truncation of the last 118 amino acids of the ABC1 protein, also destroys an *RsaI* restriction site that is present in the wild type sequence. Genotyping of this mutation in family FHA-2 and controls was carried out by PCR with forward (5'-GGG TTC CCA GGG TTC AGT AT-3') (SEQ ID NO: 12)) and reverse (5'-GAT CAG GAA TTC AAG CAC CAA-3') (SEQ ID NO: 13)) primers directed to the intronic sequences flanking exon 48. PCR was done as for the 693 variant. Fifteen microliters of PCR product was digested with 5 Units of *RsaI* at 37°C for two hours and the digestion products resolved on 1.5% agarose gels. The mutant allele is detected as

an uncut 436 bp band. The normal sequence is cut by *RsaI* to produce 332 and 104 bp bands.

Cell culture

5 Skin fibroblast cultures were established from 3.0 mm punch biopsies of the forearm of FHD patients and healthy control subjects as described (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999).

Cellular cholesterol labeling and loading

10 The protocol for cellular cholesterol efflux experiments was described in detail elsewhere (Marcil et al., Arterioscler. Thromb. Vasc. Biol. 19:159-169, 1999). The cells were ³H-cholesterol labeled during growth and free cholesterol loaded in growth arrest.

Cholesterol efflux studies

15 Efflux studies were carried out from 0 to 24 hours in the presence of purified ApoAI (10 µg protein/mL medium). Efflux was determined as a percent of free cholesterol in the medium after the cells were incubated for specified periods of time. All experiments were performed in triplicate, in the presence of
20 cells from one control subject and the cells from the study subjects to be examined. All results showing an efflux defect were confirmed at least three times.

Oligonucleotide synthesis

25 Eight phosphorothioate deoxyoligonucleotides complementary to various regions of the human *ABCI* cDNA sequence were obtained from GIBCO BRL. The oligonucleotides were purified by HPLC. The sequences of the antisense

oligonucleotides and their location are listed. One skilled in the art will recognize that other *ABC1* antisense sequences can also be produced and tested for their ability to decrease ABC1-mediated cholesterol regulation.

5	<u>Name</u>	<u>Sequence (5'- 3')</u>	<u>mRNA target</u>	<u>%</u>
	<u>control</u>			
	AN-1	GCAGAGGGCATGGCTTTATTTG (SEQ ID NO: 3)	AUG codon	46
	AN-2	GTGTTCTGCAGAGGGCATG (SEQ ID NO: 30)	AUG codon	50
	AN-3	CACTTCCAGTAACAGCTGAC (SEQ ID NO: 31)	5'-Untranslated	79
10	AN-4	CTTTGCGCATGTCCTTCATGC (SEQ ID NO: 32)	Coding	80
	AN-5	GACATCAGCCCTCAGCATCTT (SEQ ID NO: 33)	Coding	120
	AN-6:	CAACAAGCCATGTTCCCTC (SEQ ID NO: 34)	Coding	
	AN-7:	CATGTTCCCTCAGCCAGC (SEQ ID NO: 35)	Coding	
	AN-8:	CAGAGCTCACAGCAGGGA C (SEQ ID NO: 36)	Coding	

Cell transfection with antisense oligonucleotides

Cells were grown in 35 mm culture dishes until 80 % confluent, then washed once with DMEM medium (serum and antibiotics free). One milliliter of DMEM (serum and antibiotics free) containing 500 nM antisense oligonucleotides and 5 µg/ml or 7.5 µg/ml of lipofectin (GIBCO BRL) were added to each well according to the manufacturer's protocol. The cells were incubated at 37°C for 4 hours, and then the medium was replaced by DMEM containing 10% FCS. Twenty-four hours after the transfection, the total cell RNA was isolated. Ten micrograms of total RNA was resolved on a 1% of agarose-formaldehyde gel and transferred to nylon membrane. The blot was hybridized with α -³²P dCTP labeled human *ABC1* cDNA overnight at 68°C. The membrane was subsequently exposed to x-ray film. The hybridizing bands were scanned by optical densitometry and standard to 28S ribosome RNA.

Cholesterol efflux with anti-ABC1 oligonucleotides

Human skin fibroblasts were plated in 6-well plates. The cells were labeled with ^3H -cholesterol (0.2 μCi /ml) in DMEM with 10% FBS for two days when the cell reached 50% confluence. The cells were then transfected with the antisense
5 *ABC1* oligonucleotides at 500nM in DMEM (serum and antibiotic free) with 7.5 $\mu\text{g}/\text{ml}$ Lipofectin (GIBCO BRL) according to the manufacturer's protocol. Following the transfection, and the cells were loaded with nonlipoprotein (20 $\mu\text{g}/\text{ml}$) for 12 hours in DMEM containing 2 mg/ml BSA without serum. The cellular cholesterol pools were then allowed to equilibrate for 6 hours in DMEM-BSA. The cholesterol efflux mediated by ApoAI (10 μg /ml, in DMEM-BSA)
10 were then carried out which is 48 hours after transfection.

Radiolabeled cholesterol released into the medium is expressed as a percentage of total ^3H -cholesterol per well (medium + cell). Results are the mean +/- SD of triplicate dishes.

Determination of genomic structure of the ABC1 gene

Most splice junction sequences were determined from genomic sequence generated from BAC clones spanning the ABC1 gene. More than 160 kb of genomic sequence were generated. Genomic sequences were aligned with cDNA
20 sequences to identify intron/exon boundaries. In some cases, long distance PCR between adjacent exons was used to amplify intron/exon boundary sequences using amplification primers designed according to the cDNA sequence.

Functionality of the newly-discovered 60 amino acids at the N-terminus

Antisense experiments

Phosphorothioate antisense oligonucleotides were designed to be complementary to the regions of the cDNA near newly discovered translation start site. AN-6 and AN-7 both overlap the initiator methionine codon; this site is in the middle of oligonucleotide AN-6. AN-8 is complementary to the very 5' end of the ABC1 cDNA. Antisense oligonucleotide AN-1 is complementary to the region of the ABC1 cDNA corresponding to the site identified as the ABC1 initiator methionine in AJ012376. Fig. 7C shows that antisense oligonucleotide AN-6 interferes with cellular cholesterol efflux in normal fibroblasts to the same extent as does antisense oligonucleotide AN-1. Transfection with either of these antisense oligonucleotides results in a decrease in cellular cholesterol efflux almost as severe as that seen in FHA cells. In general, antisense oligonucleotides complementary to coding sequences, especially near the 5' end of a gene's coding sequence, are expected to be more effective in decreasing the effective amount of transcript than are oligonucleotides directed to more 3' sequences or to non-coding sequences. The observation that AN-6 depresses cellular cholesterol efflux as effectively as AN-1 implies that both of these oligonucleotides are complementary to ABC1 coding sequences, and that the amino terminal 60 amino acids are likely to be contained in ABC1 protein. In contrast, the ineffectiveness of AN-8 shows that it is likely to be outside the protein coding region of the transcript, as predicted by presence of an in-frame stop codon between the initiator methionine and the region targeted by AN-8.

Antibody experiments

Polyclonal and monoclonal antibodies have been generated using peptides corresponding to discrete portions of the ABC1 amino acid sequence. One of these, 20-amino acid peptide #2 (Pep2: CSVRLSYPPYEQHECHFPNKA (SEQ ID NO: 37), in which the N-terminal cysteine was added to facilitate conjugation of the peptide) corresponds to a protein sequence within the 60 amino-terminal amino acids of the newly-discovered ABC1 protein sequence. The peptide was coupled to the KLH carrier protein and 300 µg injected at three intervals into two Balb/c mice over a four week period. The spleen was harvested from the mouse with the highest ELISA-determined immune response to free peptide, and the cells fused to NS-1 myeloma cells by standard monoclonal antibody generation methods. Positive hybridomas were selected first by ELISA and then further characterized by western blotting using cultured primary human fibroblasts. Monoclonal cell lines producing a high antibody titre and specifically recognizing the 245 kD human ABC1 protein were saved. The same size ABC1 protein product was detected by antibodies directed to four other discrete regions of the same protein. The 245 kD band could be eliminated in competition experiments with appropriate free peptide, indicating that it represents ABC1 protein (Fig. 13).

The foregoing experiments indicate that ABC1 protein is detected not only by antibodies corresponding to amino acid sequences within the previously-described ABC1 amino acid sequence, but also by the Pep2 monoclonal antibody that recognizes an epitope within the newly-discovered N-terminal 60 amino acids. The N-terminal 60 amino acid region is therefore coding, and is part of the ABC1 protein.

The epitope recognized by the Pep2 monoclonal antibody is also conserved among human, mouse, and chicken. Liver tissues from these three species

employed in a Western blot produced an ABC1 band of 245 kD when probed with the Pep2 monoclonal antibody. This indicates that the 60 amino acid N-terminal sequence is part of the ABC1 coding sequence in humans, mice, and chickens. Presence of this region is therefore evolutionarily conserved and likely to be of important functional significance for the ABC1 protein.

Bioinformatic analyses of ABC1 protein sequences

Transmembrane prediction programs indicate 13 transmembrane (TM) regions, the first one being between amino acids 26 and 42 (<http://psort.nibb.ac.jp:8800/psort/helpwww2.html#ealom>). The tentative number of TM regions for the threshold 0.5 is 13. (INTEGRAL Likelihood = -7.75 Transmembrane 26-42). The other 12 TM range in value between -0.64 and -12 (full results below). It is therefore very likely that the newly-discovered 60 amino acids contain a TM domain, and that the amino end of ABC1 may be on the opposite side of the membrane than originally thought.

ALOM: TM region allocation

Init position for calculation: 1

Tentative number of TMs for the threshold 0.5: 13

INTEGRAL	Likelihood = -7.75	Transmembrane 26 - 42
INTEGRAL	Likelihood = -3.98	Transmembrane 640 - 656
INTEGRAL	Likelihood = -8.70	Transmembrane 690 - 706
INTEGRAL	Likelihood = -9.61	Transmembrane 717 - 733
INTEGRAL	Likelihood = -1.44	Transmembrane 749 - 765
INTEGRAL	Likelihood = -0.64	Transmembrane 771 - 787
INTEGRAL	Likelihood = -1.28	Transmembrane 1041 - 1057
INTEGRAL	Likelihood = -12.79	Transmembrane 1351 - 1367
INTEGRAL	Likelihood = -8.60	Transmembrane 1661 - 1677
INTEGRAL	Likelihood = -6.79	Transmembrane 1708 - 1724
INTEGRAL	Likelihood = -3.40	Transmembrane 1737 - 1753
INTEGRAL	Likelihood = -1.49	Transmembrane 1775 - 1791
INTEGRAL	Likelihood = -8.39	Transmembrane 1854 - 1870
PERIPHERAL	Likelihood = 0.69	(at 1643)
ALOM score: -12.79 (number of TMSs: 13)		

There does not appear to be an obvious cleaved peptide, so this first 60 amino acid residues are not likely to be cleaved, and are therefore not specifically a signal/targeting sequence. No other signals (e.g., for targeting to specific organelles) are apparent.

5

Agonists and Antagonists

Useful therapeutic compounds include those which modulate the expression, activity, or stability of ABC1. To isolate such compounds, ABC1 expression, biological activity, or regulated catabolism is measured following the addition of candidate compounds to a culture medium of ABC1-expressing cells. Alternatively, the candidate compounds may be directly administered to animals (for example mice, pigs, or chickens) and used to screen for their effects on ABC1 expression.

In addition its role in the regulation of cholesterol, ABC1 also participates in other biological processes for which the development of ABC1 modulators would be useful. In one example, ABC1 transports interleukin-1 β (IL-1 β) across the cell membrane and out of cells. IL-1 β is a precursor of the inflammatory response and, as such, inhibitors or antagonists of ABC1 expression or biological activity may be useful in the treatment of any inflammatory disorders, including but not limited to rheumatoid arthritis, systemic lupus erythematosus (SLE), hypo- or hyper- thyroidism, inflammatory bowel disease, and diabetes mellitus. In another example, ABC1 expressed in macrophages has been shown to be engaged in the engulfment and clearance of dead cells. The ability of macrophages to ingest these apoptotic bodies is impaired after antibody-mediated blockade of ABC1. Accordingly, compounds that modulate ABC1 expression, stability, or biological activity would be useful for the treatment of these disorders.

ABC1 expression is measured, for example, by standard Northern blot analysis using an *ABC1* nucleic acid sequence (or fragment thereof) as a hybridization probe, or by Western blot using an anti-ABC1 antibody and standard techniques. The level of ABC1 expression in the presence of the candidate molecule is compared to the level measured for the same cells, in the same culture medium, or in a parallel set of test animals, but in the absence of the candidate molecule. ABC1 activity can also be measured using the cholesterol efflux assay.

Transcriptional Regulation of ABC1 Expression

ABC1 mRNA is increased approximately 8-fold upon cholesterol loading. This increase is likely controlled at the transcriptional level. Using the promoter sequence described herein, one can identify transcription factors that bind to the promoter by performing, for example, gel shift assays, DNase protection assays, or *in vitro* or *in vivo* reporter gene-based assays. The identified transcription factors are themselves drug targets. In the case of ABC1, drug compounds that act through modulation of transcription of ABC1 could be used for HDL modulation, atherosclerosis prevention, and the treatment of cardiovascular disease. For example, using a compound to inhibit a transcription factor that represses ABC1 would be expected to result in up-regulation of ABC1 and, therefore, HDL levels. In another example, a compound that increases transcription factor expression or activity would also increase ABC1 expression and HDL levels.

Transcription factors known to regulate other genes in the regulation of apolipoprotein genes or other cholesterol- or lipid-regulating genes are of particular relevance. Such factors include, but are not limited to, the steroid response element binding proteins (SREBP-1 and SREBP-2), the PPAR (peroxisomal proliferation-activated receptor) transcription factors. Several

consensus sites for certain elements are present in the sequenced region 5' to the ABC1 gene (Fig. 16) and are likely to modulate ABC1 expression. For example, PPARs may alter transcription of ABC1 by mechanisms including heterodimerization with retinoid X receptors (RXRs) and then binding to specific proliferator response elements (PPREs). Examples of such PPARs include PPAR α , β , γ and δ . These distinct PPARs have been shown to have transcriptional regulatory effects on different genes. PPAR α is expressed mainly in liver, whereas PPAR γ is expressed predominantly in adipocytes. Both PPAR α and PPAR γ are found in coronary and carotid artery atherosclerotic plaques and in endothelial cells, smooth muscle cells, monocytes and monocyte-derived macrophages. Activation of PPAR α results in altered lipoprotein metabolism through PPAR α 's effect on genes such as lipoprotein lipase (LPL), apolipoprotein CIII (apo CIII) and apolipoprotein AI (apo AI) and AII (apo AII). PPAR α activation results in overexpression of LPL and apoA-I and apoA-II, but inhibits the expression of apo CIII. PPAR α activation also inhibits inflammation, stimulates lipid oxidation and increases the hepatic uptake and esterification of free fatty acids (FFA's). PPAR α and PPAR γ activation may inhibit nitric oxide (NO) synthase in macrophages and prevent interleukin-1 (IL-1) induced expression of IL-6 and cyclo-oxygenase-2 (COX-2) and thrombin induced endothelin-1 expression secondary to negative transcriptional regulation of NF-KB and activation of protein-1 signaling pathway. It has also been shown that PPAR α induces apoptosis in monocyte-derived macrophages through the inhibition of NF-KB activity.

Activation of PPAR α can be achieved by compounds such as fibrates, β -estradiol, arachidonic acid derivatives, WY-14,643 and LTB₄ or 8(s)HETE. PPAR γ activation can be achieved through compounds such as thiozolidinedione

antidiabetic drugs, 9-HODE and 13-HODE. Additional compounds such as nicotinic acid or HMG CoA reductase inhibitors may also alter the activity of PPARs.

Compounds which alter activity of any of the PPARs (e.g., PPAR α or PPAR γ) may have an effect on ABC1 expression and thereby could affect HDL levels, atherosclerosis and risk of CAD. PPARs are also regulated by fatty acids (including modified fatty acids such as 3 thia fatty acids), leukotrienes such as leukotriene B4 and prostaglandin J2, which is a natural activator/ligand for PPAR γ . Drugs that modulate PPARs may therefore have an important effect on modulating lipid levels (including HDL and triglyceride levels) and altering CAD risk. This effect could be achieved through the modulation of ABC1 gene expression. Drugs may also effect ABC1 gene expression and thereby HDL levels, by an indirect effect on PPARs via other transcriptional factors such as adipocyte differentiation and determination factor-1 (ADD-1) and sterol regulatory element binding protein-1 and 2 (SREBP-1 and 2). Drugs with combined PPAR α and PPAR γ agonist activity or PPAR α and PPAR γ agonists given in combination for example, may increase HDL levels even more.

A PPAR binding site (PPRE element) is found 5' to the ABC1 gene (nucleotides 2150 to 2169 of SEQ ID NO: 14). Like the PPRE elements found in the C-ACS, HD, CYP4A6 and ApoA-I genes, this PPRE site is a trimer related to the PPRE consensus sequence. Partly because of its similarity in the number and arrangement of repeats in this PPAR binding site, this element in particular is very likely to be of physiological relevance to the regulation of the ABC1 gene.

Additional transcription factors which may also have an effect in modulating ABC1 gene expression and thereby HDL levels, atherosclerosis and CAD risk include; REV-ERB α , SREBP-1 & 2, ADD-1, EBP α , CREB binding

protein, P300, HNF 4, RAR, LXR, and ROR α . Additional degenerate binding sites for these factors can be found through examination of the sequence in SEQ ID NO: 14.

Additional utility of ABC1 polypeptides, nucleic acids, and modulators

ABC1 may act as a transporter of toxic proteins or protein fragments (*e.g.*, APP) out of cells. Thus, ABC1 agonists/upregulators may be useful in the treatment of other disease areas, including Alzheimer's disease, Niemann-Pick disease, and Huntington's disease.

ABC transporters have been shown to increase the uptake of long chain fatty acids from the cytosol to peroxisomes and, moreover, to play a role in β -oxidation of very long chain fatty acids. Importantly, in x-linked adrenoleukodystrophy (ALD), fatty acid metabolism is abnormal, due to defects in the peroxisomal ABC transporter. Any agent that upregulates ABC transporter expression or biological activity may therefor be useful for the treatment of ALD or any other lipid disorder.

ABC1 is expressed in macrophages and is required for engulfment of cells undergoing programmed cell death. The apoptotic process itself, and its regulation, have important implications for disorders such as cancer, one mechanism of which is failure of cells to undergo cell death appropriately. ABC1 may facilitate apoptosis, and as such may represent an intervention point for cancer treatment. Increasing ABC1 expression or activity or otherwise up-regulating ABC1 by any method may constitute a treatment for cancer by increasing apoptosis and thus potentially decreasing the aberrant cellular proliferation characterized by this disease. Conversely, down-regulation of ABC1 by any method may provide opportunity for decreasing apoptosis and allowing

increased proliferation of cells in conditions where cell growth is limited. Such disorders include but are not limited to neurodeficiencies and neurodegeneration, and growth disorders. ABC1 could, therefore, potentially be used as a method for identification of compounds for use in the treatment of cancer, or in the treatment of degenerative disorders.

Agents that have been shown to inhibit ABC1 include, for example, the anti-diabetic agents glibenclamide and glyburide, flufenamic acid, diphenylamine-2-carbonic acid, sulfobromophthalein, and DIDS.

Agents that upregulate ABC1 expression or biological activity include but are not limited to protein kinase A, protein kinase C, vanadate, okadaic acid, and IBMX1.

Those in the art will recognize that other compounds can also modulate ABC1 biological activity, and these compounds are also in the spirit of the invention.

Drug screens based on the ABC1 gene or protein

The ABC1 protein and gene can be used in screening assays for identification of compounds which modulate its activity and may be potential drugs to regulate cholesterol levels. Useful ABC1 proteins include wild-type and mutant ABC1 proteins or protein fragments, in a recombinant form or endogenously expressed. Drug screens to identify compounds acting on the ABC1 expression product may employ any functional feature of the protein. In one example, the phosphorylation state or other post-translational modification is monitored as a measure of ABC1 biological activity. ABC1 has ATP binding sites, and thus assays may wholly or in part test the ability of ABC1 to bind ATP or to exhibit ATPase activity. ABC1, by analogy to similar proteins, is thought to

be able to form a channel-like structure; drug screening assays could be based upon assaying for the ability of the protein to form a channel, or upon the ability to transport cholesterol or another molecule, or based upon the ability of other proteins bound by or regulated by ABC1 to form a channel. Alternatively, phospholipid or lipid transport can also be used as measures of ABC1 biological activity.

There is evidence that, in addition to its role as a regulator of cholesterol levels, ABC1 also transports anions. Functional assays could be based upon this property, and could employ drug screening technology such as (but not limited to) the ability of various dyes to change color in response to changes in specific ion concentrations in such assays can be performed in vesicles such as liposomes, or adapted to use whole cells.

Drug screening assays can also be based upon the ability of ABC1 or other ABC transporters to interact with other proteins. Such interacting proteins can be identified by a variety of methods known in the art, including, for example, radioimmunoprecipitation, co-immunoprecipitation, co-purification, and yeast two-hybrid screening. Such interactions can be further assayed by means including but not limited to fluorescence polarization or scintillation proximity methods. Drug screens can also be based upon functions of the ABC1 protein deduced upon X-ray crystallography of the protein and comparison of its 3-D structure to that of proteins with known functions. Such a crystal structure has been determined for the prokaryotic ABC family member HisP, histidine permease. Drug screens can be based upon a function or feature apparent upon creation of a transgenic or knockout mouse, or upon overexpression of the protein or protein fragment in mammalian cells *in vitro*. Moreover, expression of mammalian (e.g., human) ABC1 in yeast or *C. elegans* allows for screening of

candidate compounds in wild-type and mutant backgrounds, as well as screens for mutations that enhance or suppress an ABC1-dependent phenotype. Modifier screens can also be performed in ABC1 transgenic or knock-out mice.

Additionally, drug screening assays can also be based upon ABC1 functions deduced upon antisense interference with the gene function. Intracellular localization of ABC1, or effects which occur upon a change in intracellular localization of the protein, can also be used as an assay for drug screening. Immunocytochemical methods will be used to determine the exact location of the ABC1 protein.

Human and rodent ABC1 protein can be used as an antigen to raise antibodies, including monoclonal antibodies. Such antibodies will be useful for a wide variety of purposes, including but not limited to functional studies and the development of drug screening assays and diagnostics. Monitoring the influence of agents (e.g., drugs, compounds) on the expression or biological activity of ABC1 can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase ABC1 gene expression, protein levels, or biological activity can be monitored in clinical trails of subjects exhibiting altered ABC1 gene expression, protein levels, or biological activity. Alternatively, the effectiveness of an agent determined by a screening assay to modulate ABC1 gene expression, protein levels, or biological activity can be monitored in clinical trails of subjects exhibiting decreased altered gene expression, protein levels, or biological activity. In such clinical trials, the expression or activity of ABC1 and, preferably, other genes that have been implicated in, for example, cardiovascular disease can be used to ascertain the effectiveness of a particular drug.

For example, and not by way of limitation, genes, including ABC1, that are

modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates ABC1 biological activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cholesterol levels or cardiovascular disease, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of ABC1 and other genes implicated in the disorder. The levels of gene expression can be quantified by Northern blot analysis or RT-PCR, or, alternatively, by measuring the amount of protein produced, by one of a number of methods known in the art, or by measuring the levels of biological activity of ABC1 or other genes. In this way, the gene expression can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an ABC1 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the ABC1 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the ABC1 protein, mRNA, or genomic DNA in the pre-administration sample with the ABC1 protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent

to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of ABC1 to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of ABC1 to lower levels than detected.

The *ABC1* gene or a fragment thereof can be used as a tool to express the protein in an appropriate cell *in vitro* or *in vivo* (gene therapy), or can be cloned into expression vectors which can be used to produce large enough amounts of ABC1 protein to use in *in vitro* assays for drug screening. Expression systems which may be employed include baculovirus, herpes virus, adenovirus, adeno-associated virus, bacterial systems, and eucaryotic systems such as CHO cells. Naked DNA and DNA-liposome complexes can also be used.

Assays of ABC1 activity includes binding to intracellular interacting proteins; interaction with a protein that up-regulates ABC1 activity; interaction with HDL particles or constituents; interaction with other proteins which facilitate interaction with HDL or its constituents; and measurement of cholesterol efflux. Furthermore, assays may be based upon the molecular dynamics of macromolecules, metabolites and ions by means of fluorescent-protein biosensors.

Alternatively, the effect of candidate modulators on expression or activity may be measured at the level of ABC1 protein production using the same general approach in combination with standard immunological detection techniques, such as Western blotting or immunoprecipitation with an ABC1-specific antibody. Again, useful cholesterol-regulating or anti-CVD therapeutic modulators are identified as those which produce a change in ABC1 polypeptide production. Agonists may also affect ABC1 activity without any effect on expression level.

Candidate modulators may be purified (or substantially purified) molecules

or may be one component of a mixture of compounds (*e.g.*, an extract or supernatant obtained from cells). In a mixed compound assay, ABC1 expression is tested against progressively smaller subsets of the candidate compound pool (*e.g.*, produced by standard purification techniques, *e.g.*, HPLC or FPLC; Ausubel et al.) until a single compound or minimal compound mixture is demonstrated to modulate ABC1 expression.

Agonists, antagonists, or mimetics found to be effective at modulating the level of cellular ABC1 expression or activity may be confirmed as useful in animal models (for example, mice, pigs, rabbits, or chickens). For example, the compound may ameliorate the low HDL levels of mouse or chicken hypoalphalipoproteinemias.

A compound that promotes an increase in ABC1 expression or activity is considered particularly useful in the invention; such a molecule may be used, for example, as a therapeutic to increase the level or activity of native, cellular ABC1 and thereby treat a low HDL condition in an animal (for example, a human).

One method for increasing ABC biological activity is to increase the stabilization of the ABC protein or to prevent its degradation. Thus, it would be useful to identify mutations in an ABC polypeptide (*e.g.*, ABC1) that lead to increased protein stability. These mutations can be incorporated into any protein therapy or gene therapy undertaken for the treatment of low HDL-C or any other condition resulting from loss of ABC1 biological activity. Similarly, compounds that increase the stability of a wild-type ABC polypeptide or decrease its catabolism may also be useful for the treatment of low HDL-C or any other condition resulting from loss of ABC1 biological activity. Such mutations and compounds can be identified using the methods described herein.

In one example, cells expressing an ABC polypeptide having a mutation are

transiently metabolically labeled during translation and the half-life of the ABC polypeptide is determined using standard techniques. Mutations that increase the half-life of an ABC polypeptide are ones that increase ABC protein stability. These mutations can then be assessed for ABC biological activity. They can also be used to identify proteins that affect the stability of ABC1 mRNA or protein. One can then assay for compounds that act on these factors or on the ability of these factors to bind ABC1.

In another example, cells expressing wild-type ABC polypeptide are transiently metabolically labeled during translation, contacted with a candidate compounds, and the half-life of the ABC polypeptide is determined using standard techniques. Compounds that increase the half-life of an ABC polypeptide are useful compounds in the present invention.

If desired, treatment with an agonist of the invention may be combined with any other HDL-raising or anti-CVD therapies.

It is understood that, while ABC1 is the preferred ABC transporter for the drug screens described herein, other ABC transporters can also be used. The replacement of ABC1 with another ABC transporter is possible because it is likely that ABC transporter family members, such as ABC2, ABCR, or ABC8 will have a similar mechanism of regulation.

Exemplary assays are described in greater detail below.

Protein-based assays

ABC1 polypeptide (purified or unpurified) can be used in an assay to determine its ability to bind another protein (including, but not limited to, proteins found to specifically interact with ABC1). The effect of a compound on that binding is then determined.

Protein Interaction Assays

ABC1 protein (or a polypeptide fragment thereof or an epitope-tagged form or fragment thereof) is harvested from a suitable source (e.g., from a prokaryotic expression system, eukaryotic cells, a cell-free system, or by immunoprecipitation from ABC1-expressing cells). The ABC1 polypeptide is then bound to a suitable support (e.g., nitrocellulose or an antibody or a metal agarose column in the case of, for example, a his-tagged form of ABC1). Binding to the support is preferably done under conditions that allow proteins associated with ABC1 polypeptide to remain associated with it. Such conditions may include use of buffers that minimize interference with protein-protein interactions. The binding step can be done in the presence and absence of compounds being tested for their ability to interfere with interactions between ABC1 and other molecules. If desired, other proteins (e.g., a cell lysate) are added, and allowed time to associate with the ABC polypeptide. The immobilized ABC1 polypeptide is then washed to remove proteins or other cell constituents that may be non-specifically associated with it the polypeptide or the support. The immobilized ABC1 polypeptide is then dissociated from its support, and so that proteins bound to it are released (for example, by heating), or, alternatively, associated proteins are released from ABC1 without releasing the ABC1 polypeptide from the support. The released proteins and other cell constituents can be analyzed, for example, by SDS-PAGE gel electrophoresis, Western blotting and detection with specific antibodies, phosphoamino acid analysis, protease digestion, protein sequencing, or isoelectric focusing. Normal and mutant forms of ABC1 can be employed in these assays to gain additional information about which part of ABC1 a given factor is binding to. In addition, when incompletely purified polypeptide is employed, comparison of the normal and mutant forms of the protein can be used to help distinguish true

binding proteins.

The foregoing assay can be performed using a purified or semipurified protein or other molecule that is known to interact with ABC1. This assay may include the following steps.

1. Harvest ABC1 protein and couple a suitable fluorescent label to it;
2. Label an interacting protein (or other molecule) with a second, different fluorescent label. Use dyes that will produce different quenching patterns when they are in close proximity to each other vs. when they are physically separate (i.e., dyes that quench each other when they are close together but fluoresce when they are not in close proximity);
3. Expose the interacting molecule to the immobilized ABC1 in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
4. Collect fluorescent readout data.

Another assay is includes Fluorescent Resonance Energy Transfer (FRET) assay. This assay can be performed as follows.

1. Provide ABC1 protein or a suitable polypeptide fragment thereof and couple a suitable FRET donor (e.g.,. nitro-benzoxadiazole (NBD)) to it;
2. Label an interacting protein (or other molecule) with a FRET acceptor (e.g., rhodamine);
3. Expose the acceptor-labeled interacting molecule to the donor-labeled ABC1 in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
4. Measure fluorescence resonance energy transfer.

Quenching and FRET assays are related. Either one can be applied in a given case, depending on which pair of fluorophores is used in the assay.

Membrane permeability assay

5 The ABC1 protein can also be tested for its effects on membrane permeability. For example, beyond its putative ability to translocate lipids, ABC1 might affect the permeability of membranes to ions. Other related membrane proteins, most notably the cystic fibrosis transmembrane conductance regulator and the sulfonylurea receptor, are associated with and regulate ion channels.

10 ABC1 or a fragment of ABC1 is incorporated into a synthetic vesicle, or, alternatively, is expressed in a cell and vesicles or other cell sub-structures containing ABC1 are isolated. The ABC1-containing vesicles or cells are loaded with a reporter molecule (such as a fluorescent ion indicator whose fluorescent properties change when it binds a particular ion) that can detect ions (to observe outward movement), or alternatively, the external medium is loaded with such a molecule (to observe inward movement). A molecule which exhibits differential properties when it is inside the vesicle compared to when it is outside the vesicle is preferred. For example, a molecule that has quenching properties when it is at high concentration but not when it is at another low concentration would be
15 suitable. The movement of the charged molecule (either its ability to move or the kinetics of its movement) in the presence or absence of a compound being tested for its ability to affect this process can be determined.

20 In another assay, membrane permeability is determined electrophysiologically by measuring ionic influx or efflux mediated by or modulated by ABC1 by standard electrophysiological techniques. A suitable control (e.g., TD
25 cells or a cell line with very low endogenous ABC1 expression) can be used as a

control in the assay to determine if the effect observed is specific to cells expressing ABC1.

In still another assay, uptake of radioactive isotopes into or out of a vesicle can be measured. The vesicles are separated from the extravesicular medium and the radioactivity in the vesicles and in the medium is quantitated and compared.

Nucleic acid-based assays

ABC1 nucleic acid may be used in an assay based on the binding of factors necessary for ABC1 gene transcription. The association between the *ABC1* DNA and the binding factor may be assessed by means of any system that discriminates between protein-bound and non-protein-bound DNA (e.g., a gel retardation assay). The effect of a compound on the binding of a factor to *ABC1* DNA is assessed by means of such an assay. In addition to *in vitro* binding assays, *in vivo* assays in which the regulatory regions of the *ABC1* gene are linked to reporter genes can also be performed.

Assays measuring ABC1 stability

A cell-based or cell-free system can be used to screen for compounds based on their effect on the half-life of *ABC1* mRNA or ABC1 protein. The assay may employ labeled mRNA or protein. Alternatively, *ABC1* mRNA may be detected by means of specifically hybridizing probes or a quantitative PCR assay. Protein can be quantitated, for example, by fluorescent antibody-based methods.

In vitro mRNA stability assay

1. Isolate or produce, by *in vitro* transcription, a suitable quantity of ABC1 mRNA;

2. Label the ABC1 mRNA;
3. Expose aliquots of the mRNA to a cell lysate in the presence or absence of a compound being tested for its ability to modulate *ABC1* mRNA stability;
4. Assess intactness of the remaining mRNA at suitable time points.

5

In vitro protein stability assay

1. Express a suitable amount of ABC1 protein;
2. Label the protein;
3. Expose aliquots of the labeled protein to a cell lysate in the presence or absence of a compound being tested for its ability to modulate ABC1 protein stability;
4. Assess intactness of the remaining protein at suitable time points

10

In vivo mRNA or protein stability assay

1. Incubate cells expressing ABC1 mRNA or protein with a tracer (radiolabeled ribonucleotide or radiolabeled amino acid, respectively) for a very brief time period (e.g., five minutes) in the presence or absence of a compound being tested for its effect on mRNA or protein stability;
2. Incubate with unlabeled ribonucleotide or amino acid; and
3. Quantitate the ABC1 mRNA or protein radioactivity at time intervals beginning with the start of step 2 and extending to the time when the radioactivity in ABC1 mRNA or protein has declined by approximately 80%. It is preferable to separate the intact or mostly intact mRNA or protein from its radioactive breakdown products by a means such as gel electrophoresis in order to quantitate the mRNA or protein.

15

20

25

Assays measuring inhibition of dominant negative activity

Mutant ABC1 polypeptides are likely to have dominant negative activity (i.e., activity that interferes with wild-type ABC1 function). An assay for a compound that can interfere with such a mutant may be based on any method of quantitating normal ABC1 activity in the presence of the mutant. For example, normal ABC1 facilitates cholesterol efflux, and a dominant negative mutant would interfere with this effect. The ability of a compound to counteract the effect of a dominant negative mutant may be based on cellular cholesterol efflux, or on any other normal activity of the wild-type ABC1 that was inhibitable by the mutant.

Assays measuring phosphorylation

The effect of a compound on ABC1 phosphorylation can be assayed by methods that quantitate phosphates on proteins or that assess the phosphorylation state of a specific residue of a ABC1. Such methods include but are not limited to ^{32}P labelling and immunoprecipitation, detection with antiphosphoamino acid antibodies (e.g., antiphosphoserine antibodies), phosphoamino acid analysis on 2-dimensional TLC plates, and protease digestion fingerprinting of proteins followed by detection of ^{32}P -labeled fragments.

Assays measuring other post-translational modifications

The effect of a compound on the post-translational modification of ABC1 is based on any method capable of quantitating that particular modification. For example, effects of compounds on glycosylation may be assayed by treating ABC1 with glycosylase and quantitating the amount and nature of carbohydrate released.

Assays measuring ATP binding

The ability of ABC1 to bind ATP provides another assay to screen for compounds that affect ABC1. ATP binding can be quantitated as follows.

1. Provide ABC1 protein at an appropriate level of purity and reconstitute it in a lipid vesicle;
2. Expose the vesicle to a labeled but non-hydrolyzable ATP analog (such as gamma ³⁵S-ATP) in the presence or absence of compounds being tested for their effect on ATP binding. Note that azido-ATP analogs can be used to allow covalent attachment of the azido-ATP to protein (by means of U.V. light), and permit easier quantitation of the amount of ATP bound to the protein.
3. Quantitate the amount of ATP analog associated with ABC1

Assays measuring ATPase activity

Quantitation of the ATPase activity of ABC1 can also be assayed for the effect of compounds on ABC1. This is preferably performed in a cell-free assay so as to separate ABC1 from the many other ATPases in the cell. An ATPase assay may be performed in the presence or absence of membranes, and with or without integration of ABC1 protein into a membrane. If performed in a vesicle-based assay, the ATP hydrolysis products produced or the ATP hydrolyzed may be measured within or outside of the vesicles, or both. Such an assay may be based on disappearance of ATP or appearance of ATP hydrolysis products.

For high-throughput screening, a coupled ATPase assay is preferable. For example, a reaction mixture containing pyruvate kinase and lactate dehydrogenase can be used. The mixture includes phosphoenolpyruvate (PEP), nicotinamide adenine dinucleotide (NAD⁺), and ATP. The ATPase activity of ABC1 generates ADP from ATP. The ADP is then converted back to ATP as part of the pyruvate

kinase reaction. The product, pyruvate, is then converted to lactate. The latter reaction generates a colored quinone (NADH) from a colorless substrate (NAD⁺), and the entire reaction can be monitored by detection of the color change upon formation of NADH. Since ADP is limiting for the pyruvate kinase reaction, this coupled system precisely monitors the ATPase activity of ABC1.

Assays measuring cholesterol efflux

A transport-based assay can be performed *in vivo* or *in vitro*. For example, the assay may be based on any part of the reverse cholesterol transport process that is readily re-created in culture, such as cholesterol or phospholipid efflux. Alternatively, the assay may be based on net cholesterol transport in a whole organism, as assessed by means of a labeled substance (such as cholesterol).

For high throughput, fluorescent lipids can be used to measure ABC1-catalyzed lipid efflux. For phospholipids, a fluorescent precursor, C6-NBD-phosphatidic acid, can be used. This lipid is taken up by cells and dephosphorylated by phosphatidic acid phosphohydrolase. The product, NBD-diglyceride, is then a precursor for synthesis of glycerophospholipids like phosphatidylcholine. The efflux of NBD-phosphatidylcholine can be monitored by detecting fluorescence resonance energy transfer (FRET) of the NBD to a suitable acceptor in the cell culture medium. This acceptor can be rhodamine-labeled phosphatidylethanolamine, a phospholipid that is not readily taken up by cells. The use of short-chain precursors obviates the requirement for the phospholipid transfer protein in the media. For cholesterol, NBD-cholesterol ester can be reconstituted into LDL. The LDL can efficiently deliver this lipid to cells via the LDL receptor pathway. The NBD-cholesterol esters are hydrolyzed in the lysosomes, resulting in NBD-cholesterol that can now be transported back to

the plasma membrane and efflux from the cell. The efflux can be monitored by the aforementioned FRET assay in which NBD transfers its fluorescence resonance energy to the rhodamine-phosphatidylethanolamine acceptor.

Animal Model Systems

Compounds identified as having activity in any of the above-described assays are subsequently screened in any available animal model system, including, but not limited to, pigs, rabbits, and WHAM chickens. Test compounds are administered to these animals according to standard methods. Test compounds may also be tested in mice bearing mutations in the *ABC1* gene. Additionally, compounds may be screened for their ability to enhance an interaction between ABC1 and any HDL particle constituent such as ApoAI, ApoAII, or ApoE.

The cholesterol efflux assay as a drug screen

The cholesterol efflux assay measures the ability of cells to transfer cholesterol to an extracellular acceptor molecule and is dependent on ABC1 function. In this procedure, cells are loaded with radiolabeled cholesterol by any of several biochemical pathways (Marcil et al., *Arterioscler. Thromb. Vasc. Biol.* 19:159-169, 1999). Cholesterol efflux is then measured after incubation for various times (typically 0 to 24 hours) in the presence of HDL3 or purified ApoAI. Cholesterol efflux is determined as the percentage of total cholesterol in the culture medium after various times of incubation. ABC1 expression levels and/or biological activity are associated with increased efflux while decreased levels of ABC1 are associated with decreased cholesterol efflux.

This assay can be readily adapted to the format used for drug screening, which may consist of a multi-well (e.g., 96-well) format. Modification of the

assay to optimize it for drug screening would include scaling down and streamlining the procedure, modifying the labeling method, using a different cholesterol acceptor, altering the incubation time, and changing the method of calculating cholesterol efflux. In all these cases, the cholesterol efflux assay remains conceptually the same, though experimental modifications may be made. A transgenic mouse overexpressing ABC1 would be expected to have higher than normal HDL levels.

Knock-out mouse model

An animal, such as a mouse, that has had one or both ABC1 alleles inactivated (*e.g.*, by homologous recombination) is likely to have low HDL-C levels, and thus is a preferred animal model for screening for compounds that raise HDL-C levels. Such an animal can be produced using standard techniques. In addition to the initial screening of test compounds, the animals having mutant ABC1 genes are useful for further testing of efficacy and safety of drugs or agents first identified using one of the other screening methods described herein. Cells taken from the animal and placed in culture can also be exposed to test compounds. HDL-C levels can be measured using standard techniques, such as those described herein.

WHAM chickens: an animal model for low HDL cholesterol

Wisconsin Hypo-Alpha Mutant (WHAM) chickens arose by spontaneous mutation in a closed flock. Mutant chickens came to attention through their a Z-linked white shank and white beak phenotype referred to as 'recessive white skin' (McGibbon, 1981) and were subsequently found to have a profound deficiency of HDL (Poernama *et al.*, 1990).

This chicken low HDL locus (Y) is Z-linked, or sex-linked. (In birds, females are ZW and males are ZZ). Genetic mapping placed the Y locus on the long arm of the Z chromosome (Bitgood, 1985), proximal to the ID locus (Bitgood, 1988). Examination of current public mapping data for the chicken genome mapping project, ChickMap (maintained by the Roslin Institute; <http://www.ri.bbsrc.ac.uk/chickmap/ChickMapHomePage.html>) showed that a region of synteny with human chromosome 9 lies on the long arm of the chicken Z chromosome (Zq) proximal to the ID locus. Evidence for this region of synteny is the location of the chicken aldolase B locus (ALDOB) within this region. The human ALDOB locus maps to chromosome 9q22.3 (The Genome Database, <http://gdbwww.gdb.org/>), not far from the location of human ABC1. This comparison of maps showed that the chicken Zq region near chicken ALDOB and the human 9q region near human ALDOB represent a region of synteny between human and chicken.

Since a low HDL locus maps to the 9q location in humans and to the Zq region in chickens, these low HDL loci are most probably located within the syntenic region. Thus we predicted that ABC1 is mutated in WHAM chickens. In support of this, we have identified an E⇒K mutation at a position that corresponds to amino acid 89 of human ABC1 (Figs. 14 and 15). This non-conservative substitution is at a position that is conserved among human, mouse, and chicken, indicating that it is in a region of the protein likely to be of functional importance.

Discovery of the WHAM mutation in the amino-terminal portion of the ABC1 protein also establishes the importance of the amino-terminal region. This region may be critical because of association with other proteins required to carry out cholesterol efflux or related tasks. It may be an important regulatory region (there is a phosphorylation site for casein kinase near the mutated residue), or it

may help to dictate a precise topological relationship with cellular membranes (the N-terminal 60 amino acid region contains a putative membrane-spanning or membrane-associated segment).

The amino-terminal region of the protein (up to the first 6-TM region at approximately amino acid 639) is an ideal tool for screening factors that affect ABC1 activity. It can be expressed as a truncated protein in ABC1 wild type cells in order to test for interference of the normal ABC1 function by the truncated protein. If the fragment acts in a dominant negative way, it could be used in immunoprecipitations to identify proteins that it may be competing away from the normal endogenous protein.

The C-terminus also lends itself to such experiments, as do the intracellular portions of the molecule, expressed as fragments or tagged or fusion proteins, in the absence of transmembrane regions.

Since it is possible that there are several genes in the human genome which affect cholesterol efflux, it is important to establish that any animal model to be used for a human genetic disease represents the homologous locus in that animal, and not a different locus with a similar function. The evidence above establishes that the chicken Y locus and the human chromosome 9 low HDL locus are homologous. WHAM chickens are therefore an important animal model for the identification of drugs that modulate cholesterol efflux.

The WHAM chickens' HDL deficiency syndrome is not, however, associated with an increased susceptibility to atherosclerosis in chickens. This probably reflects the shorter lifespan of the chicken rather than an inherent difference in the function of the chicken ABC1 gene compared to the human gene. We propose the WHAM chicken as a model for human low HDL for the development and testing of drugs to raise HDL in humans. Such a model could be

employed in several forms, through the use of cells or other derivatives of these chickens, or by the use of the chickens themselves in tests of drug effectiveness, toxicity, and other drug development purposes.

5 Therapy

Compounds of the invention, including but not limited to, ABC1 polypeptides, *ABC1* nucleic acids, other ABC transporters, and any therapeutic agent that modulates biological activity or expression of ABC1 identified using any of the methods disclosed herein, may be administered with a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer such compositions to patients. Although intravenous administration is preferred, any appropriate route of administration may be employed, for example, parenteral, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspension; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

Methods well known in the art for making formulations are found in, for example, Remington: The Science and Practice of Pharmacy, (19th ed.) ed. A.R. Gennaro AR., 1995, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer,

lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for agonists of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

Compounds

In general, novel drugs for the treatment of aberrant cholesterol levels and/or CVD are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (*e.g.*, semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant,

and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if
5 desired, according to methods known in the art, *e.g.*, by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (*e.g.*, taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof)
10 or the elimination of replicates or repeats of materials already known for their HDL-raising and anti-CVD activities should be employed whenever possible.

When a crude extract is found to have cholesterol-modulating or anti-CVD activities or both, further fractionation of the positive lead extract is necessary to
15 isolate chemical constituent responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having cholesterol-modulating or anti-CVD activities. The same *in vivo* and *in vitro* assays described herein for the detection of activities in mixtures of compounds can be used to
20 purify the active component and to test derivatives thereof. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful agents for the treatment of pathogenicity are chemically modified according to methods known in the art. Compounds identified as being of therapeutic value are subsequently analyzed using any
25 standard animal model of diabetes or obesity known in the art.

It is understood that compounds that modulate activity of proteins that

modulate or are modulated by ABC1 are useful compounds for modulating cholesterol levels. Exemplary compounds are provided herein; others are known in the art.

Compounds that are structurally related to cholesterol, or that mimic ApoAI or a related apolipoprotein, and increase ABC1 biological activity are particularly useful compounds in the invention. Other compounds, known to act on the MDR protein, can also be used or derivatized and assayed for their ability to increase ABC1 biological activity. Exemplary MDR modulators are PSC833, bromocriptine, and cyclosporin A.

Screening patients having low HDL-C

ABC1 expression, biological activity, and mutational analysis can each serve as a diagnostic tool for low HDL; thus determination of the genetic subtyping of the *ABC1* gene sequence can be used to subtype low HDL individuals or families to determine whether the low HDL phenotype is related to ABC1 function. This diagnostic process can lead to the tailoring of drug treatments according to patient genotype, including prediction of side effects upon administration of HDL increasing drugs (referred to herein as pharmacogenomics). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual is examined to determine the ability of the individual to respond to a particular agent).

Agents, or modulators which have a stimulatory or inhibitory effect on ABC1 biological activity or gene expression can be administered to individuals to treat disorders (e.g., cardiovascular disease or low HDL cholesterol) associated with aberrant ABC1 activity. In conjunction with such treatment, the

pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in efficacy of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of ABC1 protein, expression of ABC1 nucleic acid, or mutation content of ABC1 genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons (Eichelbaum, M., Clin. Exp. Pharmacol. Physiol., 23:983-985, 1996; Linder, M. W., Clin. Chem., 43:254-266, 1997). In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). Altered drug action may occur in a patient having a polymorphism (e.g., an single nucleotide polymorphism or SNP) in promoter, intronic, or exonic sequences of ABC1. Thus by determining the presence and prevalence of polymorphisms allow for prediction of a patient's response to a particular therapeutic agent. In particular, polymorphisms in the promoter region may be critical in determining the risk of HDL deficiency and CVD.

In addition to the mutations in the *ABC1* gene described herein, we have detected polymorphisms in the human *ABC1* gene (Fig. 11). These polymorphisms are located in promoter, intronic, and exonic sequence of *ABC1*. Using standard methods, such as direct sequencing, PCR, SSCP, or any other polymorphism-detection system, one could easily ascertain whether these polymorphisms are present in a patient prior to the establishment of a drug treatment regimen for a patient having low HDL, cardiovascular disease, or any other *ABC1*-mediated condition. It is possible that some these polymorphisms are, in fact, weak mutations. Individuals harboring such mutations may have an increased risk for cardiovascular disease; thus, these polymorphisms may also be useful in diagnostic assays.

Association Studies of *ABC1* Gene Variants and HDL Levels or Cardiovascular Disease

The following polymorphisms have been examined for their effect on cholesterol regulation and the predisposition for the development of cardiovascular disease.

Substitution of G for A at nucleotide -1045 [G(-1045)A]. This variant is in complete linkage disequilibrium with the variant at -738 in the individuals we have sequenced, and thus any potential phenotypic effects currently attributed to the variant at -738 may at least in part be due to changes at this site.

Substitution of G for A at nucleotide -738 [G(-738)A]. This variant has been found at very high frequencies in populations selected for low HDL cholesterol or premature coronary artery disease.

Insertion of a G nucleotide at position -4 [G ins (-4)]. This variant has been associated with less coronary artery disease in its carriers than in non-carriers.

Substitution of a C for G at nucleotide -57 [G(-57)C]. This variant is in complete linkage disequilibrium with the variant at -4 in the individuals we have sequenced, and thus the phenotypic effects currently attributed to the variant at -4 may at least in part be due to changes at this site.

5 *Substitution of A for G at nucleotide 730 (R219K).* We have found carriers to have significantly less cardiovascular disease.

Substitution of C for T at nucleotide 1270 (V399A). Within the French Canadian population, this variant has only been found in individuals from the low HDL population. It has also been seen in individuals with low HDL or premature coronary artery disease in individuals of Dutch ancestry.

10 *Substitution of A for G at nucleotide 2385 (V771M).* This variant has been found at an increased frequency in a Dutch population selected for low HDL and at an increased frequency in a population selected for premature coronary artery disease compared to a control Dutch population, indicating carriers of this variant may have reduced HDL and an increased susceptibility to coronary artery disease.

15 *Substitution of C for A at nucleotide 2394 (T774P).* This variant has been seen at lower frequencies in populations with coronary artery disease or low HDL than in individuals without.

20 *Substitution of C for G at nucleotide 2402 (K776N).* This variant has been found at a significantly lower frequency (0.56% vs. 2.91%, $p=0.02$) in a coronary artery disease population vs. a control population of similar Dutch background.

Substitution of C for G at nucleotide 3590 (E1172D). This variant is seen at lower frequencies in individuals with low HDL and in some populations with premature coronary artery disease.

25 *Substitution of A for G at nucleotide 4384 (R1587K).* This variant has been found at decreased frequencies in the 1/3 of individuals with the highest HDL

levels in our large Dutch coronary artery disease population ($p=0.036$), at increased frequencies in those with HDL cholesterol <0.9 mmol/L ($p<0.0001$) and at decreased frequencies in the cohorts with HDL cholesterol >1.4 mmol/L in both this population ($p=0.02$) and the Dutch control population ($p=0.003$).

5 *Substitution of G for C at nucleotide 5266 (S1731C).* Two FHA individuals who have this variant on the other allele have much lower HDL cholesterol (0.155 ± 0.025) than the FHA individuals in the family who do not have this variant on the other allele (0.64 ± 0.14 , $p=0.0009$). This variant has also been found in one general population French Canadian control with HDL at the 8th percentile (0.92) and one French Canadian individual from a population selected for low HDL and coronary disease (0.72).

10 *Substitution of G for A at nucleotide -1113 [A(-1113)G].* This variant has been seen at varying frequencies in populations distinguished by their HDL levels.

Additional polymorphisms that may be associated with altered risk for cardiovascular disease or altered cholesterol levels are as follows:

15 *Substitution of G for A at nucleotide 2723 (I883M).* This variant has been seen at a much higher frequency in individuals of Dutch ancestry with premature coronary artery disease.

Insertion of 4 nucleotides (CCCT) at position -1181.

20 *Substitution of C for A at nucleotide -479 (linkage disequilibrium with -518).*

Substitution of G for A at nucleotide -380.

Other Embodiments

25 All publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication was specifically

and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations following, in general, the principles of the invention and including such departures from the present disclosure within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.

What we claim is:

1. A substantially pure ABC1 polypeptide having ABC1 biological activity.

2. The substantially pure ABC1 polypeptide of claim 1, wherein said ABC1 polypeptide is human ABC1.

3. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 1 to 60 of SEQ ID NO: 1.

4. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 61 to 2261 of SEQ ID NO: 1.

5. The substantially pure ABC1 polypeptide of claim 1, wherein said polypeptide comprises amino acids 1 to 2261 of SEQ ID NO: 1.

6. A substantially pure ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1.

7. A substantially pure ABC1 polypeptide comprising amino acids 61 to 2261 of SEQ ID NO: 1.

8. A substantially pure ABC1 polypeptide comprising amino acids 1 to 2261 of SEQ ID NO: 1.

9. A substantially pure nucleic acid molecule that hybridizes at high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a

polypeptide having ABC1 biological activity.

10. A substantially pure nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

5

11. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 75 to 254 of SEQ ID NO: 2.

12. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 255 to 6857 of SEQ ID NO: 2.

10

13. The substantially pure nucleic acid molecule of claim 9 or 10, wherein said nucleic acid molecule comprises nucleotides 75 to 6857 of SEQ ID NO: 2.

15

14. An expression vector comprising the nucleic acid molecule of claim 9.

15. A cell expressing the nucleic acid molecule of claim 9.

16. A non-human mammal expressing the nucleic acid molecule of claim 9.

20

17. A substantially pure nucleic acid molecule comprising nucleotides 75 to 254 of SEQ ID NO: 2.

18. A substantially pure nucleic acid molecule comprising nucleotides 255 to 6857 of SEQ ID NO: 2.

25

19. A substantially pure nucleic acid molecule comprising nucleotides 75 to 6857 of SEQ ID NO: 2.

20. A substantially pure nucleic acid molecule comprising at least thirty consecutive nucleotides corresponding to nucleotides 7015-7860 of SEQ ID NO: 2.

21. The substantially pure nucleic acid molecule of claim 20, wherein said nucleic acid molecule comprises nucleotides 7015-7860 of SEQ ID NO: 2.

22. A substantially pure nucleic acid molecule that hybridizes at high stringency to a probe comprising nucleotides 7015-7860 of SEQ ID NO: 2.

23. A method of treating a human having low HDL cholesterol or cardiovascular disease, said method comprising administering to said human an ABC1 polypeptide, or cholesterol-regulating fragment thereof.

24. The method of claim 23, wherein said ABC1 polypeptide has the sequence of SEQ ID NO: 1.

25. The method of claim 23, wherein said ABC1 polypeptide comprises a mutation that increases its stability.

26. The method of claim 23, wherein said ABC1 polypeptide comprises a mutation that increases its biological activity.

27. A method of treating a human having low HDL cholesterol or cardiovascular disease, said method comprising administering to said human a nucleic acid molecule encoding an ABC1 polypeptide or a cholesterol-regulating fragment thereof.

5

28. The method of claim 27, wherein said ABC1 polypeptide has the amino acid sequence of SEQ ID NO: 1.

29. The method of claim 27, wherein said ABC1 polypeptide comprises a mutation that increases its stability.

10

30. The method of claim 27, wherein said ABC1 polypeptide comprises a mutation that increases its biological activity.

31. The method of claim 30, wherein said biological activity is regulation of cholesterol.

15

32. The method of claim 27, wherein said human has low HDL cholesterol levels relative to normal.

20

33. A method of increasing ABC1 biological activity in a human, said method comprising administering to said human a nucleic acid molecule that hybridizes at high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a polypeptide having ABC1 biological activity.

25

34. The method of claim 33, wherein said human has a disease selected from the group consisting of Alzheimer's disease, Niemann-Pick disease, Huntington's disease, x-linked adrenoleukodystrophy, and cancer.

5 35. A method of increasing ABC1 biological activity in a human, said method comprising administering to said human a compound that increases ABC1 biological activity.

10 36. The method of claim 35, wherein said human has a disease selected from the group consisting of Alzheimer's disease, Niemann-Pick disease, Huntington's disease, x-linked adrenoleukodystrophy, and cancer.

15 37. A method of preventing cardiovascular disease in a human, said method comprising administering to said human an expression vector comprising an *ABC1* nucleic acid molecule operably linked to a promoter, said *ABC1* nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

20 38. A method of preventing or ameliorating the effects of a disease-causing mutation in an *ABC1* gene in a human, said method comprising introducing into said human an expression vector comprising a promoter operably linked to an *ABC1* nucleic acid molecule encoding an ABC1 polypeptide having ABC1 biological activity.

25 39. A method of treating or preventing cardiovascular disease in an animal, said method comprising administering to said animal a compound that

mimics the activity of wild-type ABC1.

40. The method of claim 39, wherein said animal is a human.

5 41. A method of treating or preventing cardiovascular disease in an animal, said method comprising administering to said animal a compound that modulates the biological activity of ABC1.

42. The method of claim 41, wherein said animal is a human.

10 43. The method of claim 41, wherein said compound is selected from a group consisting of protein kinase A, protein kinase C, vanadate, okadaic acid, IBMX1, fibrates, β -estradiol, arachidonic acid derivatives, WY-14,643, LTB₄, 8(s)HETE, thiozolidinedione antidiabetic drugs, 9-HODE, 13-HODE, nicotinic acid, HMG CoA reductase inhibitors, and compounds that increase PPAR-mediated ABC1 expression.

15 44. The method of claim 23, 27, 39, or 41, wherein said cardiovascular disease is coronary artery disease, cerebrovascular disease, coronary restenosis, or peripheral vascular disease.

20 45. A method for determining whether a candidate compound is useful for modulating cholesterol levels, said method comprising the steps of:

- 25 (a) providing a chicken comprising a mutation in an *ABC1* gene;
- (b) administering said candidate compound to said chicken; and

(c) measuring ABC1 biological activity in said chicken,
wherein altered ABC1 biological activity, relative to a WHAM chicken not
contacted with said compound, indicates that said candidate compound modulates
cholesterol levels.

5

46. The method of claim 45, wherein said ABC1 biological activity is
transport of cholesterol.

47. A method for determining whether a candidate compound modulates
ABC1 biological activity, said method comprising the steps of:

(a) providing a cell expressing an ABC1 polypeptide comprising amino
acids 1 to 60 of SEQ ID NO: 1;

(b) contacting said cell with said candidate compound; and

(c) measuring ABC1 biological activity of said cell,
wherein altered ABC1 biological activity, relative to a cell not contacted with said
compound, indicates that said candidate compound modulates ABC1 biological
activity.

48. A method for determining whether a candidate compound modulates
ABC1 expression, said method comprising the steps of:

(a) providing a cell expressing an *ABC1* gene comprising nucleotides 75 to
254 of SEQ ID NO: 2;

(b) contacting said cell with said candidate compound; and

(c) measuring ABC1 expression of said cell,
wherein altered ABC1 expression, relative to a cell not contacted with said

compound, indicates that said candidate compound modulates ABC1 expression.

49. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:

5 (a) providing a nucleic acid molecule comprising an ABC1 promoter operably linked to a reporter gene;

(b) contacting said nucleic acid molecule with said candidate compound; and

(c) measuring expression of said reporter gene,
10 wherein altered reporter gene expression, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 expression.

50. The method of claim 49, wherein said promoter comprises 50
15 consecutive nucleotides selected from nucleotides 1 to 8238 of SEQ ID NO: 14.

51. The method of claim 50, wherein said promoter comprises a binding
site for a transcription factor selected from a group consisting of steroid response
element binding proteins, peroxisomal proliferation-activated receptors, retinoid X
20 receptors, and RAR-related orphan receptors.

52. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:

(a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ
25 ID NO: 1;

(b) contacting said polypeptide with said candidate compound; and

(c) measuring ABC1 biological activity,

wherein a change in ABC1 biological activity, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 biological activity.

53. A method for determining whether a candidate compound modulates ABC1 expression, said method comprising the steps of:

(a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

(b) contacting said polypeptide with said candidate compound; and

(c) measuring expression of said ABC1 polypeptide,

wherein a change in expression of said ABC1 polypeptide, relative to a control not contacted with said compound, indicates that said candidate compound modulates ABC1 expression.

54. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:

(a) providing an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

(b) contacting said polypeptide with said candidate compound; and

(c) measuring binding of said ABC1 polypeptide to said candidate compound, wherein binding of said ABC1 polypeptide to said compound indicates that said candidate compound modulates ABC1 biological activity.

55. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:

(a) providing (i) an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1, and (ii) a second polypeptide that interacts with said ABC1 polypeptide;

(b) contacting said polypeptides with said candidate compound; and

(c) measuring interaction of said ABC1 polypeptide with said second polypeptide, wherein an alteration in the interaction of said ABC1 polypeptide with said second polypeptide indicates that said candidate compound modulates ABC1 biological activity.

56. A method for determining whether a candidate compound increases the stability or decreases the regulated catabolism of an ABC1 polypeptide, said method comprising the steps of:

(a) providing a cell comprising an ABC1 polypeptide comprising amino acids 1 to 60 of SEQ ID NO: 1;

(b) contacting said cell with said candidate compound; and

(c) measuring the half-life of said ABC1 polypeptide, wherein an increase in said half-life, relative to a control not contacted with said compound, indicates that said candidate compound increases the stability or decreases the regulated catabolism of an ABC1 polypeptide.

57. A method for determining whether a candidate compound modulates ABC1 biological activity, said method comprising the steps of:

(a) providing an ABC1 polypeptide in a lipid membrane;

(b) contacting said polypeptide with said candidate compound; and
(c) measuring ABC1-mediated lipid transport across said lipid membrane,
wherein a change in lipid transport, relative to a control not contacted with said
compound, indicates that said candidate compound modulates ABC1 biological
activity.

58. The method of claim 49, 52, 53, 54, 55, or 57, wherein said ABC1
polypeptide is in a cell-free system.

59. The method of claim 49, 52, 53, 54, 55, or 57, wherein said ABC1
polypeptide is in a cell.

60. The method of claim 59, wherein said cell is from a WHAM chicken.

61. The method of claim 59, wherein said cell is in a human or in a non-
human mammal.

62. The method of claim 61, wherein said animal is a WHAM chicken.

63. The method of claim 52, wherein said biological activity is transport of
lipid or interleukin-1.

64. The method of claim 62, wherein said lipid is cholesterol.

65. The method of claim 64, wherein said cholesterol is HDL-cholesterol.

66. The method of claim 52, wherein said biological activity is binding or hydrolysis of ATP by the ABC1 polypeptide.

67. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising determining whether an *ABC1* gene of said patient has a mutation, wherein a mutation indicates that said patient has an increased risk for cardiovascular disease.

68. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising measuring ABC1 biological activity in said patient or in a cell from said patient, wherein increased or decreased levels in said ABC1 biological activity, relative to normal levels, indicates that said patient has an increased risk for cardiovascular disease.

69. A method for determining whether a patient has an increased risk for cardiovascular disease, said method comprising measuring ABC1 expression in said patient or in a cell from said patient, wherein decreased levels in said ABC1 expression relative to normal levels, indicates that said patient has an increased risk for cardiovascular disease.

70. The method of claim 69, wherein said ABC1 expression is determined by measuring levels of ABC1 polypeptide.

71. The method of claim 69, wherein said ABC1 expression is determined by measuring levels of *ABC1* RNA.

72. A non-human mammal comprising a transgene comprising a nucleic acid molecule encoding a dominant-negative ABC1 polypeptide.

73. A cell isolated from a non-human mammal comprising a transgene comprising a nucleic acid molecule encoding an ABC1 polypeptide having biological activity.

74. A method for determining whether a candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide, said method comprising the steps of:

- (a) providing a cell expressing a dominant-negative ABC1 polypeptide;
- (b) contacting said cell with said candidate compound; and
- (c) measuring ABC1 biological activity of said cell,

wherein an increase in said ABC1 biological activity, relative to a cell not contacted with said compound, indicates that said candidate compound decreases the inhibition of a dominant-negative ABC1 polypeptide.

75. A method for determining whether a person has an altered risk for developing cardiovascular disease, comprising examining the person's ABC1 gene for polymorphisms, wherein the presence of a polymorphism associated with cardiovascular disease indicates the person has an altered risk for developing cardiovascular disease.

76. A method for predicting a person's response to a drug, comprising determining whether the person has a polymorphism in an ABC1 gene that alters

the person's response to said drug.

77. A method for predicting a person's response to a drug, comprising determining whether the person has a polymorphism in an ABC1 promoter that alters the person's response to said drug.

78. A method for altering ABC1 expression in a cell, said method comprising contacting said cell with a compound selected from a group consisting of fibrates, β -estradiol, arachidonic acid derivatives, WY-14,643, LTB₄, 8(s)HETE, thiozolidinedione antidiabetic drugs, 9-HODE, 13-HODE, nicotinic acid, HMG CoA reductase inhibitors, and compounds that increase PPAR-mediated ABC1 expression.

79. A pharmaceutical composition comprising (i) a nucleic acid molecule that hybridizes under high stringency conditions to nucleotides 75 to 254 of SEQ ID NO: 2 and encodes a polypeptide having ABC1 biological activity; and (ii) a pharmaceutically acceptable carrier.

80. A nucleic acid that hybridizes under high stringency conditions to nucleotides 1 to 8236 of SEQ ID NO: 14.

81. A nucleic acid comprising a region that is 80% identical to at least thirty contiguous nucleotides of nucleotides 1 to 8236 of SEQ ID NO: 14.

82. A method for determining whether candidate compound modulates ABC1 biological activity, said method comprising the steps of:

(a) providing an ABC1 polypeptide;
(b) contacting said polypeptide with cholesterol and said candidate compound; and
(c) measuring binding of said cholesterol to said ABC1 polypeptide,
5 wherein binding of said cholesterol to said ABC1 polypeptide indicates that said candidate compound modulates ABC1 biological activity.

83. The method of claim 82, wherein said cholesterol is HDL cholesterol.

10 84. The method of claim 82, wherein said method is performed in a cell free assay.

85. The method of claim 82, wherein said ABC1 polypeptide comprises amino acids 1 to 60 of SEQ ID NO: 1.

15 86. the method of claim 82, wherein said cholesterol or said ABC1 polypeptide is detectably labeled.

METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS

Abstract of the Disclosure

The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).

50110.002005 AmendedApplication.wpd




Fig. 1 A

Family TD - 2




Fig. 1B

Cholesterol Efflux
(% of average control)






Fig. 1C

09525193-034500

Family FHA - 1



Family FHA - 2







Fig. 2C



Exon 30 mutation:




Fig. 4A

Exon 30
TD-1

4485

4503

4529

wt sequence

HUMAN_ABC1

MOUSE_ABC1

Patient

CAEEL_ABC

Patient

```

aagaagatgctgcctgtgTgtccccccaggggcaggggggctgcct
R R M L P V C P P G A G G L F
R R M L P V C P P G A G G L F
R R M L P V R P P G A G G L F
- - L - - - - - G G S -
aagaagatgctgcctgtgCgtccccccaggggcaggggggctgcct

```

Fig. 4B




Fig. 4C




Fig. 4D

Exon 13 mutation:





Fig. 5A

Exon 13
TD-2

1842


1864

1886

wt sequence
HUMAN_ABC1
MOUSE_ABC1
Patient
CAEEL_ABC
Patient

tgggggggcttcgcctacttgcAggatgtgggtggagcaggcaatc
N G G F A Y L Q D V V E Q A I
N G G F A Y L Q D V V E Q A I
N G G F A Y L R D V V E Q A I
- - - F M T V Q R A V D V A I
tgggggggcttcgcctacttgcGggatgtgggtggagcaggcaatc

Fig. 5B



Exon 14: FHA - 1, patient III:01




Fig. 6A

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------

Fig. 6B

Exon 41: FHA - 3, patient III:01




Fig. 6D

S740 S752 S775

| | |

aatgat gaagatGAAGATgtgaggcgggaagacag

N D - - - E D E D V R R E R Q

N D - - - E D E D V R R E R Q

N D - - - E D - - V R R E R Q

D E R D V E D S D V I A E K S

aatgat gaagat-----gtgaggcgggaagacag

 ↑

6 bp deletion

Fig. 6E

Exon 48 mutation:




Fig. 6F





Fig. 7A

0950493-004500

% Cholesterol Efflux



% Difference from Control




Fig. 7B





Fig. 7C



Mutation
Polymorphism

Fig. 8

SEQ ID NO: 1

MACWPQLRLLLWKNLTFRRRQTCQLLLEVAWPLFIFLILISVRLSYPPYEQHECHFPNKAMPSAGTLPWVQ
GIICNANNPCFRYPTPGEAPGVVGNFNKSIVARLFSDARRLLLYSQKDTSMKDMRKVLRTLQQIKKSSSNL
KLQDFLVDNETFSGFLYHNLSLPKSTVDKMLRADVILHKVFLQGYQLHLTSLCNGSKSEEMIQLGDQEVSE
LCGLPREKLAAAERVLRNMDILKPILRTLNSTSPFPSKELAEATKTLHSLGTLAQELFSMRSWSDMRQE
VMFLTNVNSSSSSTQIYQAVSRIVCGHPEGGGLKIKSLNWYEDNNYKALFGGNGTEEDAETFYDNSTTPYC
NDLMKNLESSPLSRIIWKALKPLLVGKILYTPDTPATROVMAEVNKTFOELAVFHDLEGMWHEELSPKIWTF
MENSQEMDLVRMLLDSRDNDHFWEQQLDGLDWTAQDIVAFLAKHPEDVQSSNGSVYTWREAFNETNQAI RT
ISRFMECVNLNKLEPIATEVWLINKSMELDERKFWAGIVFTGITPGSIELPHHVKYKIRMDIDNVERTNK
IKDGYWDPGPRADPFEDMRYVWGGFAYLQDVVEQAIIRVLTGTTEKKTGVYMQMPYPYCYVDDIFLRVMSRS
MPLFMTLAWIYSVAVIIKGIVYEKEARLKETMRIMGLDNSILWFSWFISSLIPLLVSAGLLVVILKLGNNLL
PYSDPVSVFVFLSVFAVVITLQCFLISTLFSRANLAAACGGIIFTLYLPYVLCVAWQDYVGFTLKI FASL
LSPVAFGFGCEYFALFEEQIGVQWDNLFESPVEEDGFNLTTSVSMMLFDTFLYGVMTWYIEAVFPQGYGI
PRPWYFPCTKSYWFGESDEKSHPGSNQKRISEICMEEEPHTHLKLGVSIGNLVKVYRDGMKVAVDGLALNF
YEGQITSFGLHNGAGKTTTMSILTGLFPPTSGTAYILGKDIRSEMSTIRQNLGVCPOHNVLFDMLTVEEHI
WIFYARLKGLSEKHVKAEMEOMALDVGLPSSKLKSKTSQLSGGMQRKLSVALAFVGGSKVVILDEPTAGVDP
YSRRGIWELLKLYRQGRITIIILSTHMHDEADVLDRIAIIISHGKLCCVGSSFLKNQLGTGYLTLVKKDVE
SSLSSCRNSSSTVSYLKKEDSVSQSSSDAGLSDHESDTLTIDVSAISNLIRKHVSEARLVEDIGHELTYV
LPYEAKEGAFVELFHEIDRLSDLGISSYGISETTLEEIFLKVAEESGVDAETSDGTLPARNRRAFGDK
QSCLRPFTEDDAADPNDSIDIDPESRETDLLSGMDGKGSYQVKGWKL TQQQFVALLWKRLLIARRSRKGFFA
QIVLPAVFVFCIALVFSLIVPPFGKYPSLELQPMYNEQYTFVSNDAPE DTGTLELLNALT KDPGFGTRCME
GNPIPDTPCQAGEEEWTTAPVPQTIMDLFQNGNWTM QNPSPACQCSSDKIKKMLPVCPPGAGGLPPPQRKQ
NTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWNNEFRYGGFSLGVSNTQALPPSQEVNDAIKQMKKHL
KLAKDSSADRFLNSLGRFMTGLDTRNNVKVWFNNKGWHAISSFLNVINNAILRANLQKGENPSHYGITAFN
HPLNLTKQQLSEVALMTTSVDVLVSI CVIFAMSFVPASFVFLIQERVSKAKHLQFISGVKPIYWL SNFV
WDMCNYVVPATLVIIIFICFQOKSYVSSTNLPVLALLLLLYGWSITPLMYPASFVFKIPSTAYVVLTSVNL
FIGINGSVATFVLELFTDNKLNNINDILKSVFLIFPHFCLGRGLIDMVKNQAMADALERFGENRFVSPLSW
DLVGRNLFAMAVEGVVFFLITVLIQYRFFIRPRPVNAKLSPLNDEDEDVRRERQRILDGGGQNDILEIKEL
TKIYRRKRKPAVDRCVGI PPGEFCGLLG VNGAGKSSTFKMLTGDTTVTRGDAFLNKNSILSNIHEVHQNM
GYCPQFDAITELLTGREHVEFFALLRGVPEKEVGKVGEWAIRKLGLVKYGEKYAGNYSGGNKRKLSTAMAL
IGGPPVVFLEPTTGMDPKARRFLWNCALSVVKEGRSVVLTSHSMEECEALCTRMAIMVNGRFRCLG SVQH
LKNRFGDGYTIVVRIAGSNPDLKPVQDFFGLAFPGSVLKEKHRNMLQYQLPSSLSSLARIFSILSQSKKRL
HIEDYSVSQTTLDQVFNFAKDQSDDDHLKDL SLHKNQTVVDVAVLTSFLQDEKV KESYV*

Fig. 9A

SEQ ID NO: 2

GTCCCTGCTGTGAGCTCTGGCCGCTGCCTTCCAGGGCTCCCGAGCCACACGCTGGGGGTG
CTGGCTGAGGGAACATGGCTTGTGGCCTCAGCTGAGGTTGCTGCTGTGGAAGAACCTCA
CTTTCAGAAGAAGACAAACATGTGAGCTGTTACTGGAAGTGGCCTGGCCTCTATTTATCT
TCCTGATCCTGATCTCTGTTCCGGCTGAGCTACCCACCCTATGAACAACATGAATGCCATT
TTCCAAATAAAGCCATGCCCTCTGCAGGAACACTTCCTTGGGTTTCAAGGGAATTATCTGTA
ATGCCAACAAACCCCTGTTTCCGTTACCCGACTCCTGGGGAGGCTCCCGGAGTTGTTGGAA
ACTTTAACAAATCCATTGTGGCTCGCCTGTTCTCAGATGCTCGGAGGCTTCTTTTATACA
GCCAGAAAGACACCAGCATGAAGGACATGCGCAAAGTTCTGAGAACATTACAGCAGATCA
AGAAATCCAGCTCAAACCTGAAGCTTCAAGATTTCTGGTGGACAATGAAACCTTCTCTG
GGTTCCTGTATCACAACCTCTCTCTCCCAAAGTCTACTGTGGACAAGATGCTGAGGGCTG
ATGTCATTCTCCACAAGGTATTTTTGCAAGGCTACCAGTTACATTTGACAAGTCTGTGCA
ATGGATCAAAATCAGAAGAGATGATTCAACTTGGTGACCAAGAAGTTTCTGAGCTTTGTG
GCCTACCAAGGGAGAACTGGCTGCAGCAGAGCGAGTACTTCGTTCCAACATGGACATCC
TGAAGCCAATCCTGAGAACACTAACTCTACATCTCCCTTCCCGAGCAAGGAGCTGGCTG
AAGCCACAAAAACATTGCTGCATAGTCTTGGGACTCTGGCCCAGGAGCTGTTTACGATGA
GAAGCTGGAGTGACATGCGACAGGAGGTGATGTTTCTGACCAATGTGAACAGCTCCAGCT
CCTCCACCCAAATCTACCAGGCTGTGTCTCGTATTGTCTGCGGGCATCCCGAGGGAGGGG
GGCTGAAGATCAAGTCTCTCAACTGGTATGAGGACAACAACCTACAAAGCCCTCTTTGGAG
GCAATGGCACTGAGGAAGATGCTGAAACCTTCTATGACAACCTCTACAACCTCCTTACTGCA
ATGATTTGATGAAGAATTTGGAGTCTAGTCTCTTTCCCGCATTATCTGGAAAGCTCTGA
AGCCGCTGCTCGTTGGGAAGATCCTGTATACACCTGACACTCCAGCCACAAGGCAGGTCA
TGGCTGAGGTGAACAAGACCTTCCAGGAACTGGCTGTGTTCCATGATCTGGAAGGCATGT
GGGAGGAACTCAGCCCCAAGATCTGGACCTTCATGGAGAACAGCCAAGAAATGGACCTTG
TCCGGATGCTGTTGGACAGCAGGGACAATGACCACTTTTGGGAACAGCAGTTGGATGGCT
TAGATTGGACAGCCCAAGACATCGTGGCGTTTTTGGCCAAGCACCCAGAGGATGTCCAGT
CCAGTAATGGTTCTGTGTACACCTGGAGAGAAGCTTTCAACGAGACTAACCAGGCAATCC
GGACCATATCTCGCTTCATGGAGTGTGTCAACCTGAACAAGCTAGAACCCATAGCAACAG
AAGTCTGGCTCATCAACAAGTCCATGGAGCTGCTGGATGAGAGGAAGTTCTGGGCTGGTA
TTGTGTTCACTGGAATTACTCCAGGCAGCATTGAGCTGCCCCATCATGTCAAGTACAAGA
TCCGAATGGACATTGACAAATGTGGAGAGGACAAATAAAATCAAGGATGGGTACTGGGACC
CTGGTCCTCGAGCTGACCCCTTTGAGGACATGCGGTACGTCTGGGGGGGCTTCGCCTACT
TGCAGGATGTGGTGGAGCAGGCAATCATCAGGGTGCTGACGGGCACCGAGAAGAAAAC TG

Fig. 9B

GTGTCTATATGCAACAGATGCCCTATCCCTGTTACGTTGATGACATCTTTCTGCGGGTGA
 TGAGCCGGTCAATGCCCCCTTTCATGACGCTGGCCTGGATTTACTCAGTGGCTGTGATCA
 TCAAGGGCATCGTGTATGAGAAGGAGGCACGGCTGAAAGAGACCATGCGGATCATGGGCC
 TGGACAACAGCATCCTCTGGTTTAGCTGGTTCATTAGTAGCCTCATTCCCTCTTCTTGTGA
 GCGCTGGCCTGCTAGTGGTCATCCTGAAGTTAGGAAACCTGCTGCCCTACAGTGATCCCA
 GCGTGGTGTGTTTGTCTTCCGTGTCCGTGTTTGCTGTGGTGACAATCCTGCAGTGCTTCCTGA
 TTAGCACACTCTTCTCCAGAGCCAACCTGGCAGCAGCCTGTGGGGGCATCATCTACTTCA
 CGCTGTACCTGCCCTACGTCTGTGTGTGGCATGGCAGGACTACGTGGGCTTCACACTCA
 AGATCTTCGCTAGCCTGCTGTCTCCTGTGGCTTTTGGGTTTGGCTGTGAGTACTTTGCCC
 TTTTGTAGGAGCAGGGCATTGGAGTGCAGTGGGACAACCTGTTTGTAGAGTCCTGTGGAGG
 AAGATGGCTTCAATCTCACCACCTTCGGTCTCCATGATGCTGTTTGTACACCTTCCTCTATG
 GGGTGATGACCTGGTACATTGAGGCTGTCTTCCAGGCCAGTACGGAATTCCCAGGCCCT
 GGTATTTTCTTGCACCAAGTCTACTGGTTTGGCGAGGAAAGTGATGAGAAGAGCCACC
 CTGGTTCCAACCAGAAGAGAATATCAGAAATCTGCATGGAGGAGGAACCCACCCACTTGA
 AGCTGGGCGTGTCCATTGAGAACCTGGTAAAAGTCTACCGAGATGGGATGAAGGTGGCTG
 TCGATGGCCTGGCACTGAATTTTTATGAGGGCCAGATCACCTCCTTCCTGGGCCACAATG
 GAGCGGGGAAGACGACCACCATGTCAATCCTGACCGGGTTGTTCCCCCGACCTCGGGCA
 CCGCCTACATCCTGGGAAAAGACATTGCTCTGAGATGAGCACCATCCGGCAGAACCTGG
 GGGTCTGTCCCCAGCATAACGTGCTGTTTGTACATGCTGACTGTGCGAAGAACACATCTGGT
 TCTATGCCCCGCTTGAAAGGGCTCTCTGAGAAGCACGTGAAGGCGGAGATGGAGCAGATGG
 CCCTGGATGTTGGTTTGCCATCAAGCAAGCTGAAAAGCAAAACAAGCCAGCTGTCAGGTG
 GAATGCAGAGAAAGCTATCTGTGGCCTTGGCCTTTGTGCGGGGATCTAAGGTTGTCATTG
 TGGATGAACCCACAGCTGGTGTGGACCCTTACTCCCGAGGGGAATATGGGAGCTGCTGC
 TGAAATACCGACAAGGCCGCACCATTATTCTCTCTACACACCACATGGATGAAGCGGACG
 TCCTGGGGGACAGGATTGCCATCATCTCCCATGGGAAGCTGTGCTGTGTGGGCTCCTCCC
 TGTTTCTGAAGAACCAGCTGGGAACAGGCTACTACCTGACCTTGGTCAAGAAAGATGTGG
 AATCCTCCCTCAGTTCCTGCAGAAACAGTAGTAGCACTGTGTCTATACCTGAAAAAGGAGG
 ACAGTGTCTCTCAGAGCAGTTCTGATGCTGGCCTGGGCAGCGACCATGAGAGTGACACGC
 TGACCATCGATGTCTCTGCTATCTCCAACCTCATCAGGAAGCATGTGTCTGAAGCCCGGC
 TGGTGAAGACATAGGGCATGAGCTGACCTATGTGCTGCCATATGAAGCTGCTAAGGAGG
 GAGCCTTTGTGGAACCTCTTTCATGAGATTGATGACCGCTCTCAGACCTGGGCATTTCTA
 GTTATGGCATCTCAGAGACGACCCTGGAAGAAATATTCCTCAAGGTGGCCGAAGAGAGTG
 GGGTGGATGCTGAGACCTCAGATGGTACCTTGCCAGCAAGACGAAACAGGCGGGCCTTCG
 GGGACAAGCAGAGCTGTCTTCGCCCCGTTCACTGAAGATGATGCTGCTGATCCAAATGATT

Fig. 9C

CTGACATAGACCCAGAATCCAGAGAGACAGACTTGCTCAGTGGGATGGATGGCAAAGGGT
CCTACCAGGTGAAAGGCTGGAACTTACACAGCAACAGTTTGTGGCCCTTTTGTGGAAGA
GACTGCTAATTGCCAGACGGAGTCGGAAAGGATTTTTTGCTCAGATTGTCTTGCCAGCTG
TGTTTGTCTGCATTGCCCTTGTGTTTCAGCCTGATCGTGCCACCCTTTGGCAAGTACCCCA
GCCTGGAACCTTCAGCCCTGGATGTACAACGAACAGTACACATTTGTCAGCAATGATGCTC
CTGAGGACACGGGAACCTTGAACCTCTTAAACGCCCTCACCAAAGACCCTGGCTTCGGGA
CCCGCTGTATGGAAGGAAACCCAATCCCAGACACGCCCTGCCAGGCAGGGGAGGAAGAGT
GGACCACTGCCCCAGTTCCCCAGACCATCATGGACCTCTTCCAGAATGGGAACTGGACAA
TGCAGAACCCCTTCACCTGCATGCCAGTGTAGCAGCGACAAAATCAAGAAGATGCTGCCTG
TGTGTCCCCCAGGGGCAGGGGGGCTGCCTCCTCCACAAAAGAAAACAAAACACTGCAGATA
TCCTTCAGGACCTGACAGGAAGAAACATTTCCGGATTATCTGGTGAAGACGTATGTGCAGA
TCATAGCCAAAAGCTTAAAGAACAAGATCTGGGTGAATGAGTTTAGGTATGGCGGCTTTT
CCCTGGGTGTGAGTAATACTCAAGCACTTCCTCCGAGTCAAGAAGTTAATGATGCCATCA
AACAAATGAAGAAACACCTAAAGCTGGCCAAGGACAGTTCTGCAGATCGATTTCTCAACA
GCTTGGGAAGATTTATGACAGGACTGGACACCAGAAATAATGTCAAGGTGTGGTTCAATA
ACAAGGGCTGGCATGCAATCAGCTCTTTCCTGAATGTCATCAACAATGCCATTCTCCGGG
CCAACCTGCAAAAGGGAGAGAACCCTAGCCATTATGGAATTACTGCTTTCAATCATCCCC
TGAATCTCACCAAGCAGCAGCTCTCAGAGGTGGCTCTGATGACCACATCAGTGGATGTCC
TTGTGTCCATCTGTGTCATCTTTGCAATGTCCTTCGTCCCAGCCAGCTTTGTCTGATTCC
TGATCCAGGAGCGGGTCAGCAAAGCAAAACACCTGCAGTTCATCAGTGGAGTGAAGCCTG
TCATCTACTGGCTCTCTAATTTTGTCTGGGATATGTGCAATTACGTTGTCCCTGCCACAC
TGGTCATTATCATCTTCATCTGCTTCCAGCAGAAGTCCATATGTGTCCTCCACCAATCTGC
CTGTGCTAGCCCTTCTACTTTTGTCTGATGGGTGGTCAATCACACCTCTCATGTACCCAG
CCTCCTTTGTGTTCAAGATCCCCAGCACAGCCTATGTGGTGCTCACCAGCGTGAACCTCT
TCATTGGCATTAAATGGCAGCGTGGCCACCTTTGTGCTGGAGCTGTTACCGACAATAAGC
TGAATAATATCAATGATATCCTGAAGTCCGTGTTCTTGATCTTCCCACATTTTTGCCTGG
GACGAGGGCTCATCGACATGGTGAAAAACCAGGCAATGGCTGATGCCCTGGAAAGGTTTG
GGGAGAATCGCTTTGTGTCACCATATCTTGGGACTTGGTGGGACGAAACCTCTTCGCCA
TGGCCGTGGAAGGGGTGGTGTCTTCTCCTCATTACTGTTCTGATCCAGTACAGATTCTTCA
TCAGGCCCAGACCTGTAAATGCAAAGCTATCTCCTCTGAATGATGAAGATGAAGATGTGA
GGCGGGAAAGACAGAGAATTCTTGATGGTGGAGGCCAGAATGACATCTTAGAAATCAAGG
AGTTGACGAAGATATATAGAAGGAAGCGGAAGCCTGCTGTTGACAGGATTTGCGTGGGCA
TTCCTCCTGGTGAGTGCTTTGGGCTCCTGGGAGTTAATGGGGCTGGAAAATCATCAACTT
TCAAGATGTTAACAGGAGATACCACTGTTACCAGAGGAGATGCTTTCCTTAACAAAATA

Fig. 9D

GTATCTTATCAAACATCCATGAAGTACATCAGAACATGGGCTACTGCCCTCA3TTTGATG
 CCATCACAGAGCTGTTGACTGGGAGAGAACACGTGGAGTTCTTTGCCCTTTT¹GAGAGGAG
 TCCCAGAGAAAGAAGTTGGCAAGGTTGGTGAGTGGGCGATTTCGGAAACTGGG²CCTCGTGA
 AGTATGGAGAAAAATATGCTGGTA³ACTATAGTGGAGGCAACAAACGCAAGCTCTCTACAG
 CCATGGCTTTGATCGGCGGGCCTCCTGTGGTGT⁴TTCTGGATGAACCCACCACAGGCATGG
 ATCCCAAGCCCGGCGGTTCTTGTGGAATTGTGCCCTAAGTGT⁵TGTCAAGGAGGGGAGAT
 CAGTAGTGCTTACATCTCATAGTATGGAAGAATGTGAAGCTCTTTGCACTA3GATGGCAA
 TCATGGTCAATGGAAGGTT⁶CAGGTGCCCTTGGCAGTGTCCAGCATCTAAAAATAGGTTTG
 GAGATGGTTATACAATAGTTGTACGAATAGCAGGGTCCAACCCGGACCTGAAGCCTGTCC
 AGGATTTCTTTGGACTTGCATTTCTGGAAGTGT⁷TTCTAAAAGAGAAACACCGGAACATGC
 TACAATACCAGCTTCCATCTTCATTATCTTCTCTGGCCAGGATATTCAGCATCCTCTCCC
 AGAGCAAAAAGCGACTCCACATAGAAGACTACTCTGTTTCTCAGACAACACTTGACCAAG
 TATTTGTGAAC⁸TTTGCCAAGGACCAAAGTGATGATGACCACTTAAAAGACCTCTCATTAC
 ACAAAAACCAGACAGTAGTGGACGTTGCAGTTCTCACATCTTTTCTACAGGATGAGAAAG
 TGAAAGAAAGCTATGTATGAAGAATCCTGTT⁹CATACGGGGTGGCTGAAAGTAAAGAGGAA
 CTAGACTTTCTTTGCACCATGTGAAGTGT¹⁰TGTGGAGAAAAGAGCCAGAAGTTGATGTGG
 GAAGAAGTAAACTGGATACTGTACTGATACTATTCAATGCAATGCAATTCAATGCAATGA
 AAACAAAATTCCATTACAGGGGCAGTGCCTTTGTAGCCTATGTCTTGTATGGCTCTCAAG
 TGAAAGACTTGAATTTAGTTTTTTTACCTATACCTATGTGAACTCTATTATGGAACCCAA
 TGGACATATGGGTTTGAAC¹¹TCACACTTTTTTTTTTTTTTTTTTTTGTTCCTGTGTATTCTCATT
 GGGGTTGCAACAATAATTCATCAAGTAATCATGGCCAGCGATTATTGATCAAAATCAAAA
 GGTAATGCACATCCTCATTCACTAAGCCATGCCATGCCCAGGAGACTGGTTTCCCGGTGA
 CACATCCATTGCTGGCAATGAGTGTGCCAGAGTTATTAGTGCCAAGTTTTTCAGAAAGTT
 TGAAGCACCATGGTGTGTCATGCTCACTTTTGTGAAAGCTGCTCTGCTCAGAGTCTATCA
 ACATTGAATATCAGTTGACAGAATGGTGCCATGCGTGGCTAACATCCTGCTTTGATTCCC
 TCTGATAAGCTGTTCTGGTGGCAGTAACATGCAACAAAAATGTGGGTGTCTCCAGGCACG
 GGAAACTTGGTTCCATTGTTATATTGTCCATGCTTCGAGCCATGGGTCTACAGGGTCAT
 CCTTATGAGACTCTTAAATATACTTAGATCCTGGTAAGAGGCAAAGAATCAACAGCCAAA
 CTGCTGGGGCTGCAACTGCTGAAGCCAGGGCATGGGATTAAAGAGATTGTGCGTTCAAAC
 CTAGGGAAGCCTGTGCCCATTTGTCTGACTGTCTGCTAACATGGTACACTGCATCTCAA
 GATGTTTATCTGACACAAGTGTATTATTTCTGGCTTTTTGAATTAATCTAGAAAATGAAA

Fig. 9E

Exon	Forward Primer	SEQ ID No	Reverse Primer	SEQ ID No	Intron(kb)	Intron (kb)
exon 1	GGGCGGATGAGGAGTCCCTCA	70	ATCCCCAATCAAAACACACA	119	intron 1	> 6.413
exon 2	GGATTCCTCCAGATCCAGTG	71	AAGTCCAAATTAAGCCACGTT	120	intron 2	> 4.241
exon 3	GACAGACTGGCATGAAGCA	72	CCAGCCATTCAAAATTCCTCC	121	intron 3	> 1.248 (1.6)
exon 4	GCACCTGGCAGTCACTCTG	73	GGTCAGGTCAATTTCCAAT	122	intron 4	> 1.512
exon 5	CGTTTCTCCAGTGTCCCAAT	74	CCCTTCACCAACCATACAA	123	intron 5	> 1.769 (3)
exon 6	CGTTTCTCCAGTGTCCCAAT	75	TGTCCTCTTCCAGTGTCCCAAT	124	intron 6	> 2.726 (10)
exon 7	ACCTTCAAGGACCCAGCTTCC	76	AGGACCTCTTCCAGTGTCCCAAT	125	intron 7	4.957
exon 8	TCGGTTCCTGTGTTTAACTCA	77	AGGAGATGACACAGGCCAAG	126	intron 8	> 2.311 (2.5)
exon 9	TCCCAAGGCTTTGAGATGAC	78	CGCACCTCTGAAAGTCTAC	127	intron 9	0.332
exon 10	GGCTCCAAAGCCCTTTGTAA	79	ACCTCACTACACCTGGGAA	128	intron 10	0.208
exon 11	GGCTGTGATGGGTGTCT	80	GCCTCTGCCTGAACCTTAT	129	intron 11	0.747
exon 12	TTTGTAATTTTGTAGTCTCTCA	81	CAAAATCATGACACCAAGTTGAG	130	intron 12	0.523
exon 13	TAGTCAGGCTTGGCTCCTA	82	CATCATCATGACACACATA	131	intron 13	1.787
exon 14	AAAGGGGCTTGGTAAAGGTA	83	CTTTAGCCCTGTGTTGAGCTA	132	intron 14	1.747
exon 15	GAATGGTCTCCCTCTAGC	84	TGCTTTTATTCAGGGACTCA	133	intron 15	1.059
exon 16	CAATGAGTGTCTGGGATG	85	CCCATGCACTGACAGATTC	134	intron 16	1.105
exon 17	GCATGAGTGTCTGGGATG	86	AAGCAGGAGACATCGCTT	135	intron 17	1.798
exon 18	TCGAAGGTTCAAGGCGAGTG	87	GGGATCAGCATGGTTCTCTA	136	intron 18	0.99
exon 19	TGCAAGTGTCAAGGCGAGTG	88	GCCTTAAGTCCCACTGCTCC	137	intron 19	1.307
exon 20	TGCAAGTGTCAAGGCGAGTG	89	ATTTCTCGGCATGTGTGT	138	intron 20	0.204
exon 21	GCAGGAGTGTCAAGGCGAGTG	90	TCACAGAGCTTACCCATGA	139	intron 21	0.706
exon 22	GCAGGAGTGTCAAGGCGAGTG	91	AACAGAGCAGGAGATGGTG	140	intron 22	> 0.866 (1.7)
exon 23	GCAGGAGTGTCAAGGCGAGTG	92	CTTCCCATCTGCAACAAAC	141	intron 23	0.986
exon 24	GCAGGAGTGTCAAGGCGAGTG	93	CTTCCCATCTGCAACAAAC	142	intron 24	1.688
exon 25	GCAGGAGTGTCAAGGCGAGTG	94	GCTAAAGGCCATCCAAAGAA	143	intron 25	0.196
exon 26	GCAGGAGTGTCAAGGCGAGTG	95	TCAAGTGCATCTGGGCATA	144	intron 26	1.396
exon 27	GCAGGAGTGTCAAGGCGAGTG	96	CTGAGTGCATCTGGGCATA	145	intron 27	1.649
exon 28	GCAGGAGTGTCAAGGCGAGTG	97	CTGAGTGCATCTGGGCATA	146	intron 28	> 0.728 (1.4)
exon 29	GCAGGAGTGTCAAGGCGAGTG	98	CAATGTGGCATCTGGGCATA	147	intron 29	> 2.589 (3)
exon 30	GCAGGAGTGTCAAGGCGAGTG	99	GAAGTACCAAGCCCATCT	148	intron 30	1.521
exon 31	GCAGGAGTGTCAAGGCGAGTG	100	CAATTCCTCCAGTGTTCAG	149	intron 31	> 0.944 (1)
exon 32	GCAGGAGTGTCAAGGCGAGTG	101	CAAAGGCTTCTTCAATCA	150	intron 32	> 1.062 (1.65)
exon 33	GCAGGAGTGTCAAGGCGAGTG	102	GATCCCTTTAACTGGCAAC	151	intron 33	1.475
exon 34	GCAGGAGTGTCAAGGCGAGTG	103	ATGCCCTGCAAGCTTAC	152	intron 34	0.522
exon 35	GCAGGAGTGTCAAGGCGAGTG	104	CTCTGCACTGTCCCTCTAC	153	intron 35	1.228
exon 36	GCAGGAGTGTCAAGGCGAGTG	105	TATCAATCAATGGCCCTGAC	154	intron 36	> 1.898 (2)
exon 37	GCAGGAGTGTCAAGGCGAGTG	106	AGAGTCCCTGCCCTCTCT	155	intron 37	0.112
exon 38	GCAGGAGTGTCAAGGCGAGTG	107	AAGCAGTACGACAGTGCAT	156	intron 38	1.545
exon 39	GCAGGAGTGTCAAGGCGAGTG	108	GGGGAACATCTGTGCTTAG	157	intron 39	1.087
exon 40	GCAGGAGTGTCAAGGCGAGTG	109	CCATTGGTGAAGTGTTCCT	158	intron 40	0.265
exon 41	GCAGGAGTGTCAAGGCGAGTG	110	AGTCAAGAACTGCTGGGT	159	intron 41	> 0.622 (0.9)
exon 42	GCAGGAGTGTCAAGGCGAGTG	111	ATTGCTCATCTGGCATAA	160	intron 42	0.909
exon 43	GCAGGAGTGTCAAGGCGAGTG	112	TCATGGATGATTTATGCTCT	161	intron 43	2.355
exon 44	GCAGGAGTGTCAAGGCGAGTG	113	GCGTGTGGAAGGCGATAAG	162	intron 44	0.372
exon 45	GCAGGAGTGTCAAGGCGAGTG	114	GCCATCATCAACAGCCCT	163	intron 45	> 1.059 (1.3)
exon 46	GCAGGAGTGTCAAGGCGAGTG	115	TGATCGCATATCTACTGGAAA	164	intron 46	0.483
exon 47	GCAGGAGTGTCAAGGCGAGTG	116	TCCCTTATTTAGAGGCACCA	165	intron 47	0.659
exon 48	GCAGGAGTGTCAAGGCGAGTG	117	GATGAGGAATCAAGGCACAA	166	intron 48	0.941
exon 49	GCAGGAGTGTCAAGGCGAGTG	118	TGGGTTCCTAATAAGAGTTTCA	167	intron 49	> 1.075

Fig. 10

Errors in public sequence (differences between all samples and Genbank entry AJ012378.1):					
Exon/Intron	Nucleotide#	Amino acid change		Sequence difference/context	SEQ ID NO:
2	T150C	no change	Public sequence	TGTCAGCTGTTACTGGAAGTGG	168
	A152G		Correct sequence:	TGTCAGCTGCTGCTGGAAGTGG	169
7	C839T	no change	Public sequence:	AGGAGCTGGCTGAAGCCACAA	170
			Correct sequence:	AGGAGCTGGCTGAAGCCACAA	171
33	C4738T	T1495I	Public sequence:	AATGATGCCACAAACAAATG	172
			Correct sequence:	AATGATGCCATCAAAACAAATG	173
35	C5017T	P1588L	Public sequence:	GAGGTGGCTCGATGACCACA	174
			Correct sequence:	GAGGTGGCTCTGATGACCACA	175
43	G5995A	R1914K	Public sequence:	TTCTTAAACAGAAATAGTATC	176
			Correct sequence:	TTCTTAAACAAAATAGTATC	177
48	C6577T	P2108L	Public sequence:	GGAGTGTTTCCAAAAGAGAAA	178
			Correct sequence:	GGAGTGTTTCTAAAAGAGAAA	179
49	G6899A	not applicable	Public sequence:	AGTAAAGAGGACTAGACTTT	180
			Correct sequence:	AGTAAAGAGGAACAGACTTT	181
Mutations:					SEQ ID NO:
13	A1864G	Q597R	More common	GCCTACTTGCAGGATGTGGTG	182
			Less common	GCCTACTTGCGGGATGTGGTG	183
14	delta CTT 2151-3	delta L893	More common	CCTCATTCCTCTTCTGTGAGCG	184
			Less common	CCTCATTCCTCTTGTGAGCG	185
15	G2385A	V771M	More common	GCAGGACTACGTGGCTTCAC	186
			Less common	GCAGGACTACATGGCTTCAC	187
18	C2799T	R909Stop	More common:	AAAAGTCTACCGAGATGGGAT	188
			Less common:	AAAAGTCTACTGAGATGGGAT	189
18	C2860T	T929I	More common	GGCAGATCACCTCCCTGCTG	190
			Less common	GGCAGATCACTCCCTTCCCTG	191
22	T3346C	M1091T	More common	ACACACCAATGGATGAAGCG	192
			Less common	ACACACCAACGGATGAAGCG	193
Intron 24	(+) G to C splice donor site	Altered transcript length	More common	CCTGGAAGAAAGTAAGTTAAGT	194
			Less common	CCTGGAAGAACTAAGTTAAGT	195
30	T4503C	C1477R	More common	GCTGCTGTGTGTCTCCCGCAGG	196
			Less common	GCTGCTGTGTGTCTCCCGCAGG	197
35	GG 4956-57 to C	Frameshift at aa1628	More common:	TAGCCATTATGGAATTAAGCT	198
			Less common:	TAGCCATTATCAATTAAGCT	199
41	delta AAGATG 5752-7	delta(E.D)1893-1894	More common	GATGAAGATGAAGATGTGAGGCGGA	200
			Less common	GATGAAGATG/TGAGGCGGA	201
48	C6504T	R2144Stop	More common	AATAGTTGTACGAATAGCAGG	202
			Less common:	AATAGTTGTATGAATAGCAGG	203
Promoter Variants:					
Location	Position Relative to Xenon cDNA	Position Relative to SEQ ID NO: 14 Containing Exon 1			SEQ ID NO:
1	G57C	8216	More common	ACACGCTGGGGGTGCTGGCTG	204
			Less common	ACACGCTGGGGGTGCTGGCTG	205
5'	(-) 4 ins G	8158	More common	GACCAGCCACGGCTCCCTG	206
			Less common	GACCAGCCACGGCGTCCCTG	207
5	A (-) 380 G	~780	More common	CATTTTCTTAGAAAAGAGAGGT	208
			Less common	CATTTTCTTAGAAAAGAGAGGT	209
5'	A (-) 479 C	~681	More common	GAAAATTAGTAATGAAGGAAG	210
			Less common	GAAAATTAGTCTGAAGGAAG	211
5'	A (-) 738 G	~422	More common	CCTCCGCTGCCAGGTTGAGGATT	212
			Less common:	CCTCCGCTGCCAGGTTGAGGATT	213
5'	A (-) 1045 G	~115	More common	TATGTGCTGACCATGGAGCTTGT	214
			Less common	TATGTGCTGACCGTGGAGCTTGT	215
5	A (-) 1113 G	~047	More common	GTGACACCCACCGAGTAGGG	216
			Less common	GTGACACCCAGCGAGTAGGG	217
5'	(-) 1181 ins CCCT	5979	More common	AGTATCCCT/TGTTCAAGAGAA	218
			Less common	AGTATCCCTCCCTTGTTCAAGAGAA	219

Fig. 11

Polymorphisms					
Exon/Intron	Nucleotide#	Amino acid change		Sequence difference/context	SEQ ID NO:
5	G548A	no change	More common	CTGGGTTCTGTATCACAAC	220
			Less common	CTGGGTTCTATATCACAAC	221
6	G730A	R219K	More common	GGCTACCAAGGAGAACTG	222
			Less common	GGCTACCAAGGAGAAACTG	223
Intron 7	G (+) 2383 T	Not applicable	Allele 1	TTTAAAGGGGTGATTAGGA	224
			Allele 2	TTTAAAGGGGTGATTAGGA	225
Intron 7	G (+) 3035 T	Not applicable	Allele 1	GAAGAAATTTGTTTTTGAAT	226
			Allele 2	GAAGAAATTTTTTTTTGAAT	227
8	C1010T	no change	More common	GCGGCATCCGAGGAGAGG	228
			Less common	GCGGCATCCTGAGGAGAGG	229
8	G1022A	no change	More common	AGGAGGGGGGCTGAAGATCA	230
			Less common	AGGAGGGGGGACTGAAGATCA	231
Intron 9	(-) 42 ins G	Not applicable	More common	AGGAGCCAAAGCTCATTTG	232
			Less common	AGGAGCCAAAGGCTCATTTG	233
Intron 13	T (+) 24 A	Not applicable	More common	AAGCCACTGTTTTAAACCACT	234
			Less common	AAGCCACTGTATTTAAACCACT	235
15	A2394C	T774P	More common	CGTGGGCTTCACTCAAGAT	236
			Less common	CGTGGGCTTCCACTCAAGAT	237
15	G2402C	K776N	More common	TCACACTCAAGATCTTCGCTG	238
			Less common	TCACACTCAACATCTTCGCTG	239
Intron 14	C (+) 16 T	Not applicable	Allele 1	GCAGCCTCAACCCGCTCTTCC	240
			Allele 2	GCAGCCTCACTCGCTCTTCC	241
17	A2723G	I883M	Allele 1	AGAAGAGAAATACAGAAATCT	242
			Allele 2	AGAAGAGAAATGTCAGAAATCT	243
Intron 17	C (+) 2000 G	Not applicable	Allele 1	GCGCAGTGCCTGTGTCTCTTA	244
			Allele 2	GCGCAGTGCCTGTGTCTCTTA	245
21	T3233G	no change	More common	GATCTAAGGTGTCTATCTCGG	246
			Less common	GATCTAAGGTGTCTATCTCGG	247
Intron 21	G (+) 118 T	Not applicable	Allele 1	CTCTTCTGTTAGCAGAAACAGA	248
			Allele 2	CTCTTCTGTATACAGAAACAGA	249
Intron 21	A (+) 563 G	Not applicable	Allele 1	CATTCTAGGATCATAGCCAT	250
			Allele 2	CATTCTAGGGGTATAGCCAT	251
Intron 24	G (+) 321 T	Not applicable	Allele 1	AAGTACAGTGGGAGAACAGCG	252
			Allele 2	AAGTACAGTGTGAGAACAGCG	253
Intron 29	A (-) 624 G	Not applicable	Allele 1	ATTCTAAAAAATAGAAATGCA	254
			Allele 2	ATTCTAAAAAGTAGAAATGCA	255
Intron 31	T (+) 30 C	Not applicable	More common	GGCCCCGCTTATTATTACT	256
			Less common	GGCCCCGCGTATTATTACT	257
Intron 33	A (+) 732 G	Not applicable	Allele 1	TGAGAGAAATTAATTGAACCGG	258
			Allele 2	TGAGAGAAATGCTTGAACCGG	259
Intron 33	C (+) 898 T	Not applicable	Allele 1	TTTGCTGAAACATCACTGAC	260
			Allele 2	TTTGCTGAAATAATCACTGAC	261
Intron 34	C (+) 234 T	Not applicable	Allele 1	AACCTCAGTTCCCTCATCTGTG	262
			Allele 2	AACCTCAGTTTCTCATCTGTG	263
34	G4834A	R1587K	More common	CTGGACACAGAAATAATGTC	264
			Less common	CTGGACACAAAAATAATGTC	265
37	C5266G	S1731C	More common	TCCTATGTGTCTCCACCAAT	266
			Less common	TCCTATGTGTCTCCACCAAT	267
Intron 43	T (+) 18 C	Not applicable	More common	AAGAAGTGGCTGTATTTTGC	268
			Less common	AAGAAGTGGCTGTATTTTGC	269
Intron 43	A (+) 1665 G	Not applicable	Allele 1	AACTGATTTGATTGGTATAGCTC	270
			Allele 2	AACTGATTTGGTGGTATAGCTC	271
48	C8521T	no change	More common	CAGGGTCCAACCGGACCTGA	272
			Less common	CAGGGTCCAATCCGGACCTGA	273
Intron 10	(+) 14 ins T	Not applicable	More common	GGGTACGGGATGGGGACAG	284
			Less common	GGGTACGGGATTTGGGGACAG	285
Exon 16	G2547A	V825I	More common	CCACTTCGGTCTCCATG	286
			Less common	CCACTTCGATCTCCATG	287
Polymorphism in an ABC1 BAC contig:					
This polymorphism is within approximately 200 kb of the ABC1 gene					
	A or G	not applicable	Allele 1	TTGGGAGGCTAAGGCAGGAGAA	274
			Allele 2	TTGGGAGGCTGAGGCAGGAGAA	275

Fig. 11

Underline = putitive promotor element

Fig. 12
Page 1 of 30

cttgttttatttctgcagaggggttctaagccattcacttcccagatgggccaataatgctttgagtaatctggagatca
 tctttaatgcccaggtgaatggaactcttccacagagggatgtgagggctgtagagcagagtgaactccctgaaactca
 gacgtcagctctttgtctctctatctctgaacacccttcttagagatcccatctctaggatgcatttctctgtagtta
 gtttctaagtcctctgttctgtctgcctttatttttttctggatttctaagccagtatccccacttggctgtctt
 aatgtagcttaacatgtctgtaataaaatgatcatcttctgagattcaaaagggtataaaggacttggagagaatt
 tcattcagttttctcaactagaataatgcttgactgtctgtaaaagaacaaaagtgtcaaagcatcctttgttca
 ctaaaatttcttttttattatagtgttactttaaatttaggaagttaaaagttaggtataaacttcttataggctgttat
 tatacaactatatgaccatacatatttacaatttaagtgcagccaaaattgcaaaatcaataccattcaaattaatac
 cttaaatgtggtgaggcagctgttgttcaactgaaaccaaattataagttgcatggcagtaaatgctatcatgctgatc
 attttgagtttggccagtcctattatcatgtgctaattgattgaattctccaccatttttctacttgtatgaccttaa
 ttgatggcacctgttccatcctcatgagtttgctacaattatactgggtgccaacacaatcataaacacaaatataaac
 ttgggctttgaaatcttgtgccagaacttggctttaaagtaagcatttaaaaaatccatatgtgtttattagactttgt
 ttagatgactgttgaatgaaaacaaagtgtttaaactcctcttagagaacttaaatataatccctcagcaatatgtat
 acagatcttctttgagaaaaactgattgtgttcagcctctcatgttacaaatggggaacctgaattctgaggtctcta
 gtgagagaacagggactggaatctgtggatcctatctgttttaataataattgtaaagtataatagataatattatatt
 aaaaagagagnnnnnacacttagaatgagcttccatgtgtgaggcactaactgattaggcattattaactagatttat
 tccttttaaggccccgcgatgtactgttatttccacatgttgtagctggggaacgtgctactcagagaggttaagtaac
 ttgtctgaggtccacaccactaacaaggagcacaggtaggggttcaaatccagataatctgactttggagctggcactct
 aactcaatgtgcctaatacgcttttcagtgggtgtcattatttgcctattctccatctgagaatattgaagtttctgact
 ccttcttgcctttctccctgcctcccggtgttatccccaggctcttggtgttccagtcctctatgtccgtccttactct
 tattcctttgctacagtgtgatccagggctcctgccttcttatcctggtagagggggccacttgctgggaaattgtc
 tccgccatggtttatccatgttgtgtgtccattagttagtagtgggaagaatcatatcatgttggcaatgaaagggggg
 ctatggctctggggtagtctagtctgaactcttatttt

[illegible]

© 2008 Pearson Education, Inc. All rights reserved. This publication is protected by copyright. Any unauthorized distribution or reproduction of this work may result in legal action against the individual(s) responsible.

ccaggcaattaacgtgggctaaattggacttttccaaagatgctgtctttgggaaacatcacacatgctttggatcagaa
aacctaggcttctaatttggtgataaggcatgaactcaggagactgttttcagtcctagtgaatggtgataattgtaatt
ataacagtagacaacatctcttttacacattttaaatcatgaaaatagaataaccttactgataattttagaaagtgggtg
attaaaagcacatttaagataatgccttaacacctagtctttccatatgcatgatgtcttaatcacacattgcaaatca
tggaacacagaatttt

[illegible]

1.2.2. *Phylogenetic analysis*

tgtcttctctgcatcaggtcacctctctcacctctgtcactgccccatcagactacaatgtctgcagggtctttctccct
gagtgtgagctccctgagcaaagcaggatgctgccccctccctttgtattccttgctccttgcttcagtgcctgtacata
agtatgggcataataagtgtcccccaaagagacattgaggattcttcaaagcacaggaccgtgatgtgagttaggacg
gagtaaggacgatgggatgtggctcatgacaatcctgaggaagctgcagctgcggcacgcagggccacactgtcatgttc
atggaccctagactggctttgtagcctccatgggccccctccatacac

tcatgactgccattgggtataaagatgaatataatccagaccagattcatgattattcatacatcttttagtgattaaactt
ttaattctgcttttaaaataaattaaaacatttctaatatgcccttaagagtatcccagcccaggccactgagcctactgt
ggttcatggataagtttggccctgggggcatgtgtgtgcatgcatgtgtgtgcacatgcatgatgagccgggccttgaag
ggtggttaagatttgggtgtgtagaccaatggagaaaaggcatttggggcagtgatgatgggtgggggagggaacatggtga
tgaatggagctgggtgtggggagccatgggagtggttagggccagcctgtggaggacctgggagccaggctgagttcta
tgcacttggcagtcacttctgtaaagcagcagaggcagttggcctagctaaagcctttcgcccttttctgcacctttac
agTGTGGCTCGCCTGTTTCTCAGATGCTCGGAGGCTTCTTTTATACAGCCAGAAAGACACCAGCATGAAGGCATGCGCAA
AGTTCTGAGAAACATTACAGCAGATCAAGAAATCCAGCTCAAgaagtaaaaaccttctctgcatccgtttataattggaa
attgacctgcaccagggaaagagagtagcccagggtgtctggggcttgttcccattagatcttccccaaggggttttctc
cttgggtggctggcctgtggggccctctccaggaggcattggtgaagaaaactaggggagctggttgccacagacagtgat
gtactaatcttctctgggaagacagaagaaaaagtccccagggaagaatactacagacttggccttagggacagctagggg
tgcagattgctgccaaactgcattttttctgaagttggccatatggttgcagtgaaatggatttatagacagagtatctctg
tgcataaagagcaattacagttgttaagttgatatggataaagtgaagtttaagcacttctttctaaaaagagaatgcaat
tcattttccccataatcatttcaattagttctgatgggcatttgaacttgttgtctttaaaaagtgaaatctttacctctga
tcgtgtaagtatccaggcaatttctgtgtgccaccaggaggtatctggggagtgggcattttctgactgaggcattgg
ctgccatagcatcagagcagccttccaggcagtggcctggcaaggggacagaggctgggtgggagcagctggctgagtgca
gccagtaatggcatgt

[illegible]

Genomic contig containing ABC1 exon 6:

agtaaaatggagaattccaaattctgaaattggttagaacatagttctgtgtcttagttaaatatcgacacttacagataa
atagcataaatgcttttctccccatatttcagcccagtcctacttaaagacaacataaattgcaaaatagtggagatgttg
ttcatctaataaaaagtgggtccaggaattcagactctggattcctgtttgccaaatcatgtgtccactcttaagaaaac
gagttggactntggatttttctttgcaagagggacaagagtgtgggagatactgagttaatgcaacttgacaggttttaag
tgtcctgtcattgtgccttgtgctttgatacattctgagtttcagtaaagagacctgatgcattggactgttgcaatgga
acctgttttaagatcttcaaagctgtattgatatgaagttctccaaaagacttcaaggacccagcttccaatcttcataa
tcctcttgtgcttgtctctctttgcatgaaatgcttcagGTATTTTTGCAAGGCTACCAGTTACATTTGACAAGTCTGT
GCAATGGATCAAAATCAGAAGAGATGATTCAACTGGTGACCAAGAAGTTTCTGAGCTTTGTGGCCTACCAAGGGAGAAA
CTGGCTGCAGCAGAGCGAGTACTTCGTTCCAACATGGACATCCTGAAGCCAATCCTGgtgagtagacttgctcactggag
aaacttcaagcactaatgcttttcggaatgtgaggcttttccttggacagcatgactttgtttttagaaaaagtagggctg
gctgggagtttgtgatataatttagttcagtggtattctaagtgttcttagtggttcttcagacttttgggccatctccc
aaaggggtgaatgggaagaataagctgggtgtggctgagtttaagccaaaagtgttttgtgcttgtttcaatcagagaaga
cctgctttttcatgtttttactattataataactaagcaagagctcatttgaaaacagagttcttcataatttaaaaaaaaa
aagtcttgaaaccattgatgggaagatggatatctatttatgttttaaaacccatcataaagatgacattgtgggctgtc
acagttggaaggccctggaattagatgagaccacactatttagcttacttagtaataacattg

Genomic exon containing ABC1 exon 7 and 8:

ccgtttggcaaatgctcagtaaaagaaaagggttagaaggggagaaaggcattttatcccaagccttcaggaatcaggat
gaggatgtcttcaccttgtggtggggagtaattatacaattagagacagcacattggagtgtggctgatatgctgtgtga
tgatagctctagctctctgcctagcagaggaaggacatttcaatagaagaaaaagtttaagaccttgcgagaaaacagag
aaaggatgtttgtctttttaagaagttgaaaacctgtttgcagacaaaagccctccagttttggcagtaaaactttcatg
caaggggaagaaaaaggcaggggatgacattgttgacaattgtgaggaattaccatgtgccaggcactgtgcgaggggctt
tgtacatatctctagtttttagtgcttataaaaaactctgtgatattgtgcacagcattttaaactttgctgcatagtgcag
aaaatggaaggatggggaatttgagtcatttgcacagggttctatagctaccccagggttcccatgactggagaattgggg
cacaggggtggcgggggagagtgagtgacaagaatcctaacaatcttatttccattgagtccttataaaaagaagtggatta
actaccacgtttttaagttttcttaaatttaggttatgtggatctggcggtttctgttttgcctgggtttgtttgtt
tttgctatgctgtcttgaacatctgtcatctttaggcctaacggtaaacacaaaaacactttacctctatagctttca
attaagatctctcagttttgtgtttgtaatagtttccaggcaagttctccctaggttcggcttctagtgtgttaaccttt
agttataaagtgaacccaaagagagaaaagtagaaacaaaacacctcacctgtttttgctcatgaattactctctatggaa
ggaacaatcatgaacacctctgcgtatcacagaggcctatctgagtcctgacgtttaagggagaccgcgtaggtccctttg
aggactgtgaattgtgggagtcctgggactctggtgaagaacccgttccagaagagatgaatgagctggacaagtctttc
atagaaccttttaggcagggttttcttagaaatgcacattgaggattatgcttggatattgtgatgacagaatgatactca
atcccttctgcatttggaaattctcttgaagaaaaacatcccaggcagctatttctcagagatagtgagtcacagccact
tctagacattttctgtgtagtcctacattataatttccacagcagtcctctgatatgacaaatgtcaaaatagcccaacctt
ctctaaacttcagagatgtctgatattgaataaaacaatgctcatagaaacatcaagaaagggtggatttttccctg
gatactttttcctgcttgacaaataacagtgagaaactgactctcacgtctgttaaattattgttcttttttcttttagctta
aaccccaacttgaggctctcagctatagcaattctgactctcacagtcgttaaattattgttcttttttcttttagctta
tgctttctgcctcaattatcttttccctgttctaatgaattattgtcctatatctgctgtgcagttaggtgacataata
cagcaattaaatatatgaattggtagacataaaagatttgactaaaactcgatgtaaaaataagtggttctacattcaattt
ccagtggttagaaacagtgctgacttgaacagagtgacagaattccatctttccctatttttgacagctttaaactttata
ttttcttctttctgtgagccgtcattaaacttggttctcaaagccattcccgattaccatcttgacagcgcagacag
atttgggaatttgcggctcagagttgtattggacacatccccccagcccacatgagatccttttaattctattgcatattaa
ctagttttaagtacaatattcctacttctatttaaaaccattaatcaaagaatgagtttgaaaatgaacaaaatgcaaact
tacagttagaataaattgtagtgcttttagttttggttaggagtcgggtttctgtttgttaaactcaagattgtgaacag
ttttaattcacttggtttatttccaatagagatttcaggtttacatttgaattcagaaacaaagttttctttctcattaca
GAGAACACTAACTCTACATCTCCCTTCCCGAGCAAGGAGCTGGCCGAAGCCACAAAAACATTGCTGCATAGTCTTGGGA
CTCTGGCCAGGAGgttaagtgtgtctttccagtagcaggaagcggatcatccactgtatcagattttcattcctgagt
ctggcaagaggtcctttgagttgaatatcacatgggatgtaataatcaattttcaaagtataagtgatgtaaacataat
gttttgatttcttatttagaaatgaagaaacctaataactatagatgtctcagagctaattggttagtgtaaacagc
tggaatctgatttagaaccttctccatttttcttttgccctaggtaatacatacatttgtaagaggagaattatct
ctgccactgcccactgactgctttgtctgaccagcaatttctccatattgcttcttcagtagcaaggccaatcatttta
ccaacacacatgcttgctaaactaacaggaataacgtggtacccttaattcagccctttcccttgaaagcatctggcttct
gaggttcaactatgggaatatggtctcttaataacattagttgagtttgcttttaggtccacatgttgacaaatgta
tcagagtaattctctgctcctaggatcagagggcctgtaggcacttgcaaaagcagttagctctgactcccagccagtgac
actccaccttctgactcccagccttgtctcaaattaggcttggaagcaggaactgtctggtgtccccagcataggaa
gctgagccagggggcagtgctcacaacaatacagactttaacgtgtaggatattggaaaaataaattttgtggggaat
tgtctcagacttggtccaccttatttttagctgcttcttaatccgtttttcttttttgggtgcttgatctaacctac
ccattttttgggtgcttgcatcattttttcaaatatcaaaaacgaactttatgttttctaacaatgaaagtattgcatgtt
cattgtggaaaatgctgaagacttgaaaaatacaaaaatgctgagatcaaacactattgatacgttagtgattttcttcc
tgtctgttctactttcttcttgaattctgctcacgtgttctgactgatgaggtctgactttgggttccctttcca
gaggagaagccttctttcagcttgccatttgttaccctggttatgaaggctggtaacctttttactaggtagagaagct
ggaccaactggggttcttccagggggagaaatgagaaagagaaactgttttgcaagtcctgtagctatttctctagggcct
gttagctgacattgacatgccttgcatgtctgcagatcccttcgcagccctctgtccctgttcttctagggccttag
agaaagcaaaagcagggtctgtaacaggggaggtgctctaaactcagggtttgggttacagctgttttcaactacatcac
tgccctggttttttttttttttttctggcattaaaaaaaaaattggaagcaggtgatgttccattgctgatgtggtgga
aactctccaagtgaacaatatagctttttcttggcagctgtttctgtgcccctgcttgctcctgggtccaggacaagcaag
gacctctgcttcttcaatagaacacctccagatcccttgatcaaaagtactcattgtctgacttgctatttctgtg
agataaatgggagaagatcaataaatgcacttgtttgtccagtcagcgtgtggaaagttgataattttgaccaaagcaca
acctgaaaggaaaagaaaaaggagtgatgtcttctgagaagctgcctaggttcagacagtgctcaccatttccctgt
atgctccacatgacaaacctgagtggtgtctcatcatgtccattttgcagatggcaccaaggctcagaaaggttaggcaac
ttttccagtcacccaatgagtttaattgacaaaactgggattcaaaccagaaactgttggaattccaaagcctgtgtgtg
cctgcttctgtgaaaaactccagtagcagactggaatagaaaggagaaccttccaagaaagaaaatacgcactagcagaacc

Fig. 12

tggaaattgggaggaaatgaggacttgaggaataagatgaatgaaagctgacctgagtttcacatctgggtgatgggaag
 ggaggacagggaggcagcatctcagatgtccaccagcaccgaccagctgcctggcattgctaggtgttgaggactcagc
 agtgaacacgcctaacttctctgctttctggggcacgtataggggtgagagacagaaacaaacaggtcagtgataaatgcc
 acaggaggatataatgcagtgagaagaaagcagggtgaaggggcatagagcatgagaaggtgcttttttaaagggggtga
 ttaggaaagctctctctaaggtgacagttggacctgaaggagatagatgcatgtctgtggtgagggaaagaaactccgaa
 cagggaagaatggcagatacaaaagacattgatgtctagagcatgcctaaggaatgtgtttaaggaccagggaaagtgaacaa
 gtgggtggggggaggagagctcagagcaggaggggtgagtgccatacaggcctggcaagactttggattcctgctgg
 gtgagatgagaatccagcggagggttgaggagggggacatgatgtgatctagagtttagactgtttacactctgggtgt
 tgggttgagaagagactgggatgggggaaaggaggacaaaggacattgtgctggattgagaaagcagtaagtcagtttc
 attcattcactcaaccgatgatgttcaataaccaccatcatccgtgggctaaaggatgaagagccatccctccctgagag
 tcaggaagcacttccagataaaagtgttgagtggtgagctgaggtgtaggagaaagagtaagagtttaccctgaaacggg
 tgctgggaagagtcataagtttggaataactcaataatttatgggtgcttctttagaaagatttgctggctttatgtggga
 agaaatttktttttttgattggggagtggtgggttggtggtgaggctgcctgtggaaagagaagtgagtggtttgactca
 ctgttattttaaaaatctctagggctgttccaaataagcaacaaaggcaaaatggcctggttctctgtccctttctgtct
 gtatgcctcgtacaggttatgaaaagaaaaagtgggaaaagctgtccacctcacctaattgtgttcttgtggagtggtgc
 tagatgccccctctctggagaaaaaaaatccttgtggcctctgacccacctctggagagcctagttcccttctggaggca
 gaaggcaaaagcttaggacctagagagtgctggaccacgcccactcacaggaaccagcaggctgtgaggttgaaagctaggg
 atatggagctttccaggctgggtgcagggcctcgtggcccttccctccctctgtgctctatagctcagctctccagg
 cgggtgtgaacacgcagtgacatttccaggaatacagggtatttattaatgatttcttgtgaaatgtttggaaatacaaaagt
 actctataaaatatttccataatagcattggggctgagaactccacaaagtgcgggaatacatttgcatgtaagacagaaag
 ctgctgggtcatttgatgcctgttgagtggcagtcacagacatgcctagggttctgactcacgctgttgaggactgttc
 tatgcaagggcacccctctgtgtggcattagatttgtgctccaccacacactgtttagcttctgtgtgatgatgagtg
 agagggcagtgctccaggccatgggtataagcatctactgccccccagggttaccaaaaccaagcgaagttgtgtctcagcg
 agctccgtgaagcatggagaagttgagtgactcagagacatgacgtgacttttcaaaggctgtaagctgacgaggggacata
 gctagggttcagacttgagtttttcttttcttttcttttcttttctttttaaagactgagttctgcttttctgcccc
 ggctggattgcagtggtgcttgggtcactgcaacctctgcctcccggttcaagcaattctcctgcctcagcctcccgag
 tagctgggattacaggcacctgccaccatgcctggccaacatttttgtatttttttagtagagatgggggttccaccatgt
 tggccaggctggtcttgaactcctgacctcaggtgatccaccgcctcgcctcccaaagtagctgggattacaggtgtga
 gccactgcacccggccagactcgagtttttcatcttaatgctttttcattgcctgacactttactgagaccaagatagg
 gaacttcacatacagtagcttttctcccaaggcggaagagggtgttcaatttctacactagagttcggggagttttaga
 aatgagtcagttatcgaggatgagagcagttcctgataggctcaaccacaatgagatgtagctgttcagagaaaagcattc
 tttatctataaaactggaagataatcccggtgaaacgaagccagccccagggttcaactccaggctgtgcttct
 caaacttttagtgagcataggaatcacctgggcatctgtgaaagctgtagatttgaattctgcaggctggcagaggggtct
 cagaactccgattttccaaatgtctccagtaagtctgtgctcctgcctggaccacagattgggtagccaggttct
 ggcaagctcatcccaaggctttgagatgacatcagacaaaatattgttctgggacatggcttttgagaggtcaagaaaata
 agatgtttcttctctctctcatccccaaaccttgcactgccccttttctccctccctaccctcttctgtcccatcc
 ctgacgccagctGTTTCAGCATGAGAAGCTGGAGTGACATGCGACAGGAGGTGATGTTTCTGACCAATGTGAACAGCTCCA
 GCTCCTCCACCCAAATCTACCAGGCTGTGTCTCGTATTGTCTGCGGGCATCCCGAGGGAGGGGGGCTGAAGATCAAGTCT
 CTCAACTGGTATGAGGACAACAACACTACAAAGCCCTCTTTGGAGGCAATGGCACTGAGGAAGATGCTGAAACCTTCTATGA
 CAACTCTACAAgtgagtgctccatgcagacccagccctgtccccaaccccatccctcccttagttctggccttggcctgt
 gtcattctctccctctgttagcagcgttagatgtctacatgccatttgcccaccagactgagctcttccctagaggagaga
 ggcttctcttgaatagctacctgtccccagttctctgaatgcagcctggcacatctcaggtgcacagtagtggttatcaa
 tggaaatgaatgattgacagccaaaccttctggttttctgggggatgtggaagggtggcttccagggtgatcaagaatgaga
 taatggcagaaggacaaatcctgcaagatctcacttatatatggaatatatgtaaggtagaaagtgtcagtttcacatga
 tgaataagttcctgggatcttgatgtacatcgtgatgactatagtttagtaacactgtatagtatacttgaatttgctaa
 gagagtagatccgaagtgttcacactacacaaaaaggcaactatgaggtgatggatttattaacagcttgattgtggtg
 atccctttacaaagtatacatatattaaaacatcacattgtataccttaaatatatacaattttatttgcagttgttaa
 ctcaaaaaagctagaaaagcattttttaaagggtgatgtactggtcttaattattaccattgagataagctttataataa
 cataaaaaagaaataacagtaatgataatagcaacaacaacaacaagaactaacatttaagtagaatttcttgtgca
 ctgtgcattctgtttaagttatctcattttaccctcatgataacctgcagggaagattctttaacccacatttcatagg
 ctgagagaggttaagtgccttgggttagagccacatcagagttaatccacaagagccaggattcaagcccaaatctgcctg
 gatctgtgctctctaagataactgttagtggtggcgtgtgtgttctcacactcagacatttgatctgcctttgtttccc
 attcttagctgcaaggcagtggttaagaacctgtgtctccatattccactcccacacttaagcacttttgtgggcccgt
 gtgcccgtatgcctcgtggcagcagggtccaatgtcacagttttaggcagtggtccttttccctgaaaacttgatgca
 ggggaacctttctcatttcccaaccacaggtgtgtcttccagacactgagtgaggcagggtttgtactttattgtaacac
 aagaaccttttctctctctggagtaaagcactccagacattcgcaagttgctttacaagccttaaaaggatgggtattgtag

Fig. 12
 Page 12 of 30

gcaactttaattaaatcccatctctctctccccagcttgcaagtgaccaaggaagccttcatttccatgacagac
ttaattgtgagggcctcctca

gcaactttaattaaatcccatctctctctccccagcttgcaagtgaccaaggaagccttcatttccatgacagac
ttaattgtgagggcctcctca

[illegible]

Page 14 of 30

[illegible]

ttgttcagagaatgagttgttttttggtttttttagtactttaacataaatctacctttagttttaagttatgcgtcac
agtttagcagttactgaagcaagccccaaagaaatttgggttggcaacactttgtagcctcggttttctctacatt
gcattgctcgtgaagcattggatcatacgtacatttcagagtcagagggcctgtccttctgtggcccagatgtggtgct
ccctctagcatgcaggctcagaggccttggcccatcacccctggctcacgtgtgtctttctttctcccttgtccttccct
ggggcctccagCTTTCTGCGGGTGATGAGCCGGTCAATGCCCTCTTCATGACGCTGGCCTGGATTTACTCAGTGGCTGT
GATCATCAAGGGCATCGTGTATGAGAAGGAGGCACGGCTGAAAGAGACCATGCGGATCATGGGCCTGGACAACAGCATCC
TCTGGTTTAGCTGGTTCATTAGTAGCCTCATTCTCTTCTTGTGAGCGCTGGCCTGCTAGTGGTCATCCTGAAGtaagg
cagcctcactcgtccttccctgccaggaaactccgaaatagctcaacacgggctaaggaggagaagaagaaaaaaatc
caagcctctggtagagaaggggtcatacctgtcatttccctgcaatttcatccatttatagttggggaaagtgaggccag
agaggggcagtgacttgcccaagggtcaaccagccgggtagcagctaagtaggatgagagtgagggttcatgctttcca
gataaccacatgctcaactgtgccatgctgtctcattggtagtgggttcatggcagcatctgaaagctatttattttctta
gatataattgggtggcgatttcttctaagtttcttaagaacaataatcagaaggatataatattgttgcaggttagactgtct
ggaagcagagcctgaaatagagtttgatgtatgggtatttatgagggctcaatacctatggaagagatatggaagatgca
ggattgggcagaggaggagtgaactgtgatatagggccaaacccgtggggcactctagagaatatgcagcttgttgga
gttgttcttcatcgagctgaaacatccagcccttctgtgtcccccaaggctccctcctgcaccacctaactcagccct
ctcaatcaatcactggatgtgggctgccctgggaaggctcgtgccccagggcctacatggctctctgctgctgtgacaaac
ccagagttgctgatgctgaggccgtctactgacagctgggcaacaaggcttccctgaatggggactctgggcagtgag
ttttgtgtctgaaccatacattaatatattttatatccgaatttcttctctgcaagcatttcatataaagacacatcag
gtaaaaataaatgtttttgaagcaaaaggagtacaaagagataagaactaactaatttaataactagttaccatctgttac
aaatagttccctactgattgccaaaggactgtttaacacatcacatgggcttcttcttctatcctcactaacccttttaac
agacaaggaaatgaggctcaggaagggtcaaggactttattgagggtccacagtaggatacagttccttgctaaaagcaacc
cctccctcatgctctgttatctaactgcaaggggaagggtcagtggcagaggtagtggctcccatgggtgggtgcataagagc
tgctctgagacaactgcatgctgggtgggtcctgcagacatgtacccatcagccggagatagggtcaaaatatccacaaga
gtttgtagattgtgggaatgcagaatccatgggtatcaagaggaaagtcaagttgctcctggccatttcttcttggctttt
agacagaaaagttagtgggataattatctcccacagctcttctgtggtggccaccagctatagtccttataaaggagaaa
ccagttgaaattaccatttgaaagaaacaaagagcaaaactgcccatgaaatgcgtagaaaagccctggactctgtgtgat
tcataactctgccattatttttctgcgtagttttgggtaagtcacttatcttctttaggatggtaatgatcagttgcctc
atcagaaagatgaacagcattacgcctctgcattgtctctaactagtaggaataaaacccctgtctttttctgtagatc
atacaagtgagtgcttgggattgttgaggcagcacatttgatgtgtctcttcttccctccagTTAGGAAACCTGCTGCCCTA
CAGTGATCCCAGCGTGGTGTTTGTCTTCTCTGTCCTGTTTGTGTGGTGACAATCCTGCAGTGCTTCCTGATTAGCACAC
TCTTCTCCAGAGCCAACCTGGCAGCAGCCTGTGGGGGCATCATCTACTTCACGCTGTACCTGCCCTACGTCCTGTGTGTG
GCATGGCAGGACTACGTGGGCTTCACACTCAAGATCTTCGCTgtgagtaacctctggcctttcttcagtggctgtaggcat
ttgaccttctcttggagtccttgaaataaaagcagcaagttgagaacagaagatgattgtcttttccaatgggacatgaac
cttagctctgattctaaagcttttaagggtaaaggccaagcatgtgttttattaaattgtttacctttagctcttctcag
tgaatcctggttgaattgaattgaatggaattttccgagagccagactgcattctgaaactggctggggataaaatggca
ttgaggaatggcttcagggcaacagatgccatctctgccctttatctcccagctctgttggctatgttaagctcatgacaa
accaaggccacaaatagaactgaaaactcttgatgtcagagatgacctctcttgtcttcttctgtgtccagtatggtgttt
tgcttgagtaaatgttttctgaaactaagcacaaactgaggagcagggtgcctcatcccacaaattcctgacttggacacttcc
tccctcgtacagagcagggggatattctggagagtggtgagccctacaagtgcaagttgtcagatgtcccagggtca
cttatcaggaaagctaagagtgactcataggatgctcctgttgccctcagctctgggcttcataggcatcagcagcccaaa
caggcacctctgatcctgagccatccttggtgagcagggagcctcagaagactgtgggtatgcgcatgtgtgtggggga
acaggattgctgagccttggggcatcttggaaacataaagttttaaaagttttatgcttcactgtatatgcatttctga
aatgtttgtatataactatgagtgggttacaattggaatcattttatagtgtacttggtagccaccactcctaagggactc
tataggtaaataactactctgcaccttatgattgatccatttgcataattcaaaattctccaggataaatttacactaga
agagatagaaaaatgagactgaccaggaatggataggtgactttgcctgttttctcacagAGCCTGCTGTCTCTCTGTGGC
TTTTGGGTTTGGCTGTGAGTACTTTGCCCTTTTTGAGGAGCAGGGCATTGGAGTGCAGTGGGACAACCTGTTTGAGAGTC
CTGTGGAGGAAGATGGCTTCAATCTCACCACTTCGGTCTCCATGATGCTGTTTGACACCTTCTCTATGGGGTGATGACC
TGGTACATTGAGGCTGTCTTTCCAGgtacactgctttgggcatctgtttggaaaatatgacttctagctgatgtccttct
tttgtgctagaatctctgcagtgcatgggcttccctgggaagtgggttgggctatagatctatagtaaacagatagtcca
aggacaggcagctgatgctgaaagtacaattgtcactactgtacagcacttggttcttgaaaactgtgtgccagggcagc
atgcaaaaatgttttatacacattgttctatttaattctcacaaggctactctgaagtagttactataataaccagcaatt
ttcaaatgagagaactgtgactcaaagacgttaagtaaccagcttgggtcacacaactgttaaatgttggttacgtggagg
tgaatccacttcggttacactgggtcaataagcccaggcgaatcctccaatgctcacccaattctgtatttctgtgtcc
tcagagggggtaacaactaggagagggttctgtttcctgagtacagggtgtttaataatttaataatactagctcaaggcctg
cctgtgatttaattagcattcaataaaaaattcatgttgtaattttctttagtacttttctaataataataactctctc
tgaccaagtccaagaggaacctgcgttggacagtttcatatgagatcaaattctgagagagcaagatttaaccctttt
ggttacccttctgactcctcccctaaggaggtatacatgaaatatttattactcctgcctgaacttcttctattgaatatg

Fig. 12
Page 16 of 30

1. *Chrysomelidae* (10 species)
 2. *Curculionidae* (10 species)
 3. *Chrysomelidae* (10 species)
 4. *Curculionidae* (10 species)
 5. *Chrysomelidae* (10 species)
 6. *Curculionidae* (10 species)
 7. *Chrysomelidae* (10 species)
 8. *Curculionidae* (10 species)
 9. *Chrysomelidae* (10 species)
 10. *Curculionidae* (10 species)

Fig. 12
Page 17 of 30

attgaaagttgtaactgcctgggtgcatgggtggccaggcctgctggaacaggttggaagcgatctgtcacctttcacttt
gatttcctgagcagctcatgtgggtgctcactgttgttctaccttgaatcttgaagattattttccagaaattgataaag
ttattttaaaaaagcacggggagagaaaaatatgccattctcatctgttctgggccaggggacactgtattctggggat
ccagtagggccagagctgacctgcctccctgtccccagGCTGACTGTGGAAGAACACATCTGGTTCTATGCCCGCTTGA
AAGGGCTCTCTGAGAAGCACGTGAAGGCGGAGATGGAGCAGATGGCCCTGGATGTTGGTTTGGCCATCAAGCAAGCTGAAA
AGCAAAACAAGCCAGCTGTCAGgtgcgggccagagctaccttccctatccctctccctcctcctcggctacacacatg
cggaggaaaatcagcactgccccagggtcccaggctgggtgcggttggttaacagaaacttgccctggctgtgcccctag
gtcctctgccttcactcactgtctggggctgggtcctggagtttgtctgtctgtttttttagGTGGAATGCAGAGAA
AGCTATCTGTGGCCTTGGCCTTGTGCGGGGATCTAAGGTTGTCATTCTGGATGAACCCACAGCTGGTGTGGACCCTTAC
TCCCGCAGGGGAATATGGGAGCTGCTGCTGAAATACCGACAAGgtgctgatgtgtatttattctgagtaaattggactga
gagagagcggggggccttttgagaagtgtggctgtatctcatggctaggcttctgtgaagccatgggatactcttctgtta
kcacagaagagataaaaggcattgagactgagattcctgagaggagatgctgtgtctttattcatcttttgtccccaac
atgggtgactaaatttatggttagttgaaagggtggatgcttaaatgaatggaagcggagagggggcaggaagacgattgg
gctctctgggttagagatctgatgtggtacagtatgaggagcacaggcaggcttgaggccaactctggcttggccctgaga
cattgggaaagtacaaacttgccctcaccttctttgccgataataatagtggtgcttacctcatagaggattaaattaaa
tgagaatgcacacaaaccacctagcacatgcctggcatatagcaagttcccaataaaatgcgtactgttcttacctct
gtgaggatgtggtacctatatacaaaagctttgccattctaggggtcatagccatacagggtgaaagggtggcttccagg
tctcttccagtgcttaccctgtataatctctctagtcctctgactgtgacaaatcagaactgagaggcctcacctgt
cccacatccttgtgtttgtgcctggcagGCCGCACCATTATTCTCTTACACACCACATGGATGAAGCGGACGTCCTGGG
GGACAGGATTGCCATCATCTCCCATGGGAAGCTGTGCTGTGTGGGCTCCTCCTGTTTCTGAAGAACCAGCTGGGAACAG
GCTACTACCTGACCTTGGTCAAGAAAGATGTGGAATCCTCCTCAGTTTCTGCGAGAAACAGTAGTAGCACTGTGTCTATAC
CTGAAAAAGgtgagctgcagtcttggagctgggctgggtgttgggtctgggcagccaggacttgctggctgtgaatgattt
ctccatctccacccttttgccatgttgaaaccaccatctcctgtctgttgccctttgaaatcatatcatacttaag
gcatggaaagctaaggggcccctctgtcccattgtgctagtctgttgatcccgttttccttttctatgaggcacana
gagtgatggagaaggctccttagaggacattattatgtcaaagaaaagagacttgtaagaggtaagagccttggctaaa
atgacctggtcgttccctgtcattacttttcaatctcattgaccttaacttttaactataaaacagccaatatttatta
ggcactgatttcatgccagagacactctgggcattgaaagaaagtaatgataatagttaattttatatagcgttggtacc
atttcaaccttttttttttttaacctctatcatctcaattaaag

Genomic contig containing ABC1 exons 23 to 28:

gtgaacacacattaaagcatgagaagcatgaactagacatgtagccaggtaaaggccttgctgagatggttggcaaaggc
ctcattgcagcattcatttggcaggccacagttcttttggcagctctgcttccctgaccttccacctcaggaagcgaggct
gttcacacggcacacacatgCCagacaggggtcctctgaagccacggctgccagtgcatgtgtcccagggaaagcttttct
ctttagttctcacacaacagagcttcttggaaagccctccccggcgaaggtgctggtggctctgacctgctccgtccctga
ccggttctcacctccttcttggccatcagGAGGACAGTGTCTCTCAGAGCAGTTCTGATGCTGGCCTGGGCAGCGACCAT
GAGAGTGACACGCTGACCATCGgttaaggactctgggggttcttattcaggtgggtgacctccccagctgggcaga
gtggaggscagaggaggagaggtgacagaggctgggtggcgctgactcaaggttgctgctgggctggggctgggtggctgag
gggtgggagcagcttgggtggcggttggcctaagtcttgctgggtgacctggggctcggttgggagctagcagggcag
tgtcccagagagctgagatgattgggggttggggaatcccttaggggagtggaactgaataccagggatgaggagctga
gggccaagccaggagggtgggatttgagcttagtacataagaagagtgaagaccaggagatgaggaacagccttccaga
tttttcttgggtagcgtgtgtaggaggccagtggtaccagtagcatatgtggaacagaagtcttgaccttgctatctct
gcctagtccaatggctggcttttcccaggaaggcttctgcttccatggactgttagattaaccttttatttaggtaaat
gagggaaacctactttataagcataggaagggtgaagaatctttaagattcctttactcaagtttcttttgaagaatc
ccagagcttaggcaatagacaccagactttgagcctcagttatccattcaccatccaccacccacccacccatccttc
catcctcccatcctccattcaccatccaccatccagctgtccaccatctacactgagtacctataatgtgcctgg
ctttgggtgatacaaagggtgaataagacatagtcctttccttggcccccaacctcagaccagagatgaacatgtggaatg
acctaacacacctggaacaggtgtggtgtatgagcggcaggcctctgatgagagggtgggggatggccagccctcactccg
aagccctctgagttgattgagccatcttgcattctggctctgcagATGTCTCTGCTATCTCCAACCTCATCAGGAAGC
ATGTGTCTGAAGCCCGGCTGGTGGAAAGACATAGGGCATGAGCTGACCTATGTGCTGCCATATGAAGCTGCTAAGGAGGGA
GCCTTTGTGGAAGTCTTTCTAGATGACCGGCTCTCAGACCTGGGCATTCTAGTTATGGCATTCTCAGAGACGAC
CTTGGGAAGAAgtaagtttaagtggtgactgtcggaatatatagcaaggccaaatgtcctaaggccagaccagtgcctgc
attgggagcaggaattatcatggagttagtcattgagtttttaggtcatcgacatctgattaatgttggccccagtgaacc
atthaagatggttagtgggagatagcaggaaagaagtgttttctctgtaccacagtagcatgcctgagatttgtgtgttga
aaccagtggtacctaacacatttacctcccaaccttaaaactcctatgcacttatttaccttttaagagcctcttactt
aagtacagtgkgaggaacagcggcatcaggatcacttgggaacttgttagaaattcagcaacttggggccagctcagacc
tactgaatcagaatcaggagcaattctctggtgtgactgtgtcacagccagggtatcaactggattctcatacataggaaa
tgacaaacggttatggatggatagtcacttgtgcccagggtgctgagatttgtttttgtttttgatttttttttaataca
ctgtgacctcattttaattctcaaaaaaagatgaaaaaatgaacactcaggaatgctgacatgagattcagaatcaggggt
ttggggcttcaaagtcacatcctctctttatccatgtaatgcctcccttagagatacaacatcacagacctgaaggctg
aaggggatataaaaagctgtctggccaagtgggtctccaagcttgacagtgcagcagaatcacctggggatattttaaaaa
taaacataactaaggttgggttcagggcctgtgaatcagaatttctggagggtgaggccttgaagtcgtatttctattgc
atactttggacacagtggtctatagactagagtttggaaatgattgcgctcattcagattctctctgattgttgaattg
ctgcatcatatttctagtgctctatttccctgctcattctgtcttggataacttatcatagtagctagcctactcaaa
gatttagagccacagtcctgaaagaagccacttgactcattccctgtaggttcagaataaaatttcttctgcgcagtgtct
gtcatagcttttttttaatttttttttatttttgatgagactggagttttgctcttattgcccagctggagtgagtg
tgcgattttggctcactgcaacctccacctccaggttcaagcgattctcctgctcagcctcccaagtagctgagatta
caagcatgtgtaccacgcccagctaattttgtatttttagtagagatgggttttatccatgttgggtcaggctgggtctcg
agctccagacctcagggtgatctgcccgcctcgccctccaaagtgtgggattataggcctgagccacagcgtcagcca
taactttaatttgaaaatgattgtctagcttgatagctctcaccactgaggaaatgttctctggcaaaaacggcttctct
cccaggttaactctgagaaagtgttattaagaaatgtggcttctacttctctgtcttacggggctaacatgccactcagt
aatataataatcggtggcagtggtgactactctcgtaatgttgggtgcttataatgttctcatctctctcattttccagATA
TTCCTCAAGGTGGCCGAAGAGAGTGGGGTGGATGCTGAGACCTCAGgttaactgccttgaggggagaatggcacacttaaga
tagtgcttctgctggcttctcagtgacagagattgttcttcttcccttgaattgttctattgcatctcattttag
agtgtaggttgttgcagatggggaaggttgtttgttggtaaaaaataaagtatgggattcttcttctgtgccttca
gATGGTACCTTGCCAGCAAGACGAAACAGGCGGGCCTTCGGGGACAAGCAGAGCTGTCTTCGCCCCTTCACTGAAGATGA
TGCTGCTGATCCAAATGATTCTGACATAGACCCAGgtctgttagggcaagatcaaacagtgctcactgtttgaatgtga
aattctctctcatgctctcacctgttttcttggatggcctttagccaaggtgatagatccctacagagtcacaaagagaa
gtgaggaaatggttaaaagccactgttcttgcagcatcgtgcagtgatcaaacctgaaagagcctatccatatcactt
cctttaagacataaagatgggtgctcaatcctctgaacccatgtatttattatctttctgctgggggtcctagtcttctg
tatacattaggtgtttaaattgttgaacaaatattcattcgagtagatgagtgatttgaagagtcagaaaggggaattt
gctgttagagtttaattgtaccctaagacttagatatttgaggctgggcatgggtggctcatgccagtaatccagcgtt
gagaggctgaggtgggtagatcacctgaggtcaggagtttgagaccagctcgaccaacaaggtgaaaccccgctctact
aaatacaaaaaattagccgagtggtggcacatgcctgtcatccagctacttgggaggctgaggcaggagaatcgctt
gaacccaggaggcagaggttgcagtcagccacggttgcgccattgcactccagactgggcaacaagagtgaaaactccat
ctcaaaaaagaaaaaaaagaattagatatttggatgagtggtcttctgtgtgtttaaactgagatggagaggagagcta

Fig. 12
Page 19 of 30

agacatcaaaacaaatattgttaagatgtaaaagcacatcagttaggtatcattagtttaggacaaggatttctagaaaat
 ttttaggaacagaaaactttccagttctctcaccctgctcaaagagtgtatggctcttacattatataaactgcctga
 cttcatacagtatcagttacttagatcatttgaaatgtgtccacgttttaccaaaatataatagggtgagaagctgagatg
 ctaattgccattgtgtattctcaaatatgtcaagctacgtacatggcctgtttcatagagtagtctataagaaattgatg
 acttgattcatccgaatggctggctgtaacacctgggttacgcatgaacacctctttcagttgtctcaagacacctttct
 tttctgtacttatcagacaaggactgaaaggcagagactgctactgttagacattttgagtcagcttttcttgacat
 agctttgtcatgaaagccctttacttctgagaaacttctagcttcagacacatgccttcaagatagttgttgaagacacc
 agaagaaggagcatggcaatgccgaaaacacctaagataataggtgacctcagtggtggcttcttgacagAATCCAGAGA
 GACAGACTTGCTCAGTGGGATGGATGGCAAAGGGTCTACCAGGTGAAAGGCTGGAAACTTACACAGCAACAGTTTGTGG
 CCTTTTGTGGAAGAGACTGCTAATTGCCAGACGGAGTGGAAAGGATTTTTTGCTCAGgtgagacgtgctgttttcgcc
 agagactctggcttcatgggtgggtgctgaggctctgtgaccagtgaaggcaggatagcatcctgggtcaagatatggatgc
 cggagccagatttatctgtatttcaatcccagttctattccttgccagttgtgtatccgctggcaagttacttctctatg
 cctcaatctcctcatctgtaaaatggggataataatattacctgcaatacagggtgtgtacgaaaataaaaatgaatagg
 tgcttagaatggggcctgacattagtaagtgttagttttgtgtgtgtatgtttatttttatgttgaggagaacataa
 aaaggacaaagtgtagaaaaactgggtgggtgtattcagctgtcataacatgagagttgttatgccagatgcacttgac
 atgtgaatttattagaaacatgatttttctctgagttgtgtttaactcaaactgatagaaaagataggtcagaatatag
 ttggccaacagagaagacttgttagactattgtctgcatgtcagtggttgcatgctaacttgcttagttagaaaggttaa
 attttttactctataaaaatcaagaaatatagagaaaaggctctgcagagagcttttcatttgatgatgtggatatgtta
 agagcgggagtttggagcatacagagctcaagttgaatcctgactttgctacttattggctatatgaccttgggcaagct
 gcttagtctctctgatcctcagttacctttgtttgttgatgatgaccattgataacacaaccataaataatgacaacata
 gagatagttctcattatagtagttgttatacagaattattcactcaatgttaattttctgcattgaaatcccagaacatt
 agaattggggggcatttatttgaatctttaagggtataaggaatacattttctcagcaataaatgggaaggagtttgggttaa
 cttataaaagtatacccaagtcattttttttcagagaagatatggtagaaaagtccttaggaggttgaagaaggaaattggata
 tttattctttctgagactatcatgggagataatgactatggttgctccatgattggagccgttgctgtagagttgggttta
 ttatagtgtaggatttgaatgggcatgtgttctcagacctcagaataaaaagagaaaactgaggccagtgaggagcgtg
 acttcacatgggtacacttgtgctagagacagaaccaggattcaggacttctggctcctgggtcctgggttcatggcccaa
 tgtagtctttctcagtcctcaggaggaggaaggcaggaccagtggttctgagtcaccctgaatgtgagcactatttact
 tcgtgaacttcttggcttagtgccctcgcagggtggccataacctctggccttgtgttgccagagaaaagggttagttt
 caggctccattgcttcccagctgccaagaatgccttggtgcagcacagtcataggccctgcattcctcattgcccgtgctg
 gttggctcggggaggtgggtgactcgtagggtattgccccttgcccttgtttctaacttgccgtttcctgctgtccc
 cctgccccctccactgcctgggtaaagATTGTCTTGCCAGCTGTGTTTGTCTGCATTGCCCTTGTGTTTCAGCCTGATCGT
 GCCACCCTTTGGCAAGTACCCAGCCTGGAACCTTCAGCCCTGGATGTACAACGAACAGTACACATTTGTCAGgtatgttt
 gtcttctacatcccaggagggggtaagattcgagcagaccaaagatgtttacgagggccaagggaatggacttcagaatt
 acacgggtggaat

[illegible]

Fig. 12
Page 21 of 30

Genomic contig containing ABC1 exons 30 and 31:

tcttggcagtcctctactcatttttccagcacatcgagcataagatccagactctttcccaggcctctctcatctggctcct
ctcctcctcctttatcattactcttcttctgtagcttatcctactccagccatgctgtcttcttattatcctaaaaarta
gaaatgcattttcttcttagggcctttgtacctgcacttgccatcgcttttgctcagaatgttctttttgccaagcttttg
cccagcttggtctccatcattgttatgttttggctgaaatgtcttctttagtaggttcatttctcccagtcactgtctt
tttattttgctttattttgggccaatctaagggttatcttattagtgtatttgttgttcgtctcctccatgggcatacacct
ccatgaaggcaggtattttcaccttaggcctcgaatatactggacagcatctggcacgtagtagatgtcaacgaatgt
ttgttgtgtgagcaaatgggttgggtgattggattgaactgagttcagtatgtaaatatttagggcctctttgcattctat
tttacttatgtataaaatgatacataatgatgatataaatgatgtcacagtgtacaaggctgttgtgggatcaagcaatc
aaatgagatcatgcttgtcttttccaaatgggtgaggaatagatgcattgttgtgggtgttacggaatgatcctgtgctc
ctgaggcaacagaaaggccaggccatctctggaatcctactcttgcgtgtcttccctttgcagAGACACGCCCTGCCAGG
CAGGGGAGGAAGAGTGGACCACTGCCCCAGTTCCCCAGACCATCATGGACCTCTCCAGAATGGGAACCTGGACAATGCAG
AACCTTTCACCTGCATGCCAGTGTAGCAGCGACAAAATCAAGAAGATGCTGCCTGTGTGTCCCCCAGGGGCAGGGGGGCT
GCCTCTCCACAAGtgagtcactttcagggggtgattgggcagaaagggtgcaggatgggctggtagcttccgcttggaa
gcaggaatgagtgagatatcatgttgggaggggtctgtttcagtcctttttgttttttttctgaggcggagtc
ttgctctgtcgccaggctggagtgctgtggcatgatcttgccctactgcacccctccacctcccagggttcaagcgattct
cctgcctcagcctcctgagtagctgggattacaggcagcaccaccatgtctggctaatttttgtgttttttagtagagat
agggtttcgccgtgttggctaggctgggtctggaattcctgacctcaggtgatccacccgcctcggcctcccaaagtgtg
ggattacaggcgtgagccactacgcccagccctgtttcagtccttaactcgcttcttgtcataagaaaaagcatgtgagt
tttgaggggagaagggttggaccacactgtgcccagctgtcccacagcagtaaaagtacaggacagactgtggcaggc
ctggcttccaatcttggctctgcaacaaatgagctggtagcctttgacaggcctgggctgtttcttcacctctgaatta
gggaggctggaccagaaaactcctgtggatcttgtcaactctgggtattcttagagactctgtttgggaaggagtcctgag
ccatttttttttcttgagaatttcaggaagaggagtgcttatgatagctctctgctgcttttatcagcaaccaaattgc
aggatgaggacaagcaattctaaatgagtagcaggaactaaaagaaggcttgggtaccactcttgaaaaataatagctagtc
caggtgcggggtggctcacacctgtaatctcagtattttgggtgcccagggtggactgatcacctaagggtcaggagttcg
aaaccagcttggccaatgtggcgaaaccctgtctctactaaaaattcaaaaaattagccaggcatgggtggcacatgcctgt
aatcccagttacttgggaggctgaagcaggagaattgcttgaacctgggaggtggaggtcgaggaggccaaaattgcgc
cactgtactccagcctgagcaacacagcaaaactccatatcaaaaaataaaatgaataaaataacagctaattctagtc
cagtataactccagtgaacagaagatttattagccatagtgaatgatgggtgcttccctaaaaatctcttgactacaaagaa
tctcatttcaatgtttattgttttagatgttcagaataaattcttgggaaagaccttggcttgggtgtaagtgaattaccag
tgccgagggcaggggtgaaccaagtctcagtgctgggtgactgagggcagtgctcgggacctgtagtcagggttccgggtca
cactgtggacatgggtcactgttgtccttgatttgttttctgtttcaattcttgtctataaagaccgctatgcttgggttt
catgtgatgacagAGAAAAACAAAACACTGCAGATATCCTTCAGGACCTGACAGGAAGAAACATTTCCGATTATCTGGTGA
AGACGTATGTGCAGATCATAGCCAAAAGgtgactttttactaaacttggccctgccttattattactaattagaggaat
taaagacctacaaataacagactgaaacagtgggggaaatgccagattatggcctgattctgtctatttgaagttagga
tattatcccaaactagaaaagatgacgagaggactgtgaacattcagttgtcagcttcaaggctgaggcagcctgggtct
agaatgaaaatagaaatggattcaacgtcaaattttgcccac

Genomic contig containing ABC1 exon 32: _

gcatgctggagtgatagtgaccatgagtttctaagaaagaagcataatcttccatcatgtcatccacaattgaaatatta
 ttgttaattgaaaaagcttctaggccaggcacggtggctcatgcctgtaatcccagcacttttaggagccaaggcgggtgg
 atcacttgaggtcaggagtttgagaccagcctggccaacatggggaaaccctgtctctactaaaaatacaaaaataagctg
 ggcgtggtggtgogtgccctgtaatcccagctacttgggaggctgaggcaggagaactgcttgaatctgggagggcggaggt
 tgcagtgagctgagttcatgccattgcattccagcctgggcaacaagagcgaaaccatctccaaaagaaaaaaaaaaga
 aagaaaaagcttctagtttggttacatcttgggtctataagggtggtttgtaaattgggttaacccaaggcctggttctcat
 ataagtaatagggtatattatgatggagagaaggctggaagaggcctgaacacaggcttcttttctctagcacaaccctac
 aaggccagctgattctagggttatttctgtccgttccttatatcctcaggtggatatttactccttttgcatcattagga
 ataggctcagtgctttcttgaactgatttttgttcttctgtctctgcagCTTAAAGAACAAGATCTGGGTGAATGAGT
 TTAGgtaagttgctgtcttcttggcacgttttagctcagggggaggatggtgttgtaggtgtgcttggattgaagaaagcc
 ttggggattgtttgtcactcacacacttgtgggtgccatctcactgtgagga

600 500 400 300 200 100

Genomic contig containing ABC1 exons 33 to 36:

gctttatagagtttctgcctagagcatcatggctcagtgcccagcagccctccagaggcctctgaatatttgataact
gatttccttgaggagaatcagaaatctcctgcaggtgtctagggatttcaagtaagtagtgtgtgaggggaatacctac
ttgtactttcccccaaacagattcccagggcttcttaaggactcaaggacaatttctaggcatttagcacgggactaa
aaaggtcttagaggaaataagaagcgccaaaaccatctctttgcactgtatttcaaccatttgccttctgggttttga
aggaacaggtgggactggggacagaagagttcttgaagccagtttgtccatcatggaaaatgagataggtgatgtggcta
cgtcagggggccgaaggctccttggtactgatttccgtctttctctctgccttttccccaaaggccaggacccttgga
tctctgggcagagcagacgcaggccctataatagccctcatgctagaaaggagccggagcctgtgtataaggccagcgc
agcctactctggacagtgcagggttccactctcccaactccccactctgcttgcctccagaccacattcacacacgagc
cactgggttgaggagcatctgtgagatgaaacaccattctttcctcaatgtctcagctatctaaactgtgtgtgtaatca
ggccaggtcctccctgctgggcagaaaccatgggaagttaagagatggccaaactttattagaggaagctgacgtgtaact
tctgaggcaaaaatttagccctcctttgaacaggaatttgactcagtgaaacttgtacacactcgcactgagctgtctgt
gatgatactgtgcacccactgtctgggttttaatgtcaggctgtcttttagGTATGGCGGCTTTTCCCTGGGTGTCAG
TAATACTCAAGCACTTCTCCGAGTCAAGAAGTTAATGATGCCATCAAACAAATGAAGAAACACCTAAAGCTGGCCAAGg
taaaatctctatcgtaagatgtatcagaaaaatgggcatgtagctgtctgggatataggagtagttggcaggttaaacgga
tcacctggcagctcattgttctgaatatgttggcatacagagccgtctttggcatttagcgatttgagccagacaaaact
gaattacttagttgtacgtttaaaagtgtaggtcaaaaaaaatccagaggccaggagctgtggctcatgctgtaatcc
tagcactttgggaggtgaaagcgggtggatcacttgaggtcaggaggtcgagaccagcctggcctacatgacaaaacccc
gtatctactaaaaatacaaaaaaattagctgggcttgggtggcacacacctgtaatcccagctacttgggagggtgaggca
ggagaattgcttgaaccctgtaggaagaggttgttagtgagccaagatcgacacgttgcactccagcctgggcaacaagag
caaaactccatctcaaaaaacaaatataatccagagatttaaaagctctcagaggctgggcgaggtggcttacacctgtt
atcccagcattttgggatgcccaggcgggcgaagcacaaggtcaggagtttgagaccagcctggccaacatagtgaacc
ctgtctctgctaaaaacatagaaaaattagccgggcatggtggcgctgcgcctgtaatcccagctactcgggagggtgagg
tgagagaattrettgaacccgggagggcgaggttgcagtgagccagattgcaccactgcactccagcctgggcgacaga
gcaagactccatctcaaaaaaagctctcagaacaaccaggtttacaaaatttggcagttggtaataaaactgggtttcaa
acatactttgctgaaayaatcactgactaaataggaaatgaatcttttttttttttttttaagctggcaagctgggtctg
taggacctgataagtaactcacttcatttctctgtgtctcagggtttccatttttaggtgagaattaaaggggtctgataa
aacagaccctaggattgtggacagcagtgatagtcctagagtcacaagtctgcttttgagtgtgaggcccatgtatctg
gcacatctgcaggcagagcgtgggttctggctcttcagatgatgcccgtggagcactttgaggagctcaccaccacgtg
ataaccagacattaaaatcttggggcttggcatcccaggatttctctgtgattccttctagacttgtggcatcatggcag
catcactgctgtagatttctagtcacttgggtctcaggagccgtttatattaatggcttcacatttaatttcagtgaacaa
ggtagtggtgctgtcttccagggccgtctgtgtgcccaggttccagattgactgttggcccttatctatgtgaaca
gtcacaactgaggcaggtttctgtgtttacagGACAGTTCTGCAGATCGATTTCTCAACAGCTTGGGAAGATTTATGAC
AGGACTGGACACCAGAAATAATGTCAAGgtaaacgcgtgtctttgttctagtagctttttgatgaacaataatccttatg
tttcttgagtagtactttcaactcatggttaaagttggcaggggcattcacacagaaaaagagcaaaactattaactttaccag
tgaggcagtagcgggtgtagtgtagtgattcagagaatttgccttggcaccagacataccaggtaaccttgactaagttact
taacctatctaaacctcagtttccctcatctgtgaaatggagacagtaatcatagctatttccaaactgttgtgagaattc
aatgagttaaaggtataaggtcctcaccacagccgtggccacatagtcagtgatcactatgtcctgaacactgtaatta
cttcgccatattctctgatcatagtggtttgccttgggtatgtgactagaatttcttctgaggtttatgggcaggttgg
tgggtatgcacctgctgcaggagcccggtttgggggacattacctgtacctgggtatgttttctttcagGTGTGGTTCAA
TAACAAGGGCTGGCATGCAATCAGCTCTTCTCTGAATGTCATCAACAATGCCATTCTCCGGGCCAACCTGCAAAAGGGAG
AGAACCCTAGCCATTATGGAATTACTGCTTTCAATCATCCCCTGAATCTCACCAGCAGCAGCTCTCAGAGGTGGCTCTg
taagtgtggctgtgtctgtatagatggagtggggcaaggagaggggttatggagaaggggagaaaaatgtgaatctcatt
gtaggggaacagctgcagagaccgttatattatgataaactctggattgatccaggctctgggcagaagtataagtttac
gaattggctgggttgggcttcttgaactgcagaagagaaaaatgacactgatatgtaaaaaatcgtaacatttagtgaattca
tataaagttagttcaaaaaattgttaattaaattataaatttaattataaagtgtttaatcagtttgatttgtttaaaaacca
ctgttttaaaatttgggtggaatatgtttttattagcttgtatcttttaattcctaaattaaagctgtgtgtgtgtgtgtgt
gt
atacagatctgggtttgaatctgggtctctaaactttatagatgtatgatattaaatgaggcagttcatgtaaattgcca
gccagcactcagcagagagtgtatatttcacacacattagataacctttcctgtatgtggagcatggcagttcctgtttt
tgctttactcctacaggataactaatataggacactaggtctttataccaagaccccatgtaatgggttatgagacct
tcttcttataaaaaatctgacagaatttttggatgtgttagatcaataggctgcatactgttattttcaagttgatttaca
gccagaaatattaattttttgagtagttacagagtaatatcttctgtctcatttagttttcaagcccactagtccttt
gtgtgtgaaaattttacaacttactgtcttacaaggtcatgaacagtggaacaaagtgaatgccattaaccactctgact
tcttctcattagtttttattgtgacagtggaactcttttgacctcagtaataaccagtttggcatttacattgtcatattttta
gacttaaaaaatgatcatcttaaccctgaataaaatgtgtctgggtgaacagatgtttttccttgggtgtgcctcagatc

Fig. 12
Page 24 of 30

tctgtgtgtgtgtacgtgtgtgtttgtctgtgtgtccatgtcctcactgattgagccctaactgcatcaaagacccctca
gattttcacacgctttttctctccagGATGACCACATCAGTGGATGTCCTTGTGTCCATCTGTGTTCATCTTTGCAATGTC
CTTCGTCCCAGCCAGCTTTGTCGTATTCTTGATCCAGGAGCGGGTCAGCAAAGCAAAACACCTGCAGTTTCATCAGTGGAG
TGAAGCCTGTCATCTACTGGCTCTCTAATTTTGTCTGGGATATGgtaaggacacaggcctgctgtatctttctgatgtct
gtcagggccatggattgatatggataagaaagaaagagctctggctatcatcaggaaatgttccagctactctaaagatg
tatgaaaaagaaatagccagaggcaggtgatcactttcatgacaccaaacacagcattgggtaccagagttcatgtcaca
ccagaggggaaaattctgtacacaatgatgaaaattaataccactaccacttaagttcctatgtgacaactttcccaagaa
tcagagagataacaagtcaaaaactccaagtcaatgcctctaacttctctgatgggttttaacctccagagtcagaatgttc
tttgcccttactaggaaagccatctgtcatttagaaaaactctgtacattttatcagcagcttatccatccattgcaaatat
tgtttttgtgccasccacaatatattgcttctatttggaccaatatgggggatttgaaggaattctgaagttctaattat
atttcaactctactttacaatatctccctgaaatatatctccctgtaacttctattaattataagctacacagagcaa
ctaattcttctcccaccgaacaagtccctggatatttaaaaaataactctcatactctcatttaacctgagtattaccag
ataagatgatatatgagaatacaccttgaacctccgaagcactgtacaaatgtgagcaatgatgggtggagatgatgatg
agatctttgtgttttataccaagcccttagactgtgtcactcttctgatccggttgtccttgtatggccatgctgtata
ttgtgaatgtcccgttttcaaaagcaaagccaagaattaaccttgtgttcaggctgtgggtctgaatgggtatgggtccag
agggagttgatcttttagctcacacttctattactgcagcacaaagattttgcattttggaaggagcacccgtcttactggc
aacttagtggttaaaccaaaacctccatttcacacaaatgattgtgaaattcgggtctccttcattctatacaaatcatt
tgatttttttgaaactaaactttatatttatccatattaaattacatgggttttatttttgttttatcttgattcagtaa
ttactcctttcagtaaacacagactgagtgctgtgtgtctgacttatgccaggcataggtgattcagagatgaaaggtca
agtccctgaaccatctcttgtcttctgggtattatctgtcctccctgcttttagagctcctgaaatttgc tagaagca
tgtcttcacetaagttgttgataaacacatcaagtaggattggactgaggcagagccctgtagtctgaagctgcagttct
tctagcggctgacaagccccactatcacttccctgctgggtgctttgctctgccagctgtgaattctcataattgtcctat
cgtcaagtctttatttctgcattttactgcttgatacactgtcaggacagactttaaaattattctcagtgcgatgaaac
aattctgacattcatgttatgagcagttacctcataaatagattacatg

00591660

Genomic contig containing ABC1 exons 37 to 41:

aaattactctgactgggaatccatcggttcagtaagtttactgagtgtagacaccttggttgactgttgaaagacagaaa
gggcatgtagtttataaaatcagccaaggggaaaatgcttgctcaaaatgtattgtcgggtattttgattaatagtttatg
tggttcattaattcagagttactctccaatatgtttatctgccctttcttgctgataatgggtgaaaacttggtgatg
cattgtatattttagtttaggggtgaactggatgtctttgttttccacttttagTGCAATTACGTTGTCCCTGCCACACTGG
TCATTATCATCTTCATCTGCTTCCAGCAGAAGTCCTATGTGTCTCCCTCCACCAATCTGCCTGTGCTAGCCCTTCTACTTTTG
CTGTATGGGtaagtcacctctgagtgagggagctgcacagtggaataaggcatttggtgcccagtggtcagaaggagggcag
ggactctcagtagacacttatctttttgtgtctcaacagGTGGTCAATCACACCTCTCATGTACCCAGCCTCCTTTGTGT
TCAAGATCCCCAGCACAGCCTATGTGGTGCTCACCAGCGTGAACCTCTTCATTGGCATTAAATGGCAGCGTGGCCACCTTT
GTGCTGGAGCTGTTTACCGACAATgtgagtcacgagagagaacactcctgctgggatgagcatctctgggagccagagg
acagtggttaattgtgatcttattccacttgctcagtggtattgacactgctgactgccttgctcctgtcttcagagtcgtg
cttccctgagaaggcaaagcacctttctttcttgctgtgccttacattttgctggtcaagcctttcagtttcttttgaca
gttttttttacttctttcttttttcaatgttgctcttaccagagtagctcctctgccttccactttacacatgagagct
gggcgacgcattcagtcctaaggcttttaccatcacctctcttggtgtttttattgtcatctctaagatcaatgccttta
gccttgatcataaccttgaaactctaactctcaaattctcacttgccctagtgagattgctccatttagatagatatagatac
cccaacctggatatgtcctagttttctttcccttggaacttaatgctttcttgccatccctgtcacactcagtgccac
taccatccactcggttgcccaagctggctcttagagttatcctagatgcttgctttgctgttgagatttcccacattca
actggttatgttgctcagttcttccaggtatggacctctaaaataaggcttctctccattccggttgctcattgcctttgt
ccaaacacagcacacaaggccttttacagttgcacaaactcttctctgcccataccaccacaccctttcccagctgtaagc
ttcagatgagttgctccaaccaccatgctcctgtaggcctggcttgaaatgccttcttctgtcacagggtctggttagt
atatcccttgcccttcaagatttagctaaaatgtgaagcttctctacctgctgggaggtgttctctctttctctgtgc
tctcagagtccttagtccatgcctccagtacaacgtacatccacttacatggtaatttctgtttacatacttttctctac
toggagtgagtgctgttttctaataattttgcctctccctagccctagcacagtgcatccagcgtatagccccttattca
gttggtagatatgttgccactgttgccctgtggatcataagttctgatgtatttgagaagaatttctaaaattctgaca
aaactcctgaaactcaaataattgaccagacatgagcaatttgcttttcaaagtctaagggttttttaattggatttgcttt
aattaaatctagcctgttttctaagctttattcattatttctccatactcagagcatttctccagattttctaaagaatag
aattttattgtacatatcatcagctatgcctgtgctatttaattgggtatctgaattaaaagggtctgggttgctccctag
agaatcaaatttttcttccactcccatatttcagaacttgatacatttttaggataaaccatgaatgacaccctgttctt
ctccctcaccctcccttccctcccatatttttttttttttttttttagAAGCTGAATAATATCAATGATATCCTGAAGTC
CGTGTCTTGATCTTCCACATTTTTGCCTGGGACGAGGGCTCATCGACATGGTGAAAAACCAGGCAATGGCTGATGCC
TGGAAGGTTTGgtgagtgaaagcagtggtgtaggtgctttaatggagatggcactctgcataggccttggtacctga
actttgttttgaaagaagcaggtgactaagcacaggatgttccccacccccatgcccagtgacagggtcatgccaac
acagctgggtgtggcatgggttttgtagacacaaccatttgctgtgtctctgacagcattgagaaaagtgaagggtcag
tttgaaaggaaggaataatagtggtatttgcttggtccactggctcatgcccactgtctgggttggttagaagcactggaa
aagtcaaaccataactttgagaattaggtgatcagggaatcagaaggaaagatgcaaactttggctcttttaggcgaatc
atgtgcctgcagatgaggtcattttatttcttttccacagctctataaaattataatgtattacatcttttctaccttta
gaatgggttaaaaatatttctccggtagccatattgattatttcatccattagataatatagtc aaatgggcatgttat
ttactgttcatagaagaggggtttttgcaacttgggtcacaaggagatatgtaagggaatttaagggaatgggtacatgg
aactagatttaattgaatctagtggtttaattgattcactaggatatatgctactgaaagggtgaatctgcttaaagtgt
ttctgatattttatttactaaaacttagaattttatataaaatactgactgtgaaaattacttggtgctgttgctttt
aaaaggatttttgcatgtctcattaaaaaaagaaatactagatatcttcagtgaaattacaaatcgaatacacattggc
tctgaaattctgattgatactgggtcataaaaagttttcccaaatcagacttggaagtgatcactctctgttactctt
tttctctgtcatgggtgatagccatttgtgtttattggaagatcggtgaattttaagggaacataggcccaaatttgagg
aagggtccatgggttttgatccctccattctgaccggatctctgcattgtgtctactagGGGAGAATCGCTTTGTGTCAAC
ATTATCTTGGGACTTGGTGGGACGAAACCTCTTCGCCATGGCCGTGGAAGGGGTGGTGTCTTCTCCTCATTACTGTTCTGA
TCCAGTACAGATTCTTCATCAGGCCCAGgtgagctttttcttagaaccctggagcacctgggttgagggtcacagaggag
gcgcacagggaacactcaccaatgggggttgcttgaaactgaaactcaaaatattgtgataaaactgattttctctgatgtg
ggcatcccgagccccctcctgcccactcctggagactgtggcaagtaggttttataatactacgttagagactgaatct
ttgtcctgaaaaatagtttgaaagggttcatttttctgttttttcccccaagACCTGTAAATGCAAAGCTATCTCCTCTG
AATGATGAAGATGAAGATGTGAGGCGGGAAAGACAGAGAATCTTGTAGGTGGAGGCCAGAATGACATCTTAGAAATCAA
GGAGTTGACGAAGgtgagagagtacaggttacaatagctcattctcagttttttcagctttatgtgctgtaaccagca
gtttgtgacttgcttaataaaaagggtcattgtgttcccaaatgtacatctataccaaggttctgtcaattttattttaa
aacaccatggagacttcttaagaattcttactgagaattcttttgatatagaattccattctcgaatactttggttt
tatatgcttacatttatgtgttagttattaaaaacataactaatttgatatctagtcaactgagtagagagataatggt
gatt

Fig. 12
Page 26 of 30

Genomic contig containing exons 42 through 45:

ttttaaaatacctgcaatacatatatatgttgaatagatgaaaaattatgtagatgataatgaatgatacggttctaaaa
agacagggttaaaaagtaagttcacttttattttgagcttcagaatcattcagaagccagtcgccacaaacgcagaccaag
gctcttggcacatcaaatatgcctatggcttaggggtattgacaagctcttatgttgcagtgtatgtgggttatagtcctg
ccttccacagttgcttgggagagctgtgagtcactgaggcttatgaatgtttacattttgtttgttgcagATATATAGAA
GGAAGCGGAAGCCTGCTGTTGACAGGATTTGCGTGGGCATTCTCTGTTGAGgtaaagacactttgtctatattgcgtt
tgtccctattagttcagactatctctacccaatcaagcaacgatgctcgttaagagggtaaaagtggttttaagggttc
tgtatattatgccaggatggagcaattagtcacgcagaagagaggggacctgtatgtcaagagaatgatttcagagaatcc
aatacaatttaagaaaaagcatggggctggggcgagtgattcactcctgtaatcccagcactttgggaggccgaggtggg
cggactcacgaggtcaggagattgagaccatcctggccaacatggtgaaacccatctctactataaaatacaaaaattag
ctgggcatagtagtgcattcctgtagtcccagctactcgggaggctgaggcaggagaattgcttgaacctaggaggggga
gggtgcccagattgcgtgctgcactccagcctgggtgacagagtgcagctcatgtcaacaacaaaaacagaaaaagcacg
cacatctaaaaacatgcttttgtgatccatttgggatgggtgatgacattcaaatagtttttaaaaatagattttctcctt
tctgggttccgcttgtgttcttttatgcccttttggcagagtaggtggtgcaatttggctagtctggctttcattactgtt
tttcacacattaaacttggcctcaacttgacaactcaataatatttataaatacacgccacacttaaaatgggtcccatta
tgaaatacatatttaaatatctatacagatgtgtttaaaccagaataatttgattcttctctgatatttaagaattgaa
gggttgaggtagttacgtgttaggggcatttatattcatgtttttagagtttgcttatacaacttaattcttcttctca
gTGCTTTGGGCTCCTGGGAGTTAATGGGGCTGGAATAATCATCAACTTTCAAGATGTTAACAGGAGATACCACTGTTACCA
GAGGAGATGCTTTCCTTAACAAAAATAGgtgagaaaagaagtggcctgtatatttgcgtgcaaagactttgttttaattta
tttaagaaataggttgttatttttgattacagtgggtatttttagagttcataaaaaatgttgaaatatagtaaagggttaa
agaagcacataaaaatcatccatgatttcaatatctagagataatcacaaattacatttcttctcagtcctcattctcttct
tttaacagctttattcaggtataatttacatacaatataaatttgcttgttttttaagagtataatttagtgatttttgggt
aaattgagagttttgcaaccatcaccacaatccagttttagaactttccatcacccacatctgtcttatatacacata
taaatgtgccatacaattgagatcatactgtatgtagaatttaaaatagtttttattgttaatgagtgattatgaata
tttcccagtggttacatttccctaagatgtggaattttacattgctacataaaaatccccctatgtacatgtacctataat
ttatttaataaattccttataaatgttggacacattagtttccatttttactatgtaaatatgtccctgtatacatctt
ttattatttctcaggaacaattcctacaaagtaaatgcccctctcaagagcatacaaaattgactgagccaccgttag
gccatttctgagactgcacaggtcacaaagcaatctgatcttgggaatacagctacattttataggcttcttagataa
tgtaactctaagtaactttaaatatgtggggcttctctgggcttttttttttgagacggagtttccactcttactgcacca
ggctggagagcaatggcgaccttggctcactgcaacctccgctcccagggtcaagcgatttctcctgcctcagcctcc
tgagtagctgagattacaggtgcccgcacaaatgcctgcctaatttttttgattttcagtagagatgggggtttcccat
gttggccagactgggtctcgagctcctgacctcaggtgatccacctgcctcagcctcccaaagttctgggattacaggcat
gagccactgcgcccggcttctctggacttattatgtggagagatagtacaaggcagtggtttcagagtttttgacct
gaccgttgtgggaaatacattttatatctcaacctagtagtacacacagacatgtagacacatgtataacctaaagttt
cataaagcagtagctactgttactaattgtagtgcactctgtatttcttattctaccttatactgcgtcattaaaaaag
tgctgggtcatgacccactaaatttttcccaaaccctaatagaacaatgactcacaatttgaacacactggacaggggg
atagccaataaaaattgaaaagagcaaggaaattaatgtattcatgatctcctctcctgtctcttacatttttgcagtagc
aatgtaaaggaaatcctaagagaacagacattctgggaatagcaggcctagcgtgcacaactgctttcctaggttgcctc
ctagtaccaagctcctgacgcataatagcagtggtgagtaataaccagcccatagtaagggttgtcacagggaactgggtgta
agaactgatttgrttggtatagctgtgagggcctggcaggtgtccacgtgtgcctcaatcctaattctgaaaaaggctg
accctgggggtgctaattagatacacagagaggaatgaatgtcgcagaaggccaagttcatggcaatgccgctgtggct
gaggtgcagtcacagctctggaacgtgaacactgaacttctctcacatgtgattcttcaactgactggcttcatagaacc
ccaaagccaccccaccacacataaaattgtgtctctaggttctgtgtgctcacactcaaaatttctgggccttctcatt
tggtgcatgtgaatggtgcatatgagtgaagtctagggtgggcttagcggttaaagccctgggggtggtgactgagat
tgttggttaaagaatgtgcagtggttggcatgacctcagaaattctgaaatgggactgcacctgcagactgaagtgttcag
agagccagggaggtgcaaggactggggagggttagaggcaggaacccctgcctgccaggaagagctagcatcctgggggcag
aaaggctgtgctttcaagtagcagcagatgtattgggtatcttggtaatggagaagcatactttacaggaacattaggcca
gattgtctaacagagtagtctctacctgcttaaaatctaagtagtttcttgcctttgcagTATCTTATCAAACATCCA
TGAAGTACATCAGAACATGGGCTACTGCCCTCAGTTTGATGCCATCACAGAGCTGTTGACTGGGAGAGAACACGTGGAGT
TCTTTGCCCTTTTGAGAGGAGTCCCAGAGAAAGAAGTTGGCAAGgtactgtgggcacctgaaagccagcctgtctcctt
ggcatcctgacaatatataccttatggcttttccacacgcattgacttcaggctgttttccctcatgaatgcagcagcac
aaaatgctgggttcttctgtatctgctttcagggtggaaacctgtaacggtgggtggggcagggctgggtgggcagagagggga
gtgctgctcccaccacagagtccttctccctgctttggctcctcaccagttgtcagggttatgattatagaatctagtc
ctactcagtgaaagaactttcatacatgtatgtgtaggacagcatgataaaatccccagccagaccaaagtcagggtgc
tttttatcactgtagTTGGTGAGTGGGCGATTGGGAACTGGGCCTCGTGAAGTATGGAGAAAAATATGCTGGTAACATA
TAGTGGAGGCAACAAACGCAAGCTCTCTACAGCCATGGCTTTGATCGGCGGGCCTCTGTGGTGTCTCTGgtgagtataa

項目	1990年	1991年	1992年	1993年	1994年	1995年	1996年	1997年	1998年	1999年	2000年	2001年	2002年	2003年	2004年	2005年	2006年	2007年	2008年	2009年	2010年	2011年	2012年	2013年	2014年	2015年	2016年	2017年	2018年	2019年	2020年	2021年	2022年	2023年	2024年	2025年	2026年	2027年	2028年	2029年	2030年	2031年	2032年	2033年	2034年	2035年	2036年	2037年	2038年	2039年	2040年	2041年	2042年	2043年	2044年	2045年	2046年	2047年	2048年	2049年	2050年	2051年	2052年	2053年	2054年	2055年	2056年	2057年	2058年	2059年	2060年	2061年	2062年	2063年	2064年	2065年	2066年	2067年	2068年	2069年	2070年	2071年	2072年	2073年	2074年	2075年	2076年	2077年	2078年	2079年	2080年	2081年	2082年	2083年	2084年	2085年	2086年	2087年	2088年	2089年	2090年	2091年	2092年	2093年	2094年	2095年	2096年	2097年	2098年	2099年	2100年																																																								
人口	120,000,000	121,000,000	122,000,000	123,000,000	124,000,000	125,000,000	126,000,000	127,000,000	128,000,000	129,000,000	130,000,000	131,000,000	132,000,000	133,000,000	134,000,000	135,000,000	136,000,000	137,000,000	138,000,000	139,000,000	140,000,000	141,000,000	142,000,000	143,000,000	144,000,000	145,000,000	146,000,000	147,000,000	148,000,000	149,000,000	150,000,000	151,000,000	152,000,000	153,000,000	154,000,000	155,000,000	156,000,000	157,000,000	158,000,000	159,000,000	160,000,000	161,000,000	162,000,000	163,000,000	164,000,000	165,000,000	166,000,000	167,000,000	168,000,000	169,000,000	170,000,000	171,000,000	172,000,000	173,000,000	174,000,000	175,000,000	176,000,000	177,000,000	178,000,000	179,000,000	180,000,000	181,000,000	182,000,000	183,000,000	184,000,000	185,000,000	186,000,000	187,000,000	188,000,000	189,000,000	190,000,000	191,000,000	192,000,000	193,000,000	194,000,000	195,000,000	196,000,000	197,000,000	198,000,000	199,000,000	200,000,000	201,000,000	202,000,000	203,000,000	204,000,000	205,000,000	206,000,000	207,000,000	208,000,000	209,000,000	210,000,000	211,000,000	212,000,000	213,000,000	214,000,000	215,000,000	216,000,000	217,000,000	218,000,000	219,000,000	220,000,000	221,000,000	222,000,000	223,000,000	224,000,000	225,000,000	226,000,000	227,000,000	228,000,000	229,000,000	230,000,000	231,000,000	232,000,000	233,000,000	234,000,000	235,000,000	236,000,000	237,000,000	238,000,000	239,000,000	240,000,000	241,000,000	242,000,000	243,000,000	244,000,000	245,000,000	246,000,000	247,000,000	248,000,000	249,000,000	250,000,000	251,000,000	252,000,000	253,000,000	254,000,000	255,000,000	256,000,000	257,000,000	258,000,000	259,000,000	260,000,000	261,000,000	262,000,000	263,000,000	264,000,000	265,000,000	266,000,000	267,000,000	268,000,000	269,000,000	270,000,000	271,000,000	272,000,000	273,000,000	274,000,000	275,000,000	276,000,000	277,000,000	278,000,000	279,000,000	280,000,000	281,000,000	282,000,000	283,000,000	284,000,000	285,000,000	286,000,000

Genomic contig containing ABC1 exons 46 to 49:

ngccnngttnaaaangaaaatttnnnnnnaaattnaannttanngngnnntttccccagaaaaaacnaaaangatttcn
ccnngggggggnccccnancnaaaaaggccccnctntttngngngagggaagnttttttggaaatttttaatttttgg
tccccaaaaacctattattgagaatttaattacataaaaaagttactcagaatatttgagtttctgcatcaataagacat
ttataaataatgacctgttttcaaatgaatttgaaagttactctaattctttgattcatcaagaaaataactagaatggca
agttaaaaatttaagctgttttcaaatgacttctgcattttaaaacaaaatttatctttgatttttttccccccagcaaat
aagacttattttatttcttaattacagGATGAACCCACCACAGGCATGGATCCCAAAGCCCGCGGTTCTTGTGGAATTGTG
CCCTAAGTGTGTCAAGGAGGGGAGATCAGTAGTGCTTACATCTCATAGgtccgtagtaaaagtcttgggttccctcactgt
gggatgttttaactttccaagttagaatatgcatcattttgtaaaaattagaaaatacagaaaagcaagagtaaaacaa
ttattacctgaaattatatatgcatattcttcaaaaaatgcaagccagtagataaatactgctctttttcacttaatatat
tgtaaacattatttccaagtcagtgcatcttaggtgtcattttcttatagctggatagtagtccattaggatatactcttatt
taactattccccctttttagacatttggattattttccaactgttccaaatttgtaaacaccactacactgaacagcatc
atccctatatccacatgtacttgaacagaatacaattccctaggaagctggaatgctggaagtcaggtgatgttctca
tggttacagagaatctctctaaaactaaaacctcttctgttttaccgcagTATGGAAGAATGTGAAGCTCTTTGCACTA
GGATGGCAATCATGGTCAATGGAAGGTTTCAGGTGCCCTTGGCAGTGTCCAGCATCTAAAAATAGgttaataaagataat
ctttgggtagtgccctagtgagaaggcttgatattttattcttttggtagtatataaatgggtgctctaaaaataaaggga
ataaaactgagcaaaacagtagtagtggaaagaatgagggtttgaagtcgcaactgcattcaaattctgtctttaccatt
tactggttctgtgactcttgggcaagttacttaactactgtaagagttagtttccctggaagatctacctctagctttg
tgctatagatgaaatgaaaaaaatttacatgtgccagtagctggtagagcgcaagctttggagtcacacacaaatgggtt
tgcatcctggccctaccaattatgagctctgagccatgggcaagtgaactaactccctgggctcagtttctctgtaacat
ctgtcagacttcaatgggtccaggtgaggattaaaggagatcatgtattttacagcacatggcagtggttccacataaaat
aagttatttagtaaatgataactgggttccctctctcagaaacttatcttgggctgccaggggccgcccctttttcatggc
acaagttgggttcccagggttcagttattcttttaaatagttttctggagatcctccatttgggtatttttctgtcttc
agGTTTGGGAGATGGTTATACAATAGTTGTACGAATAGCAGGGTCCAACCCGACCTGAAGCCTGTCCAGGATTTCTTTGG
ACTTGCATTCTCTGGAAGTGTTCYAAAAGAGAAACACCGGAACATGCTACAATACCAGCTTCCATCTTCATTATCTTCTC
TGGCCAGGATATTTCAGCATCTCTCTCCAGAGCAAAAAGCGACTCCACATAGAAGACTACTCTGTTTCTCAGACAACACTT
GACCAAGtaagctttgagtgctcaaaacagatttacttctcaggggtgtggattcctgccccgacactcccgcctataggct
caagagcagtttgtagtcttgaattgggtgcttgaattcctgatctactattcctagctatgctttttactaaacctctctg
aacctgaaaaggagatgatgectatgtactctataggattattgtgagaatttactgtaataataaccataaaaaactac
catttagtgagcacctaccatgggcccaggcattttacttgggtgcctaattcctattttaaattagataaaaaagtagcaaat
aggctctgacacttaagaagtactcagtaaatattttcttccctcttccctttaaataagaccgtagtgccaaagtaaa
tggtgactgagcagttgggtgatgtagggtggggggcgatatagaagtcagtttttggccgggctgggtggctcatgc
ctgtaatcccagcactttgggaggctgaggagcaggcagatcatgaggtcaggagatccagataatcctggccaacagggt
tgaaaccccgctctctactaaaaatacaaaaattagctgggcatgggtgggtgcgcacttgtagtcccagctacttgcgaggc
tgaggcaggagaattgctcgaacccaggaggtggaggttacagtgagccaaggtctcgccactgcactccagcctgggga
cagagcaagacccatttcaaggggggaaaaaaagtccatttttaagttgttattgcttttttcaagttattcttccctcc
ttcacacacagttttctagttaatccatttatgtaattctgtatgctcctacttgacctaatttcaacatctggaaaaat
agaactagaataaagaatgagcaagttgagtggtatttataaaggtccatcttaattcttttaacagGTATTTGTGAAGTT
TGCCAAGGACCAAGTGATGATGACCACTTAAAGAGCTCTCATTACACAAAAACCAGACAGTAGTGGACGTTGCAGTTC
TCACATCTTTTCTACAGGATGAGAAAGTGAAGAAAGCTATGTATGAAGAATCCTGTTTCATACGGGGTGGCTGAAAGTAA
AGAGGAAGTACTTTCTTTTGACCATGTGAAGTGTGTGGAGAAAAGAGCCAGAAGTTGATGTGGGAAGAAGTAACT
GGATACTGTACTGATACTATTCAATGCAATGCAATTCATGcaatgaaaacaaaattccattacaggggagtgcccttg
tagcctatgtcttgtagtggctctcaagtgaagacttgaatttagttttttacctaacctatgtgaaactctattatgg
aaccatggacatatgggtttgaactcacacttt
taattcatcaagtaaatcatggccagcattatttgatacaaaatcaaaaggtaatgcacatcctcattcactaagccatgcc
atgccaggagagactgggtttcccggtgacacatccattgctggcaatgagtggtgccagagttatttagtgccaagttttca
gaaagtttgaagcaccatgggtgtgcatgctcacttttgtaagagctgctctgctcagagttctatcaacattgaatatca
gttgacagaatgggtgccatgctgggtaacatcctgctttgattccctctgataagctgttctgggtggcagtaacatgca
acaaaaatgtgggtgtctccaggcagcggaacttggttccattgttatattgtcctatgcttcgagccatgggtctaca
gggtcatccttatgagactcttaatatacttagatcctggtaagaggcaagaatcaacagccaaactgctggggctgc
aactgctgaagccagggtcatgggattaaagagattgtgcgttcaaacctaggggaagcctgtgcccatttgtcctgactgt
ctgctaacatgggtacactgcacatcaagatgtttatctgacacaagtgattatttctgggttttttgaattaatctagaa
aatgaaaagatggagttgtattttgacaaaaatgtttgtactttttaatgttatttggaaattttaagttctatcagtgac
ttctgaatccttagaatggcctctttgtagaacctgtggtagagagtagtgccactgcccactattttttattttct
tatgtaagtttgcataatcagtcagtagtgcttagaaagcaatgtgatggtcaggatctcatgacatttatatttgagt
ttctttcagatcatttaggatactcttaattctcacttcatcaatcaaatattttttgagtgtagtgcagagag

Fig. 12
Page 29 of 30

[illegible]




Fig. 13




Fig. 14




Fig. 15

No.	Name	Location in SEQ ID No. 14	Sequence	Sequence Strand Length
1	PPRE	58-69	AGGTAAAAGTCA	12 Complement
2	PPRE	1997-2009	AGAGTAGAGGGCA	13 Lead
3	PPRE	2150-2161	ATGTCAAGTTCA	12 Lead
4	PPRE	2156-2169	AGTTCAAAGGGCA	14 Lead
5	PPRE	4126-4139	AGGCCAGCAGGGCC	14 Complement
6	PPRE	5075-5087	AGGGCAGAAAGTGA	13 Lead
7	PPRE	6604-6615	ATGCCAAGGTCA	12 Complement
8	PPRE	6731-6743	GGGGCAAGGGTA	13 Complement
9	PPRE	7220-7233	AGGTAATGAGGACA	14 Complement
10	PPRE	7554-7568	GGATCACGAGGTCA	15 Complement
1	SRE	159-166	CAGCCCAT	8 Lead
2	SRE	1133-1140	CAGCTCAC	8 Complement
3	SRE	1145-1152	CACACCAC	8 Lead
4	SRE	1809-1816	CAGCCCTC	8 Complement
5	SRE	1894-1901	CAGCCCAT	8 Lead
6	SRE	2563-2570	CAACCCAC	8 Lead
7	SRE	3303-3310	CAGCTCAC	8 Lead
8	SRE	3470-3477	CCGCCAC	8 Lead
9	SRE	4784-4791	CTCCCCAC	8 Complement
10	SRE	4802-4809	CAGCCTAC	8 Complement
11	SRE	4970-4977	CACCTCAC	8 Complement
12	SRE	6487-6494	CAGCCTAC	8 Complement
13	SRE	6565-6572	CACCCAAC	8 Complement
14	SRE	6727-6734	CACCTAC	8 Lead
15	SRE	7041-7048	CACCCAAC	8 Lead
16	SRE	8059-8066	CAGCCCTC	8 Complement
1	ROR(retinoic acid receptor related)	166-172	AGGGTCA	7 Complement
2	ROR(retinoic acid receptor related)	166-173	AAGGGTCA	8 Complement
3	ROR(retinoic acid receptor related)	363-370	ATGGGTCA	8 Lead
4	ROR(retinoic acid receptor related)	364-370	TGGGTCA	7 Lead
5	ROR(retinoic acid receptor related)	2218-2225	TAGGGTCA	8 Lead
6	ROR(retinoic acid receptor related)	2219-2225	AGGGTCA	7 Lead
7	ROR(retinoic acid receptor related)	3643-3649	TGGGTCA	7 Lead
8	ROR(retinoic acid receptor related)	6604-6610	AAGGTCA	7 Complement
1	SREBP-1 or "E box"	473-479	ACACCTG	7 Complement
2	SREBP-1 or "E box"	536-541	ACACATG	7 Lead
3	SREBP-1 or "E box"	537-543	TCATGTG	7 Complement
4	SREBP-1 or "E box"	655-661	TCATGTG	7 Complement
5	SREBP-1 or "E box"	925-931	ACACTTG	7 Lead
6	SREBP-1 or "E box"	967-973	TCACTTG	7 Lead
7	SREBP-1 or "E box"	968-974	TCAAAGTG	7 Complement
8	SREBP-1 or "E box"	1063-1069	ACAGGTG	7 Complement
9	SREBP-1 or "E box"	1104-1110	TCACTTG	7 Lead
10	SREBP-1 or "E box"	1105-1111	TCAAAGTG	7 Complement
11	SREBP-1 or "E box"	1561-1567	TCACTTG	7 Lead
12	SREBP-1 or "E box"	1670-1676	TCAAATG	7 Lead
13	SREBP-1 or "E box"	1748-1754	ACACTTG	7 Lead
14	SREBP-1 or "E box"	1749-1755	ACAAAGTG	7 Complement
15	SREBP-1 or "E box"	1852-1858	TCATGTG	7 Lead
16	SREBP-1 or "E box"	1853-1859	ACACATG	7 Complement
17	SREBP-1 or "E box"	1899-1905	ACAAATG	7 Complement
18	SREBP-1 or "E box"	2199-2205	ACACGTG	7 Lead
19	SREBP-1 or "E box"	2393-2399	ACAGCTG	7 Complement
20	SREBP-1 or "E box"	2659-27005	ACACCTG	7 Lead
21	SREBP-1 or "E box"	2677-2683	TCACATG	7 Complement
22	SREBP-1 or "E box"	2740-2746	ACAACTG	7 Complement
23	SREBP-1 or "E box"	2969-2975	ACAAATG	7 Lead
24	SREBP-1 or "E box"	2979-2985	ACACATG	7 Lead
25	SREBP-1 or "E box"	2981-2987	ACATGTG	7 Lead
26	SREBP-1 or "E box"	2980-2986	ACATGTG	7 Complement
27	SREBP-1 or "E box"	2982-2988	ACACATG	7 Complement
28	SREBP-1 or "E box"	3461-3467	TCAGGTG	7 Lead
29	SREBP-1 or "E box"	3462-3468	TCACCTG	7 Complement
30	SREBP-1 or "E box"	3547-3553	TCAACTG	7 Complement
31	SREBP-1 or "E box"	3752-3758	ACACATG	7 Lead
32	SREBP-1 or "E box"	4226-4232	TCACCTG	7 Lead
33	SREBP-1 or "E box"	4582-4588	ACACGTG	7 Complement
34	SREBP-1 or "E box"	4588-4594	TCAGTTG	7 Lead
35	SREBP-1 or "E box"	4861-4867	TCAGGTG	7 Lead
36	SREBP-1 or "E box"	4951-4957	ACAAATG	7 Lead
37	SREBP-1 or "E box"	5096-5102	TCAAATG	7 Complement
38	SREBP-1 or "E box"	5912-5918	ACAGTTG	7 Lead
39	SREBP-1 or "E box"	5913-5919	TCAACTG	7 Complement
40	SREBP-1 or "E box"	6245-6251	ACACATG	7 Complement
41	SREBP-1 or "E box"	6288-6294	ACAACTG	7 Complement
42	SREBP-1 or "E box"	6623-6629	TCATTTG	7 Lead
43	SREBP-1 or "E box"	6836-6842	TCACCTG	7 Lead
44	SREBP-1 or "E box"	6837-6843	ACAGGTG	7 Complement
45	SREBP-1 or "E box"	7032-7038	ACAGGTG	7 Complement

Fig. 16

46 SREBP-1 or "E box"	7069-7075	TCAGGTG	7 Lead
47 SREBP-1 or "E box"	7101-7107	ACATATG	7 Complement
48 SREBP-1 or "E box"	7138-7144	ACAGTTG	7 Lead
49 SREBP-1 or "E box"	7139-7145	TCAACTG	7 Complement
50 SREBP-1 or "E box"	7240-7246	ACACCTG	7 Complement
51 SREBP-1 or "E box"	7467-7473	ACAGGTG	7 Lead
52 SREBP-1 or "E box"	7640-7646	TCATTTG	7 Lead
53 SREBP-1 or "E box"	7641-7647	TCAAATG	7 Complement
54 SREBP-1 or "E box"	7653-7659	TCAGTTG	7 Lead
55 SREBP-1 or "E box"	7654-7660	ACAACTG	7 Complement
56 SREBP-1 or "E box"	7735-7741	ACAAATG	7 Lead
57 SREBP-1 or "E box"	7838-7844	TCAGGTG	7 Complement
58 SREBP-1 or "E box"	7880-7886	TCATCTG	7 Complement
59 SREBP-1 or "E box"	8051-8057	TCAGCTG	7 Lead
60 SREBP-1 or "E box"	8052-8058	TCAGCTG	7 Complement

Fig. 16

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS, the specification of which

☒ is attached hereto.

☐ was filed on _____ as Application Serial No. _____
and was amended on _____.

☐ was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

FOREIGN PRIORITY RIGHTS: I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
			Yes/No

PROVISIONAL PRIORITY RIGHTS: I hereby claim priority benefits under Title 35, United States Code, §119(e) and §120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status
60/124,702	March 15, 1999	Pending
60/138,048	June 8, 1999	Pending
60/139,600	June 17, 1999	Pending
60/151,977	September 1, 1999	Pending

COMBINED DECLARATION AND POWER OF ATTORNEY

NON-PROVISIONAL PRIORITY RIGHTS: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bieker-Brady, Ph.D. Reg. No. 39,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, Mary Rose Scozzafava, Ph.D., Reg. No.36,268, James D. DeCamp, Ph.D., Reg. No. 43,580.

Address all telephone calls to: Paul T. Clark at 617/428-0200.

Address all correspondence to: Paul T. Clark at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Michael R. Hayden	Vancouver, British Columbia CANADA	4484 West 7 th Avenue Vancouver, British Columbia V6R 1W9 CANADA	USA and CANADIAN
Signature:			Date:

COMBINED DECLARATION AND POWER OF ATTORNEY

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Angela R. Wilson	Richmond, British Columbia CANADA	7100 Langton Road Richmond, British Columbia V7C 4B2 CANADA	CANADIAN
Signature:			Date:

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Simon N. Pimstone	Vancouver, British Columbia CANADA	4746 West 6 th Avenue Vancouver, British Columbia V6T 1C5 CANADA	CANADIAN
Signature:			Date:

SEQUENCE LISTING

<110> Hayden, Michael R.
Wilson, Angela R.
Pimstone, Simon N.

<120> METHODS AND REAGENTS FOR MODULATING
CHOLESTEROL LEVELS

<130> 50110/002005

<150> 60/124,702

<151> 1999-03-15

<150> 60/138,048

<151> 1999-06-08

<150> 60/139,600

<151> 1999-06-17

<150> 60/151,977

<151> 1999-09-01

<160> 287

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2261

<212> PRT

<213> Homo sapiens

<400> 1

Met	Ala	Cys	Trp	Pro	Gln	Leu	Arg	Leu	Leu	Leu	Trp	Lys	Asn	Leu	Thr
1				5					10					15	
Phe	Arg	Arg	Arg	Gln	Thr	Cys	Gln	Leu	Leu	Leu	Glu	Val	Ala	Trp	Pro
			20					25					30		
Leu	Phe	Ile	Phe	Leu	Ile	Leu	Ile	Ser	Val	Arg	Leu	Ser	Tyr	Pro	Pro
		35				40					45				
Tyr	Glu	Gln	His	Glu	Cys	His	Phe	Pro	Asn	Lys	Ala	Met	Pro	Ser	Ala
	50				55					60					
Gly	Thr	Leu	Pro	Trp	Val	Gln	Gly	Ile	Ile	Cys	Asn	Ala	Asn	Asn	Pro
65				70						75				80	
Cys	Phe	Arg	Tyr	Pro	Thr	Pro	Gly	Glu	Ala	Pro	Gly	Val	Val	Gly	Asn
			85					90					95		
Phe	Asn	Lys	Ser	Ile	Val	Ala	Arg	Leu	Phe	Ser	Asp	Ala	Arg	Arg	Leu
			100					105				110			
Leu	Leu	Tyr	Ser	Gln	Lys	Asp	Thr	Ser	Met	Lys	Asp	Met	Arg	Lys	Val
		115				120						125			
Leu	Arg	Thr	Leu	Gln	Gln	Ile	Lys	Lys	Ser	Ser	Ser	Asn	Leu	Lys	Leu

	130					135					140				
Gln 145	Asp	Phe	Leu	Val	Asp 150	Asn	Glu	Thr	Phe	Ser 155	Gly	Phe	Leu	Tyr	His 160
Asn	Leu	Ser	Leu	Pro 165	Lys	Ser	Thr	Val	Asp 170	Lys	Met	Leu	Arg	Ala	Asp 175
Val	Ile	Leu	His 180	Lys	Val	Phe	Leu	Gln 185	Gly	Tyr	Gln	Leu	His	Leu	Thr 190
Ser	Leu	Cys 195	Asn	Gly	Ser	Lys	Ser	Glu 200	Glu	Met	Ile	Gln	Leu	Gly	Asp 205
Gln 210	Glu	Val	Ser	Glu	Leu	Cys 215	Gly	Leu	Pro	Arg	Glu	Lys	Leu	Ala	Ala 220
Ala 225	Glu	Arg	Val	Leu	Arg	Ser 230	Asn	Met	Asp	Ile	Leu	Lys	Pro	Ile	Leu 240
Arg	Thr	Leu	Asn 245	Ser	Thr	Ser	Pro	Phe	Pro	Ser 250	Lys	Glu	Leu	Ala	Glu 255
Ala	Thr	Lys 260	Thr	Leu	Leu	His	Ser	Leu 265	Gly	Thr	Leu	Ala	Gln	Glu	Leu 270
Phe	Ser	Met 275	Arg	Ser	Trp	Ser	Asp	Met 280	Arg	Gln	Glu	Val	Met	Phe	Leu 285
Thr	Asn 290	Val	Asn	Ser	Ser	Ser 295	Ser	Ser	Thr	Gln	Ile	Tyr	Gln	Ala	Val 300
Ser 305	Arg	Ile	Val	Cys	Gly 310	His	Pro	Glu	Gly	Gly 315	Gly	Leu	Lys	Ile	Lys 320
Ser	Leu	Asn 325	Trp	Tyr	Glu	Asp	Asn	Asn 330	Tyr	Lys	Ala	Leu	Phe	Gly	Gly 335
Asn	Gly 340	Thr	Glu	Glu	Asp	Ala	Glu	Thr 345	Phe	Tyr	Asp	Asn	Ser	Thr	Thr 350
Pro	Tyr 355	Cys	Asn	Asp	Leu	Met	Lys	Asn 360	Leu	Glu	Ser	Ser	Pro	Leu	Ser 365
Arg	Ile 370	Ile	Trp	Lys	Ala	Leu 375	Lys	Pro	Leu	Leu	Val	Gly	Lys	Ile	Leu 380
Tyr 385	Thr	Pro	Asp	Thr	Pro 390	Ala	Thr	Arg	Gln	Val	Met	Ala	Glu	Val	Asn 400
Lys	Thr	Phe 405	Gln	Glu	Leu	Ala	Val	Phe	His 410	Asp	Leu	Glu	Gly	Met	Trp 415
Glu	Glu	Leu 420	Ser	Pro	Lys	Ile	Trp	Thr 425	Phe	Met	Glu	Asn	Ser	Gln	Glu 430
Met	Asp 435	Leu	Val	Arg	Met	Leu	Leu	Asp 440	Ser	Arg	Asp	Asn	Asp	His	Phe 445
Trp	Glu 450	Gln	Gln	Leu	Asp	Gly 455	Leu	Asp	Trp	Thr	Ala	Gln	Asp	Ile	Val 460
Ala 465	Phe	Leu	Ala	Lys	His 470	Pro	Glu	Asp	Val	Gln	Ser	Ser	Asn	Gly	Ser 480
Val	Tyr	Thr 485	Trp	Arg	Glu	Ala	Phe	Asn 490	Glu	Thr	Asn	Gln	Ala	Ile	Arg 495
Thr	Ile	Ser 500	Arg	Phe	Met	Glu	Cys	Val 505	Asn	Leu	Asn	Lys	Leu	Glu	Pro 510
Ile	Ala 515	Thr	Glu	Val	Trp	Leu	Ile	Asn 520	Lys	Ser	Met	Glu	Leu	Leu	Asp 525
Glu	Arg 530	Lys	Phe	Trp	Ala	Gly 535	Ile	Val	Phe	Thr	Gly	Ile	Thr	Pro	Gly 540

Ser	Ile	Glu	Leu	Pro	His	His	Val	Lys	Tyr	Lys	Ile	Arg	Met	Asp	Ile
545					550					555					560
Asp	Asn	Val	Glu	Arg	Thr	Asn	Lys	Ile	Lys	Asp	Gly	Tyr	Trp	Asp	Pro
				565					570					575	
Gly	Pro	Arg	Ala	Asp	Pro	Phe	Glu	Asp	Met	Arg	Tyr	Val	Trp	Gly	Gly
			580					585					590		
Phe	Ala	Tyr	Leu	Gln	Asp	Val	Val	Glu	Gln	Ala	Ile	Ile	Arg	Val	Leu
		595					600					605			
Thr	Gly	Thr	Glu	Lys	Lys	Thr	Gly	Val	Tyr	Met	Gln	Gln	Met	Pro	Tyr
	610					615					620				
Pro	Cys	Tyr	Val	Asp	Asp	Ile	Phe	Leu	Arg	Val	Met	Ser	Arg	Ser	Met
625					630					635					640
Pro	Leu	Phe	Met	Thr	Leu	Ala	Trp	Ile	Tyr	Ser	Val	Ala	Val	Ile	Ile
				645					650					655	
Lys	Gly	Ile	Val	Tyr	Glu	Lys	Glu	Ala	Arg	Leu	Lys	Glu	Thr	Met	Arg
			660					665					670		
Ile	Met	Gly	Leu	Asp	Asn	Ser	Ile	Leu	Trp	Phe	Ser	Trp	Phe	Ile	Ser
		675					680					685			
Ser	Leu	Ile	Pro	Leu	Leu	Val	Ser	Ala	Gly	Leu	Leu	Val	Val	Ile	Leu
						695					700				
Lys	Leu	Gly	Asn	Leu	Leu	Pro	Tyr	Ser	Asp	Pro	Ser	Val	Val	Phe	Val
705						710				715					720
Phe	Leu	Ser	Val	Phe	Ala	Val	Val	Thr	Ile	Leu	Gln	Cys	Phe	Leu	Ile
				725					730					735	
Ser	Thr	Leu	Phe	Ser	Arg	Ala	Asn	Leu	Ala	Ala	Ala	Cys	Gly	Gly	Ile
			740					745					750		
Ile	Tyr	Phe	Thr	Leu	Tyr	Leu	Pro	Tyr	Val	Leu	Cys	Val	Ala	Trp	Gln
		755					760					765			
Asp	Tyr	Val	Gly	Phe	Thr	Leu	Lys	Ile	Phe	Ala	Ser	Leu	Leu	Ser	Pro
	770						775				780				
Val	Ala	Phe	Gly	Phe	Gly	Cys	Glu	Tyr	Phe	Ala	Leu	Phe	Glu	Glu	Gln
785					790					795					800
Gly	Ile	Gly	Val	Gln	Trp	Asp	Asn	Leu	Phe	Glu	Ser	Pro	Val	Glu	Glu
				805					810					815	
Asp	Gly	Phe	Asn	Leu	Thr	Thr	Ser	Val	Ser	Met	Met	Leu	Phe	Asp	Thr
			820					825					830		
Phe	Leu	Tyr	Gly	Val	Met	Thr	Trp	Tyr	Ile	Glu	Ala	Val	Phe	Pro	Gly
		835					840					845			
Gln	Tyr	Gly	Ile	Pro	Arg	Pro	Trp	Tyr	Phe	Pro	Cys	Thr	Lys	Ser	Tyr
	850					855					860				
Trp	Phe	Gly	Glu	Glu	Ser	Asp	Glu	Lys	Ser	His	Pro	Gly	Ser	Asn	Gln
865					870					875					880
Lys	Arg	Ile	Ser	Glu	Ile	Cys	Met	Glu	Glu	Glu	Pro	Thr	His	Leu	Lys
				885					890					895	
Leu	Gly	Val	Ser	Ile	Gln	Asn	Leu	Val	Lys	Val	Tyr	Arg	Asp	Gly	Met
			900					905					910		
Lys	Val	Ala	Val	Asp	Gly	Leu	Ala	Leu	Asn	Phe	Tyr	Glu	Gly	Gln	Ile
		915					920					925			
Thr	Ser	Phe	Leu	Gly	His	Asn	Gly	Ala	Gly	Lys	Thr	Thr	Thr	Met	Ser
	930					935					940				
Ile	Leu	Thr	Gly	Leu	Phe	Pro	Pro	Thr	Ser	Gly	Thr	Ala	Tyr	Ile	Leu

945		950		955		960
Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg Gln Asn Leu Gly						
	965		970			975
Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu Thr Val Glu Glu						
	980		985			990
His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser Glu Lys His Val						
	995		1000			1005
Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly Leu Pro Ser Ser						
	1010		1015			1020
Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly Met Gln Arg Lys						
	1025		1030			1035
Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys Val Val Ile Leu						
	1045		1050			1055
Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg Arg Gly Ile Trp						
	1060		1065			1070
Glu Leu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile Ile Leu Ser Thr						
	1075		1080			1085
His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg Ile Ala Ile Ile						
	1090		1095			1100
Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu Phe Leu Lys Asn						
	1105		1110			1115
Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys Lys Asp Val Glu						
	1125		1130			1135
Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Ser Thr Val Ser Tyr Leu						
	1140		1145			1150
Lys Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp Ala Gly Leu Gly						
	1155		1160			1165
Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val Ser Ala Ile Ser						
	1170		1175			1180
Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu Val Glu Asp Ile						
	1185		1190			1195
Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala Ala Lys Glu Gly						
	1205		1210			1215
Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg Leu Ser Asp Leu						
	1220		1225			1230
Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu Glu Glu Ile Phe						
	1235		1240			1245
Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu Thr Ser Asp Gly						
	1250		1255			1260
Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly Asp Lys Gln Ser						
	1265		1270			1275
Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp Pro Asn Asp Ser						
	1285		1290			1295
Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu Ser Gly Met Asp						
	1300		1305			1310
Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu Thr Gln Gln Gln						
	1315		1320			1325
Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala Arg Arg Ser Arg						
	1330		1335			1340
Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val Phe Val Cys Ile						
	1345		1350			1355
						1360

Ala	Leu	Val	Phe	Ser	Leu	Ile	Val	Pro	Pro	Phe	Gly	Lys	Tyr	Pro	Ser		
				1365					1370						1375		
Leu	Glu	Leu	Gln	Pro	Trp	Met	Tyr	Asn	Glu	Gln	Tyr	Thr	Phe	Val	Ser		
			1380					1385						1390			
Asn	Asp	Ala	Pro	Glu	Asp	Thr	Gly	Thr	Leu	Glu	Leu	Leu	Asn	Ala	Leu		
		1395					1400					1405					
Thr	Lys	Asp	Pro	Gly	Phe	Gly	Thr	Arg	Cys	Met	Glu	Gly	Asn	Pro	Ile		
	1410					1415						1420					
Pro	Asp	Thr	Pro	Cys	Gln	Ala	Gly	Glu	Glu	Glu	Trp	Thr	Thr	Ala	Pro		
1425					1430					1435					1440		
Val	Pro	Gln	Thr	Ile	Met	Asp	Leu	Phe	Gln	Asn	Gly	Asn	Trp	Thr	Met		
				1445					1450						1455		
Gln	Asn	Pro	Ser	Pro	Ala	Cys	Gln	Cys	Ser	Ser	Asp	Lys	Ile	Lys	Lys		
			1460					1465						1470			
Met	Leu	Pro	Val	Cys	Pro	Pro	Gly	Ala	Gly	Gly	Leu	Pro	Pro	Pro	Gln		
	1475						1480						1485				
Arg	Lys	Gln	Asn	Thr	Ala	Asp	Ile	Leu	Gln	Asp	Leu	Thr	Gly	Arg	Asn		
	1490					1495						1500					
Ile	Ser	Asp	Tyr	Leu	Val	Lys	Thr	Tyr	Val	Gln	Ile	Ile	Ala	Lys	Ser		
1505					1510					1515					1520		
Leu	Lys	Asn	Lys	Ile	Trp	Val	Asn	Glu	Phe	Arg	Tyr	Gly	Gly	Phe	Ser		
			1525						1530						1535		
Leu	Gly	Val	Ser	Asn	Thr	Gln	Ala	Leu	Pro	Pro	Ser	Gln	Glu	Val	Asn		
		1540						1545					1550				
Asp	Ala	Ile	Lys	Gln	Met	Lys	Lys	His	Leu	Lys	Leu	Ala	Lys	Asp	Ser		
	1555					1560						1565					
Ser	Ala	Asp	Arg	Phe	Leu	Asn	Ser	Leu	Gly	Arg	Phe	Met	Thr	Gly	Leu		
	1570					1575						1580					
Asp	Thr	Arg	Asn	Asn	Val	Lys	Val	Trp	Phe	Asn	Asn	Lys	Gly	Trp	His		
1585				1590						1595					1600		
Ala	Ile	Ser	Ser	Phe	Leu	Asn	Val	Ile	Asn	Asn	Ala	Ile	Leu	Arg	Ala		
				1605					1610					1615			
Asn	Leu	Gln	Lys	Gly	Glu	Asn	Pro	Ser	His	Tyr	Gly	Ile	Thr	Ala	Phe		
		1620					1625						1630				
Asn	His	Pro	Leu	Asn	Leu	Thr	Lys	Gln	Gln	Leu	Ser	Glu	Val	Ala	Leu		
	1635					1640						1645					
Met	Thr	Thr	Ser	Val	Asp	Val	Leu	Val	Ser	Ile	Cys	Val	Ile	Phe	Ala		
	1650					1655					1660						
Met	Ser	Phe	Val	Pro	Ala	Ser	Phe	Val	Val	Phe	Leu	Ile	Gln	Glu	Arg		
1665				1670						1675					1680		
Val	Ser	Lys	Ala	Lys	His	Leu	Gln	Phe	Ile	Ser	Gly	Val	Lys	Pro	Val		
			1685						1690						1695		
Ile	Tyr	Trp	Leu	Ser	Asn	Phe	Val	Trp	Asp	Met	Cys	Asn	Tyr	Val	Val		
		1700						1705					1710				
Pro	Ala	Thr	Leu	Val	Ile	Ile	Ile	Phe	Ile	Cys	Phe	Gln	Gln	Lys	Ser		
	1715						1720						1725				
Tyr	Val	Ser	Ser	Thr	Asn	Leu	Pro	Val	Leu	Ala	Leu	Leu	Leu	Leu	Leu		
	1730					1735					1740						
Tyr	Gly	Trp	Ser	Ile	Thr	Pro	Leu	Met	Tyr	Pro	Ala	Ser	Phe	Val	Phe		
1745				1750						1755					1760		
Lys	Ile	Pro	Ser	Thr	Ala	Tyr	Val	Val	Leu	Thr	Ser	Val	Asn	Leu	Phe		

Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile Phe Ser
 2180 2185 2190
 Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr Ser Val
 2195 2200 2205
 Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys Asp Gln
 2210 2215 2220
 Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn Gln Thr
 2225 2230 2235 2240
 Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu Lys Val
 2245 2250 2255
 Lys Glu Ser Tyr Val
 2260

<210> 2
 <211> 7864
 <212> DNA
 <213> Homo sapiens

<400> 2
 gtccctgctg tgagctctgg ccgctgcctt ccagggctcc cgagccacac gctgggggtg 60
 ctggctgagg gaacatggct tgttggcctc agctgaggtt gctgctgtgg aagaacctca 120
 ctttcagaag aagacaaaca tgtcagctgt tactggaagt ggcctggcct ctatttatct 180
 tctgatcct gatctctgtt cggctgagct acccacccta tgaacaacat gaatgccatt 240
 ttccaaataa agccatgccc tctgcaggaa cacttccttg gggttcagggg attatctgta 300
 atgccaacaa cccctgtttc cgttaccga ctctgggga ggctcccga gttgttgaa 360
 actttaacaa atccattgtg gctcgctgt tctcagatgc tcggaggctt cttttataca 420
 gccagaaaga caccagcatg aaggacatgc gcaaagttct gagaacatta cagcagatca 480
 agaaatccag ctcaaacttg aagcttcaag atttcctggg ggacaatgaa accttctctg 540
 gggtcctgta tcacaacctc tctctcccaa agtctactgt ggacaagatg ctgagggtg 600
 atgtcattct ccacaaggta tttttgcaag gctaccagtt acatttgaca agtctgtgca 660
 atggatcaaa atcagaagag atgattcaac ttggtgacca agaagtttct gagctttgtg 720
 gcctaccaag ggagaaactg gctgcagcag agcgagtact tcgttccaac atggacatcc 780
 tgaagccaat cctgagaaca ctaaactcta catctccctt cccgagcaag gagctggctg 840
 aagccacaaa aacattgctg catagtcttg ggactctggc ccaggagctg ttcagcatga 900
 gaagctggag tgacatgcga caggaggtga tgtttctgac caatgtgaac agctccagct 960
 cctccacca aatctaccag gctgtgtctc gtattgtctg cgggcatccc gagggagggg 1020
 ggctgaagat caagtctctc aactggtatg aggacaacaa ctacaaagcc ctctttggag 1080
 gcaatggcac tgaggaagat gctgaaacct tctatgacaa ctctacaact ccttactgca 1140
 atgatttgat gaagaatttg gagtctagtc ctctttcccg cattatctgg aaagctctga 1200
 agccgctgct cgttgggaag atcctgtata cacctgacac tccagccaca aggcaggtca 1260
 tggctgaggt gaacaagacc ttccaggaac tggctgtgtt ccatgatctg gaaggcatgt 1320
 gggaggaact cagccccaag atctggacct tcatggagaa cagccaagaa atggaccttg 1380
 tccggatgct gttggacagc agggacaatg accacttttg ggaacagcag ttggatggct 1440
 tagattggac agcccaagac atcgtggcgt ttttggccaa gcaccagag gatgtccagt 1500
 ccagtaatgg ttctgtgtac acctggagag aagctttcaa cgagactaac caggcaatcc 1560
 ggaccatata tgccttcatt gagtgtgtca acctgaacaa gctagaacct atagcaacag 1620
 aagtctggct catcaacaag tccatggagc tgctggatga gaggaagttc tgggctggta 1680
 ttgtgttcac tgggaattact ccaggcagca ttgagctgcc ccatcatgtc aagtacaaga 1740
 tccgaatgga cattgacaat gtggagagga caaataaaat caaggatggg tactgggacc 1800
 ctggtcctcg agctgacccc tttgaggaca tgcggtacgt ctgggggggc ttcgcctact 1860
 tgcaggatgt ggtggagcag gcaatcatca ggggtgctgac gggcaccgag aagaaaactg 1920

gdgtgtctat	atgcaacaga	tgccttatcc	ctgttacgtt	gatgacatct	ttctgcggt	1980
gatgagccgg	tcaatgcccc	tcttcatgac	gctggcctgg	atttactcag	tggctgtgat	2040
catcaagggc	atcgtgtatg	agaaggaggc	acggctgaaa	gagaccatgc	ggatcatggg	2100
cctggacaac	agcatcctct	ggtttagctg	gttcattagt	agcctcattc	ctcttcttgt	2160
gagcgtggc	ctgctagtgg	tcacctcgaa	gttaggaaac	ctgctgccct	acagtgatcc	2220
cagcgtggg	tttgtcttcc	tgtccgtgtt	tgtgtgggtg	acaatcctgc	agtgttccct	2280
gattagcaca	ctcttctcca	gagccaacct	ggcagcagcc	tgtgggggca	tcactacttt	2340
cacgctgtac	ctgccctacg	tcctgtgtgt	ggcatggcag	gactacgtgg	gcttcacact	2400
caagatcttc	gctagcctgc	tgtctcctgt	ggcttttggg	tttggctgtg	agtactttgc	2460
cctttttgag	gagcagggca	ttggagtgc	gtgggacaac	ctgtttgaga	gtcctgtgga	2520
ggaagatggc	ttcaatctca	ccacttcggg	ctccatgatg	ctgtttgaca	ccttcctcta	2580
tgggggtgatg	acctgggtaca	ttgaggctgt	ctttccaggc	cagtacggaa	ttcccaggcc	2640
ctgggtatttt	ccttgcacca	agtcctactg	gtttggcgag	gaaagtgatg	agaagagcca	2700
ccctggttcc	aaccagaaga	gaatatcaga	aatctgcatg	gaggaggaac	ccaccacttt	2760
gaagctgggc	gtgtccattc	agaacctggg	aaaagtctac	cgagatggga	tgaaggtggc	2820
tgtcgatggc	ctggcactga	atttttatga	gggccagatc	acctccttcc	tgggccacaa	2880
tggagcgggg	aagacgacca	ccatgtcaat	cctgaccggg	ttgttcccc	cgacctcggg	2940
caccgcctac	atcctgggaa	aagacattcg	ctctgagatg	agcaccatcc	ggcagaacct	3000
gggggtctgt	ccccagcata	acgtgctgtt	tgacatgctg	actgtcgaag	aacacatctg	3060
gttctatgcc	cgcttgaaag	ggctctctga	gaagcacgtg	aaggcggaga	tggagcagat	3120
ggccctggat	gttggtttgc	catcaagcaa	gctgaaaagc	aaaacaagcc	agctgtcagg	3180
tggaatgcag	agaaagctat	ctgtggcctt	ggcctttgtc	gggggatcta	aggttgtcat	3240
tctggatgaa	cccacagctg	gtgtggaccc	ttactcccg	aggggaatat	gggagctgct	3300
gctgaaatac	cgacaaggcc	gcaccattat	tctctctaca	caccacatgg	atgaagcgga	3360
cgtcctgggg	gacaggattg	ccatcatctc	ccatgggaag	ctgtgctgtg	tgggctcctc	3420
cctgtttctg	aagaaccagc	tgggaacagg	ctactacctg	accttgggtca	agaaagatgt	3480
ggaatcctcc	ctcagttcct	gcagaaacag	tagtagcact	gtgtcatacc	tgaaaaagga	3540
ggacagtgtt	tctcagagca	gttctgatgc	tggcctgggc	agcgaccatg	agagtgcac	3600
gctgaccatc	gatgtctctg	ctatctccaa	cctcatcagg	aagcatgtgt	ctgaagcccg	3660
gctgggtggaa	gacatagggc	atgagctgac	ctatgtgctg	ccatatgaag	ctgctaagga	3720
gggagccttt	gtggaactct	ttcatgagat	tgatgaccgg	ctctcagacc	tgggcatttc	3780
tagttatggc	atctcagaga	cgaccttggg	agaaatatct	ctcaagggtg	ccgaagagag	3840
tgggggtggat	gctgagacct	cagatgggtac	cttgccagca	agacgaaaca	ggcgggcctt	3900
cgggggacaag	cagagctgtc	ttcgcccggt	caactgaagat	gatgctgctg	atccaaatga	3960
ttgctgacat	agaccagaaa	tccagagaga	cagacttgct	cagtgggatg	gatggcaaag	4020
ggtcctacca	ggtgaaaggc	tggaaactta	cacagcaaca	gtttgtggcc	cttttgtgga	4080
agagactgct	aattgccaga	cggagtcgga	aaggattttt	tgtctcagatt	gtcttgccag	4140
ctgtgtttgt	ctgcattgcc	cttgtgttca	gcctgatcgt	gccacccttt	ggcaagtacc	4200
ccagcctgga	acttcagccc	tggatgtaca	acgaacagta	cacatttgtc	agcaatgatg	4260
ctcctgagga	cacgggaacc	ctggaactct	taaacgccct	caccaaagac	cctggcttcc	4320
ggaccgctg	tatggaagga	aacccaatcc	cagacacgcc	ctgccaggca	ggggagggaag	4380
agtggaccac	tgccccagtt	ccccagacca	tcattggacct	cttcagaat	gggaactgga	4440
caatgcagaa	cccttcacct	gcattgccagt	gtagcagcga	caaaatcaag	aagatgctgc	4500
ctgtgtgtcc	cccaggggca	ggggggctgc	ctcctccaca	aagaaaacaa	aacactgcag	4560
atatacttca	ggacctgaca	ggaagaaaca	tttcggatta	tctgggtgaag	acgtatgtgc	4620
agatcatagc	caaaagctta	aagaacaaga	tctgggtgaa	tgagtttagg	tatggcggct	4680
tttccctggg	tgtcagtaat	actcaagcac	ttcctccgag	tcaagaagtt	aatgatgcca	4740
tcaaacaaat	gaagaaacac	ctaaagctgg	ccaaggacag	ttctgcagat	cgatttctca	4800
acagcttggg	aagatttatg	acaggactgg	acaccagaaa	taatgtcaag	gtgtggttca	4860
ataacaaggg	ctggcatgca	atcagctctt	tctgaatgt	catcaacaat	gccatttctc	4920
gggccaacct	gcaaaaggga	gagaacccta	gccattatgg	aattactgct	ttcaatcatc	4980

ccctgaatct	caccaagcag	cagctctcag	aggtggctct	gatgaccaca	tcagtggatg	5040
tccttggtgc	catctgtgtc	atctttgcaa	tgtccttcgt	cccagccagc	tttgtcgtat	5100
tcctgatcca	ggagcggggtc	agcaaagcaa	aacacctgca	gttcatcagt	ggagtgaagc	5160
ctgtcatcta	ctggctctct	aattttgtct	gggatatgtg	caattacgtt	gtccctgccca	5220
cactgggtcat	tatcatcttc	atctgcttcc	agcagaagtc	ctatgtgtcc	tccaccaatc	5280
tgctgtgtct	agcccttcta	cttttgctgt	atgggtgggtc	aatcacacct	ctcatgtacc	5340
cagcctcctt	tgtgttcaag	atccccagca	cagcctatgt	ggtgctcacc	agcgtgaacc	5400
tcttcattgg	cattaatggc	agcgtggcca	cctttgtgct	ggagctgttc	accgacaata	5460
agctgaataa	tatcaatgat	atcctgaagt	ccgtgttctt	gatcttccca	catttttgcc	5520
tgggacgagg	gctcatcgac	atggtgaaaa	accaggcaat	ggctgatgcc	ctggaaaggt	5580
ttggggagaa	tcgctttgtg	tcaccattat	cttgggactt	ggtgggacga	aacctcttcg	5640
ccatggccgt	ggaaggggtg	gtgttcttcc	tcttactgt	tctgatccag	tacagattct	5700
tcacagggcc	cagacctgta	aatgcaaagc	tatctcctct	gaatgatgaa	gatgaagatg	5760
tgaggcggga	aagacagaga	attcttgatg	gtggaggcca	gaatgacatc	ttagaaatca	5820
aggagttgac	gaagatatat	agaaggaagc	ggaagcctgc	tgttgacagg	atttgcgtgg	5880
gcattcctcc	tgggtgagtgc	tttgggctcc	tgggagttaa	tggggctgga	aaatcatcaa	5940
ctttcaagat	gttaacagga	gataccactg	ttaccagagg	agatgctttc	cttaacaaaa	6000
ataggtatct	tatcaaacat	ccatgaagta	catcagaaca	tgggctactg	ccctcagttt	6060
gatgccatca	cagagctggt	gactgggaga	gaacacgtgg	agttctttgc	ccttttgaga	6120
ggagtcccag	agaaagaagt	tggcaagggt	ggtgagtggg	cgattcggaa	actgggcctc	6180
gtgaagtatg	gagaaaaata	tgctggtaac	tatagtggag	gcaacaaacg	caagctctct	6240
acagccatgg	ctttgatcgg	cgggcctcct	gtgggtgttc	tggatgaacc	caccacaggc	6300
atggatcca	aagcccggcg	gttcttgtgg	aattgtgcc	taagtgttgt	caaggagggg	6360
agatcagtag	tgcttacatc	tcatagtatg	gaagaatgtg	aagctctttg	cactaggatg	6420
gcaatcatgg	tcaatggaag	gttcagggtgc	cttggcagtg	tccagcatct	aaaaaatagg	6480
tttggagatg	gttatacaat	agttgtacga	atagcagggt	ccaaccogga	cctgaagcct	6540
gtccaggatt	tctttggact	tgcatttctc	ggaagtgttc	taaaagagaa	acaccggaac	6600
atgctacaat	accagcttcc	atcttcatta	tcttctctgg	ccaggatatt	cagcatcctc	6660
tcccagagca	aaaagcgact	ccacatagaa	gactactctg	tttctcagac	aacacttgac	6720
caagtatttg	tgaactttgc	caaggaccaa	agtgatgatg	accacttaaa	agacctctca	6780
ttacacaaaa	accagacagt	agtggacgtt	gcagttctca	catcttttct	acaggatgag	6840
aaagtgaag	aaagctatgt	atgaagaatc	ctgttcatac	ggggtggctg	aaagtaaaga	6900
ggaactagac	tttcctttgc	accatgtgaa	gtgttgtgga	gaaaagagcc	agaagttgat	6960
gtgggaagaa	gtaaaactgga	tactgtactg	atactattca	atgcaatgca	attcaatgca	7020
atgaaaacaa	aattccatta	caggggagct	gcctttgtag	cctatgtctt	gtatggctct	7080
caagtgaag	acttgaattt	agttttttac	ctatacctat	gtgaaactct	attatggaac	7140
ccaatggaca	tatgggtttg	aactcacact	tttttttttt	tttttgttcc	tgtgtattct	7200
cattgggggt	gcaacaataa	ttcatcaagt	aatcatggcc	agcgattatt	gatcaaaatc	7260
aaaaggtaat	gcacatcctc	attcactaag	ccatgccatg	cccaggagac	tggtttcccg	7320
gtgacacatc	cattgctggc	aatgagtgtg	ccagagttat	tagtgccaag	tttttcagaa	7380
agtttgaagc	accatggtgt	gtcatgctca	cttttgtgaa	agctgctctg	ctcagagtct	7440
atcaacattg	aatatcagtt	gacagaatgg	tgccatgcgt	ggctaacatc	ctgctttgat	7500
tccctctgat	aagctgttct	ggtggcagta	acatgcaaca	aaaatgtggg	tgtctccagg	7560
cacgggaaac	ttggttccat	tgttatattg	tcctatgctt	cgagccatgg	gtctacaggg	7620
tcacctttat	gagactotta	aatatactta	gatcctggta	agaggcaaag	aatcaacagc	7680
caaactgctg	gggctgcaac	tgctgaagcc	agggcatggg	attaaagaga	ttgtgcgttc	7740
aaacctaggg	aagcctgtgc	ccatttgtcc	tgactgtctg	ctaacatggg	acactgcac	7800
tcaagatgtt	tatctgacac	aagtgtatta	tttctggctt	tttgaattaa	tctagaaaat	7860
gaaa						7864

<210> 3
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 3
 gcagagggca tggctttatt tg 22

 <210> 4
 <211> 24
 <212> DNA
 <213> Homo sapiens

 <400> 4
 ctgccaggca ggggaggaag agtg 24

 <210> 5
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 5
 gaaagtgact cacttgtgga gga 23

 <210> 6
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 6
 aaaggggctt ggtaagggtg 20

 <210> 7
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 7
 catgcacatg cacacacata 20

 <210> 8
 <211> 27
 <212> DNA
 <213> Homo sapiens

 <400> 8
 ctttctgcgg gtgatgagcc ggtcaat 27

 <210> 9
 <211> 20
 <212> DNA

```

<213> Homo sapiens

<400> 9
ccttagcccg tggtgagcta 20

<210> 10
<211> 26
<212> DNA
<213> Homo sapiens

<400> 10
cctgtaaatg caaagctatc tcctct 26

<210> 11
<211> 26
<212> DNA
<213> Homo sapiens

<400> 11
cgtcaactcc ttgatttcta agatgt 26

<210> 12
<211> 20
<212> DNA
<213> Homo sapiens

<400> 12
gggttcccag gggttcagtat 20

<210> 13
<211> 21
<212> DNA
<213> Homo sapiens

<400> 13
gatcaggaat tcaagcacca a 21

<210> 14
<211> 10545
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(10545)
<223> n = a, t, c, or g

<400> 14
acctcttata gaatgataga attcctctgg aatgattgga taacttcatt tcatccttga 60
cttttacctt ggaggatttc ttaccctttt tggcttctca aatttgacta ttaaaatgtt 120
gcctttaaaa ataggaacac agtttcaggg gggagtacca gcccatgacc cttctgcaag 180

```

gccccctaac	tcaaggtagt	ttccctggaa	ctgtggttta	tggaatgttt	caggagtgtg	240
aggaggata	atttaagget	gtccatagcaa	ggataccctt	aaggatagag	ggcccagtag	300
catctggagg	ccagaaaagt	taaaactgagg	cagtcagatt	agcttcaggc	tcaattaagc	360
tgatgggtca	gcctgggaga	aattgcagga	tgactctcaa	tatcccctcc	cacccccaca	420
gcagccacga	tctgtctgtc	tttaatcatg	ggtgcagtga	acctgttctt	tccagggtgtc	480
ttggccttca	gtaaccttgt	taggcttgtc	cctgaacgtg	gctaccgatc	caaagacaca	540
tgatcagaga	ggcaattaga	gaacagacct	tttccaaagc	aagcatgttc	tgttgggctt	600
agaagtttca	tgctcctaata	ttataggacc	ctgtgcatct	ctctggagat	gaggcacatg	660
agtcatatct	gtgattcttg	cttttgtgtc	aacatctcat	gaataggcaa	tcagagcttt	720
ggcaccaatg	tattttcagt	tcatatctga	tgtagttaaa	tccacctcct	gctttgtagt	780
ttactggcaa	gctgtttttg	atataagaca	tctagaacac	tgtaaataata	taacattttt	840
atttgtctat	tatacctcaa	ttacgaaaaa	gacatctaga	agcaacctca	tcaagagaga	900
tactgaggcc	gggcatggta	gctcacactt	gcaatcccat	tactttggga	ggctgaggca	960
ggtagatcac	ttgagggtcaa	gagtttgaaa	ccagcctggc	caacatgttg	aaacctgttc	1020
tctattaaaa	atacaaaaaa	gttagctggg	cttgggtggg	ggcacctgta	atcccagcta	1080
ctccggaggc	tgaggcgagga	gaatcacttg	aacctgggag	gcagagggtg	cagtgcagctg	1140
agatcacacc	actgcactcc	aacctgggca	ccagagttag	attacatcta	aaaaataaaa	1200
taaagtaata	aaaaagagag	atattgatag	ctgttggttg	aaatttcaac	ttccatctca	1260
cttctggtaa	ctttttggaa	gtttgttgaa	caaagtggaa	tacacgcaca	tacacacaca	1320
cacatactct	cttgtttgtt	taaggtttaa	tgaaatagct	gtcatataat	cactgttttt	1380
gaaagaggag	aattagttgc	tatctgtaca	ttttgggtat	gtgaactatt	tggatagaac	1440
tctgagaaat	gcattcagaa	caacaaacaa	aatcatagga	gaaatagcta	agtgggaagg	1500
ggcatataag	agttgttgaa	aaagttatct	cttgagaaac	cagctctaata	gctaggcaag	1560
tcacttgctt	tggggggaggc	ctcagcttct	ctgtctataa	gattgcagca	gggtgtgtgt	1620
gggaatgagt	cttcaacatt	ccaagagatt	ttatctacta	atacgacagt	caaatggagc	1680
atgactttgt	ggaagcctct	cctcttccac	ccagaggggc	caatttctct	gtcccagtga	1740
gatgttgaca	cttgatatgat	ccctgcttgg	agacttccct	cttctggaac	ctgccctggc	1800
tcaggcatga	gggctgactg	tcacccttcg	ataggagccc	agcactaaag	ctcatgtgtt	1860
ggcagtgttc	ttgcgggaag	gaaaaagacc	agccagccca	tttgttactg	cacaagcaaa	1920
cagcttctgg	tagctgtaca	gatacatgca	ctttctttcc	tcactgtgtt	tccatagaca	1980
gatttagtgc	tgtagaagag	tagagggcag	tcacgggaag	gagttcctgt	ttttcttttg	2040
gctatgccaa	atggggaaaa	atcctcctat	cttgtctttt	tagtgtcatc	ctctctcccc	2100
ttttcttctt	ctttataatt	ctcatctctc	atctctcctg	gaaatgtgca	tgtcaagttc	2160
aaaagggcac	aatgttttgg	tgaggaagag	gtggggagaac	acgtgccagg	tgctaactag	2220
ggtcatcatt	tcccccttca	cagccagctt	cctgtgaatg	tgtgtgtgtg	tgtgtgtgtg	2280
tgtgtgtgtg	tgtgtgtgtg	tgtgtatttc	ttttgccagc	atcactgaat	ctgtctgctg	2340
tctggtatct	cagggttttg	tttagggaaa	agtaaaagta	attttataat	cccagctgtc	2400
atttaagcca	cccctttgtg	ggtagcataat	gggtccactct	ctcagttcat	tgtcctaag	2460
atgcttcac	agaaaggaat	aacttccacc	ccgttactct	ctgtccctct	actctgcttt	2520
atttttcttc	gtcaatccta	ccaccaccac	ccactgtttg	aacaaccac	tattatttgt	2580
ctgtttccca	tccctggtag	aataggagcc	ccatgaatga	aggaactttg	cttctgttgt	2640
tcaccactga	atctctaagg	tatggaacac	acctggcatg	tgataggcac	tcgataaata	2700
tttggtgtgg	ctcatgggca	ccttgcagag	ttaaggctgc	agttgtttgt	ggaatttata	2760
agtggtaatg	aataatttatc	tactattcct	cttccaaggc	gatcacacaa	taatcaggct	2820
ttacactatc	cagttcttag	gtcttccaag	ttatgacttg	tgaggatagt	taattatgat	2880
aatagaaggc	agtttatattg	gttcagattt	attgatgtgt	aatttaccac	agtaagactt	2940
cccctttaca	aaagtatgat	gagttttgac	aaatggatac	acatgtgtat	ctaccactgc	3000
catgctcctt	ttcagttctgt	cgtccccctc	acccatgacc	actggtcacc	actgcagtga	3060
tttctgtccc	cttcatttca	ccttttccag	aatgtcatat	aaatggaatc	atgcagtatg	3120
tagttttttg	tgtctggctt	atttttctta	gcattaggct	tttgggattc	atccaggttg	3180
tcgcatgtaa	cagtagctta	ttccttttta	tggctgagta	agtgtcccag	ttttatttat	3240

atattttat	atgaggaggt	gtctcactct	gtcaccag	ctggagtgcg	gtagcgcat	3300
ctcagctcac	tgcaacctcc	gcctcccagg	ttcaagcaat	tctcctgcct	cctgagtagc	3360
tgggattaca	ggcaccaccc	gccacgccc	actaat	atatttttag	tagagatggg	3420
gtttcaccat	gttggccagg	ctgatctcaa	actcttgacc	tcaggtgatc	cgccacctc	3480
tggctcccaa	agtgttagga	ttacaggcat	gagccactgt	gcccagcccc	agttttat	3540
attcaccagt	tgatggctct	ttcgacaact	aattgtttcc	agtttttggc	tattctgtat	3600
aaggcttcta	taaatattca	caaataccta	ggatgggatg	actgggtcat	ataatagtac	3660
tgtataacct	tagcagaaac	tgtcaaacta	ttttccaaag	tggctcttcc	attttacaat	3720
tccacagtgt	attgagtc	agtgtctcca	tacacatgct	agcactttta	atatttaatt	3780
tagtgggtat	gtaatgat	ctcattgtgg	ttttaatttg	catttctctg	cagctaata	3840
tgagtgtttc	tgcttatttg	ggaagggttt	aatttagcag	tctgttgat	tctgtagata	3900
ttataaactt	caaaatatca	gtggcatttg	cagttaaaat	ttccttaaaa	aattggccaa	3960
aggtttccag	cagtcacttc	tgccatgccc	aaactgtatg	aaacaaggct	gaggtgtgga	4020
gattgtcaca	ttttggcaag	gagtgatcca	cttgggtgac	tgatgagacc	cagagagcgt	4080
acgcctcggg	cttgaggggtg	aggacggggc	ggaagtcgac	tgcatggccc	tgctggcctt	4140
gggaggctgc	ccagtcctta	gctaaagctg	gcagttatgg	gaaacagact	tagattctat	4200
tacgtttttc	aggatgtccc	aggagtcacc	tgggaagctc	agcagtcctt	tgtgactttc	4260
aagcatatgg	tagaagctgc	tgaacacaga	gctccctctt	tggggataat	ttgcccaa	4320
catttaataca	ggcttgagaa	atgagttacc	acaggtccag	gagtgtgtcc	acccttgaat	4380
tctgacaccc	tatttctcct	atccgtctct	taattaatta	agcagacatc	cccaagtgt	4440
tacgacaagc	caggaccctt	ttgcatacta	agggaaacag	ggatgaagga	aacagaaatg	4500
gtctctgtct	tgactcagaa	ggtagaaatc	ctctttccca	gccaagtctt	cctagggagc	4560
acgtaggaag	ggctctgaac	ccacgtgtca	gttgccaggg	aggatatcag	gaaaggacat	4620
tgaagaagtg	gagacctaag	tttgagacct	aggcattagc	caggctagca	gtgcttgaaa	4680
aagtgtctta	ggacaagaga	actcaccagt	gaagtc	tggtaggaga	gcgtgcagca	4740
tattctgagc	ctgtatacac	atctccagg	cattgcttag	cagggtgggga	gtggcaagag	4800
agtaggctgg	agtcacagaa	gggaggccag	gtagaccttg	gtgagcactg	gactctatgt	4860
tcaggtgctg	aggagctggc	aaaagggttt	aagtcgggga	gaggcatgtt	cagatatattg	4920
gtctagctga	gtaacttttg	gtgctctgtg	acaaatgggt	gggagaccag	tgaggtggca	4980
gttgccggtca	tctaggagca	ggatcagagt	ggcctattga	ctgggatgac	tgtgaagtgg	5040
gatcctttcc	agccagtaac	tggaaatgtg	tatgagggca	gaagtgaagt	tactgcattt	5100
gaaacattga	gaaatctagt	acatagtact	gtctctttta	tatctttttt	tttttttttt	5160
ttgatttttg	tttgtttggt	cactaacttg	gaaaactgat	gtggaaatgt	ccctttggct	5220
tcagttacct	gagcagaagg	ggccgggcat	tgccaaactc	tcctcttagg	acagaattgc	5280
tcccagtatt	gatcattgtg	ttctgagttg	ggggagcaaa	ttgtgcagga	ggccagggtca	5340
gtgccaagg	gggtgggagg	aattggagca	ggaagcttgc	ctaagtgtgc	ccagcaaagc	5400
cacggtagaa	ctttctactg	tggctctatg	ctacttctta	gcaaccttct	ccatgtgctt	5460
cctggagagt	ccttggagtc	agaacctttt	tcttgaaacc	cagacacttt	acttccaaga	5520
aaatgctgtc	caagaaaact	cactcttccc	ttcttctcat	gaacgttgtg	tagagggtgtg	5580
tcttctcttc	ctttgagctt	ttccactcag	ggtttagggg	aggatgatt	ctatatatttg	5640
gtttggctct	gggtactgca	acactaggct	attaagattt	catccttact	gctttgcccc	5700
tcctatcttt	ccagaaaccc	acaatggatt	tgctagaaat	aatggaacgt	cctgtttgga	5760
caggatataa	ccatttctca	gctagaggat	attgttggaa	tgaagaaaga	taaatgggga	5820
gaagggaact	cacattgctt	tggcacttaa	attaagccat	gtactgtgtt	gggaaattat	5880
ttatattatc	tcgttgaatc	cacagtagaa	cacagttgaa	caccatacaa	ggtaagtatt	5940
gtcatcctta	ttttaccatg	aggaaattga	tgcttagaga	gcataaagcc	ttggccaggg	6000
gcacatagtt	gggaagccgg	ggctaattca	tgcttgggct	ctttctgata	gttttccctt	6060
tttaattgtc	ccctcctcat	tgttaccttg	gggatttcaa	gagattcatg	tagcttctaa	6120
atcaacgaac	tgattcctgg	agagcagctt	ctgtatgaga	aaaatctagc	taattattta	6180
tttcagtgtc	tctggaatgc	aagctctgtc	ctgagccact	tagaaaacaa	tttgggatga	6240
caagcatgtg	tctcacaatg	ctgctctggg	tgccagtgtc	gtgctgccag	ttgtcatctt	6300

tgaacaaact	gatgcagtgc	tggtttaact	cttcctcttt	ttggagtaag	aaactttgga	6360
ggcctgtgtc	cttctagaag	tttgctgagc	aaatggtaag	gaaaagaaat	aggtcctaag	6420
gcttgactat	ttcagagaat	ttcttgattt	attggactgt	caatgaatga	attggaatac	6480
atagtggtag	gctgtctttt	cttctcagac	actgcaattt	cctccaatct	cttgactttt	6540
ctagaagttt	taatccaagt	ccttggttggg	tggtagataa	aagggatttg	ttctactaga	6600
gactgacctt	ggcatggaga	tctcatttgg	actcacagat	ttctagtcta	gcgcttggtt	6660
ttgtatccat	acctcgctac	tgcattctta	gttccttctg	ctccttgttc	ctcatgccca	6720
gtgtcccacc	ctacccttgc	ccctactcct	ctagaggcca	cagtgattca	ctgagccatt	6780
tcataagcac	agctaggaga	gttcattggc	accaagtgcc	agcagggccg	aattttcacc	6840
tgtgtgtcct	cccttccatt	tttcatcttc	tgccccctcc	ccagctttaa	ctttaatata	6900
actacttggg	actattccag	cattaaataa	gggtaactgc	tggatgggtg	gctgggatac	6960
acagaatgta	gtatcccttg	ttcacgagaa	gaccttcttg	ccctagcatg	gcaaacagtc	7020
ctccaaggag	gcacctgtga	cacccaacgg	agtagggggg	cgggtgtgtt	aggtgcaggt	7080
ggaacaaggc	cagaagtgtg	catatgtgct	gaccatggga	gcttgtttgt	cggtttcaca	7140
gttgatgccc	tgagcctgcc	atagcagact	tgtttctcca	tgggatgctg	ttttctttcc	7200
agagacacag	cgctaggggt	gtcctcatta	cctgagagcc	aggtgtcggc	agcattttct	7260
tgggtgtttac	tcacactcat	ctaaggcacg	ttgtggtttt	ccagattagg	aaactgcttt	7320
attgatgggtg	cttttttttt	ttttttttga	gacagagtct	cgctctgtcg	ccatgctgga	7380
gtgtagtggtc	acaatcttgg	ctcactgcac	ctccgcctgc	caggttcagc	gattctcctg	7440
cctcagcctc	ccaagtagct	gggactacag	gtgcctgcc	ccatgccag	ctaatttttg	7500
tatttttagt	agagacgggg	tttcaccgta	ttggctagga	tggctctcgat	ttcttgacct	7560
cgtgatccgc	ctgcctcggc	ctcccaaagt	gctgggatta	taggcttgag	ccaccacgcc	7620
tggccgatgg	tgtcttttat	catttgaagg	actcagttgt	ataaccact	gaaaattagt	7680
atgtaaggaa	gttcagggaa	tagtataagt	cactccaggc	ttgaggcaaa	atttacaat	7740
gctgctgact	ttgtatgtaa	ggggaggcat	tttcttagaa	aagagaggta	ggtctctggg	7800
attccagtat	gccatttcca	tctcagtggt	ttttggccac	ctgagagagg	tctattttca	7860
gaaatgcatt	cttcattccc	agatgataac	atctatagaa	ctaaaatgat	taggaccata	7920
acacgtagct	cctagcctgc	tgtcggaaca	cctcccgagt	ccctctttgt	gggtgaaccc	7980
agaggctggg	agctgggtgac	tcatgatcca	ttgagaagca	gtcatgatgc	agagctgtgt	8040
gttggagggtc	tcagctgaga	gggctggatt	agcagtcctc	attgggtgat	ggctttgcag	8100
caataactga	tggctgtttc	ccctcctgct	ttatctttca	gttaatgacc	agccacggcg	8160
tccctgctgt	gagctctggc	cgctgccttc	cagggctccc	gagccacacg	ctgggggtgc	8220
tggctgaggg	aacatggctt	gttggcctca	gctgaggttg	ctgctgtgga	agaacctcac	8280
tttcagaaga	agacaaacag	taagcttggg	tttttcagca	gcgggggggt	ctctcatttt	8340
ttctttgtgg	ttttgagttg	gggattggag	gagggaggga	gggaagggaag	ctgtgttggg	8400
tttcacacag	ggattgatgg	aatctggctc	ttatggacac	agaactgtgt	ggccgggata	8460
tggcatgtgg	cttatcatag	agggcagatt	tgcagccagg	tagaaatagt	agcttttggt	8520
tgtgctactg	cccaggcatg	agttctgatc	cctaggacct	ggctccgaat	cgcccctgag	8580
caccccaactt	tttctttttg	ctgcagccct	gggaccacct	ggctctccaa	aagcccctaa	8640
tgggcccctg	tatttctgga	agctgtgggt	gaagtgaagt	agtggcccca	ctcttagaga	8700
tcaatactgg	gtatcttggg	gtcaatctgg	attcttttct	tcaggcctgg	aggaatataa	8760
taactgagac	ttgttttatt	tctgcagagg	gttctaagcc	attcacttcc	cagatggggc	8820
aataatgctt	tgagtaatct	ggagatcatc	tttaatgcgc	aggtgaatgg	aactcttcca	8880
cagaggggatg	tgagggctgt	agagcagagt	gaactccctg	aaactcagac	gtcagctctt	8940
tgtctctcta	tctctgaaca	cccttcttta	gagatcccat	ctctaggatg	catttctctg	9000
tagttagttt	ctaagtctct	tgttctgttt	ctgcctttat	ttttttttcc	tggattctaa	9060
gccagtatcc	ccacttggct	gtcttaaatgt	agcttaacat	gtctgtaatc	aaaatgatca	9120
tctttctgag	attcaaaggg	ctataaggga	ctttggagag	aatttcattc	agttttcctc	9180
aaactagaat	aatgcttgca	ctgtctgtaa	aagaacaaaa	gtgtcaaagc	atccttttgt	9240
tcactaaatt	tcttttttta	ttatagtgtt	acttaaatat	taggaagtta	aaagtaggta	9300
taaactttct	ataggctgtt	attatacaac	tatatgacct	atacatattt	acaaattaag	9360

tttcattctg	ttgtgccgtc	tatgcaaact	attcttgata	gttttatggt	aacagtgttt	1380
ttttgttcca	tgagataaat	ttatacatgc	tcattgtgga	aaatttagaa	aagacaggaa	1440
agtattaaaa	acatcmcytt	tttttttttt	tttttttttt	tttttttamg	cagacagagt	1500
cttgctctgt	cgcccaggcc	ggagtgcagt	ggcgtgatct	cagctcacag	caacctccgc	1560
ttcccagggt	taagtgattc	tcctgcctca	gcctcccaag	tagctgggag	tacaggcatg	1620
caccaccacg	cccggcta	tttgtatatt	tagtagagat	ggggtttcac	catgttggcc	1680
aggctgggtc	caaactcctg	acctcaggtg	atccgcctgc	cttggcctcg	caaagtctcg	1740
ggattatagg	caggagccac	tgcgccagcc	acacctacgt	tcttatcatc	ctagtacatc	1800
cactgtcatt	atcttgctgt	atttccttct	gccagtcctc	actctgatca	tgcagtggcg	1860
tgatcatgca	gtgatctcgg	ctcactgcaa	cctaggcctt	ctgggttcga	gtgattctcc	1920
tgccttagcc	tcctgggttc	aagtgattct	cttgccttgg	cctcccaagt	agctgggatt	1980
acaggcatac	acccccatgc	ccatctaatt	tttgtatatt	tagtagacac	agcgtttcac	2040
taaaattttg	tatttttagt	agagatgggg	tttcaccatg	ttggccaggc	tggctctcaa	2100
ctcctgacct	caggtgatcc	gcctgccttg	gcctcacaaa	gtgattacag	gcatgagcca	2160
ctgcatccat	cgccaaaaag	attttttaaa	agagttta	gtagaacat	atcaaaagtc	2220
tttggaata	aaaaacagtt	ttttaaaaa	atcagaaata	aaacaacaaa	tataataata	2280
aataaaaaca	cccaaaacaa	tctgaagcac	gagcacctag	cagaaagggt	caattatgat	2340
ctattcatag	agtggaaat	caagtagaca	ttacaggaca	tgttttaaga	ttatatttta	2400
tgtcatggga	aatgctctcc	cagtatgatg	ttaaatgaaa	aaacagaata	caaaagtata	2460
tatgctgcat	agtctcaata	ttgtagagaa	aaaatattat	ttatgtatgc	atgaaaaaag	2520
acaaaagatg	ttaacagaga	tccattgtta	cttcagttta	ctagggattg	tctctgggag	2580
gtaggattaa	ggtgatttat	atttaccttt	ttaaactttt	ctgtattttt	ttattttcaa	2640
attttccata	aaaatataag	gacttgaaga	tcaagaaaaa	atctctgctt	tggctcagtg	2700
cagtcgtcac	gcctgtaatc	ccagcagttt	gggagcccta	ggggagagga	tcacttgaac	2760
ccaagagttt	gacgttccag	tgagctatga	tctccggatc	gtaccgcctg	gacgatggag	2820
caagaccctg	tctcaaaaaa	aaaaatcttt	gctttttttt	tttgtttggt	tttgagacgg	2880
agtctctctc	tgttgcccca	gctggagtag	agtggcacia	tctcagctca	ccgcaacctc	2940
tgcctcctgg	gttcaagcga	ttctcttgcc	tcagcctccc	aagtacctgg	gattccatgc	3000
accaccact	atgccagct	acttttttgt	atcttcagta	gagacagggt	ttcaccatgt	3060
tggccaggct	ggtctcgaat	tcctgacctc	agctgatcca	ccggccttgg	cctcccaaa	3120
tgctgggatt	acaggcatga	gccactgtgc	ccagcccaat	cttttgcttt	ttttaaaaaa	3180
agaagacaaa	aagggtttt	ataccagtat	tatcttggtc	gtgtgactct	gaagccacag	3240
ttgtaagtta	taattactct	gaaacacaag	gcctgtgac	tcttttgggc	tcttttggtg	3300
ttatcttgat	tacaacgttg	gaatatagaa	atgaaaggaa	tgggagaggt	gatagacttc	3360
aggcagtgt	actagtgtgc	tgaacactac	tggctcaatt	atattgtgtc	tagtgatttc	3420
catcttgctc	gtctgcta	ttatgcctg	gtaactcact	gaggcagggt	tttccttttg	3480
agaaacctca	ttgttttaac	cagtgtatca	tgcttgttta	gaagttcaat	gatcttttta	3540
actcatcgga	gaagatgatg	accagacctg	gacagatggg	gaaggacttt	gcactctctc	3600
tttacagtcc	tgagtgcaca	cagggtcaata	tggaaactatg	tgtgaatttt	cattgtcttt	3660
gagagccctc	ttctctgccc	catagggagc	agctttgtgt	gcaattagag	gagcaagggt	3720
tgtgtgtatt	tagcacagca	ggttggcctg	gtcctctcct	ctcaacatag	tcaccacata	3780
cctggcacta	tgctaaggct	gggaatgcag	acagatgggt	gcctgctttc	agagtgtctc	3840
atgtgctgag	gaagccagca	acagaaacag	atgatttcag	gagctccagg	aaaaatgctac	3900
aggaggagt	tgcctgggtt	actggagtag	cacaggagga	gggcttctag	ctcaggctga	3960
gatttttagta	aaggaaatta	tgccacgatg	aatcctgaag	aatgaataga	agtgaaccag	4020
ataaagcacg	ataggaagca	tcttccttta	cctaagggaa	gacacagagg	tatatggaat	4080
ggtatgttaa	aagggtggga	ctccaaacag	ttctgttaaa	gcttagagag	tgggtgggaga	4140
gactggagaa	gttgattaat	tagtaaatga	agttgtctgt	ggatttccca	gatcccagtg	4200
gcattggata	tccatattat	ttttaaaatt	acagtgttct	atcttatttc	ccactcagtg	4260
tcagctgctg	ctggaagtgg	cctggcctct	atcttcttct	ctgatcctga	tctctgttcg	4320
gctgagctac	ccaccctatg	aacaacatga	atgtaagtaa	ctgtggatgt	tgcctgagac	4380

tcaccaatgg	caggggaaaat	ccagggaatt	aacgtgggct	aaattggact	tttccaaaga	4440
tgctgtcttt	gggaaacatc	acacatgctt	tgatcagaa	aacctaggct	tctaatttgt	4500
tgataaggca	tgaactcagg	agactgtttt	cagtcctagt	gaatggtgat	aattgtaatt	4560
ataacagtag	acaacatctc	ttttacacat	tttaaactcat	gaaaatagaa	taaccttact	4620
gataatttta	gaaagtgggtg	attaaaagca	catttaagat	aatgccttaa	cacctagtct	4680
tttccatatg	catgatgtct	taatcacaca	ttgcaaatca	tggaacacag	aattttt	4736

<210> 16

<211> 4768

<212> DNA

<213> Homo sapiens

<400> 16

atctttacaat	cacagtcttt	ctcttagggc	tgggctcagt	gggtggattg	acactgcaga	60
aatggccaga	tctaaaggat	caacattttac	gtagctggga	aatgtagctg	ggacttcagt	120
ttcactgccc	tagtgatttt	tcctaccact	aagcagctca	gtccataccc	ctacgagacc	180
cacaagctta	tgagatactg	ttcttccagg	aaagcagtgg	ggccagggcc	accttttaat	240
tgtgttttctt	ggcctgggtcc	catctttctc	acaatatata	gcaacagtta	tttacttgct	300
gatttttctaa	tgcacatcac	acatagtcac	attaaacaca	cacacacaca	cacacacaca	360
cacacacccc	tcaagaaaca	ttttctgaga	cgtgatttcc	tgatttcac	aaaaaagaaa	420
agagcggggc	aggcacagtg	ggaagtcaag	gtgggtggat	cacttgaggt	caggagtgtg	480
aaaccagcct	ggccaacacg	gtggaacctc	gtctctacta	aaaatacaaa	aattagccag	540
gcgtgggtggc	gcacacctgt	aatcccagct	actggggagg	ctgaggcagg	agaattgctt	600
caacctgcga	ggctgagggt	gcagtgagcc	gagattgcgc	cattgcactc	cagcctgggc	660
aacagagtga	gactctgtct	caaaaaaaaa	aaaaaaaaaa	aaagcataaa	ctgaaattta	720
tatgcaattt	atatgcctgt	gagataattc	tgttttctct	tttggaaacc	caaagagatt	780
tttttgattg	atgagcaaat	acatttttaga	ttttatttaa	gcattatgcc	aagcaccact	840
gaagtataag	tttcaagggc	aaactcagtt	ttttcatcta	ctagacgaat	gattttctgg	900
aatgattaca	agcaggcaag	atggtgtagt	ggaaatagca	aatgtcttcg	gcatcagaca	960
agttgggggt	tgtttgatc	ctgcctctgc	ccttcaccga	ggttgtgatc	ttgggcagat	1020
tgttgagttt	taacctagat	tcctctgact	ccagatcata	aattttcaga	aaagttctga	1080
aattcttgta	tatactgatg	gtaaatgaga	cttttcttta	catctatgca	cttctttggt	1140
tgtttgtttt	gagatggctc	tgctctgttg	cccagactgg	agtgcagtag	tgcaatctcc	1200
gctcactaca	atgtctgcct	cccagggttc	agtgagcctc	ctgcctcagc	ctcccaaata	1260
gctgagacta	caggcatgtg	ccaccacgtc	cggctaattt	ttgtattttt	agtagagaca	1320
gggttttgcc	atgttgacca	cactggtctc	gaactcctgg	cctcaggtga	ttcgcccgcc	1380
tcagcctccc	aaagtgcctg	gattacaggc	atgagccacc	atgcccggcc	atatccatgc	1440
acttcttgca	accttacctt	cttttctcat	caccctccag	ggacctagt	ggaagagcag	1500
agttaaaagt	taagggtgaaa	cttgagagag	tgtcttgtcc	ctaggaacaa	aggactgggt	1560
tgaaattctc	tgtaaattctt	ccccagttca	aaccagaggt	atcaaggtct	taaaaacttc	1620
cctgggtcct	gagagcccat	tatatatttt	acttgtcttc	ctgtacaccc	actgcctagt	1680
cctgatccta	cttttgtttg	caaataggat	ggggcacaa	gtacaaggaa	gggcctttgc	1740
cacccttgct	aagggtatac	ctgaaatacc	ttcaccatca	ctgcctgtg	ctgcttttca	1800
cctatgccag	tctgtctaca	gtgccagtgt	ctcctggcat	tgaaagggga	gaatcttttg	1860
gtcctttgag	tatttggttg	ggttacataa	atctccctga	atgaagagca	gctgacttag	1920
gcaagggggc	ttgtttgggt	ttccttgaac	tattaacagg	aagataggga	gattaactgt	1980
gtaaatgttc	aataggccag	agtccttgca	gagggtggcc	acagtgatca	gatcttatca	2040
catccttgct	ttgggtgttg	cctctctggg	tggagtatgg	atagaaaaga	aagaaagacc	2100
ctatattgaa	atgcaaagtg	cagcaagtcc	tgactttgga	ttacttctc	agcccatttg	2160
catgaaaata	aaaagatgaa	taaaacaagg	ttcccacttt	ggagggaggt	ggtagctgtg	2220
agatggaagg	agtgttcctg	ctgggcaaca	gcagagtaag	tgctggggta	gattcactcc	2280

cacagtgcct	ggaaaaatcct	cataggctca	tttgttgagt	ctttgtccta	caccaggcac	2340
tctgcaaaaa	cgctttgcct	gcaagggtctc	atgcgatgct	caccacagct	ctgtgaagtt	2400
aattgtactt	ttatcaccat	tttacagatg	agaaaaactga	gggtatgggg	tcaatgactt	2460
ggctaaagtc	actgcttagc	aagctgcagg	gactggatgt	gaattccaat	tggtttgact	2520
ccaaagcctg	tgaagctact	tgttcttcac	cacctagagc	tgtggttctt	gataactgtg	2580
aactcctttg	gggtcacaaa	tagccctgag	aatatgatag	aagcaggagc	tctggccttt	2640
ctgtccatac	ctgaacagggt	ccttgggtta	agagcccctc	gtccagggcc	tattaatctt	2700
gatcctcata	agcagcatcc	atgtattacg	gccgcaaacc	aaactgtgcc	agaccgaatc	2760
ctaggacca	gccccaaatat	gtcccatcat	ccttttggtta	agaagctcat	tgtaagaaag	2820
aaagaggaga	gcaagaggat	gacctagtgc	atggggcctc	attgttttaa	ttagtgacaa	2880
aacaacaata	ataacaacaa	aacccccgaa	gcttcacaga	tgacatcaga	ccccaagcct	2940
gtgtgttttt	caggtgccct	tgaggagctt	tgtagctggc	agaggagggtg	aaactgacaa	3000
atgtttggca	gatggaggag	agtaccagag	gggtttgaga	tgagctaaat	tccaatctaa	3060
ccgcagtgtt	gaggaagagg	cctggattgg	gaccatggag	atggggggtc	tactcccagt	3120
cacgccagct	gactttgcga	gtgttctttg	tcagtcactt	tatcttattt	tattttattt	3180
tatttttttg	aaatggagtt	tcgctcttgt	cgcccaggct	ggagtgaat	ggcgcgatct	3240
tggctcactg	caacctcccc	ctcctgagtt	caagcgattc	tcctgcctca	gcctccagag	3300
tacctgggat	tacaggcgcc	tgccaccaag	cccatcgaat	ttttgtatgc	ttagtagaga	3360
cagggtttcg	ccatgttggc	cagggtggtc	ttgaactcct	gacctcaggt	gatccgcccc	3420
ccttggcctc	ccaaagtgtc	gggattacag	gcgcgagcca	ctgtgccag	cccacttcac	3480
cttaccgtag	ttacctcctt	agagtatgaa	aaaataggct	tagggcatcc	ccaagtcccc	3540
tctatgtctg	agagctgagg	ctggctgtca	aagaggaact	aaggatgcca	gggactttct	3600
gcttaggacc	cctctcatca	cttctccaac	gctggtatca	tgaaccccat	tctacagatg	3660
atgtccacta	gattaagaat	ggcatgtgag	gccaaagttc	cacctgagag	tcagttttat	3720
tcagaagaga	caggtctctg	ggatgtgggg	aatgggacgg	acagacttgg	catgaagcat	3780
tgtataaatg	gagcctcaaa	atcgcttcag	ggaattaatg	tttctccctg	tgtttttcta	3840
ctcctcgatt	tcaacaggcc	attttccaaa	taaagccatg	ccctctgcag	gaacacttcc	3900
ttgggttcag	gggattatct	gtaatgccaa	caaccctgt	ttccgttacc	cgactcctgg	3960
ggaggctccc	ggagttgttg	gaaactttta	caaatccatg	taagtatcag	atcaggtttt	4020
ctttccaaac	ttgtcagtta	atccttttcc	ttcctttctt	gtcctctgga	gaattttgaa	4080
tggctggatt	taagtgaagt	tgtttttgta	aatgcttgtg	tgatagagtc	tgcagaatga	4140
gggaagggag	aattttggag	aatttggggg	atttggggta	tccatcacct	cgagtattta	4200
tcatttctgt	atgttgtgaa	catttcaagt	cctgtctgct	agctattttg	gaatatacta	4260
tatgttggtt	atgatatcat	gcagcagacg	tgcatctgaa	tgggctggct	ctaggagcta	4320
gagggtaggg	gctggcacia	agatgcagtc	tggaaggggtc	cctgcccata	agaagcttac	4380
agccaaggct	aggggagttc	tgtcttctct	gcacaggtc	acctctctca	cctctgtcac	4440
tgccccatca	gactacaatg	tctgcaggtc	tttctccctt	gagtgtgagc	tccctgagca	4500
aagcaggatg	ctgccccttc	cctttgtatt	ccttgctcct	tgettccagt	cctgtacata	4560
agtatgggca	taataagtgt	cccccaaatg	agacattgag	gattcttcaa	atgcacagga	4620
ccgtgatgtg	agttaggacg	gagtaaggac	gatgggatgt	ggctcatgac	aatcctgagg	4680
aagctgcagc	tgcggcacgc	agggccacac	tgtcatgttc	atggacccta	gactggcttt	4740
gtagcctcca	tgggcccctt	ccatacac				4768

<210> 17

<211> 1295

<212> DNA

<213> Homo sapiens

<400> 17

tcatgactgc	cattgggtata	aagatgaata	taatccagac	cagattcatg	attattcata	60
catttttagt	gtattaactt	ttaattctgc	ttttaaaata	aattaaaaca	ttctaataatg	120

cccttaagag	tatcccagcc	caggccactg	agcctactgt	ggttcatgga	taagtttgcc	180
cctgggggca	tgtgtgtgca	tgcattgtgtg	tgcacatgca	tgatgagccg	ggccttgaag	240
ggtggtaaga	tttgggtgtg	tagaccaatg	gagaaaaggca	tttggggcag	tgatgatggg	300
tgggggaggg	aacatgggtga	tgaatggagc	tgggtgtggg	gagccatggg	agtgggttag	360
ggccagcctg	tggaggacct	gggagccagg	ctgagttcta	tgcacttggc	agtcacttct	420
gtaaagcagc	agaggcagtt	ggcctagcta	aagcctttcg	ccttttcttg	caccctttac	480
agtgtggctc	gcctgttctc	agatgctcgg	aggcttcttt	tatacagcca	gaaagacacc	540
agcatgaagg	acatgcgcaa	agttctgaga	acattacagc	agatcaagaa	atccagctca	600
agtaagtaaa	aaccttctct	gcatccggtt	ataattggaa	attgacctgc	accagggaaa	660
agagtagccc	aggtgtctgg	ggcttgttcc	cattagatct	tccccaaggg	gtttttctcc	720
ttggtggctg	gcctgtgggg	cccctctcca	ggaggcattg	gtgaagaaac	taggggagct	780
ggttgccaca	gacagtgatg	tactaatctt	ctctgggaag	acagaagaaa	agtccccagg	840
gaagaatact	acagacttgg	ccttagggac	agctaggggt	gcagattgct	gccaaactgca	900
ttttttctga	agttggccat	atgggtgcag	tgaatggatt	tatagacaga	gtatttctgt	960
gcatataaga	gcaattacag	ttgtaagttg	atatggataa	gtgaaagtta	agcacttctt	1020
tctaaaaaga	gaatgcaatt	cattttcccc	taatcatttc	aattagtctg	atgggcattt	1080
gaacttggtg	tctttaaaaa	gtgaaatctt	tacctctgat	ctggtaagta	tccaggcaat	1140
ttcttgtgtg	ccaccagga	ggatatctggg	gagtgggcat	tttctgactg	aggcattggc	1200
tgccatagca	tcagagcagc	cttcaggga	gtggcctggc	aaggggacag	aggctggtgg	1260
gagcagctgg	ctgagtgcag	ccagtaatgg	catgt			1295

<210> 18
 <211> 2188
 <212> DNA
 <213> Homo sapiens

<400> 18						
agctctccag	gtgattctga	tgcatactta	agtttgagaa	ccattgcttg	ttttgcatta	60
aacaggagat	tagtctctgc	agcttgtggg	aataaagctt	taaatctctc	caatttttagc	120
tctgtgaaaa	ggcagtgggg	agacaggaat	gaacggacta	gtgccacaaa	gctcagggtgg	180
ggtgggtgag	atcatttaga	agagaaagac	cgggcatggt	ggctcacgcc	tgtactgtca	240
gcactttggg	aggccaaggc	aggttggatc	acaaggctag	gagtttgaga	ccagcctgcc	300
tatcatgggtg	aaaccctgtc	tgtactaaag	ataaaaaaaaa	aaaaatttgc	cagtcatggt	360
gatgcatacc	tgtaatccca	gctactcggg	aggctgaggc	aggagaatct	cttgaacccg	420
ggaggcgggg	gttgacagtga	gctgagattc	caccattgca	ctccaacctc	ggtgacaggg	480
tgagactccg	tctcaaaaata	aaaaaaaaaaa	aagaaaagga	aaggctgtgt	gtgtgtgtat	540
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtta	cagcaccatc	acactgtttg	agttgaggag	600
cacatgctga	gtgtggctca	acatgttacc	agaaagcaat	attttcatgc	ctctcctgat	660
atggcgatgc	tcccctatct	cattcctgtg	tgtgttttagc	caggcaactg	ttgatcatca	720
atattatgat	aacgtttctc	cactgtccca	ttgtgcccac	tttttttttt	tttttgagtt	780
acttactaaa	taaaaataaa	acactatttc	tcaatagact	tgaagcttca	agatttcctg	840
gtggacaatg	aaaccttctc	tgggttcctg	tatcacaacc	tctctctccc	aaagtctact	900
gtggacaaga	tgtgaggggc	tgatgtcatt	ctccacaagg	taagctgatg	cctccagctt	960
cctcagtagg	gctgatggca	attacgttgt	gcagctactg	gaaagaaatg	aataaacctt	1020
tgtccttgta	atgggtggtga	aggggagggg	ggtagtttga	atacaacttc	acttaatttt	1080
acttccctat	tcaggcagga	attgccaaac	catccaggag	tggaatatgc	aacctggcgt	1140
catgggcccag	ctgggttaaaa	taaaattgat	ttctggctta	tcacttggca	tttgtgatga	1200
tttctccta	caagggatac	attttaagtt	gagttaaact	taaaaaata	tcacagttct	1260
gaggcaataa	ccgtgggttaa	gggttattga	tctggaggag	ctctgtctaa	aaaattgagg	1320
acaggagact	ttagacaagg	gtgtatttgg	agacttttaa	gaattttata	aaataagggc	1380
tggacgcagt	ggcactgagt	tgagaactgt	tgcttgcttt	gcattaaata	ggagatcagt	1440

```

ccctgcagct tgtggaata aggttttaa tctctccaat tttagctctg tgagatggca 1500
ctggggaaac agaaatgaac ggactagtgt cacaaagctc aggtgggatg gacgagatca 1560
cttcaaaggt ctgtaatccc acgtctataa tcccagcact ttggggaggcc aaggcgggaa 1620
aatcacttga ggtcaggagt tgcagaccat cctggccaac aatgcaaagc ctgtctctac 1680
taaaaaatatg aaaattagct cagcgtggtg gcatgctcct gtagtcccag ctactcgtga 1740
ggctgagaca ggagaatcgt ttgaacctgg gaggcggagg ttgcagttag ccaatatcac 1800
gccattgcac tccagcctgg ctgacagagt gagactccat ctcaaaaaaa aaaaaaaaaa 1860
aagaatttta taaaatcagg aaataatatt agtggttatg ttgaatttta actttagaat 1920
catagaaaac ttctctctggc atcattatta gacagctcct gtgcagtggg tagcaccaga 1980
cccagcttgc atggttattg atttttcaga gacacttttt gagcttattc tctggcagaa 2040
aggggaactg cttcctcccc tatctcgtgt ctgcatacta gcttgtcttt acaagaagca 2100
gaagtagtgg aaatgtttat tcttgaaaat aagctttttg cttcacatga tctagaattt 2160
ttaaatttag aaaaatgtgc ttactgcg 2188

```

```

<210> 19
<211> 1183
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(1183)
<223> n = a, t, c, or g

```

```

<400> 19
agtaaaatgg agaattccaa attctgaaat tgtagaaca tagttctgtg tcttagttaa 60
atatcgacac ttacagataa atagcataaa tgctttctcc ccatatttca gccagtcct 120
acttaaagac aacataaatt gcaaaatagt gaggatgttg ttcattctaat aaaagtgggt 180
ccaggaattc agactctgga ttctgttttg ccaaatcatg tgtccactc ttaagaaaac 240
gagttggact ntggattttt ctttgcaaga gggacaagag tgtgggagat actgagttaa 300
tgcaacttgc aggttttaag tgcctgttca ttgtgccttg tgctttgata cattctgagt 360
ttcagtaaag agacctgatg cattggactg ttgcaatgga acctgtttta agatcttcaa 420
agctgtattg atatgaagtt ctccaaaaga cttcaaggac ccagcttcca atcttcataa 480
tctctctgtg cttgtctctc tttgcatgaa atgcttcag gtatttttgc aaggctacca 540
gttacatttg acaagtctgt gcaatggatc aaaatcagaa gagatgattc aacttgggtga 600
ccaagaagtt tctgagcttt gtggcctacc aaggagagaa ctggctgcag cagagcgagt 660
acttcgttcc aacatggaca tctgaagcc aatcctgggt agtagacttg ctactggag 720
aaacttcaag cactaatgct ttcggaatgt gaggttttc cttggacagc atgactttgt 780
ttttagaaa agtacggctg gctgggagtt tgtgatataa tttagttcag tggattcta 840
agtgttctta gtgttcttcc agacttttgg gccatctccc aaagggtgaa tgggaagaat 900
aagctgggtg tggctgagtt taagccaaaa gttttttgtg cttgtttcaa tcagagaaga 960
cctgcttttt catgttttta ctattataat actaagcaag agctcatttg aaaacagagt 1020
tcttcatatt taaaaaaaaa agtcttgaa accattgatg ggaagatgga tatctattta 1080
tgtttaaaaa cccatcataa agatgacatt gtgggctgtc acagttggaa ggccctggaa 1140
ttagatgaga ccacactatt tagcttactt agtaataaca ttg 1183

```

```

<210> 20
<211> 8981
<212> DNA
<213> Homo sapiens

```


<400> 20

ccgtttggca	aatgctcagt	aaaagaaaag	ggttagaagg	ggagaaaggc	atztatccc	60
aagccttcag	gaatcaggat	gaggatgtct	tcaccttgtg	gtggggagta	attatacaat	120
tagagacagc	acattggagt	gtggctgata	tgctgtgtga	tgatagctct	agctctctgc	180
ctagcagagg	aaggacatctt	caatagaaga	aaaagtttaa	gaccttgccg	agaaacagag	240
aaaggatgtt	tgtcttttta	agaagttgaa	aaccctgttt	gcagacaaaa	gccctccagt	300
tttggcagta	aactttcatg	caagggaaga	aaaaggcagg	ggatgacatt	gttgacaatt	360
gtgaggaatt	accatgtgcc	aggcactgtg	cgaggggctt	tgtacataatc	ctctagtttt	420
agtgtttata	aaaactctgt	gatatgtgca	cagcattttta	aacttttgctg	catagtgcag	480
aaaatggaag	gatgggggat	ttgagtcatt	tgcccagggt	tctatagcta	cccaggttc	540
ccatgactgg	agaattgggg	cacaggggtg	cgggggagag	tgagtgacaa	gaatcctaac	600
aatcttattt	ccattgagtc	cttataaaaag	aagtggatta	actaccacgt	ttttaagttt	660
ttcttaaatt	taggttatgt	ggatctggcg	tttcttggtt	tgtcctgggt	ttgttttgtt	720
tttgctatgc	tgtcttgaac	atctgtcatc	ttgtaggcct	aacggtaaac	acaaaaacac	780
tttacctcct	atagctttca	attaagatct	ctcagtttgt	gtttgtaata	gttttccagg	840
caagttctcc	ctaggttcgg	cttctagtgt	gttaaccttt	agttataaag	tgaacccaaa	900
gagagaaagt	agaaacaaaa	cacctcacct	gtttttgctc	atgaattact	ctctatggaa	960
ggaacaatca	tgaacacctc	tgcgtatcac	agaggcctat	ctgagtctga	cgtttaaggg	1020
agaccgcgta	ggtccttttg	aggactgtga	atgtgggagt	cctgggactc	tgggtgaagaa	1080
cccgttccag	aagagatgaa	tgagctggac	aagttctttc	atagaacctt	taggcaggtt	1140
ttcttagaaa	tgcacattga	ggattatgct	tggatattgt	gatgatcaga	atgatactca	1200
atcccttctg	catttggaat	tctctttgaa	agaaaacatc	ccaggcagct	atctctcaga	1260
gatagtgagt	cccagccact	tctagacatt	ttcttggtga	gtctacatta	taatttcaca	1320
gcagtctctg	atatgacaaa	tgtcaaaaata	gccaacctt	ctctaaactt	cagagatgtc	1380
tgatatgata	ttgaataaaa	caatgctcat	agaaacatca	agaaagggtg	attttccctg	1440
gatacttttt	tctgtcttga	caaataacag	tgaagaaact	gatctcacgt	ctttttctct	1500
ttggaagcct	gaacactcag	aacccaactt	gaggctcctc	agctatagca	attctgactt	1560
cacagtctgt	aaattattgt	tctttttttt	cttttagctta	tgctttctgc	cctaatttat	1620
cttttccctg	ttctaataaa	ttattgtcct	atatctgctg	tgcagttagg	tgacatataa	1680
cagcaattaa	atatatgaat	tggtagatat	aaagatttga	ctaaaactcg	atgtaaaaat	1740
aagtgttcta	cattcaattt	ccagtgttag	aaacagtgtc	gacttgaaca	gagtgacaga	1800
attccatctt	tccctatttt	tgacagcttt	aaactttata	ttttcttctt	ttcttgtag	1860
ccgtcattaa	cttgtttctc	aaagccattc	ccgtattacc	catcttgtag	acgcagacag	1920
atttgggaat	ttgcggtcag	agttgtattg	gacacatccc	cccagcccac	atgagatcct	1980
tttaatctat	tgcataattaa	ctagttttaa	gtacaataat	cctacttcat	ttaaaaccat	2040
taatcaaaga	atgagtttga	aaatgaacaa	aatgcaaact	tacagttaga	aataattgta	2100
gtgtcttttag	ttttgggttag	gagtcgggtt	cttgttttgt	aaactcaaga	ttgtgaacag	2160
ttttaattca	cttgtttatt	tccaatagag	atctcaggtt	tacatttgaa	ttcagaaaca	2220
aagttttctt	tctcattaca	gagaacacta	aactctacat	ctcccttccc	gagcaaggag	2280
ctggccgaag	ccacaaaaaac	attgctgcat	agtcttgga	ctctggccca	ggaggttaagt	2340
tgtgtctttc	cagtaccagg	aagcggatca	tccactgtat	cagtattttc	attcctgagt	2400
ctggcaagag	gtccttttga	gttgaatata	acatgggatg	taatatcaat	tttcaaagta	2460
taagtgatgt	aaacaataat	gttttgattt	ccttatttta	gaaatgaaga	aacctaaaaac	2520
tcatagatgt	ctcagagcta	attggttagt	ggctaacagc	tggatatcta	gtttagaacc	2580
ttctccattt	tttctttttg	cccctaggta	atcatacatt	tgtaaagagg	agaattatct	2640
ctgccactgc	ccatgcaactg	cttttgtctg	accagcaatt	tctccatatt	gcttcttcag	2700
tagcaaggcc	aatcatttta	ccaacacaca	tgcttgctaa	ctaacaggaa	taacgtggta	2760
cccctaattc	agccctttcc	cttgaaagca	tctggcttct	gaggttcaac	tatgggaata	2820
tgggtctctta	atgaacatta	agttgagttt	gccttttagg	tccacatgtt	gacaaatgta	2880
tcagagtaat	ctctgtccta	ggatcagagg	gcctgtaggc	acttgcaaaa	gcagtttagct	2940
ctgactccca	gccagtgcac	actccacctt	tctgactccc	agccttgtct	caaatttaggc	3000

ttggaagcga	ggaactgtct	ggtgtccccc	agcataggaa	gctgagccag	ggggcagtgc	3060
tcacaaacaa	tacagacttt	aacgtgtagg	atattggaaa	ataataattt	gtggggaaat	3120
tgtctcagac	ttgggtccacc	cttatttttta	gctgcttctc	taatccgttt	ttcttttttt	3180
ggtgcttgta	tctaacctac	ccatttttttg	gtgcttgcat	catttttttca	aatatcaaaa	3240
acgaacttta	tgtttttctaa	caatgaaagt	attgcatggt	cattgtggaa	aatgctgaag	3300
acttggaaaa	tacaaaaaatg	ctgagatcaa	acactattga	tacgttagtg	tatttcttcc	3360
tgtcctgttc	tacttttcttt	ctttgaattc	tgctcacgtg	tttctgactg	atgaggctctg	3420
acttttggg	tctttttcca	gaggagaagc	cttctttcag	cttgccattt	gttaccctgg	3480
ttatgaaggc	tggtaacctt	ttttactagg	tagagaagct	ggaccaactg	gggttcttcc	3540
agggggagaa	tgagaaagag	aaactgtttt	gcaagtccgt	agctatttct	ctagggccct	3600
gttagctgac	attgacatgc	cttgcatgct	tctgcagatc	ccctcgcagc	cctctgtccc	3660
ttgttcattt	ctggccttag	agaaagcaaa	gcagggtctg	taacagggga	ggctgcctct	3720
aaactcaggg	tttggttaca	gctgttttca	cttacatcac	tggccctggg	tttttttttt	3780
tttctggcat	taaaaaaaaa	aattggaagc	aggtgatggt	cccattgctg	atgtggtgga	3840
aactctccaa	gtgaacaata	tacgtttttc	ttggcagctg	tttcttgctg	cctgcttgct	3900
cctgggtccag	gacaagcaag	gaccatctgc	ctctttcaat	agaacacctc	cagatccctt	3960
tgatcaaaag	ttactcattg	tctgacttgc	tatttctgtg	agataaatgg	gagaagatca	4020
ataaatgcac	ttgtttgtcc	agtcagcgtg	tggaaagtgt	ataattttga	ccaaagcaca	4080
accctgaaag	gaaaagaaaa	agggagtga	tgtcttctga	gaagctgcct	aggttcagac	4140
agtgtcacc	atttcctgt	atgctccaca	tgacaaacct	gagtgggtct	catcatgtcc	4200
attttgcaga	tggcaccag	gctcagaaag	gttaggcaac	ttttccagtc	acccaatgag	4260
ttaattgaca	aaactgggat	tcaaaccag	aactgttgga	ttccaaagcc	tgtgttggtg	4320
cctgcttcgt	gaaaaactcc	agtagcgact	ggaatagaaa	ggagaacctt	ccaagaaaga	4380
aaatacgcac	tagcagaacc	tggaaattgg	gaggaaatga	ggacttgagg	aataagatga	4440
atgaaagctg	acctgagttt	cacatctggg	tgatgggaag	ggaggacagg	gaggcagcat	4500
ctcagatgtc	caccagcac	cgaccagctg	cctggcattg	ctaggtgttg	aggactcagc	4560
agtgaacacg	ctaacttctc	tgttttcttg	gggcacgtat	aggggtgagag	acagaaacaa	4620
acaggctcag	gtacaatgcc	acaggaggga	tatatgcagt	gaagaaaaag	cagggttaagg	4680
ggcatagagc	atgagaaggt	gcttttttta	aaggggktga	ttaggaaagc	tctctctaag	4740
gtgacagttg	gacctgaagg	agatgatagc	atgtctgtgg	tgagggaagg	aaactccgaa	4800
caggaagaat	ggcagataca	aagacattga	tgctagagca	tgcctaagga	atgtgtttta	4860
ggaccaggga	aagtgaagca	gtggtggggg	gaggagagga	gctcagagca	ggaggagggtg	4920
agtgccatac	aggcctggca	agactttgga	ttcctgctgg	gtgagatgag	aatccagcgg	4980
agggcttgag	ggaggggaca	tgatgtgatc	tagagtttag	actgtttaca	ctctggttgt	5040
tgggttgaga	agagactggg	atgggggaaa	gggaggacaa	aggacattgt	gctggattga	5100
gaaagcagta	agtcagtttc	attcattcac	tcaaccgatg	atgttcaa	accaccatca	5160
tccgtgggct	aaaggatgaa	gagccatccc	tccctgagag	tcaggaagca	cttcccagat	5220
aaagtttgga	gtgtgagctg	aggtgttaga	gaaagagtaa	gagtttacc	ctgaaacggg	5280
tgctgggaag	agtcaatagt	ttggaataac	tcaataattt	atgggtgctt	tttagaaaga	5340
tttgctggct	ttatgtggga	agaaatttkt	ttttttgatt	ggggagtggg	gggttggtgg	5400
tgaggctgcc	tgtggaaaga	gaagtgagt	ttttgactca	ctgttattta	aaaatctcta	5460
gggctgttcc	aataagcaac	aaaaggcaaa	atggcctggg	tctctgtccc	ctttctgtct	5520
gtatgcctcg	tacaggttat	gaaaagaaaa	agttgggaaa	agctgtccac	ctcaccta	5580
tgtgttcttg	tggagtgtgc	tagatgcccc	ctctctggag	aaaaaaaaatc	cttgtggcct	5640
ctgaccacac	tctggagagc	ctagtccct	tctggaggca	gaaggcaaag	cttaggacct	5700
agagagtgt	ggaccacgcc	actcacagga	accagcaggc	tgtgagggtg	aaagctaggc	5760
atatggagct	ttccaggctg	ggtgcagggc	ctcgtggccc	ttccccctccc	ctctgtgtct	5820
tatagctcag	tcttcccagg	cgggtgtgaac	acgcagtgc	atttccagga	atacagggat	5880
ttattaatga	tttcttgatg	aatgtttgga	aatacaaaag	actctataaa	tatttcataa	5940
tagcattggg	gctgagaact	ccacaaagt	ccggaataca	tttgcattga	agacagaacg	6000
ctgcctgggt	cattgatgcc	tgttgagtgg	cagtcacaga	cactgcctag	ggtttctgac	6060

tcacgctggt	gggactgttc	tatgcagggc	accctcttgt	gtggcatagg	atttgtgcct	6120
caccacacac	tgttgtagct	ttgctgtctt	gatgatgagt	agagggcagt	gtccaggcca	6180
tggataaagc	atctactgcc	ccccaggggt	acaaaaacca	agccaagttg	tgtctcagcg	6240
agctccgtga	agcatggaga	agttgagtac	tcagagacat	gacgtgactt	ttcaaaggct	6300
gtaagctgac	gagggacata	gctaggggtc	agacttgagt	ttttcttttt	ctttttcttt	6360
ttcttttttt	tttaagactg	agtcttgctt	ttgtcgccca	ggctggattg	cagtgggtgt	6420
tggctcactg	caacctctgc	ctcccggggt	caagcaattc	tcctgcctca	gcctccccag	6480
tagctgggat	tacaggcacc	tgccaccatg	cctggccaac	atTTTTgtat	tttttttagta	6540
gagatggggt	ttcaccatgt	tggccagggt	ggtcttgaac	tcctgacctc	aggtgatcca	6600
cccgctcga	cctcccaaag	tactgggatt	acaggtgtga	gccactgcac	ccggcccaga	6660
ctcgagtttt	tcatcttaat	gctttttcat	tgcttgacac	tttactgaga	ccaagatagg	6720
gaacttcaca	tacagtacct	tttctcccaa	ggcggaagag	ggctgttcaa	tttctacact	6780
agagttcggg	gagtttttaga	aatgagtcag	ttatcgagga	tgagagcagt	tcctgatagg	6840
ctcaaccaca	atgagatgta	gctgttcaga	gaaagcattc	ttttatctat	aaactggaag	6900
ataatcccg	tgaaacgaag	cccagcccca	ggggcttcac	taactccagg	ctgtgcttct	6960
caaacttttag	tgagcatagg	aatcacctgg	gcactcttgtg	aagctgtaga	tttgaattct	7020
gcaggtcggc	agaggggtct	cagaatccgc	atttccaaca	atgtctccag	taatgctgat	7080
gctgctcgtc	cctggaccac	agattgggta	gccaggttct	ggcaagctca	tcccaaggct	7140
ttgagatgac	atcagacaaa	atatgttctg	ggacatggct	tttgagaggt	caagaaaata	7200
agatgtttct	ttctcttctc	atccccaaac	cttgcactgc	ccttttctcc	cttcccctac	7260
cctcctttct	gtcccatcc	ctgacgccag	ctgttcagca	tgagaagctg	gagtgcacatg	7320
cgacaggagg	tgatgtttct	gaccaatgtg	aacagctcca	gctcctccac	ccaaatctac	7380
caggctgtgt	ctcgtattgt	ctgcgggcat	cccaggggag	gggggctgaa	gatcaagtct	7440
ctcaactggg	atgaggacaa	caactacaaa	gccctctttg	gaggcaatgg	caactgaggaa	7500
gatgctgaaa	ccttctatga	caactctaca	agtgagtgct	catgcagacc	ccagccctgt	7560
ccccaaaccc	atccctccct	tagttctggc	cttggcctgt	gtcatctcct	ccctctgtag	7620
cagcgttaga	tgtctacatg	cccatTTGCC	caccagactg	agctcttcct	agaggagaga	7680
ggcttctctt	gaatagctac	ctgtccccag	ttctctgaat	gcagcctggc	acatctcagg	7740
tgcacagtag	tgtttatcaa	tggaaatgaat	gattgacagc	caaccttctg	gttttctggg	7800
ggatgtggaa	gggtggcttc	caggggtgatc	aagaatgaga	taatggcaga	aggacaaatc	7860
ctgcaagatc	tcacttatat	atggaatata	tgtaaggtag	aaagtgtcag	tttcacatga	7920
tgaataagtt	cctgggatct	tgatgtacat	cgtgatgact	atagttagta	acactgtata	7980
gtatacttga	aatttgctaa	gagagtagat	ccgaagtgtt	cacactacac	aaaaaaggca	8040
actatgaggt	gatggattta	ttaacagctt	gattgtgggtg	atcctttttac	aaagtataca	8100
tatatataaaa	catcacattg	tataccttaa	atatatacaa	tttttatttg	tcagttgtaa	8160
ctcaaaaaag	ctagaaaagc	atttttaaaa	aggatgatgt	actggctcta	atattaccat	8220
tgagataaag	tttataataa	cataaaaaaga	aataacagta	atgataatag	caacaacaac	8280
aacaacaaag	aactaacatt	taagtagaat	ttcttTGTGCA	ctgtgcattc	tgtttaagtt	8340
atctcatTTT	accctcatga	taacctgcag	ggaagattct	tttaaccac	atttcatagg	8400
ctcagagagg	ttaaagtgcct	tggtttagagc	cacatcagag	ttaatccaca	agagccagga	8460
ttcaagccca	aatctgcctg	gatctgtgct	ctctaagata	actgttagtg	gtggcgtgtg	8520
tgttctcaca	ctcagacatt	tgatctgccc	tttgtttccc	attcttagct	gcaaggcagt	8580
gttaaagaac	cctgtgtctc	catatccact	ccccacactt	aagcactttt	gtgggcccgt	8640
gtgccgtatg	cctcgtggca	gcagggatcc	aatgtcacag	ttttaggcag	tggcatcctt	8700
ttccttgaaa	acttgatgca	ggggaacctt	tctccatttc	caaccacagg	tgtgtctttc	8760
agacactgag	tgaggcagggt	tttgtacttt	attgtaaacac	aagaaccttt	tcttctctgg	8820
agtaaagcac	tccagacatt	cgcaagttgc	tttacaagcc	ttaaaaggat	ggtattgtag	8880
gcaactttta	ttaaatccca	tctcctcctc	tccccagct	tgcaagttga	cccaaggaag	8940
ccttcatTTT	catgacagac	ttaatTGTGA	gggcacTCTC	a		8981

<210> 21
 <211> 20284
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(20284)
 <223> n = a, t, c, or g

<400> 21
 actgtgtag caaggatggt ctgatctcc tgacctcgtg atccgcctgt atcggcctcc 60
 caaagtgctg ggattacagg cgtgaaccac tgcgccctgt tgagaatttt tttttttttt 120
 tttgggagaa agagtttctgc tcttggtgcc cgggctagag tgcagtgaca caatctcggc 180
 tcaactgcaac ctctgcctcc tgggttcaag caattctcct gcctcagcct catgcgtcac 240
 cacgccagc taatttttgta ttttttagtag agacaggggt tctccatgtt ggtcaggctg 300
 gtctcgaaact cccaacctca ggtggttcgc ccgccttggc ctcccaaagt gctgggattg 360
 caggcatgag ccaactgcgc cagccccaaa ttttggtttt tgcttgaaaa ctgaggtctg 420
 aattcagcct tctggttgcc cctcaagagt cagtttaaat gttggtcatg ttagttgtca 480
 gtgaaaacaa tgggtgaggct ggcattgagag tgtgaatctg gatgggaggg cttgtgcttc 540
 atgaaaacat ttttccagat cagctcagtc gtgagttatc cgtcattgac gttataataa 600
 gctctgatta tttatcaagc atcattcttt atagatatct cagtttaatc tgagataatc 660
 ttctccacat ctctccacat agatgttatg aattttactt ttacagagga gccaactgag 720
 gctcagataa gttacttatt atatgactag tagtggtaga gctgggggtt caactaagaa 780
 ctctctggct ccaaagccct tgtaagtttc tatcagtata tgaccatgca tatgagcatt 840
 tgtctctcct cttcttcata gctccttact gcaatgattt gatgaagaat ttggagtcta 900
 gtcctctttc ccgcattatc tggaaagctc tgaagccgct gctcgttggg aagatcctgt 960
 atacacctga cactccagcc acaaggcagg tcatggctga ggtaagctgc cccagccca 1020
 agactccctc cccagaatct cccagaact gggggcaaaa aactcaaggc agcttcagag 1080
 gtgtgcgcta agtataactca cggctcttct ggaattccca gagtgaacac ctcaagtctg 1140
 atgcagacca gagctgggcc agctccccag tctggtgatc agaatacatg ttacaagcag 1200
 gcatttcttg gggatgggga ggactggcac agggctgctg tgatggggta tcttttcagg 1260
 gaggagccaa acgctcattg tctgtgcttc tctcctttt tctgcggtcc ctggctccc 1320
 acctgactcc aggtgaacaa gaccttcag gaactggctg tgttccatga tctggaaggc 1380
 atgtgggagg aactcagccc caagatctgg accttcattg agaacagcca agaaatggac 1440
 cttgtccggg tgagtgtccc tcccattatt accatgtgcc tgcttgatac tggagagggtg 1500
 agtttctggt cactttccca ggtgtgagtg aggtgagaat tctttcagtt tatctagctg 1560
 ggggaatgta gtgagcatag cttaaagtcac agggcaccac ctctccagaa gtacaggcca 1620
 tgggtgcagag ataacgctgt gcataatcagc atccatgcc ctcacggtca aatagcagtt 1680
 ttctgcaaaa cttagtgagg gctggtgttt ggaagtggag ttgagtaatt gcagtaccct 1740
 attttccctt ttgctgcagc ctctcagcca gccacagcat ctccctgtgt cttggtagggt 1800
 tttggaaaga agtgtgggag caaaagcatg atgttacatg tagactggcc tgagatactc 1860
 attctcaggg cactgtgtga atgatgagct gctgttactg tgtggagggg aaatgcactt 1920
 agtgcttcag agccacttga aagggataag tgctctagag acaattgggt tcaaagtgtg 1980
 agcaggctga gcaagaacag aatgtctcct ttgcctgagc ctgagtgtctg ttaatcacat 2040
 ctctctgcct tgggctgagt tagagaatca ttagactatt tctgtttcc atggtgaggg 2100
 aggcctcttc cttttgtctc tgctccctt aagaagcagg tgaggatttt gccaggtttc 2160
 ttgttttgaa cttatttgac ttttaagggcg gctgggtttt agagactgta cctacctagg 2220
 ggggaacactt ccgaagtta ggactattcc ctgatccgct gggaggcagg ttactgagga 2280
 agtcccttta aaaacaaagg agtttatact gagaaaagca taaacagtga tttgtatgga 2340
 ttcacactga ctaatatagc tcatgccatt aaagtggggt ctcttctcta aaggagggtt 2400

atatgatcta	gccccgtaga	cctaagtgtg	gtttcagacc	tgttcttcct	ggtcctctcc	2460
ttggaatcca	tatttctact	agttggactt	tttctgtttg	tctggctctc	agaggattat	2520
aggaggccct	gtgaagtgac	tcagtgaatt	ttgattttgtg	ggcaagtaga	tggttcccta	2580
gtctgaaatt	gactttgcct	taggtgcttc	aattcttcat	aagctcccag	ttcttaaagg	2640
acaagatcct	tgtaaacatg	gcaatggcat	tcattaggaa	tctagctggg	aaaatccagt	2700
gtgtatgctt	ggaaatgagg	gatctggggc	tggagagaaa	ggcatgggca	tgccttgagg	2760
ggacttggtg	gtcaagctga	ggacctttac	tttaagctct	aggggaccag	gcaaggggag	2820
atgtagatac	gttactctga	tgggggtggat	gaattgaaga	aggatgaggc	aagaatgaag	2880
gcagagacca	gggaggaggc	tctccaagtg	gccaaaggcat	aaagcaagaa	atgaggcctg	2940
gtgactgctt	agtggcagag	cagtgaagaa	gagggaggca	tcaaagtgag	tctcgatttc	3000
tagctgggtg	ggtggtagcg	atgtccagta	ggccagtggc	tactgaggtc	tgcagtggag	3060
gaggggtggt	gggctggaga	cagatgatga	gggagtcac	agcctgtggg	tggaagaaaa	3120
gggaacctct	tccaactggt	ttctttgctt	cttccctctc	tttctctttt	tttttttttt	3180
tggacagagt	cttgctctgt	cacccaggct	gaaatgcagt	ggcatgatct	tggctcacca	3240
cagcctccgc	ctcctgggtt	caagcaatc	tcctgtctca	gcctccagag	tagctgggat	3300
tacaggcaca	tatcactgtg	cccggcta	ttttgtattt	tcagtggaga	tgggatttca	3360
ccatgttggg	cgggctggaa	tgaactcctg	acctcaagtg	atccacctgc	ctcagcctcc	3420
caaagtgttg	ggattacagg	catgagccac	cgcgcccggc	ctttcttccc	tctcttaaag	3480
agtgtttatt	taattccaca	aacatgagct	tgtcaccccc	tgtagcctgg	catctcctac	3540
acgaggtgat	ggctgaggct	tctgcttctg	ctggggtagc	tctgatcttt	ctgctttctc	3600
tggcactgtc	tacccatggt	gcctcacccc	acaggtccca	gggcacctct	ctcgggcaag	3660
tcttggaacc	ctctgacact	gatttgcctc	cttttctgag	ctgcttttag	ccacccatcc	3720
tcgggacctg	ttttctctct	gcctccaccc	ctgcgggcag	tcttaggtct	cctgccctct	3780
acgagcaccc	cagagaggcc	acgtgctcag	tgatctcagt	gggcgcctct	ttctagtctt	3840
gctattcttt	ttggccatgt	tgttcagaaa	ccatactggg	cagggccgac	ttcacccctaa	3900
aggctgcgtc	tcttccactc	gcttttgttt	gttccaaata	aagtggcttc	agaattgcta	3960
accctagcct	ctgtgaactt	gtgaggtaca	atthttgtgtc	tgttatgtta	acaaaaatac	4020
atacatacct	tcctgggtgat	gggtataaatt	gctattctct	attggaaagc	aatttggaat	4080
gaaaatttaa	agaaccattt	taaaatatgc	tatcctgcgt	acctccattc	caccaccccc	4140
cagggatgta	gcctactgaa	ataattttta	agaagtcacc	atatgagaga	aatggttatt	4200
gctatattgt	tattgtgaga	aattggaaat	agactaaatg	ttcagacta	taggaataat	4260
taatgaaatt	acataactc	tatacaatca	ttatgctgcc	attgaaataa	taaatacaaa	4320
ggcgcaaggg	gggaaaagct	tataatgtta	gtgaaactaa	gactgatttt	tttataaagc	4380
agcagttttc	agacccttgg	agactccaat	tcggtagaac	cagagcttca	tcttctctgt	4440
cgaagctgtg	acaggagttg	caaatgcctc	tccttttttg	tgagtttgca	gctgctgttt	4500
ttccggcagc	acatctgtgc	aggcctctgc	ctcggccctc	ctggatctgc	tgattgagca	4560
gcggattgat	ctgtccttct	ctttcgtgtt	gacctatgtg	aggaaccaac	tggcaaggga	4620
acaagaaatg	gaaataggcc	tcctttgcat	catgacctgt	acatcctgca	attggaaaag	4680
attgtacttt	agttgggtta	accagcagca	ttatttttct	aaactaagca	gtaagaagga	4740
attagggttt	atgtgggatc	aacagactgg	gtctcaaaag	aggaagggtga	tagaacacag	4800
tggggagggg	gaggtgcact	agaaacagag	ggcctatgct	ttcattctgg	ctttgctact	4860
taatagctgt	gtgacccaat	cttagagact	taacctctct	gaacttccat	tttctcatgt	4920
ataaaatggg	aaatattaaa	ggatactcac	tgggctgggtg	gcttgtgcct	gtaatcccag	4980
cacttgggga	ggttgagggtg	ggaggatcac	ttgagcccag	gtgttcaaga	ccagcccagg	5040
caacatggca	agactctgtc	tctatgaaaa	aattaaaaat	tagccagggtg	tgggtggtgtg	5100
cacctgtagt	cttagctact	tggtaggctg	agatgggagg	atcacttggg	cttgggagggt	5160
caaggctgcg	gtgagctgtg	attccatcac	tgcactccag	cccgggcggc	agagcgagac	5220
actgaatcca	aacgacaaca	acaacaaaag	gcaaaaaaat	aaaagtgcc	tctttatgga	5280
gttgtgtaag	gtgaagcata	tacactattc	aacatagtaa	ctatataaag	gaagtattgt	5340
tgttgttact	gtagttaata	ccattaagtg	agatgtttcg	tatagtggaa	agcacatgga	5400
ctctgaattc	agactggtct	gactttgagt	ctcagctcca	catctagtaa	tactatgacc	5460

aagccctgggt	taaaaatcatg	tttttttttc	ttcagcctca	gtcttctcac	atataaaaata	5520
gggacactgt	catttacctc	agttttctgt	gaggataaaa	caacgacagt	gtatatgcaa	5580
gtattttgta	aattttgtag	tgctcctcaa	gatttagttg	gtgtttacta	cttgtacttt	5640
ctcactggaa	tggcagatgc	tgttggacag	cagggacaat	gaccactttt	gggaacagca	5700
gttggatggc	ttagattgga	cagcccaaga	catcgtggcg	tttttggcca	agcaccagca	5760
ggatgtccag	tccagtaatg	gttctgtgta	cacctggaga	gaagctttca	acgagactaa	5820
ccaggcaatc	cggaccatat	ctcgcttcat	ggaggtgaat	ctggtgctgg	gatcatttag	5880
aaaagactta	acggcttctt	tctctgagac	gttacaataa	ggttcaggca	ggaggcaagt	5940
ttagaaataa	tgtatagtct	catttacaaa	actatccctc	aagcctaaca	caggatttga	6000
taacaaaagg	cacttaataa	atgttagttg	agtggttgaa	tgagtaaata	aactctagct	6060
ttagtaaatt	aactctagct	tattctatat	aggctcaaga	gaatatttct	acccattttc	6120
ttctaggttt	tcctatctca	gtgactaatg	gtagcaaagc	attcccttaa	aaaggcatta	6180
tttgtaaac	ttayctaaaa	tcgaattcgg	gtccaattaa	atttttgaaa	ttttatatta	6240
aaaattatat	tagtagggat	gggtaagagg	tgttttggtc	tggttggttg	gttagttgct	6300
atgactcaga	attgctaaga	aaacagaaaa	gtaagataag	atcattgttt	taacctcttt	6360
tcctccacaa	aatcaataaa	taacatatcc	ctaaattact	cttagaattt	ctcttaaatt	6420
gcagtgaaaa	acccaaatcc	ttcattcttg	gttgaagggt	ggaaaactac	gttagagagg	6480
attagagaga	gaggatgagc	aatcgtgtag	tcagcccttg	cctcctagtg	taggatttgt	6540
ctcagccact	gcttggtgtc	ctggctgcca	acgttctcat	gaaggctgtt	cttctatcag	6600
tgtgtcaacc	tgaacaagct	agaaccata	gcaacagaag	tctggctcat	caacaagtcc	6660
atggagctgc	tggatgagag	gaagtctctg	gctggtattg	tgttcaactg	aattactccm	6720
rgcagcattg	agctgcccc	tcagtgtcaag	tacaagatcc	gaatggacat	tgacaatgtg	6780
gagaggacaa	ataaaatcaa	ggatgggtaa	gtggaatccc	atcacaccag	cctgggtcttg	6840
gggaggcca	gagcacctat	tatattagga	caagaggtag	tttattttta	ctaaaaattt	6900
ggtagaaatt	tcaacaacaa	caaaaaaact	caacttggtg	tcattgattt	ggtgaaattg	6960
gtacatgact	tgttggaagg	tttttcatag	gtcataaaat	aacagtatct	tttgatttag	7020
catttctact	caagggaatt	aattccagga	attttggtgg	caggcacctg	taatcccagc	7080
tactcgggag	gctgaggcag	gagaattgct	tgaaccacag	aggcagaggt	tgcagtgagc	7140
taagatcgca	tcattgcact	ccgcctggg	caataagagt	gaaactccat	ctcaaaaaaa	7200
aaaaagatac	aaaaatagaa	aaaggggctt	ggtaagggta	gtaggggttt	gggcaatttt	7260
tttttttttt	ttttttttta	ttgtatgggt	ctaaaggaat	ggttgattac	ctgtgggttg	7320
gttttaggta	ctgggacctt	ggctctcgag	ctgacctctt	tgaggacatg	cggtagctct	7380
gggggggctt	cgctacttg	caggatgtgg	tggagcaggc	aatcatcagg	gtgctgacgg	7440
gcaccgagaa	gaaaactggt	gtctatatgc	aacagatgcc	ctatccctgt	tacgttgatg	7500
acatgtaagt	tacctgcaag	ccactgtttt	taaccagttt	atactgtgcc	agatgggggt	7560
gtatatatgt	gtgtgcatgt	gcatgcatgt	gtgaatgatc	tggaaataag	atgccagatg	7620
taagttgtca	acagttgcag	ccacatgaca	gacatagata	tatgtgcaca	cactagtaaa	7680
cctctttcct	tctcatccat	ggttgccact	tttatctttt	tatttttatt	tttttttttg	7740
agatggagtc	tcgctctgac	gcccaggctg	gagtgcagtg	gctcgatctc	ggctcactgc	7800
aacctttgcc	tcccgggttc	aaactattct	cctgcctcag	cctccacagt	agctgggact	7860
acaggctcat	gctgccacgc	cgggtgact	ttttgtattt	tagtagagac	gaggtttcac	7920
catgttacct	aggctagact	tcaactcctg	agctcaggca	atccaccctc	cttggcctcc	7980
caaagtgtct	ggattacagg	tgtgagccac	tgcaccacgc	ccaccacttt	aattttttac	8040
actctacctt	tttggctcaa	atttgctcaa	tctgcaagct	taaaatgtgt	catgacaaac	8100
acatgcaagc	acatactcac	acatagatgc	agaaacagcg	tctaaactta	taaaagcaca	8160
gtttatgtaa	atgtgtgcac	ttcttctccc	taggtggtaa	accacatttc	aaaacaaccc	8220
aaataaaaact	gaacaaagct	tcttctctct	agacttttta	gaaaatcttt	cagtgtctgag	8280
tcactaagct	gccaaagtct	cattgtggga	actatgcctt	tggatgtaat	gatttcttct	8340
aagacaatgg	gcggagggtg	agttattgca	gacatctgaa	atatgtaatg	tttcttccag	8400
attctggaaa	ttctcttatt	ctctgtgggt	gggtgggtgg	gtgggatgtg	tgtgtgtgtg	8460
tgtgtgtgtg	tgtgtgtgtg	tgtgtaggga	tcaggatgcg	ggaggagctg	ggttctgctt	8520

gtattggttc	tctgttttgc	attgaatagt	gtgtttcctt	gtatggctat	ctatagcttt	8580
tcaaggtcac	cagaaattat	cctgtttttc	accttctaaa	caattagctg	gaatttttca	8640
aaggaagact	tttacaaaga	cccctaagct	aaggtttact	ctagaaagga	tgtcttaaga	8700
cagggcacag	gagttcagag	gcattaagag	ctgggtgctg	ttgtcatgta	gtgagtatgt	8760
gcctacatgg	taaagctttg	acgtgaacct	caagttcagg	gtccaaaatc	tgtgtgcctt	8820
tttactttgc	acatctgcat	tttctattct	agcttggaa	ctgaaacatt	gacaagagct	8880
gcctgaaatg	tatgtctgtg	gtgtgattag	agttacgata	agcaagtcaa	tagtgagatg	8940
accttgagg	tgttgaactt	ttgtgagaga	atgagttggt	tttttgtttt	ggttttttagt	9000
actttaacat	aatctacctt	tagtttaagt	atcgctcaca	gttacctagt	tactgaagca	9060
agcccccaaa	gaaatttggt	ttggcaacac	tttggttagcc	tcgtttttct	ctctacattg	9120
cattgctcgt	gaagcattgg	atcatacgta	catttcagag	tctagagggc	ctgtccttct	9180
gtggcccgaga	tgtggtgctc	cctctagcat	gcaggctcag	aggccttggc	ccatcaccct	9240
ggctcacgtg	tgtcttttct	tctccccttg	tccttccttg	gggcctccag	ctttctgcgg	9300
gtgatgagcc	ggtcaatgcc	cctcttcatg	acgctggcct	ggatttactc	agtggctgtg	9360
atcatcaagg	gcatcgtgta	tgagaaggag	gcacggctga	aagagaccat	gcgatcatg	9420
ggcctggaca	acagcatcct	ctggtttagc	tggttcatta	gtagcctcat	tcctcttctt	9480
gtgagcgctg	gcctgctagt	ggtcatcctg	aaggtaaggc	agcctcactc	gctcttccct	9540
gccaggaaac	tccgaaatag	ctcaacacgg	gctaaggagg	gagaagaaga	aaaaaaatcc	9600
aagcctctgg	tagagaaggg	gtcatacctg	tcatttcctg	caatttcatc	catttatagt	9660
tggggaaagt	gaggcccaga	gaggggcagt	gacttgccca	aggtcaaccc	agccgggtag	9720
cagctaagta	ggatgagagt	gcagggttca	tgctttccag	ataaccacat	gctcaactgt	9780
gccatgctgt	ctcattggta	gtggttcatg	gcagcatctg	aaagctattt	attttcttag	9840
atataattggg	tggcgattct	tcctaagttt	ctaagaacaa	taatcagaag	gatatatat	9900
gttgcagggt	agactgtctg	gaagcagagg	ctgaaataga	gtttgatgta	tgggtattta	9960
tgagggctca	atacctatgg	aagagatatg	gaagatgcag	gattgggcag	agggaggagt	10020
tgaactgtga	tatagggcca	accccgtagg	gcactctaga	gaatatgcag	cttggtggag	10080
ttgtttctca	togagctgaa	acatccagcc	ctttgtgctc	ccccaaggcc	tcctcctga	10140
caccacctac	ctcagccctc	tcaatcaatc	actggatgtg	ggctgccttg	ggaaggctgt	10200
gcccaggggc	ctacatggct	ctctgctgct	gtgacaaacc	cagagttgct	gatgcctgag	10260
gccgtctact	gacagctggg	caacaaggct	tccttgaatg	gggactctgg	gcagtgcagt	10320
tttgtgtctg	aaccatacat	taatatattt	atatccgaat	tttctttctc	tgcaagcatt	10380
tcataataag	acacatcagg	taaaaataaa	tgtttttgaa	gcaaaaggag	tacaaagaga	10440
taagaactaa	ctaatttaaat	actagttacc	atctgttaca	aatagttcct	actgattgcc	10500
aaggactgtt	taaacacatc	acatgggctt	cttcttctat	cctcactaac	ccttttaaca	10560
gacaaggaaa	tgaggctcag	gaaggctcaag	gactttattg	aggttcacac	gtaggataca	10620
gttcttgcta	aaagcaaccc	ctccctcatg	ctctgttatc	taactgcaag	gggaagggtca	10680
gtggcagagg	tagtgggtccc	atgggttggtg	cataagagct	gctctgagac	aactgcatgc	10740
tggtgggtcc	tgagacatg	tacccatcag	ccggagatag	gctcaaaata	tccacaagag	10800
tttggatgat	tgtgggaatg	cagaatccat	ggtgatcaag	agggaaagtc	aagttgcctg	10860
gccattttcc	ttggctttta	gacagaaaag	ttacgtggga	tattatctcc	cacagctctt	10920
ctgtggtgcc	accagtcata	gtccttatat	aaggagaaac	cagttgaaat	tacctattga	10980
agaaacaaag	agcaaaactcg	cccactgaaa	tgcgtagaaa	gccctggact	ctgttgtatt	11040
cataactctg	ccattatttt	tctgcgtagt	tttgggtaag	tcacttatct	tctttaggat	11100
ggtaatgata	agttgcctca	tcagaaagat	gaacagcatt	acgcctctgc	attgtctcta	11160
acatgagtag	gaataaacc	tgtctttttt	ctgtagatca	tacaagttag	tgcttgggat	11220
tgttgaggca	gcacatttga	tgtgtctctt	ccttcccagt	taggaaacct	gctgccctac	11280
agtgatccca	gcgtgggtgtt	tgtcttctct	tcctgtgttg	ctgtgggtgac	aatcctgcag	11340
tgcttctga	ttagcacact	cttctccaga	gccaaacctg	cagcagcctg	tgggggcatc	11400
atctacttca	cgctgtacct	gccctacgtc	ctgtgtgtgg	catggcagga	ctacgtgggc	11460
ttcacactca	agatcttctg	tgtgagtacc	tctggccttt	cttcagtggc	tgtaggcatt	11520
tgaccttctt	ttggagtccc	tgaataaaaag	cagcaagttg	agaacagaag	atgattgtct	11580

tttccaatgg	gacatgaacc	ttagctctag	attctaagct	ctttaagggg	aagggcaagc	11640
atttgtgttt	attaaattgt	ttacctttag	tcttctcagt	gaatcctggg	tgaattgaat	11700
tgaatggaat	ttttccgaga	gccagactgc	atcttgaact	gggctgggga	taaattggcat	11760
tgaggaatgg	cttcaggcaa	cagatgccat	ctctgccctt	tatctcccag	ctctgttggc	11820
tatgttaagc	tcatgacaaa	ccaaggccac	aaatagaact	gaaaactctt	gatgtcagag	11880
atgacctctc	ttgtcttcct	tgtgtccagt	atgggtgttt	gcttgagtaa	tgttttctga	11940
actaagcaca	actgaggagc	aggtgcctca	tcccacaaat	tcctgacttg	gacacttcct	12000
tccctcgtac	agagcagggg	gatatcttgg	agagtgtgtg	agcccctaca	agtgcaagtt	12060
gtcagatgtc	cccaggtcac	ttatcaggaa	agctaagagt	gactcatagg	atgctcctgt	12120
tgctcagtc	tgggcttcat	aggcatcagc	agcccccac	aggcacctct	gatcctgagc	12180
catccttggc	tgagcagggg	gcctcagaag	actgtgggta	tgcgcatgtg	tgtgggggaa	12240
caggattgct	gagccttggg	gcatcttttg	aaacataaag	ttttaaaagt	tttatgtctc	12300
actgtatatg	catttctgaa	atgtttgtat	ataatgagtg	gttacaaatg	gaatcatttt	12360
atatgttact	tggtagccca	ccactcccta	aagggaactct	ataggtaaatt	actacttctg	12420
caccttatga	ttgatccatt	ttgcaaattc	aaatttctcc	aggtataatt	tacactagaa	12480
gagatagaaa	aatgagactg	accaggaaat	ggataggtga	ctttgcctgt	ttctcacaga	12540
gcctgctgtc	tctgtgggct	tttgggtttg	gctgtgagta	ctttgccctt	tttgaggagc	12600
agggcattgg	agtgcagtg	gacaacctgt	ttgagagtcc	tgtggaggaa	gatggcttca	12660
atctcaccac	ttcgggtctcc	atgatgctgt	ttgacacctt	cctctatggg	gtgatgacct	12720
ggtacattga	ggctgtcttt	ccagggtacac	tgctttgggc	atctgtttgg	aaaatatgac	12780
ttctagctga	tgtcctttct	ttgtgctaga	atctctgcag	tgcatgggct	tccctgggaa	12840
gtgggtttgg	ctatagatct	atagtaaaca	gatagtccaa	ggacaggcag	ctgatgctga	12900
aagtacaatt	gtcactactt	gtacagcact	tgtttcttga	aaactgtgtg	ccaggcagca	12960
tgcaaaatgt	tttatacaca	ttgcttcatt	taattctcac	aaggctactc	tgaagtagtt	13020
actataataa	ccagcaattt	tcaaatagaga	gaactgtgac	tcaaagacgt	taagtaacca	13080
gctttgggtca	cacaactggt	aaatgtttgg	acgtggagg	gaatccactt	cggttacact	13140
gggtcaataa	gcccaggcga	atcctcccaa	tgctcaccca	attctgtatt	tctgtgtcct	13200
cagagggggg	acaactagga	gagggttctgt	ttcctgagta	cagggttgta	ataattaaat	13260
atactagctc	taaggcctgc	ctgtgattta	attagcattc	aataaaaaat	catgttgaat	13320
ttttcttttag	tacttctttc	ttaataataat	acatcttctt	gaccaagtcc	aagaggaacc	13380
tgcgttggac	agttttcata	tgagatcaaa	ttctgagaga	gcaagattta	accctttttg	13440
gttcaccttc	tgatcctccc	ctaaggaggt	atacatgaaa	tatttattac	tcctgcctga	13500
acttctttca	ttgaatatgc	aattttgcag	catgcagatt	ctggatttaa	attctgagtc	13560
ttaacttact	ggctgagggg	ccttg gatag	gctccttatt	cctcagtttc	ctcatctcta	13620
aaatggggat	ggcacctgcc	ccgtgggttg	ttggaaggac	ttacagaggt	gcagaatgta	13680
cggtgtacat	agcaggtttc	agcaaatgtt	agctccctct	ttccccacat	ccattcaaatt	13740
ctgttccttc	tccaaaggat	gtgtcaagga	ggaaatggac	ctggctggga	aaccctcaga	13800
atactgggat	gatgtgagc	ttggctcata	cctgtgcttt	gctttcaggc	cagtaaggaa	13860
ttcccaggcc	ctgggtatttt	ccttgcacca	agtcctactg	gtttggcgag	gaaagtgatg	13920
agaagagcca	ccctgggttc	aaccagaaga	gaatgtcaga	aagtaagtgc	tgttgacctc	13980
ctgctctttc	tttaacctag	tgtgtgtgcc	tctgctaact	gttgggggca	agcgatgtct	14040
cctgcctttc	taaaagactg	tgaaccact	ccaggggcag	agaaatcaca	tgcagtgtcc	14100
ctttccaaat	cctcccatgc	catttatgtc	caatgctgtt	gacctattgg	gagttcacgg	14160
tctcgatccc	tgaggggacat	tttctttgtt	gtcttggctt	ctagaagagt	atcttttact	14220
tgccccctcc	caaacacaca	tttcatgggt	tcctaacaag	ctagaagaaa	gaggtaaaga	14280
caagcgtgat	tgtggaacca	tagcctcgct	gcctgcctgt	gacatgggtga	cctgtgtatc	14340
agcctgtgtg	ggctgagacc	aagtggctac	cacagagctc	agcctatgct	tcataatgta	14400
atcattaccc	agatccctaa	tcctctcttg	gctcttaact	gcagacagag	atgtccacag	14460
ctcatcaaag	gctctgcttc	tgggttcttt	gtgcttagag	tggcttcccta	aatatttaatt	14520
aggtcccttt	tctgccagtc	tcttctgtgc	ccatcccttg	attgcccttg	gtaaaagtat	14580
gatgccccct	agtgtagcac	gcttgcctgc	tgttccctaatt	catcttctcc	tacctcctct	14640

ttacacctag	ctcctgtttc	agtcacctag	aaatgctcac	agtcgctgga	atatgtcatg	14700
ttcttccaca	cctccatgcc	tttgtaggta	ctgtttgctc	tcacaggaga	actttctctc	14760
taacttgcc	atcttctcaa	ctcctccttt	ctctccaaga	tctagttccg	gatccccctc	14820
cctgagcatc	cctccttggg	tctcaggtag	tcagtcactc	tctgccctga	acttccatgg	14880
cacgtgaaag	aaaatctttt	tattttaaaa	caattacaga	ctcacaagaa	gtaatacaaa	14940
ttacatgagg	gggttccctt	aaacctttca	tccagtttcc	ccaatggtag	cagcatgtgt	15000
aactgtagaa	tagtatcaaa	accatgaaat	tgacataggt	acaattcaca	aaccttcttc	15060
agatttcact	agctttatgt	gcgctcattt	gtgtgtgtgt	gtgcgtattt	agttctatgc	15120
aattttatca	tgtgtgaatt	catgtaatta	ctagctcagt	caagctgcag	aaatatctca	15180
ttgtcacaaa	gctccttcat	gctacccctt	aatggccaca	gccacctccc	ttcttcctca	15240
gttcctgaca	cctgtcaacc	actaatgcgt	tccctgtttt	tacagtttta	ttatttctag	15300
aatgttacat	aaatggaacc	atacagtagg	tatccttttg	atactggctt	tttttttttt	15360
ttcactcagc	agtattccct	tagatctatc	caagtttgtt	gtgtcaacag	ttcattcctc	15420
ttcactgctg	agtagtggtc	cctgggaggg	gtgtatcaca	gttccatggc	atttttagat	15480
gtatttttta	aacagctttc	agcatcctct	attttaattg	ttcatcaagt	cctttttccc	15540
aatagactct	gaatgctcct	ttatcatcgt	attcccatca	ccaacatcag	tacccaaata	15600
ggccctaaat	aaacatttat	agcctcctgc	ctgcctgaga	aaccagggtg	gacatggaga	15660
gaaggcactt	ctgaaagtct	aagcgcagtg	csctgtgtcc	ttacactcca	ctcctcagtg	15720
ctttctgtgg	gttcattttc	gtcttctctc	ctgtcacagt	ctgcatggag	gaggaacca	15780
cccacttgaa	gctgggcgtg	tccattcaga	acctggtaaa	agtctaccga	gatgggatga	15840
aggtggctgt	cgatggcctg	gcactgaatt	tttatgaggg	ccagatcacc	tccttcctgg	15900
gccacaatgg	agcggggaag	acgaccacca	tgtagaaga	gggtgtggtt	ccgcagaat	15960
cagccacagg	agggttctgc	agtagagtta	gaaatttata	ccttaggaaa	ccatgctgat	16020
ccctgggcca	aggggaaggag	cacatgagga	gttgccgaat	gtgaacatgt	tatctaata	16080
tgagtgtctt	tccacgtgct	agtttgctag	atgttatttc	ttcagcctaa	aacaagctgg	16140
ggcctcagat	gacctttccc	atgtagttca	cagaattctg	cagtggctct	ggaacctgca	16200
gccacgaaaa	gatagattac	atatgttgga	gggagttggt	aattcccagg	aactctgtct	16260
ctaagcagat	gtgagaagca	cctgtgagac	gcaatcaagc	tgggcagctg	gcttgattgc	16320
cttccttgcg	acctcaagga	ccttacagtg	ggtagtatca	ggaggggtca	ggggctgtaa	16380
agcaccagcg	ttagcctcag	tggcttccag	cacgattcct	caaccattct	aaccattcca	16440
aagggtatat	ctttgggggg	tgacattctt	ttcctgtttt	ctttttaatc	tttttttaa	16500
acatagaatt	aatatattat	gagcttttca	gaagattttt	aaaaggcagt	cagaaatcct	16560
actacctaac	acaaaaattg	tttttatctt	tgaataatat	gttcttggtt	gtccattttc	16620
catgcatcgc	atgttaggca	tacaaaatac	attttttaaa	gaatactttc	attgcaaatt	16680
ggaaacttcg	tttaaaaaat	gctcatacta	aaattggcat	ttctaacca	tagggccact	16740
tgtagtatt	taccgaagca	aaaggacagc	tttgctttgt	gtgggtctgg	tagggttcat	16800
tagaaaggaa	tgggggcggt	gggagggttg	gtgttctgtt	ctctctgcag	actgaatgga	16860
gcatctagag	ttaagggtag	gtcaaccctg	acttctgtac	ttctaaattt	ttgtcctcag	16920
gtcaatcctg	accgggttgt	tccccccgac	ctcgggcacc	gcctacatcc	tgggaaaaga	16980
cattcgctct	gagatgagca	ccatccggca	gaacctgggg	gtctgtcccc	agcataacgt	17040
gctgtttgac	atgtgagtac	cagcagcacg	ttaagaatag	gccttttctg	gatgtgtgtg	17100
tgtcatgcc	tcatgggagg	agtgggactt	aagcatttta	ctttgctgtg	tttttgtttt	17160
ttcttttttt	ctttttttatt	tttttgagat	ggagtctcgc	tctgtagcca	ggctggactg	17220
tagtggcgcg	atctcggtct	actgcaacct	tggcctccca	ggttcaagcg	attctcctgc	17280
ctcagcctcc	cgagtagctg	ggactctagg	cacacaccac	catgccagc	taatttttgt	17340
gttttttagta	gagacggggg	ttcaccatgt	tggccaggat	ggtctcaatg	tcttgacctc	17400
gtgatccgcc	cacctcggtc	tcccaaagtg	ctgggaacac	aggcatgagc	cactgtgtct	17460
ggccacattt	tactttcttt	gaatatggca	ggctcacctc	cgtgaacacc	ttgagacct	17520
gttgttcttt	gatttttagga	gaagtgggag	gtgaatgggt	gagctgtaga	ggtgacatca	17580
gccagccag	tggatggggg	cttgggaaac	attgcttccc	attattgtca	tgctggaggg	17640
cccttttagcc	catcctctcc	ccccgccacc	ctccttattg	aggcctggag	cagacttccc	17700

agacctggta	gtgcttcagg	gccctgggat	gatggaccta	tatttgctgc	ttaagacatt	17760
tgctcccaact	caggttgtcc	catcagccat	aaggccccc	gggagcccg	gtgatggagc	17820
agagagagac	ctgagctctg	caatcttggg	caaggctttt	cccttatgtt	tcttcttatc	17880
taaagtgaac	agctggggct	catgtgctcc	ctcctcatct	aaagtgaaca	catggggctc	17940
atgtgcaggg	tcttccccgc	tttcagagcc	tgaggtcccc	tgaggctcag	gaaggctgct	18000
ccaggtgagt	gccgagctga	cttcttgggtg	gacgtgctgt	ggggacagcc	cattaaagac	18060
cacatcttgg	ggccctgaaa	ttgaaagttg	taactgcctg	gtgcatggtg	gccaggcctg	18120
ctggaaacag	gttggaagcg	atctgtcacc	tttcactttg	atttcctgag	cagctcatgt	18180
ggttgctcac	tgttggttcta	ccttgaatct	tgaagattat	ttttcagaaa	ttgataaagt	18240
tattttaaaa	agcacgggga	gagaaaaata	tgcccattct	catctgttct	gggccagggg	18300
acactgtatt	ctgggggtatc	cagtagggcc	cagagctgac	ctgcctccct	gtccccaggc	18360
tgactgtcga	agaacacatc	tggttctatg	cccgttgaa	agggctctct	gagaagcacg	18420
tgaaggcgga	gatggagcag	atggccctgg	atgttggttt	gccatcaagc	aagctgaaaa	18480
gcaaaacaag	ccagctgtca	gggtgcggccc	agagctacct	tccctatccc	tctcccctcc	18540
tcttccggct	acacacatgc	ggaggaaaat	cagcactgcc	ccagggtccc	aggctgggtg	18600
cggttggtaa	cagaaacttg	tccctggctg	tgcccctagg	tctctgcct	tactcactg	18660
tctggggctg	gtcctggagt	ttgtcttgct	ctgttttttt	gtaggtggaa	tgagagaaa	18720
gctatctgtg	gccttggcct	ttgtcggggg	atctaagggt	gtcattctgg	atgaaccac	18780
agctggtgtg	gacccttact	cccgcagggg	aatatgggag	ctgctgctga	aataccgaca	18840
aggtgcctga	tgtgtatttta	ttctgagtaa	atggactgag	agagagcggg	gggcttttga	18900
gaagtgtggc	tgtatctcat	ggctaggctt	ctgtgaagcc	atgggatact	cttctgttak	18960
cacagaagag	ataaagggca	ttgagactga	gattcctgag	aggagatgct	gtgtctttat	19020
tcatcttttt	gtccccaaca	tgggtgacta	aatttatggt	tagttgaaag	ggtggatgct	19080
taaatgaatg	gaagcggaga	ggggcaggaa	gacgattggg	ctctctgggt	agagatctga	19140
tgtggtacag	tatgaggagc	acaggcaggc	ttggagccaa	ctctggcttg	gccctgagac	19200
attgggaaag	tcacaacttg	cctcaccttc	tttgccgata	ataatagtgg	tgcgttacct	19260
catagaggat	taaattaaat	gagaatgcac	acaaaccacc	tagcacaatg	cctggcatat	19320
agcaagttcc	caaataaaat	gcgtactgtt	cttacctctg	tgaggatgtg	gtacctatat	19380
atacaaagct	ttgccattct	aggggtcata	gccatacagg	gtgaaagggt	gcttccagggt	19440
ctcttccagt	gcttaccctt	gctaatatct	ctctagtccc	tgtcactgtg	acaaatcaga	19500
actgagaggc	ctcacctgtc	ccacatcctt	gtgtttgtgc	ctggcaggcc	gcaccattat	19560
tctctctaca	caccacatgg	atgaagcggg	cgtcctgggg	gacaggattg	ccatcatctc	19620
ccatgggaag	ctgtgctgtg	tgggctcctc	cctgtttctg	aagaaccagc	tgggaacagg	19680
ctactacctg	accttgggtca	agaaagatgt	ggaatcctcc	ctcagttcct	gcagaaacag	19740
tagtagcact	gtgtcatacc	tgaaaaagggt	gagctgcagt	cttgagctg	ggctggtgtt	19800
gggtctgggc	agccaggact	tgttggtgtg	gaatgatttc	tccatctcca	ccccttttgc	19860
catgttgaaa	ccaccatctc	cctgctctgt	tgcccctttg	aaatcatatc	atacttaagg	19920
catggaaagc	taagggggccc	tctgctccca	ttgtgctagt	tctgttgaat	cccgttttcc	19980
ttttcctatg	aggcacanag	agtgatggag	aaggctccta	gaggacatta	ttatgtcaaa	20040
gaaaagagac	ttgtcaagag	gtaagagcct	tggctacaaa	tgacctggtc	gttcctgctc	20100
attacttttc	aatctcattg	accttaactt	ttaaactata	aaacagccaa	tatttattag	20160
gcactgattt	catgccagag	acactctggg	cattgaaaga	aagtaatgat	aatagttaat	20220
tttatatagc	gttggttacca	tttcaacctt	tttttttttt	taacctctat	catctcaatt	20280
aaag						20284

<210> 22

<211> 7052

<212> DNA

<213> Homo sapiens

<400> 22

gtgaacacac	attaaagcat	gagaagcatg	aactagacat	gtagccaggt	aaaggccttg	60
ctgagatggg	tggcaaaggc	ctcattgcag	cattcattgg	caggccacag	ttcttttggc	120
agctctgctt	cctgaccttt	caccctcagg	aagcgaggct	gttcacacgg	cacacacatg	180
ccagacaggg	tcctctgaag	ccacggctgc	cagtgcattg	gtcccaggga	aagctttttc	240
cttttagttct	cacacaacag	agcttcttgg	aagccctccc	cggcgaaggt	gctgggtggc	300
ctgccttgct	ccgtccctga	cccgttctca	cctccttctt	tgccatcagg	aggacagtgt	360
ttctcagagc	agttctgatg	ctggcctggg	cagcgaccat	gagagtgaca	cgctgaccat	420
cggtaaggac	tctgggggtt	cttattcagg	tgggtgcctga	gcttcccca	gctgggcaga	480
gtggaggcag	aggaggagag	gtgcagaggc	tgggtggcgt	gactcaaggt	ttgctgctgg	540
gctggggctg	gggtggctgc	gggggtgggag	cagcttggtg	gcgggttggc	ctaagtcttg	600
ctgggggtgc	tggggctcgg	tttgggagct	agcagggcag	tgtcccagag	agctgagatg	660
attgggggtt	ggggaatccc	ttaggggagt	ggacactgaa	taccagggat	gaggagctga	720
gggccaagcc	aggagggtgg	gatttgagct	tagtacataa	gaagagtgag	agcccaggag	780
atgaggaaca	gccttccaga	tttttcttgg	gtagcgtgtg	taggaggcca	gtgtcaccag	840
tagcatatgt	ggaacagaag	tcttgaccct	tgctatctct	gcctagtcc	aatggctggc	900
ttttcccagg	aaggcttctg	cttccatgga	ctgttagatt	aaccctttat	ttaggtaa	960
gagggaaacct	actttataag	cataggaaag	ggtgaagaat	cttttaagat	tcctttactc	1020
aagttttctt	ttgaagaatc	ccagagctta	ggcaatagac	accagacttt	gagcctcagt	1080
tatccattca	cccatccacc	caccaccca	cccatccttc	catcctcca	tcctccatt	1140
cacccatcca	cccatccagc	tgtccacca	ttctacactg	agtacctata	atgtgcctgg	1200
ctttggtgat	acaaagggtga	ataagacata	gtcctttcct	ttgccccaa	ccctcagacc	1260
agagatgaac	atgtggaatg	acctaaccac	ctggaacagg	tgtggtgtat	gagcggcagg	1320
cctctgatga	gaggggtggg	gatggccagc	cctcactccg	aagcccctct	gagttgattg	1380
agccatcttt	gcattctggt	cctgcagatg	tctctgctat	ctccaacctc	atcaggaagc	1440
atgtgtctga	agcccggtct	gtggaagaca	tagggcatga	gctgacctat	gtgtgccat	1500
atgaagctgc	taaggaggga	gcctttgttg	aactctttca	tgagattgat	gaccggctct	1560
cagacctggg	catttctagt	tatggcatct	cagagacgac	cctggaagaa	gtaagttaag	1620
tggctgactg	tcggaatata	tagcaaggcc	aaatgtccta	aggccagacc	agtagcctgc	1680
attgggagca	ggattatcat	ggagttagtc	attgagtttt	taggtcatcg	acatctgatt	1740
aatgttggcc	ccagtgaagc	atttaagatg	gtagtgggag	atagcaggaa	agaagtgttt	1800
tcctctgtac	cacagtacat	gcctgagatt	tgtgtgttga	aaccagtgg	acctaacaca	1860
tttacatccc	aaccttaaac	tcctatgcac	ttattttacc	tttaatgagc	ctctttactt	1920
aagtacagtg	kgaggaacag	cggcatcagg	atcacttggg	aacttgtag	aaattcagca	1980
acttggggcc	agctcagacc	tactgaatca	gaatcaggag	caattctctg	gtgtgactgt	2040
gtcacagcca	ggtatcaact	ggattctcat	acataggaaa	tgacaaacgt	ttatggatgg	2100
atagtctact	tgtgccaggt	gctgagattt	gttttttgtt	ttttgatttt	tttttaata	2160
ctgtgacctc	atttaattct	caaaaaaaga	tgaaaaaatg	aacactcagg	aatgctgaca	2220
tgagattcag	aatcaggggt	ttggggcttc	aaagtccatc	ctctctttat	ccatgtaatg	2280
cctcccctta	gagatacaac	atcacagacc	ttgaaggctg	aaggggatat	aaaagctgtc	2340
tggccaagtg	gtctccaagc	ttgacagtgc	agcagaatca	cctggggata	ttattaaaaa	2400
taaacatact	aagggttggc	ttcagggcct	gtgaatcaga	atttctggag	gtgaggcctt	2460
gaagtctgta	tttctattgc	atactttgga	cacagtggtc	tatagactag	agtttggaaa	2520
tgattgcgct	cattcagatt	ctcttctgat	gtttgaattg	ctgccatcat	atttctagt	2580
ctctatttcc	tcctgctcat	tctgtcttgg	ataacttatc	atagtactag	cctactcaaa	2640
gatttagagc	cacagtccct	aaagaagcca	cttgactcat	tcctgtagg	ttcagaataa	2700
atttcttctg	cgcagtgtct	gtcatagctt	tttttaaat	tttttttatt	tttgatgaga	2760
ctggagtgtt	gctcttattg	cccaagctgg	agtgcagtgg	tgcgattttg	gctcactgca	2820
acctccacct	cccaggttca	agcgattctc	ctgcctcagc	ctcccaagta	gctgagatta	2880
caagcatgtg	ctaccacgcc	cagctaattt	tgtattttta	gtagagatgg	gttttatcca	2940
tgttgggtcag	gctggtctcg	agctccagac	ctcaggtgat	ctgcccgcct	cggcctccca	3000

aagtgtctggg	attatagggc	tgagccacag	cgctcagcca	taactttaat	ttgaaaatga	3060
ttgtctagct	tgatagctct	caccactgag	gaaatgttct	ctggcaaaaa	cggcttctct	3120
cccaggtaac	tctgagaaag	tgttattaag	aaatgtggct	tctactttct	ctgtcttacg	3180
gggctaacat	gccactcagt	aatataataa	tcgtggcagt	ggtgactact	ctcgtaatgt	3240
tggtgtcttat	aatgtttctca	tctctctcat	tttccagata	ttcctcaagg	tggccgaaga	3300
gagtgggggtg	gatgtctgaga	cctcaggtaa	ctgccttgag	ggagaatggc	acacttaaga	3360
tagtgcccttc	tgctggcttt	ctcagtgcac	gagtattgtt	cctttccctt	tgaattgttc	3420
tattgcattc	tcatattgtag	agtgtagggt	tggtgcagat	ggggaagggt	tgttttgttg	3480
taaaataaaat	aaagtatggg	attcttttct	tgtgccttca	gatggtacct	tgccagcaag	3540
acgaaacagg	cgggccttcg	gggacaagca	gagctgtcct	cgcccgttca	ctgaagatga	3600
tgctgtctgat	ccaaatgatt	ctgacataga	cccaggctctg	ttagggcaag	atcaaacagt	3660
gtcctactgt	ttgaatgtga	aattctctct	catgctctca	cctgttttct	ttggatggcc	3720
tttagccaag	gtgatagatc	cctacagagt	ccaaagagaa	gtgaggaaat	ggtaaaagcc	3780
acttgttctt	tgcagcatcg	tgcatgtgat	caaacctgaa	agagcctatc	catatcactt	3840
cctttaaaga	cataaagatg	gtgcctcaat	cctctgaacc	catgtattta	ttatcttttc	3900
tgcggggtcc	tagtttcttg	tatacattag	gtgtttaatt	gttgaacaaa	tattcattcg	3960
agtagatgag	tgattttgaa	agagtcagaa	aggggaattt	gctgttagag	ttaattgtac	4020
cctaagactt	agatatttga	ggctgggcat	ggtggctcat	gccagtaatc	ccagcgcttt	4080
gagaggctga	ggtgggtaga	tcacctgagg	tcaggagtgt	gagaccagtc	tgaccaacaa	4140
ggtgaaaccc	cgtctctact	aaatacaaaa	aattagccga	gtgtgggtggc	acatgcctgt	4200
catcccagct	acttgggagg	ctgaggcagg	agaatcgctt	gaaccagga	ggcagagggt	4260
gcagtcagcc	acggttgccg	cattgcactc	cagactgggc	aacaagagtg	aaaactccat	4320
ctcaaaaaag	aaaaaaaaag	aattagatat	tttggtatgag	tgtgtctttg	tgtgtttaac	4380
tgagatggag	aggagagcta	agacatcaaa	caaataattgt	taagatgtaa	aagcacatca	4440
gttaggtatc	attagttttag	gacaaggatt	tctagaaaat	ttttagggaac	agaaaacttt	4500
ccagtctctc	caccctctgt	caaagagtgt	atggctctta	cattatatac	aactgcctga	4560
cttcatacag	tatcagtact	tagatcattt	gaaatgtgtc	cacgttttac	caaaatataa	4620
tagggtgaga	agctgagatg	ctaattgcc	ttgtgtattc	tcaaataatgt	caagctacgt	4680
acatggcctg	tttcatagag	tagtctataa	gaaattgatg	acttgattca	tccgaatggc	4740
tggctgtaac	acctgggttac	gcatgaacac	ctcttttcag	ttgtctcaag	acacctttct	4800
tttctgtact	tatcagacaa	ggactgaaag	gcagagactg	ctactgttag	acatttttag	4860
tcaagctttt	ccttggacat	agctttgtca	tgaagccct	ttacttctga	gaaacttcta	4920
gcttcagaca	catgccttca	agatagttgt	tgaagacacc	agaagaagga	gcatggcaat	4980
gccgaaaaca	cctaagataa	taggtgacct	tcagtgttgg	cttcttgacg	aatccagaga	5040
gacagacttg	ctcagtggga	tggatggcaa	agggctctac	caggtgaaag	gctggaaact	5100
tacacagcaa	cagtttgtgg	cccttttgtg	gaagagactg	ctaattgcc	gacggagtgc	5160
gaaaggattt	tttgtctcagg	tgagacgtgc	tgttttcgcc	agagactctg	gcttcatggg	5220
tgggtgtcag	gctctgtgac	cagtgaaggc	aggatagcat	cctgggtcaag	atatggatgc	5280
cggagccaga	tttatctgta	tttcaatccc	agttctattc	cttgccagtt	gtgtatccgc	5340
tggcaagtta	cttctctatg	cctcaatctc	ctcatctgta	aaatggggat	aataatatta	5400
cctgcaatac	agggttggtta	cgaaaataaa	aatgaatagg	tgcttagaat	ggggcctgac	5460
attagtaagt	gcttagtttt	gtgtgtgtat	atgttatttt	tattttggag	gagaacataa	5520
aaaggacaaa	gtgtagaaaa	actggttggg	tgtattcagc	tgtcataaca	tgagagttgt	5580
tatgcccaga	tgcacttgac	atgtgaattt	attagaaaca	tgatttttct	ctgagttgat	5640
gtttaactca	aactgataga	aaagatagg	cagaatatag	ttggccaaca	gagaagactt	5700
gttagactat	tgtctgcatg	tcagtgtttg	catgctaact	tgcttagtta	gaaagggtta	5760
attttttcac	tctataaaat	caagaaatat	agagaaaagg	tctgcagaga	gtctttcatt	5820
tgatgatgtg	gatattgtta	agagcgggag	tttggagcat	acagagctca	agttgaatcc	5880
tgactttgct	acttattggc	tatatgacct	tgggcaagct	gcttagtctc	tctgatcctc	5940
agttaccttt	gtttgttgat	gatgaccatt	gataacacaa	ccataaataa	tgacaacata	6000
gagatagttc	tcattatagt	agttgttata	cagaattatt	cactcaatgt	taattttctg	6060

cattgaaatc	ccagaacatt	agaattgggg	gcattatttg	aatctttaag	gttataagga	6120
atacatttct	cagcaataaa	tggaggaggt	tttgggttaa	cttataaaag	ataccaaggt	6180
catttttttt	cagagaagat	atggtagaaa	gtcttaggag	gttgaagaag	gaattggata	6240
tttattcttt	ctgagactat	catgggagat	aatgactatg	gttgtccatg	attggagccg	6300
ttgtgtaga	gttggtttta	ttatagtgtg	ggatttgaat	gggccatgtg	ttctcagacc	6360
tcagaataaa	aagagaaaac	tgaggccagt	ggggagcgtg	acttcacatg	ggtacacttg	6420
tgctagagac	agaaccagga	ttcaggactt	ctggctcctg	gtcctgggtt	catggcccaa	6480
tgtagtcttt	ctcagtcttc	aggaggagga	agggcaggac	ccagtgttct	gagtcaccct	6540
gaatgtgagc	actattttact	tcgtgaactt	cttggccttag	tgccctctgcc	aggtggccat	6600
aacctctggc	cttgtgtttg	cagagaaaag	gttttagttt	caggctccat	tgcttcccag	6660
ctgccaagaa	tgcccttggtg	cagcacagtc	ataggccctg	cattcctcat	tgccgtgctg	6720
gttggtcggg	gaggtgggct	ggactcgtag	ggatttgccc	cttggccttg	tttctaacac	6780
ttgccgtttc	ctgctgtccc	cctgccccct	ccactgcctg	ggtaaagatt	gtcttgccag	6840
ctgtgtttgt	ctgcattgcc	cttgtgttca	gcctgatcgt	gccacccttt	ggcaagtacc	6900
ccagcctgga	acttcagccc	tggatgtaca	acgaacagta	cacatttgct	aggtatgttt	6960
gtcttctaca	tcccaggagg	gggtaagatt	cgagcagacc	aaagatgttt	acgagggcca	7020
aggaatgga	cttcagaatt	acacggtgga	at			7052

<210> 23
 <211> 2534
 <212> DNA
 <213> Homo sapiens

<400> 23	
gggaagcatt	taaaaaaaaaa aaagtatata tatatatata tatatatata tgtaatgtga 60
attggcctct	ttttctctaa gcccacattt tcttcttaca tagttcaggt ttactttatt 120
ttttcctttc	cggtctgtga ccctgtattg cccgtagtgtg tggaaacatag catgtgtttg 180
tgacctgtgc	ctgttatttt tgtgctttct agttgtgcat gcaaagagta caaagttttc 240
ttgccctttc	ttggaaaatc ctgcttgtct gtgccaaagg gataattgtg aaagcacttt 300
tgaaatactt	aatgagttga ttttcttcaa attaaaaaaaa atatatataat gtatatgtgt 360
atgtacatgt	gtgtacacat acacaccttt atacatacag cccattttaa acaagctcca 420
ctttggagtg	ctctacgtca ccctgatgcc gaatacaggg ccagagtctg agatccttct 480
gggtggtttc	tgtgttttgt tcatttctgt tttaagagcc tgtcacagag aaatgcttcc 540
taaaatgttt	aatttataaa aacattttta tctctcgatt actggtttta atgaattact 600
aagctggctg	cctctcatgt acccacagca atgatgctcc tgaggacacg ggaaccctgg 660
aactcttaaa	cgccctcacc aaagaccctg gcttcgggac ccgctgtatg gaaggaaacc 720
caatcccgtg	agtgccactt tagccataag cagggcttct tgtgcttgtt gcttggtttg 780
atttctaata	tgctgcattt atcaactgca tgccacattg tgaccgccag catttgccct 840
ttgaattatt	attatgtttt atttacaata agcgaaggta gtaaccgaac taaattatct 900
aggaacaaac	gtttggagag tcttctaaca ccgyscaaag cacgtcatta cagacatttg 960
tttactgatt	tagaacctta atatttaatt taaatacgca ctttacactt actgatgaaa 1020
tgcttttctc	ttctttctct cccagccccct gtacttaagt gcttcaatag gctctcatta 1080
tatatgattt	ttaggttttg cttatcagct tcttcgcttt tataatctga aaagatggca 1140
tatgaatttt	tataaaaaagg gacactttct tcttctcaaa ttgtatattt ttattgtact 1200
ttccttcaaa	accccccttt aaaaagtaag cagtggataa ataaattcag tgaagcatcc 1260
atatgaccct	taagtgagtg taggggaagg gaggtcacca gatcactgtg agtgaagatg 1320
gtggagaggt	gaggatctta tgaggccgtg ctcaaggctg gtagaggtgg gttagtgttt 1380
ccagggttag	gcagaatctc agctgaggtc atgaaacaac agtgatctct gaaaaattat 1440
ggcaagggtg	gaagggtgctg gagaattgga gagggggcaa acttgacttt caagtttcaa 1500

tgggaagata	ggtgactctg	cacaccacag	aacagtgagc	atgataacct	gtttatacaa	1560
ggttctagag	cagattttcta	aatggatagc	tactgtgtgc	ttgtttgttc	ttaattagta	1620
ttggatagtt	actaaatact	tgtagtagct	tagtacataa	tgggtggtaa	atcctagcag	1680
ctaataattg	ttcccaaata	accagatgac	aaggatagag	aaggacacag	acacggccta	1740
tctggatttc	atgggtgcctt	tgattttcca	catgaagggt	gtgtagggaa	gatagaagca	1800
tgagatgaga	tgataatata	gttatctgga	ttcatcactg	gccagctgaa	ccatatgaac	1860
tcatggattg	atgctagctt	aggaaggctc	tgtaggagcc	agaactgggc	tgagagccag	1920
cccatagaga	caaaagaggc	ccggccctga	catcagaggg	ttcaaactg	atgtctgagc	1980
cccacctaca	gtctgccgga	ggtgggttga	aggaagagcc	tttatcctta	caattcttac	2040
tgaaattcaa	atTTTTtaggt	tttgcaaaaa	aatggtggac	ctgaaggaaa	tttgacagga	2100
gcatgtctca	gctgtatttta	aatttgtctc	agccaatccc	cttttgaatg	ttcagagtgt	2160
aagcttcagg	agggcagcgc	gtcttagtgt	gacttttctg	gtcagttcag	gtgctttaag	2220
gagacaatta	gagatcaatc	tggaaaactt	catttgaatt	tttaatacat	aagaaaacaa	2280
taagaaatag	ttaaaaatat	atattttatat	aatatatata	tgtgtgtgtg	tgtgtgtgtg	2340
tgtgtgtgtg	tatatatata	tatatTTTTat	ttattttattt	ttttttgaga	tggagtctcg	2400
ctctgttgcc	caggctggag	tgcagtggct	caatcttggc	tactgccac	ctctgcctcc	2460
caggttcaag	tgattctcct	acctcagcct	cctgagtagc	tgggattaca	agcatgtgcc	2520
accacactgg	ctaa					2534

<210> 24
 <211> 2841
 <212> DNA
 <213> Homo sapiens

<400> 24						
tcttgcagct	ctctactcat	ttttcagcac	atcgagcata	agatccagac	tctttcccag	60
gcctctctca	tctggctcct	ctcctcctcc	tttatcatta	ctcttcttcg	tagcttatcc	120
tactccagcc	atgctgtctt	cctattatct	ctaaaaarta	gaaatgcatt	tcttcctagg	180
gcctttgtac	ctgcacttgc	catcgctttt	gctcagaatg	ttctttttgc	caagcttttg	240
cccagcttgt	tctccatcat	tgttatgttt	tggctgaaat	gtcttctctt	agtaggttca	300
ttctcccag	tcactgtctt	tttattttgc	tttatttttg	gccatctaag	gttatcttat	360
tagtgtatTT	gttgttcgtc	tcctccatgg	gcatacacct	ccatgaaggc	aggtattttc	420
accttaggcc	ctcgaatata	ctggacagca	tctggcacgt	agtagatgct	caacgaatgt	480
ttgttgtgtg	agcaaatggg	tgggtgattg	gattgaactg	agttcagtat	gtaaatatTT	540
agggcctctt	tgcattctat	tttactttat	tataaaatga	tacataatga	tgatataaaT	600
gatgtcacag	tgtacaaggc	tgttgtggga	tcaagcaatc	aaatgagatc	atgcttgtct	660
tttccaaatg	gtgaggggaT	agatgcatgt	ttgtggttgt	tacggaatga	tcctgtgctc	720
ctgaggcaac	agaaaggcca	ggccatctct	ggtaatccta	ctcttgctgt	cttccctttg	780
cagagacacg	cctgccagg	caggggagga	agagtggacc	actgccccag	ttccccagac	840
catcatggac	ctcttccaga	atgggaactg	gacaatgcag	aacccttcac	ctgcatgccA	900
gtgtagcagc	gacaaaatca	agaagatgct	gcctgtgtgt	cccccagggg	caggggggct	960
gcctcctcca	caagtgagtc	actttcaggg	ggtgattggg	cagaaggggt	gcaggatggg	1020
ctggtagctt	ccgcttggaA	gcagggaatga	gtgagatatc	atgttggggag	ggtctgtttc	1080
agtctttttt	gtttttttgt	tttttttctg	aggcggagtc	ttgctctgtc	gccaggtctg	1140
gagtgtgtgt	gcatgatctt	gcctcactgc	aacctccacc	tcccagggtc	aagcgattct	1200
cctgcctcag	cctcctgagt	agctgggatt	acaggcacgc	accaccatgt	ctggctaatt	1260
tttgtgtttt	tagtagagat	agggtttcgc	cgtgtttggc	aggctggctc	ggaattcctg	1320
acctcaggtg	atccaccgcg	ctcggcctcc	caaagtgtct	ggattacagg	cgtgagccac	1380
tacgccacgc	cctgttttcag	tctttaactc	gcttcttgtc	ataagaaaaa	gcatgtgagt	1440
tttgagggga	gaagggtttg	accacactgt	gcccattgct	gtcccacagc	agtaaagtca	1500
caggacagac	tgtggcaggc	ctggcttcca	atcttggctc	tgcaacaaat	gagctggtag	1560

cctttgacag	gcctgggctt	gtttcttcac	ctctgaatta	gggaggctgg	accagaaaac	1620
tcctgtggat	cttgtcaact	ctgggtattct	tagagactct	gtttgggaag	gagtcctgag	1680
ccattttttt	tttcttgaga	atctcaggaa	gaggagtgtc	tatgatagct	ctctgctgct	1740
tttatcagca	accaaattgc	aggatgagga	caagcaattc	taaatgagta	caggaactaa	1800
aagaaggctt	ggttaccact	cttgaaaata	atagctagtc	caggtgcggg	gtggctcaca	1860
cctgtaatct	cagtattttg	ggatgccgag	gtggactgat	cacctaaggt	caggagtctg	1920
aaaccagctt	ggccaatgtg	gcgaaaccct	gtctctacta	aaaattcaaa	aattagccag	1980
gcatggtggc	acatgcctgt	aatcccagtt	acttgggagg	ctgaagcagg	agaattgctt	2040
gaacctggga	ggtggagggtc	gcagggagcc	aaaattgcgc	cactgtactc	cagcctgagc	2100
aacacagcaa	aactccatat	caaaaaataa	aatgaataaa	ataacagcta	atctagtcac	2160
cagtataact	ccagtgaaca	gaagatttat	taggcatagt	gaatgatggg	gcttcctaaa	2220
aatctcttga	ctacaaagaa	tctcattttca	atgtttattg	tttagatgtt	cagaataaat	2280
tcttgggaaa	gaccttggtc	tgggtgtaagt	gaattaccag	tgccgagggc	aggggtgaacc	2340
aagtctcagt	gctggttgac	tgagggcagt	gtctgggacc	tgtagtcagg	tttccggtca	2400
cactgtggac	atgggtcactg	ttgtccttga	tttgttttct	gtttcaattc	ttgtctataa	2460
agaccggtat	gcttggtttt	catgtgatga	cagagaaaac	aaaacactgc	agatatcctt	2520
caggacctga	caggaagaaa	catttcggat	tatctggtga	agacgtatgt	gcagatcata	2580
gccaaaaggt	gactttttac	taaacttggc	ccctgcctta	ttattactaa	ttagagggaat	2640
taaagaccta	caaataacag	actgaaacag	tgggggaaat	gccagattat	ggcctgattc	2700
tgtctattgg	aagttttagga	tattatccca	aactagaaaa	gatgacgaga	gggactgtga	2760
acattcagtt	gtcagcttca	aggctgaggc	agcctggtct	agaatgaaaa	tagaaatgga	2820
ttcaacgtca	aattttgcca	c				2841

<210> 25
 <211> 852
 <212> DNA
 <213> Homo sapiens

<400> 25		
gcatgctgga	gtgatagtga ccatgagttt ctaagaaaga agcataattt ctccatatgt 60	
catccacaat	tgaaatatta ttgttaattg aaaaagcttc taggccaggc acggtggctc 120	
atgcctgtaa	tcccagcact ttaggagcca aggcgggtgg atcacttgag gtcaggagtt 180	
tgagaccagc	ctggccaaca tggggaaacc ctgtctctac taaaaataca aaataagctg 240	
ggcgtgggtg	tgcgtgcctg taatcccagc tacttgggag gctgaggcag gagaactgct 300	
tgaatctggg	aggcggagggt tgcagtgagc tgagttcatg ccattgcatt ccagcctggg 360	
caacaagagc	gaaaccatct cccaaaagaa aaaaaaaaga aagaaaaagc ttctagtttg 420	
gttacatctt	ggtctataag gtggtttgta aattggttta acccaaggcc tggttctcat 480	
ataagtaata	gggtatttat gatggagaga aggcctggaag aggcctgaac acaggcttct 540	
tttctctagc	acaaccctac aaggccagct gattctaggg ttatttctgt ccgttcctta 600	
tatcctcagg	tggatattta ctctttttgc atcattagga ataggctcag tgctttcttt 660	
gaactgattt	tttgtttctt tgtctctgca gcttaaagaa caagatctgg gtgaatgagt 720	
ttaggtaagt	tgctgtcttt ctggcacgtt tagctcaggg ggaggatggg gttgtagggtg 780	
tgcttggatt	gaagaaaaggc ttggggattg tttgtcactc acacacttgt ggggtgccatc 840	
tcactgtgag	ga	852

<210> 26
 <211> 6289
 <212> DNA
 <213> Homo sapiens

<400> 26

gctttataga	gtttctgcct	agagcatcat	ggctcagtg	ccagcagccc	ctccagaggc	60
ctctgaatat	ttgatatact	gatttccttg	aggagaatca	gaaatctcct	gcaggtgtct	120
agggatttca	agtaagtagt	gttgtgaggg	gaatacctac	ttgtactttc	ccccaaacc	180
agattcccga	ggcttcttaa	ggactcaagg	acaatttcta	ggcatttagc	acgggactaa	240
aaaggtctta	gaggaaataa	gaagcgccaa	aaccatctct	ttgcaactgt	tttcaaccga	300
tttgccttc	tgggttttga	aggaacaggt	gggactgggg	acagaagagt	tcttgaagcc	360
agtttgtcca	tcatggaaaa	tgagataggt	gatgtggcta	cgtcaggggg	cccgaaggct	420
ccttgttact	gatttccgct	ttttctctct	gccttttccc	caagggccag	gacccctgga	480
tctctgggca	gagcagacgc	aggccccctat	aatagccctc	atgctagaaa	ggagccggag	540
cctgtgtata	aggccagcgc	agcctactct	ggacagtgc	gggttcccac	tctcccaact	600
ccccatctgc	ttgcctccag	acccacattc	acacacgagc	cactgggttg	gaggagcatc	660
tgtgagatga	aacaccattc	tttctcaat	gtctcagcta	tctaactgtg	tgtgtaatca	720
ggccaggctc	tccctgctgg	gcagaaacca	tgggagttaa	gagattgcca	acatttatta	780
gaggaagctg	acgtgtaact	tctgaggcaa	aatttagccc	tcctttgaac	aggaatttga	840
ctcagtgaac	cttgtagaca	ctcgcactga	gtctgctgct	gatgatactg	tgcacccac	900
tgtctgggtt	ttaatgtcag	gctgttcttt	taggtatggc	ggcttttccc	tgggtgtcag	960
taataactcaa	gcacttcctc	cgagtcaaga	agttaatgat	gccatcaaac	aaatgaagaa	1020
acacctaag	ctggccaagg	taaaatatct	atcgtaagat	gtatcagaaa	aatgggcatg	1080
tagctgctgg	gatataggag	tagttggcag	gttaaaccga	tcacctggca	gctcattggt	1140
ctgaatatgt	tggcatacag	agccgtcttt	ggcatttagc	gatttgagcc	agacaaaact	1200
gaattactta	gttgtagctt	taaaagtgt	ggtcaaaaac	aaatccagag	gccaggagct	1260
gtggctcatg	cctgtaatcc	tagcactttg	ggaggctgaa	gcgggtggat	cacttgaggt	1320
caggagtctg	agaccagcct	ggcctacatg	acaaaacccc	gtatctacta	aaaatacaaa	1380
aaaattagct	gggcttggtg	gcacacacct	gtaatcccag	ctacttggga	ggctgaggca	1440
ggagaattgc	ttgaaccctg	taggaagagg	ttgtagttag	ccaagatcgc	accgttgcac	1500
tccagcctgg	gcaacaagag	caaaactcca	tctcaaaaaa	caaattaaat	ccagagattt	1560
aaaagctctc	agaggctggg	cgcgggtggc	tacacctgtt	atcccagcat	tttgggatgc	1620
cgaggcgggc	aaagcacaag	gtcaggagtt	tgagaccagc	ctggccaaca	tagtgaaacc	1680
ctgtctctgc	taaaaacata	gaaaaattag	ccgggcatgg	tggcgtgcgc	ctgtaatccc	1740
agctactcgg	gaggctgagg	tgagagaatt	rcctgaaccc	gggaggcgga	ggttgtagtg	1800
agcccagatt	gcaccactgc	actccagcct	gggcgacaga	gcaagactcc	atctcaaaaa	1860
aagctctcag	aacaaccagg	tttacaaatt	tggtcagttg	gtaaataaac	tgggtttcaa	1920
acatactttg	ctgaaayaat	cactgactaa	ataggaaatg	aatctttttt	tttttttttt	1980
taagctggca	agctgggtctg	taggacctga	taagtactca	cttcatttct	ctgtgtctca	2040
ggtttcccat	ttttagggtga	gaattaaggg	gctctgataa	aacagaccct	aggattgtgg	2100
acagcagtga	tagtcctaga	gtccacaagt	ctgcttttga	gtgatggggc	catgtatctg	2160
gcacatctgc	aggcagagcg	tggttctggc	tcttcagatg	atgccggtgg	agcactttga	2220
ggagtcctca	ccccaccgtg	ataaccagac	attaaaatct	tggggctttg	catcccagga	2280
tttctctgtg	attccttcta	gacttgtggc	atcatggcag	catcactgct	gtagatttct	2340
agtcacttgg	ttctcaggag	ccgtttatct	aatggcttca	catttaattt	cagtgaacaa	2400
ggtagtggca	ttgctcttca	cagggcgcgc	ctgttgtcca	caggttccag	attgactgtt	2460
gccccttatc	tatgtgaaca	gtcacaactg	aggcaggttt	ctgttgttta	caggacagtt	2520
ctgcagatcg	atttctcaac	agcttgggaa	gatttatgac	aggactggac	accagaaata	2580
atgtcaaggt	aaaccgctgt	ctttgttcta	gtagcttttt	gatgaacaat	aatccttatg	2640
tttcttgagg	tactttcaac	tcatggtaaa	gttggcaggg	gcattcacaa	cagaaaagag	2700
caaactatta	actttaccag	tgaggcagta	cgggtgtagt	tagtgattca	gagaatttgc	2760
tttgccacca	gacataccag	gtaaccttga	ctaagttact	taacctatct	aaacctcagt	2820
tycctcatct	gtgaaatgga	gacagtaatc	atagctatct	ccaaactgtt	gtgagaattc	2880
aatgagttaa	aggtataagg	tcctcaccac	agcgcctgcc	cacatagtca	gtgatcacta	2940
tgtcctgaac	actgtaatta	cttcgccata	ttctctgata	atagtgtttt	gccttggtat	3000
gtgactagaa	tttctttctg	aggtttatgg	gcattggttg	tgggtatgca	cctgcctgca	3060

ggagcccggt	ttgggggcat	taccttgtac	ctggatatgtt	ttctttcagg	tgtggttcaa	3120
taacaagggc	tggcatgcaa	tcagctcttt	cctgaatgtc	atcaacaatg	ccattctccg	3180
ggccaacctg	caaaaggagg	agaaccctag	ccattatgga	attactgctt	tcaatcatcc	3240
cctgaatctc	accaagcagc	agctctcaga	gggtggctctg	taagtgtggc	tgtgtctgta	3300
tagatggagt	ggggcaaggg	agagggttat	ggagaagggg	agaaaaatgt	gaatctcatt	3360
gtaggggaac	agctgcagag	accgttatat	tatgataaat	ctggattgat	ccaggctctg	3420
ggcagaagtg	ataagtttac	gaattggctg	gttgggcttc	ttgaactgca	gaagagaaaa	3480
tgacactgat	atgtaaaaat	cgtaacattt	agtgaattca	tataaagtga	gttcaaaaaat	3540
tgттаattaa	attataattt	aattataagt	gtttaatcag	tttgatttgt	ttaaaaacca	3600
ctgtttttaa	tttggtggaa	tatgttttta	ttagcttgta	tctttaattc	ctaaattaa	3660
ctgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gaagtttaaa	3720
gccaggatga	gctagtttaa	agtatgcagc	ctttggagtc	atacagatct	gggtttgaat	3780
ctggctctcta	aactttatag	atgtatgata	ttaaatgagg	cagttcatgt	aaattgccaa	3840
gccagcact	cagcacagag	ttgatatttc	acacacatta	gatacctttc	ctgtatgtgg	3900
agcatggcag	ttcctgtttc	tgctttactc	ctacaggata	ctaataatag	acactaggat	3960
ctttatacca	agaccccatg	taatgggctt	atgagaccat	tcttcttata	aaaatctgac	4020
agaatttttg	tatgtgttag	atcaataggg	tgcatactgt	tattttcaag	ttgatttaca	4080
gccagaaata	ttaattttatt	tgagtagtta	cagagtaata	tttctgctct	catttagttt	4140
tcaagcccca	ctagtccttt	gtgtgtgaaa	atttacaact	tactgctctt	acaaggtcac	4200
gaacagtgga	ccaaagtga	tgccattaac	cactctgact	tccttcatta	gttttattgt	4260
gacagtggac	tcttttgacc	tcagtaatac	cagtttgga	tttacattgt	catattttta	4320
gacttaaaaa	tgatcatctt	aacctgaat	aaaatgtgtc	tggtgaacag	atgtttttcc	4380
ttggctgtgc	ctcagatata	tctgtgtgtg	tgtacgtgtg	tggtgtctct	tgtgtccatg	4440
tcctcactga	ttgagcccta	actgcatcaa	agacccctca	gattttcaca	cgctttttct	4500
ctccaggatg	accacatcag	tggatgtcct	tgtgtccatc	tgtgtcatct	ttgcaatgtc	4560
cttcgtccca	gccagctttg	togtattcct	gatccaggag	cgggtcagca	aagcaaaaca	4620
cctgcagttc	atcagtggag	tgaagcctgt	catctactgg	ctctctaatt	ttgtctggga	4680
tatggtaagg	acacaggcct	gctgtatctt	tctgatgtct	gtcagggcca	tggattgata	4740
tggataagaa	agaaagagct	ctggctatca	tcaggaaatg	ttccagctac	tctaaagatg	4800
tatgaaaaag	aaatagccag	aggcagggtga	tcactttcat	gacaccaaac	acagcattgg	4860
gtaccagagt	tcatgtcaca	ccagagggaa	aattctgtac	acaatgatga	aaattaatac	4920
cactaccact	taagttccta	tgtgacaact	ttcccaagaa	tcagagagat	acaagtcaaa	4980
actccaagtc	aatgcctcta	acttctctga	tgggttttaa	cctccagagt	cagaatgttc	5040
tttgctttac	taggaaagcc	atctgtcatt	tagaaaactc	tgtacatttt	atcagcagct	5100
tatccatcca	ttgcaaatat	tgtttttgtg	ccasccacaa	tatattgctt	ctatttggac	5160
caatatgggg	gatttgaagg	aattctgaag	ttctaattat	atttcaactc	tactttacaa	5220
tatctccctg	aaatatatct	ccctgtaact	tctattaatt	ataagctaca	cagagcaaat	5280
ctaattcttc	tcccaccgaa	caagtccctg	gatattttaa	aataactctc	atactctcat	5340
ttaacctgag	tattaccag	ataagatgat	atatgagaat	acacettgta	acctccgaag	5400
cactgtacaa	atgtgagcaa	tgatgggtga	gatgatgatg	agatctttgc	tgtttatacc	5460
aagcccctta	gactgtgtca	ctcttctgat	cgggttgtcc	ttgtatggcc	atgctgtata	5520
ttgtgaatgt	cccgttttca	aaagcaaaagc	caagaattaa	ccttgtgttc	aggctgtggg	5580
ctgaatggtt	atgggtccag	agggagttga	tctttagctc	acacttctat	tactgcagca	5640
caaagatttt	gcatttttga	aggagcaccg	tcttactggc	aacttagtgg	taaaccacaaa	5700
cctccatttc	acacaaatga	ttgtgaaatt	cgggtctcct	tcattctata	caaattcatt	5760
tgattttttt	gaaactaaac	tttatattta	tccatattaa	attacatggg	ttttattttt	5820
gttttatctt	gattcagtaa	ttactccttt	cagtaaacac	agactgagtg	ctgtgtgtct	5880
gacttatgcc	aggcataggt	gattcagaga	tgaaagggtca	agtccctgaa	cccctctctt	5940
gtcttcctgg	gtattatctg	tccctccctg	ctttagagct	cctgaaattt	gctagaagca	6000
tgtcttcac	taagttgttg	ataaacacat	caagtaggat	tggactgagg	cagagccctg	6060
tagtctgaag	ctgcagttct	tctagcggct	gacaagcccc	actatcactt	ccctgctggt	6120

gctttgctct	gccagctgtg	aattctcata	attgtcctat	cgtaagctct	ttattttctgc	6180
attttactgc	ttgatacact	gtcaggacag	actttaaaat	tattctcagt	gcatgaaac	6240
aattctgaca	ttcatgttat	gagcagttac	ctcataaata	gattacatg		6289

<210> 27
 <211> 4244
 <212> DNA
 <213> Homo sapiens

<400> 27						
aaattactct	gactgggaat	ccatcgttca	gtaagtttac	tgagtgtgac	accttggtctt	60
gactgttgga	aagacagaaa	gggcatgtag	tttataaaat	cagccaagg	gaaaatgctt	120
gtcaaaatgt	attgtcgggt	atgttgatta	atagtttatg	tggcttcatt	aattcagagt	180
tactctccaa	tatgtttatc	tgccctttct	tgtctgataa	tggtgaaaac	ttgtgtgatg	240
cattgtatat	ttgatttagg	gggtgaactgg	atgtctttgt	tttacttttt	agtgcatta	300
cgttgtccct	gccacactgg	tcattatcat	cttcatctgc	ttccagcaga	agtcctatgt	360
gtcctccacc	aatctgcctg	tgctagccct	tctacttttg	ctgtatgggt	aagtcacctc	420
tgagtgaggg	agctgcacag	tggataaggc	atgttggtgc	cagtgtcaga	aggagggcag	480
ggactctcag	tagacactta	tctttttgtg	tctcaacagg	tggccaatca	cacctctcat	540
gtaccagcc	tcttttgtgt	tcaagatccc	cagcacagcc	tatgtgggtg	tcaccagcgt	600
gaacctcttc	attggcatta	atggcagcgt	ggccaccttt	gtgctggagc	tgttcaccga	660
caatgtgagt	catgcagaga	gaacactcct	gctgggatga	gcctctctgg	gagccagagg	720
acagtgttta	attgtgatct	tattccactt	gtcagtggta	ttgacactgc	tgactgcctt	780
gtcctgtctt	cagagtctgt	cttccctgag	aaggcaaagc	acctttcttt	cttgctgtgc	840
cttacatttt	gctgggtcaag	cctttcagtt	tcttttgaca	gtttttttta	cttctttctt	900
ttttcaatgt	tgtctttacc	aagagttagt	cctctgcctt	ccactttaca	catgagagct	960
gggagcagca	ttcagtccta	aggctttttac	catcacctct	cttggtgttt	ttattgtcat	1020
ctctaagatc	aatgccttta	gccttgatca	taaccttgaa	ctctaacttc	aaattctcac	1080
ttgcctagtg	gattgctcca	tttagatagt	atatagatac	cccaacctgg	atatgtccta	1140
gttttctttc	cccttggaac	ttaatgcttt	tcttgccatc	cctgtcacac	tcagtggcac	1200
taccatccac	tgggttgccc	aagctggctc	ttagagttat	cctagatgct	tgctttgctg	1260
ttgcagattt	cccacattca	actggttatg	ttgtcagttc	ttccaggtat	ggacctctaa	1320
aataaggcct	cctctccatt	ccgggtgtca	ttgcctttgt	ccaaacacag	cacacaaggc	1380
cttttacagt	tgcacaactc	ttcctgtcca	taccaccac	acctttccc	agctgtaagc	1440
ttcagatgag	ttgcctccaa	ccaccatgct	cctgtaggcc	tggcttgaaa	tgcccttctt	1500
ctgtcacagg	gtctggtagt	atatcccttg	cccttcaaga	tttagctaaa	atgtgaagct	1560
ttccttacct	gctgggaggt	gttctctctt	ttctctgtgc	tctcagagtc	cttagtccat	1620
gcctccagta	caacgtacat	ccacttacat	ggtaatttcc	tgtttacata	cttttcctac	1680
tcggagtgga	gtctgtttct	taataatttt	gcctctccca	tgccctagca	cagtgcaccc	1740
agcgtatagc	cccttattca	gttggttagat	atgtggccac	tggtgccttg	tgggatcata	1800
agttctgatg	tatttgagaa	gaatttctaa	aattctgaca	aaatcctgaa	actcaaatat	1860
tgaccagac	atgagcaatt	tgtttttcaa	atgctaagg	atttttaatg	gatttgcttt	1920
aattaaatct	agcctgtttc	taagctttat	tcattatttc	tccatactca	gagcatttct	1980
ccagattttc	taaagaatag	aattttattg	ctacatatca	tcagctatgc	ctgctgctat	2040
ttaattggta	tctgaattaa	aaggctctgg	ttgtccctag	agaatcaa	tttttcttca	2100
ctcccatatt	tcagaacttg	atacattttt	aggataaacc	atgaatgaca	cccgtttctt	2160
ctccctcacc	ctcccttccc	tcccattttt	tttttttttt	tttttttagaa	gctgaataat	2220
atcaatgata	tctgaagtc	cgtgttcttg	atcttcccac	atttttgcct	gggacgaggg	2280
ctcatcgaca	tggtgaaaaa	ccaggcaatg	gctgatgccc	tggaaagggt	tgggtgagtga	2340

agcagtggtgct	gtaggatgct	ttaatggaga	tggcactctg	cataggcctt	ggtaccctga	2400
actttgtttt	ggaaagaagc	aggtgactaa	gcacaggatg	ttccccacc	cccatgcccc	2460
gtgacagggc	tcatgccaac	acagctgggt	gtggcatggg	ttttgtgaca	caaccatttg	2520
tctgtgtctc	tgatagcatt	gagaaaagt	aaagggcagt	tttgaaggta	aggaaaatag	2580
tgttatttgc	ttggatccac	tggctcatgc	cactgtctgg	gttggttaga	agcactggaa	2640
aagtcaaac	ataactttga	gaattaggtg	atcaggggat	cagaaggaaa	gatgcaaact	2700
ttggctcttt	taggcgaatc	atgtgcctgc	agatgaggtc	atattattatc	ttttacacag	2760
tctataaaat	tataatgtat	tacatctttt	tctaccttta	gaatggttaa	aaatatttct	2820
ccggtagcca	tatgattatt	attcatccat	tagataatat	agtcaaattg	gccatgttat	2880
ttactgttca	tagaagaggg	gcttttttgc	acttgggcta	caaaggagat	atgtaaggaa	2940
tttaagggaat	ggttacatgg	aactagat	aattgaatct	agtggtttaa	ttgattcact	3000
aggatatatg	ctactgaaag	gggaatctgc	ttaaagtgtc	ttctgatatt	tattattact	3060
aaaacttaga	atattattaa	aatactgact	gtgaaaatta	cttgggtcgt	ttgccttttt	3120
aaaaggattt	ttggcatgtc	tcattaaaaa	aagaaatact	agatatcttc	agtgaagtta	3180
caaatcgaat	acacattggc	tctgaaattc	tgattgatac	tgggtcataa	aaagttttcc	3240
caaatcagac	ttggaaagt	atcactctct	tgttactctt	ttttccttgt	catgggtgat	3300
agccatttgt	gtttatttga	agatcgggtg	attttaagga	acataggccc	aaatttgagg	3360
aagggccatg	gtttttgatc	cctccattct	gaccggatct	ctgcattgtg	tctactaggg	3420
gagaatcgct	ttgtgtcacc	attatcttgg	gacttggtgg	gacgaaacct	cttcgccatg	3480
gccgtggaag	gggtggtgtt	cttctcatt	actgttctga	tccagtacag	attcttcac	3540
agggccaggt	gagctttttc	ttagaaccgc	tggagcacct	ggttgagggt	cacagaggag	3600
gcgcacaggg	aaacactcac	caatgggggt	tgcattgaac	tgaactcaa	atatgtgata	3660
aaactgattt	tctgatgtg	ggcatccgc	agccccctcc	ctgcccctcc	tggagactgt	3720
ggcaagtagg	ttttataata	ctacgttaga	gactgaatct	ttgtcctgaa	aaatagtttg	3780
aaaggttcat	ttttcttgtt	ttttcccca	agacctgtaa	atgcaaagct	atctcctctg	3840
aatgatgaag	atgaagatgt	gaggcgagg	agacagagaa	ttcttgatgg	tggaggccag	3900
aatgacatct	tagaaatcaa	ggagttgacg	aaggtgagag	agtacagggt	acaatagctc	3960
atcttcagtt	tttttcagct	ttatgtgtg	taaccagca	gtttgctgac	ttgcttaata	4020
aaagggcatg	tgttcccaaa	atgtacatct	ataccaaggt	tctgtcaatt	ttattttaaa	4080
aacaccatgg	agacttctta	aagaattctt	actgagaatt	cttttgtgat	atgaattccc	4140
attctcgaat	actttgggtt	tatatgttta	catttatgtg	ttagttatta	aaacatacta	4200
atattgtata	tctagtcaaa	ctgagtagag	agataatggt	gatt		4244

<210> 28

<211> 5023

<212> DNA

<213> Homo sapiens

<400> 28

ttttaaaata	cctgcaatac	atatatatgt	tgaatagatg	aaaaattatg	tagatgataa	60
tgaatgatac	ggttctaaaa	agacagggtta	aaaagtaagt	tcacttttat	tttgagcttc	120
agaatcattc	agaagccagt	cgccacaaac	gcagaccaag	gctcttggca	catcaaatat	180
gcctatggct	taggggttatt	gacaagtctt	atgttgacgt	gtatgtgggt	tatagtctctg	240
ccttccacag	ttgcttggga	gagctgtgag	tcactgaggc	ttatgaatgt	ttacattttg	300
tttgttgacg	atatatagaa	ggaagcggaa	gcctgctgtt	gacaggattt	gcgtgggcat	360
tcctcctggt	gaggtaaaga	cactttgtct	atattgcgtt	tgtccctatt	agttcagact	420
atctctaccc	aatcaagcaa	cgatgctcgt	taagaggtaa	aagtggattt	taaaggcttc	480
tgtattttatg	ccaggatgga	gcaattagtc	atcgagaaga	gagggaccct	gtatgtcaag	540
agaatgattt	cagagaatcc	aatacaattt	aagaaaaagc	atggggctgg	gcgcagtgat	600
tcactcctgt	aatcccagca	ctttgggagg	ccgaggtggg	cggactcacg	aggtcaggag	660
attgagacca	tcctggccaa	catggtgaaa	ccccatctct	actataaata	caaaaattag	720

ctgggcatag	tagtgcattc	ctgtagtccc	agctactcgg	gaggctgagg	caggagaatt	780
gcttgaacct	aggaggggga	ggttgcccag	attgcgctgc	tgactccag	cctggtgaca	840
gagtgagact	catgtcaaca	acaaaaacag	aaaaagcacg	cacatctaaa	acatgctttt	900
gtgatccatt	tgggatggtg	atgacattca	aatagttttt	taaaaataga	ttttctcctt	960
tctggtttcc	gtttgtgttc	ttttatgccc	ttttgccaga	gtaggtggtg	caatttggtc	1020
agctggcttt	cattactggt	tttcacacat	taactttggc	ctcaacttga	caactcaaat	1080
aatatattata	aatacagcca	cacttaaaat	ggccccatta	tgaaatacat	atttaaatat	1140
ctatacgatg	tgttaaaacc	aagaaaatat	ttgattcttc	tctgatattt	aagaattgaa	1200
ggtttgaggt	agttacgtgt	taggggcatt	tatattcatg	tttttagagt	ttgcttatac	1260
aacttaatct	ttccttttca	gtgctttggg	ctcctgggag	ttaatggggc	tggaaaatca	1320
tcaactttca	agatgttaac	aggagatacc	actgttacca	gaggagatgc	tttccttaac	1380
aaaaataggt	gagaaaagaa	gtggccttgta	ttttgctgca	aagactttgt	ttttaattta	1440
tttaaagaaa	taggttggtta	tttttgatta	cagtgggtatt	tttagagttc	ataaaaaatgt	1500
tgaaatatag	taaagggtaa	agaagcacat	aaaatcatcc	atgatttcaa	tatctagaga	1560
taatcacaat	ttacatttcc	tttcagtctc	attctcttct	tttaacagct	ttattcaggt	1620
ataattttaca	tacaatataa	tttgcttggt	ttttaagagt	ataatttagt	gatttttggt	1680
aaattgagag	ttttgcaacc	atcaccacaa	tccagtttta	gaacttttcc	atcaccaccac	1740
atctgtctta	tatacacata	taaatgtgcc	atacaattga	gatcatactg	tatgtagaat	1800
ttaaaatttag	tttttattgt	taatgagtgt	attatgaata	tttcccagtg	ggttacattt	1860
cctaagatgt	ggaattttac	attgctacat	aaaatcccc	tatgtacatg	tacctataat	1920
ttatttaata	aattccttat	aaatggtgga	cacattagtt	tccatttttc	actatgtaaa	1980
tatgtccctg	tatacatctt	ttattatttc	ctcaggaaca	attcctacaa	agtaaattgc	2040
cctctctaaa	gagcatacaa	attgactgag	ccaccgttag	gccattttct	gagactgcac	2100
aggtcacaaa	gcaatctgat	ctttgggaat	acagctacat	tttataggct	tcttagataa	2160
tgttactcta	agtactttaa	atatgtgggg	cttctctggg	cttttttttt	tttgagacgg	2220
agtttcactc	ttactgcccc	ggctggagag	caatggcgcg	accttggtct	actgcaacct	2280
ccgctccca	ggttcaagcg	attctcctgc	ctcagcctcc	tgagtagctg	agattacagg	2340
tgcccgccac	aatgcctgcc	taattttttt	gtattttcag	tagagatggg	gtttcaccat	2400
gttggccaga	ctgggtctga	gctcctgacc	tcagggtgatc	cacctgcctc	agcctcccaa	2460
agttctggga	ttacaggcat	gagccactgc	gcccggcttc	tctggactta	ttatgtggag	2520
agatagtaca	aggcagtggc	tttcagagtt	ttttgaccat	gaccgttgtg	ggaaatacat	2580
tttatatctc	aacctagtat	gtacacacag	acatgtagac	acatgtataa	cctaaagttt	2640
cataaagcag	tacctactgt	tactaattgt	agtgcactct	gctatttctt	attctacctt	2700
atactgcgtc	attaaaaaag	tgctgggtcat	gaccactaa	atttatttcc	caaaccacta	2760
atgaacaatg	actcacaatt	tgaacacact	ggacaggggg	atagccaata	aaattgaaaa	2820
gagcaaggaa	attaatgtat	tcatgatctc	ctctcctgtc	tcttacattt	ttgcagtagc	2880
aatgtaaagg	aatcctaaga	gaacagacat	tctgggaata	gcaggcctag	cgctgcacaa	2940
ctgcttttct	aggcttgctc	ctagtaccaa	gctcctgacg	catatagcag	tggcagtaat	3000
aaccagccca	tagtaagggt	tgtcacaggg	actgggtgta	agaactgatt	tgrttggtat	3060
agctgtgagg	gcctggcacg	gtgtccacgt	gtgcctcaat	cctaattctg	aaaaaggctg	3120
accctggggg	tgctaattag	atacacagag	aggaatgaat	gctgccagaa	ggccaagtcc	3180
atggcaatgc	cgctgtggct	gaggtgcagt	catcagtctg	gaacgtgaac	actgaacttc	3240
tctcacatgt	gattcttcac	ttgactggct	tcatagaacc	ccaaagccac	cccaccacca	3300
cataaattgt	gtctctaggt	tctgtgttgc	tcacactcaa	aatttctggg	ccttctcatt	3360
tggtgcatgt	gaatgggtgca	tatgagtga	gtctaggatg	gggccttagc	gttaaagccc	3420
tggggtagtg	tgactgagat	tgttggtaaa	gaatgtgcag	tggttggcat	gacctcagaa	3480
attctgaaat	gggactgcac	ctgcagactg	aagtgttcag	agagccaggg	aggtgcaagg	3540
actggggagg	gtagaggcag	gaacctgcc	tgccaggaag	agctagcatc	ctgggggcag	3600
aaaggctgtg	ctttcaagta	gcagcagatg	tatttggtatc	tttgtaatgg	agaagcatac	3660
tttacaggaa	cattaggcca	gattgtctaa	ccagagtatc	tctacctgct	taaaatctaa	3720
gtagttttct	tgtcctttgc	agtatcttat	caaacatcca	tgaagtacat	cagaacatgg	3780

gctactgccc	tcagtttgat	gccatcacag	agctgttgac	tgggagagaa	cacgtggagt	3840
tctttgccct	tttgagagga	gtcccagaga	aagaagttgg	caaggtagctg	tgggcacctg	3900
aaagccagcc	tgtctccttt	ggcatcctga	caatatatac	cttatggctt	ttccacacgc	3960
attgacttca	ggctgttttt	cctcatgaat	gcagcagcac	aaaatgctgg	ttctttgtat	4020
ctgctttcag	ggtggaaaacc	tgtaacggtg	gtggggcagg	gctgggtggg	cagagaggga	4080
gtgctgctcc	caccacacga	gtcccttctc	cctgcttttg	ctcctcacca	gttgtcagggt	4140
tatgattata	gaatctagtc	ctactcagtg	aaagaacttt	catacatgta	tgtgtaggac	4200
agcatgataa	aattcccaag	ccagacccaa	gtcaaggtgc	tttttatcac	tgtaggttgg	4260
tgagtgggcg	attcggaaac	tgggcctcgt	gaagtatgga	gaaaaatatg	ctggtaacta	4320
tagtggaggc	aacaaacgca	agctctctac	agccatggct	ttgatcggcg	ggcctcctgt	4380
ggtgtttctg	gtgagtataa	ctgtggatgg	aaaactgttg	ttctggcctg	agtggaaaac	4440
atgactgttc	aaaagtccta	tatgtccagg	gctgttgtat	gattggcttg	tcttcccca	4500
gggacagcag	agcaaccttg	gaaaagcaga	gggaagcttc	tcccttggca	cacactgggg	4560
tggctgtacc	atgcctgcag	atgctcccaa	atagaggcac	tccaagcact	ttgtttctta	4620
gcgtgattga	ggctggatat	gtgatttgat	ctttctctgg	aacattcttt	ctaatcatct	4680
ttgtgttcat	tccctgaaaa	tgaagagtgt	ggacacagct	ttaaaatccc	caaggtagca	4740
actaggtcac	agttccttac	acacggatag	atgaaaaaca	gatcagactg	ggaagtggcc	4800
cttgaccttt	tttcttctgt	agataagagc	attgatgtta	ttacgggaag	aagcctttga	4860
ggcttttatg	tattccacct	cggctctgga	tttgtttctg	taaggctaac	agttgcaata	4920
tactagggtg	atctgagtga	gctggaatta	aaaaaaaaaa	ggaatttcac	cccaatctta	4980
tactgacttc	aatagagggt	tcagacaaaa	agttgttttg	tat		5023

<210> 29
 <211> 5138
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(5138)
 <223> n = a, t, c, or g

<400> 29						
ngccnngttn	aaaangaaaa	tttnnnnnaa	attnaanntt	anngngngnn	tttccccaga	60
aaaaacnaaa	angatttccn	cccngggggg	ncceccnant	cnaaaaggcc	ccncttnttt	120
gnngngaggg	aaagnttttt	ttggaatttt	taattttttg	tccccaaaa	cctattattg	180
agaatttaat	tacataaaaa	agtactcaga	atattttgag	ttcctgcac	aataagacat	240
ttataataat	gaccttggtt	acaaatgaat	ttgaaagtta	ctctaattct	ttgattcatc	300
aagaaataac	tagaatggca	agttaaaatt	taagctgttt	caaagatgct	tctgcattta	360
aaaacaaatt	tatctttgat	tttttttccc	cccagcaaat	aagacttatt	ttatttcta	420
tacaggatga	accaccaca	ggcatggatc	ccaaagccc	gcggttcttg	tgggaattgtg	480
ccctaagtgt	tgtcaaggag	gggagatcag	tagtgcttac	atctcatagg	tccgtagtaa	540
agctctgggt	tctcactgt	gggatgtttt	aactttccaa	gtagaatatg	cgatcatttt	600
gtaaaaatta	gaaaatacag	aaaagcaaa	agtaaaacaa	ttattacctg	aaattatata	660
tgcatattct	tacaaaaatg	caagcccagt	ataaatactg	ctctttttca	cttaatatat	720
tgtaaacatt	attccaagtc	agtgcattta	ggtgtcattt	cttatagctg	gatagtattc	780
cattaggata	tactcttatt	taactattcc	cccttttgta	gacatttgga	ttattttcaa	840
cttgttcaca	attgtaaaca	ccactacact	gaacagcatc	atccctatat	ccacatgtac	900
ttgtaacaga	atacaattcc	ctaggaagct	ggaatgctgg	aagtcatggt	gatgttctca	960

tggttacaga	gaatctctct	aaaactaaaa	cctctttctg	ttttaccgca	gtatggaaga	1020
atgtgaagct	ctttgcaacta	ggatggcaat	catggtcaat	ggaaggttca	ggtgccttgg	1080
cagtgtccag	catctaaaaa	ataggttaata	aagataat	ctttgggata	gtgcctagt	1140
agaaggcttg	atatttattc	ttttgtgagt	atataaat	tgccctctaaa	ataaagggaa	1200
ataaaaactga	gcaaaacagt	atagtggaaa	gaatgagggc	tttgaagtcc	gaactgcatt	1260
caaattctgt	ctttaccatt	tactgggtct	gtgactcttg	ggcaagttac	ttaactactg	1320
taagagttag	tttccctgga	agatctacct	cctagctttg	tgctatagat	gaaatgaaaa	1380
aaatttacat	gtgccagtac	tgggtgagagc	gcaagctttg	gagtcacaca	caaatgggtt	1440
tgcatcctgg	ccctaccaat	tatgagctct	gagccatggg	caagtgacta	actccctggg	1500
cctcagtttc	tctgtaacat	ctgtcagact	tcatgggtcc	aggtgaggat	taaaggagat	1560
catgtattta	cagcacatgg	catggtgctt	cacataaaat	aagtatttag	taaatgataa	1620
ctggttcctt	ctctcagaaa	cttatttctg	ggcctgccag	gggccgccct	ttttcatggc	1680
acaagtggg	ttcccagggg	tcagtattct	tttaaatagt	tttctggaga	tcctccattt	1740
gggtattttt	tcctgctttc	aggtttggag	atggttatac	aatagttgta	cgaatagcag	1800
ggtccaaccc	ggacctgaag	cctgtccagg	atctctttgg	acttgcat	cctggaagt	1860
ttcyaaaaga	gaaacaccgg	aacatgctac	aataccagct	tccatcttca	ttatcttctc	1920
tggccaggat	attcagcatc	ctctcccaga	gcaaaaagcg	actccacata	gaagactact	1980
ctgtttctca	gacaacactt	gaccaagtaa	gctttgagtg	tcaaaacaga	ttacttctc	2040
aggggtgga	ttcctgcccc	gacactcccg	cccataggtc	caagagcagt	ttgtatcttg	2100
aattggtgct	tgaattcctg	atctactatt	cctagctatg	ctttttacta	aacctctctg	2160
aacctgaaaa	gggagatgat	gcctatgtac	tctataggat	tattgtgaga	atttactgta	2220
ataataacca	taaaaactac	catttagtga	gcacctacca	tgggcccaggc	attttacttg	2280
gtgcctaatac	ctattttaaat	tagataaaaa	agtaccaa	aggtcctgac	acttaagaag	2340
tactcagtaa	atattttctt	ccctcttccc	tttaatcaag	accgtatgtg	ccaaagtaaa	2400
tggatgactg	agcagttggg	gatgtagggg	tggggggcga	tatagaaagt	cagtttttgg	2460
ccgggcgtgg	tggctcatgc	ctgtaatccc	agcactttgg	gaggctgagg	agcaggcaga	2520
tcatgaggtc	aggagatcca	gataatcctg	gccaacaggg	tgaacccccg	tctctactaa	2580
aaatacaaaa	attagctggg	catggtgggtg	cgcacttgta	gtcccagcta	cttgcgaggc	2640
tgaggcagga	gaattgctcg	aacccaggag	gtggagggtta	cagtgagcca	aggtctcgcc	2700
actgcactcc	agcctgggga	cagagcaaga	ccccatttca	aggggggaaa	aaaagtctat	2760
ttttaagttg	ttattgcttt	tttcaagtat	tcttccctcc	ttcacacaca	gttttctagt	2820
taatccattt	atgtaattct	gtatgctcct	acttgaccta	atttcaacat	ctggaaaaat	2880
agaactagaa	taaagaatga	gcaagttgag	tggatattat	aaaggtccat	cttaatcttt	2940
taacaggtat	ttgtgaactt	tgccaaggac	caaagtgatg	atgaccactt	aaaagacctc	3000
tcattacaca	aaaaccagac	agtagtggac	gttgacgttc	tcacatcttt	tctacaggat	3060
gagaaaagtga	aagaaagcta	tgtatgaaga	atcctgttca	tacgggggtg	ctgaaagtaa	3120
agaggaaacta	gactttcctt	tgcaccatgt	gaagtgttgt	ggagaaaaga	gccagaagtt	3180
gatgtgggaa	gaagtaaact	ggatactgta	ctgatactat	tcaatgcaat	gcaattcaat	3240
gcaatgaaaa	caaaattcca	ttacaggggc	agtgcctttg	tagcctatgt	cttgtatggc	3300
tctcaagtga	aagacttgaa	tttagttttt	tacctatacc	tatgtgaaac	tctattatgg	3360
aacccaatgg	acatatgggt	ttgaactcac	actttttttt	ttttttttgt	tcctgtgtat	3420
tctcattggg	gttgcaacaa	taattcatca	agtaatcatg	gccagcgatt	attgatcaaa	3480
atcaaaaagg	aatgcacatc	ctcattcact	aagccatgcc	atgccagga	gactggtttc	3540
ccggtgacac	atccattgct	ggcaatgagt	gtgccagagt	tattagtgcc	aagtttttca	3600
gaaagtttga	agcaccatgg	tgtgtcatgc	tcacttttgt	gaaagctgct	ctgctcagag	3660
tctatcaaca	ttgaatatca	gttgacagaa	tggtgccatg	cgtggctaac	atcctgcttt	3720
gattccctct	gataagctgt	tctgggtggc	gtaacatgca	acaaaaatgt	gggtgtctcc	3780
aggcacggga	aacttggttc	cattgttata	ttgtcctatg	cttcgagcca	tgggtctaca	3840
gggtcatcct	tatgagactc	ttaaatatac	ttagatcctg	gtaagaggca	agaatcaac	3900
agccaaactg	ctggggctgc	aactgctgaa	gccagggcat	gggattaaag	agattgtgcg	3960
ttcaaaccta	gggaagcctg	tgcccat	tcctgactgt	ctgctaacat	ggtacactgc	4020

atctcaagat	gtttatctga	cacaagtgta	ttatttctgg	ctttttgaat	taatctagaa	4080
aatgaaaaga	tggagttgta	ttttgacaaa	aatgtttgta	ctttttaatg	ttatttggaa	4140
ttttaagttc	tatcagtgac	ttctgaatcc	ttagaatggc	ctctttgtag	aaccctgtgg	4200
tatagaggag	tatggccact	gcccactatt	tttattttct	tatgtaagtt	tgcatatcag	4260
tcatgactag	tgccatagaa	gcaatgtgat	ggtcaggatc	tcatgacatt	atatttgagt	4320
ttctttcaga	tcathtagga	tactcttaat	ctcacttcac	caatcaaata	ttttttgagt	4380
gtatgctgta	gctgaaagag	tatgtacgta	cgtataagac	tagagagata	ttaagtctca	4440
gtacacttcc	tgtgccatgt	tattcagctc	actgggtttac	aaatataggt	tgtcttgagg	4500
ttgtaggagc	ccactgtaac	aatactgggc	agcctttttt	tttttttttt	taattgcaac	4560
aatgcaaaaag	ccaagaaaag	ttaaggggtca	caagtctaaa	caatgaattc	ttcaacaggg	4620
aaaacagcta	gcttgaaaac	ttgctgaaaa	acacaacttg	tgtttatggc	atttagtacc	4680
ttcaaaataat	tggttttgca	gatattggat	accccatata	atctgacagt	ctcaaatttt	4740
tcatctcttc	aatcactagt	caagaaaaaa	tataaaaaca	acaaataact	ccatatggag	4800
catttttctag	agttttctaa	cccagttctta	tttttctagt	cagtaaacad	ttgtaaaaat	4860
actgtttcac	taatacttac	tgttaactgt	cttgagagaa	aagaaaaata	tgagagaact	4920
attgtttggg	gaagttcaag	tgatctttca	atatcattac	taacttcttc	cactttttcc	4980
agaatttgaa	tattaacgct	aaagggtgta	gacttcagat	ttcaaattaa	tctttctata	5040
ttttttaaat	ttacagaata	ttatataacc	cactgctgaa	aaagaaacaa	atgattgttt	5100
tagaagttaa	aggtcaatat	tgatttttaa	atattaag			5138

<210> 30
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 30	
gtgttcctgc	agagggcatg
	20

<210> 31
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 31	
cacttcagtc	aacagctgac
	20

<210> 32
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 32	
ctttgcgcac	gtccttcacg c
	21

<210> 33
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 33
gacatcagcc ctcagcatct t 21

<210> 34
<211> 19
<212> DNA
<213> Homo sapiens

<400> 34
caacaagcca tgttccctc 19

<210> 35
<211> 18
<212> DNA
<213> Homo sapiens

<400> 35
catgttccct cagccagc 18

<210> 36
<211> 19
<212> DNA
<213> Homo sapiens

<400> 36
cagagctcac agcagggac 19

<210> 37
<211> 21
<212> PRT
<213> Homo sapiens

<400> 37
Cys Ser Val Arg Leu Ser Tyr Pro Pro Tyr Glu Gln His Glu Cys His
1 5 10 15
Phe Pro Asn Lys Ala
20

<210> 38
<211> 14
<212> DNA
<213> Homo sapiens

<400> 38
gcctgtgtgt cccc 14

<210> 39
<211> 14
<212> DNA
<213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(14)
 <223> n = t or c

<400> 39
 gcctgtgngt cccc

14

<210> 40
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 40
 aagaagatgc tgcctgtgtg tccccaggg gcaggggggc tgcct

45

<210> 41
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 41
 Lys Lys Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro
 1 5 10 15

<210> 42
 <211> 15
 <212> PRT
 <213> Mus musculus

<400> 42
 Lys Lys Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu Pro
 1 5 10 15

<210> 43
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 43
 Lys Lys Met Leu Pro Val Arg Pro Pro Gly Ala Gly Gly Leu Pro
 1 5 10 15

<210> 44
 <211> 5
 <212> PRT
 <213> Caenorhabditis elegans

<400> 44
 Leu Leu Gly Gly Ser
 1 5

<210> 45
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 45
 aagaagatgc tgcctgtgcg tccccacagg gcaggggggc tgcct 45

<210> 46
 <211> 14
 <212> DNA
 <213> Homo sapiens

<400> 46
 gcctacttgc agga 14

<210> 47
 <211> 14
 <212> DNA
 <213> Homo sapiens

<400> 47
 gcctacttgc ggga 14

<210> 48
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 48
 tgggggggct tgcctactt gcaggatgtg gtggagcagg caatc 45

<210> 49
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 49
 Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile
 1 5 10 15

<210> 50
 <211> 15
 <212> PRT
 <213> Mus musculus

<400> 50
 Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile
 1 5 10 15

<210> 51

<211> 15
 <212> PRT
 <213> Homo sapiens

<400> 51
 Trp Gly Gly Phe Ala Tyr Leu Arg Asp Val Val Glu Gln Ala Ile
 1 5 10 15

<210> 52
 <211> 12
 <212> PRT
 <213> Caenorhabditis elegans

<400> 52
 Phe Met Thr Val Gln Arg Ala Val Asp Val Ala Ile
 1 5 10

<210> 53
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 53
 tgggggggct tcgcctactt gcgggatgtg gtggagcagg caatc 45

<210> 54
 <211> 25
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(25)
 <223> n is a, t, c, or g.

<400> 54
 tcattcctct tgnngcncn gnncn 25

<210> 55
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 55
 agtagcctca ttctcttctt tgtgagcgct ggctgctag tggtc 45

<210> 56
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 56
 Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val
 1 5 10 15

<210> 57
 <211> 15
 <212> PRT
 <213> Mus musculus

<400> 57
 Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu Val Val
 1 5 10 15

<210> 58
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 58
 Ser Ser Leu Ile Pro Leu Val Ser Ala Gly Leu Leu Val Val
 1 5 10

<210> 59
 <211> 15
 <212> PRT
 <213> Caenorhabditis elegans

<400> 59
 Ile Asn Tyr Ala Lys Leu Thr Phe Ala Val Ile Val Leu Thr Ile
 1 5 10 15

<210> 60
 <211> 42
 <212> DNA
 <213> Homo sapiens

<400> 60
 agtagcctca ttctcttgt gacgcctggc ctgctagtgg tc 42

<210> 61
 <211> 25
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(25)
 <223> n is a, t, c, or g.

<400> 61
 tgatgaagat gananncn gn ngcga 25

<210> 62
 <211> 36
 <212> DNA
 <213> Homo sapiens

<400> 62
 aatgatgaag atgaagatgt gaggcgggaa agacag

36

<210> 63
 <211> 12
 <212> PRT
 <213> Homo sapiens

<400> 63
 Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln
 1 5 10

<210> 64
 <211> 12
 <212> PRT
 <213> Mus musculus

<400> 64
 Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln
 1 5 10

<210> 65
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 65
 Asn Asp Glu Asp Val Arg Arg Glu Arg Gln
 1 5 10

<210> 66
 <211> 15
 <212> PRT
 <213> Caenorhabditis elegans

<400> 66
 Asp Glu Arg Asp Val Glu Asp Ser Asp Val Ile Ala Glu Lys Ser
 1 5 10 15

<210> 67
 <211> 30
 <212> DNA
 <213> Homo sapiens

<400> 67
 aatgatgaag atgtgaggcg ggaaagacag

30

```

<210> 68
<211> 14
<212> DNA
<213> Homo sapiens

<400> 68
agttgtacga atag                                     14

<210> 69
<211> 14
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(14)
<223> n is t or c.

<400> 69
agttgtanga atag                                     14

<210> 70
<211> 20
<212> DNA
<213> Homo sapiens

<400> 70
ggctggatta gcagtcctca                               20

<210> 71
<211> 20
<212> DNA
<213> Homo sapiens

<400> 71
ggatttccca gatcccagtg                               20

<210> 72
<211> 20
<212> DNA
<213> Homo sapiens

<400> 72
gacagacttg gcatgaagca                               20

<210> 73
<211> 20
<212> DNA
<213> Homo sapiens

<400> 73

```


<211> 25
 <212> DNA
 <213> Homo sapiens

 <400> 80
 tttgttaaatt ttgtagtgct cctca 25

 <210> 81
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 81
 tagtcagccc ttgcctccta 20

 <210> 82
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 82
 aaaggggctt ggtaagggtg 20

 <210> 83
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 83
 gatgtggtgc tccctctagc 20

 <210> 84
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 84
 caagtgagtg cttgggattg 20

 <210> 85
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 85
 gcaaattcaa atttctccag g 21

 <210> 86
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 86
tcaaggagga aatggacctg 20

<210> 87
<211> 20
<212> DNA
<213> Homo sapiens

<400> 87
ctgaaagtgc aagcgagtg 20

<210> 88
<211> 20
<212> DNA
<213> Homo sapiens

<400> 88
tgcagactga atggagcatc 20

<210> 89
<211> 20
<212> DNA
<213> Homo sapiens

<400> 89
gccagggggac actgtattct 20

<210> 90
<211> 20
<212> DNA
<213> Homo sapiens

<400> 90
aggtcctctg ccttcactca 20

<210> 91
<211> 20
<212> DNA
<213> Homo sapiens

<400> 91
ccagtgccta cccctgctaa 20

<210> 92
<211> 21
<212> DNA
<213> Homo sapiens

<400> 92
cacacaacag agcttcttgg a 21

<210> 93
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 93
 acctggaaca ggtgtggtgt 20

 <210> 94
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 94
 gggctaacat gccactcagt a 21

 <210> 95
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 95
 gtttgttgca gatggggaag 20

 <210> 96
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 96
 caccagaaga aggagcatgg 20

 <210> 97
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 97
 ctggactcgt agggatttgc 20

 <210> 98
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 98
 gcctgtcaca gagaaatgct t 21

 <210> 99
 <211> 21
 <212> DNA

<213> Homo sapiens

<400> 99
ttacggaatg atcctgtgct c 21

<210> 100
<211> 20
<212> DNA
<213> Homo sapiens

<400> 100
agtcagggttt ccggtcacac 20

<210> 101
<211> 22
<212> DNA
<213> Homo sapiens

<400> 101
ccgttcctta taccctcagg tg 22

<210> 102
<211> 21
<212> DNA
<213> Homo sapiens

<400> 102
ccttgtagac actcgactg a 21

<210> 103
<211> 20
<212> DNA
<213> Homo sapiens

<400> 103
tgttgtccac aggttccaga 20

<210> 104
<211> 20
<212> DNA
<213> Homo sapiens

<400> 104
tgagggttat gggcatggtt 20

<210> 105
<211> 20
<212> DNA
<213> Homo sapiens

<400> 105

atgtttttcc ttggctgtgc	20
<210> 106	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 106	
atctgccctt tcttgtctga	20
<210> 107	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 107	
agggagctgc acagtggata	20
<210> 108	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 108	
tcactcccat atttcagaac ttga	24
<210> 109	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 109	
tgtttattgg aagatcggtg aa	22
<210> 110	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 110	
cgttagagac tgaatctttg tcttg	25
<210> 111	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 111	
agtctgcct tccacagttg	20
<210> 112	

<211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 112
 ggtagttacg tgtaggggc a 21

 <210> 113
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 113
 caggaacatt aggccagatt g 21

 <210> 114
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 114
 catgtatgtg taggacagca tga 23

 <210> 115
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 115
 ctgtttcaaa gatgcttctg c 21

 <210> 116
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 116
 cctaggaagc tggaatgctg 20

 <210> 117
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 117
 gggttcccag gggttcagtat 20

 <210> 118
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 118	
cttgacctaa tttcaacatc tgg	23
<210> 119	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 119	
atccccaact caaaaccaca	20
<210> 120	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 120	
aagtccaatt tagcccacgt t	21
<210> 121	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 121	
ccagccattc aaaattctcc	20
<210> 122	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 122	
ggtgcaggtc aatttccaat	20
<210> 123	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 123	
ccccttcacc accattacaa	20
<210> 124	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 124	
tgtccaagga aaagcctcac	20

<210> 125
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 125
 aggacctctt gccagactca 20

 <210> 126
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 126
 aggagatgac acaggccaag 20

 <210> 127
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 127
 cgcacacctc tgaagctacc 20

 <210> 128
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 128
 acctcactca cacctgggaa 20

 <210> 129
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 129
 gcctcctgcc tgaaccttat 20

 <210> 130
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 130
 caaaatcatg acaccaagtt gag 23

 <210> 131
 <211> 20
 <212> DNA

<213> Homo sapiens

<400> 131
catgcacatg cacacacata 20

<210> 132
<211> 20
<212> DNA
<213> Homo sapiens

<400> 132
ccttagcccg tggtgagcta 20

<210> 133
<211> 21
<212> DNA
<213> Homo sapiens

<400> 133
tgcttttatt cagggactcc a 21

<210> 134
<211> 20
<212> DNA
<213> Homo sapiens

<400> 134
cccatgcact gcagagattc 20

<210> 135
<211> 19
<212> DNA
<213> Homo sapiens

<400> 135
aaggcaggag acatcgctt 19

<210> 136
<211> 20
<212> DNA
<213> Homo sapiens

<400> 136
gggatcagca tggtttccta 20

<210> 137
<211> 20
<212> DNA
<213> Homo sapiens

<400> 137

gcttaagtcc cactcctccc 20

<210> 138
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 138
 attttcctcc gcatgtgtgt 20

<210> 139
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 139
 tcacagaagc ctagccatga 20

<210> 140
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 140
 aacagagcag ggagatggtg 20

<210> 141
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 141
 tctgcacctc tcctcctctg 20

<210> 142
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 142
 actggggcca acattaatca 20

<210> 143
 <211> 20
 <212> DNA
 <213> Homo sapiens

<400> 143
 cttccccatc tgcaacaaac 20

<210> 144

<210> 157
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 157
 ggggaacatc ctgtgcttag 20

 <210> 158
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 158
 ccattggtga gtgtttccct 20

 <210> 159
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 159
 agtcagcaaa ctgctgggtt 20

 <210> 160
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 160
 attgctccat cctggcataa 20

 <210> 161
 <211> 23
 <212> DNA
 <213> Homo sapiens

 <400> 161
 tcatggatga ttttatgtgc ttc 23

 <210> 162
 <211> 20
 <212> DNA
 <213> Homo sapiens

 <400> 162
 gcgtgtggaa aagccataag 20

 <210> 163
 <211> 20
 <212> DNA

<213> Homo sapiens

<400> 163
gccaatcata caacagccct 20

<210> 164
<211> 23
<212> DNA
<213> Homo sapiens

<400> 164
tgatcgcata ttctacttgg aaa 23

<210> 165
<211> 22
<212> DNA
<213> Homo sapiens

<400> 165
tccctttatt ttagaggcac ca 22

<210> 166
<211> 21
<212> DNA
<213> Homo sapiens

<400> 166
gatcaggaat tcaagcacca a 21

<210> 167
<211> 24
<212> DNA
<213> Homo sapiens

<400> 167
tgggttccat aatagagttt caca 24

<210> 168
<211> 22
<212> DNA
<213> Homo sapiens

<400> 168
tgtcagctgt tactggaagt gg 22

<210> 169
<211> 22
<212> DNA
<213> Homo sapiens

<400> 169

<211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 176
 ttccttaaca gaaatagtat c 21

 <210> 177
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 177
 ttccttaaca aaaatagtat c 21

 <210> 178
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 178
 ggaagtgttc caaaagagaa a 21

 <210> 179
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 179
 ggaagtgttc taaaagagaa a 21

 <210> 180
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 180
 agtaaagagg gactagactt t 21

 <210> 181
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 181
 agtaaagagg aactagactt t 21

 <210> 182
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 182	
gcctacttgc aggatgtggt g	21
<210> 183	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 183	
gcctacttgc gggatgtggt g	21
<210> 184	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 184	
cctcattcct cttcttgtga gcg	23
<210> 185	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 185	
cctcattcct cttgtgagcg	20
<210> 186	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 186	
gcaggactac gtgggcttca c	21
<210> 187	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 187	
gcaggactac atgggcttca c	21
<210> 188	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 188	
aaaagtctac cgagatggga t	21

<210> 189
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 189
 aaaagtctac tgagatggga t 21

 <210> 190
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 190
 ggccagatca cctccttcct g 21

 <210> 191
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 191
 ggccagatca tctccttcct g 21

 <210> 192
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 192
 acacaccaca tggatgaagc g 21

 <210> 193
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 193
 acacaccaca cggatgaagc g 21

 <210> 194
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 194
 cctggaagaa gtaagttaag t 21

 <210> 195
 <211> 21
 <212> DNA

<213> Homo sapiens

<400> 195
cctggaagaa ctaagttaag t 21

<210> 196
<211> 21
<212> DNA
<213> Homo sapiens

<400> 196
gctgcctgtg tgtccccag g 21

<210> 197
<211> 21
<212> DNA
<213> Homo sapiens

<400> 197
gctgcctgtg cgtccccag g 21

<210> 198
<211> 22
<212> DNA
<213> Homo sapiens

<400> 198
tagccattat ggaattactg ct 22

<210> 199
<211> 21
<212> DNA
<213> Homo sapiens

<400> 199
tagccattat caattactgc t 21

<210> 200
<211> 26
<212> DNA
<213> Homo sapiens

<400> 200
gatgaagatg aagatgtgag gcggga 26

<210> 201
<211> 20
<212> DNA
<213> Homo sapiens

<400> 201

gatgaagatg tgaggcggga	20
<210> 202	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 202	
aatagttgta cgaatagcag g	21
<210> 203	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 203	
aatagttgta tgaatagcag g	21
<210> 204	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 204	
acacgctggg ggtgctggct g	21
<210> 205	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 205	
acacgctggg cgtgctggct g	21
<210> 206	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 206	
gaccagccac ggcgtccctg	20
<210> 207	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 207	
gaccagccac gggcgtccct g	21
<210> 208	

<211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 208
 cattttctta gaaaagagag gt 22

 <210> 209
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 209
 cattttctta gagaagagag gt 22

 <210> 210
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 210
 gaaaattagt atgtaaggaa g 21

 <210> 211
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 211
 gaaaattagt ctgtaaggaa g 21

 <210> 212
 <211> 25
 <212> DNA
 <213> Homo sapiens

 <400> 212
 cctccgctg ccagggttcag cgatt 25

 <210> 213
 <211> 25
 <212> DNA
 <213> Homo sapiens

 <400> 213
 cctccgctg ccgggttcag cgatt 25

 <210> 214
 <211> 25
 <212> DNA
 <213> Homo sapiens

<213> Homo sapiens

<400> 227
gaagaaattt ttttttttga tt 22

<210> 228
<211> 21
<212> DNA
<213> Homo sapiens

<400> 228
gcgggcatcc cgaggaggagg g 21

<210> 229
<211> 21
<212> DNA
<213> Homo sapiens

<400> 229
gcgggcatcc tgaggaggagg g 21

<210> 230
<211> 21
<212> DNA
<213> Homo sapiens

<400> 230
agggaggggg gctgaagatc a 21

<210> 231
<211> 21
<212> DNA
<213> Homo sapiens

<400> 231
agggaggggg actgaagatc a 21

<210> 232
<211> 20
<212> DNA
<213> Homo sapiens

<400> 232
aggagccaaa cgctcattgt 20

<210> 233
<211> 21
<212> DNA
<213> Homo sapiens

<400> 233

aggagccaaa gcgctcattg t 21

<210> 234
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 234
 aagccactgt ttttaaccag t 21

<210> 235
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 235
 aagccactgt atttaaccag t 21

<210> 236
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 236
 cgtgggcttc acactcaaga t 21

<210> 237
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 237
 cgtgggcttc ccaactcaaga t 21

<210> 238
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 238
 tcacactcaa gatcttcgct g 21

<210> 239
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 239
 tcacactcaa catcttcgct g 21

<210> 240

<211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 240
 gcagcctcac ccgctcttcc c 21

 <210> 241
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 241
 gcagcctcac tcgctcttcc c 21

 <210> 242
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 242
 agaagagaat atcagaaatc t 21

 <210> 243
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 243
 agaagagaat gtcagaaatc t 21

 <210> 244
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 244
 gcgcagtgcc ctgtgtcctt a 21

 <210> 245
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 245
 gcgcagtgcg ctgtgtcctt a 21

 <210> 246
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 246	
gatctaaggt tgtcattctg g	21
<210> 247	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 247	
gatctaaggt ggtcattctg g	21
<210> 248	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 248	
ctcttctggt agcacagaag aga	23
<210> 249	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 249	
ctcttctggt atcacagaag aga	23
<210> 250	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 250	
cattctaggg atcatagcca t	21
<210> 251	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 251	
cattctaggg gtcatagcca t	21
<210> 252	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 252	
aagtacagtg ggaggaacag cg	22

<210> 253
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 253
 aagtacagtg tgaggaacag cg 22

 <210> 254
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 254
 attcctaaaa aatagaaatg ca 22

 <210> 255
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 255
 attcctaaaa agtagaaatg ca 22

 <210> 256
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 256
 ggccctgcc ttattattac t 21

 <210> 257
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 257
 ggccctgcc gtattattac t 21

 <210> 258
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 258
 tgagagaatt acttgaaccc gg 22

 <210> 259
 <211> 22
 <212> DNA

<213> Homo sapiens

<400> 259

tgagagaatt gcttgaaccc gg

22

<210> 260

<211> 21

<212> DNA

<213> Homo sapiens

<400> 260

tttgctgaaa caatcactga c

21

<210> 261

<211> 21

<212> DNA

<213> Homo sapiens

<400> 261

tttgctgaaa taatcactga c

21

<210> 262

<211> 22

<212> DNA

<213> Homo sapiens

<400> 262

aacctcagtt ccctcatctg tg

22

<210> 263

<211> 22

<212> DNA

<213> Homo sapiens

<400> 263

aacctcagtt tcctcatctg tg

22

<210> 264

<211> 21

<212> DNA

<213> Homo sapiens

<400> 264

ctggacacca gaaataatgt c

21

<210> 265

<211> 21

<212> DNA

<213> Homo sapiens

<400> 265

ctggacacca aaaataatgt c 21

<210> 266
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 266
 tcctatgtgt cctccaccaa t 21

<210> 267
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 267
 tcctatgtgt gctccaccaa t 21

<210> 268
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 268
 aagaagtggc ttgtattttg c 21

<210> 269
 <211> 21
 <212> DNA
 <213> Homo sapiens

<400> 269
 aagaagtggc ctgtattttg c 21

<210> 270
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 270
 aactgatttg attggtatag ctg 23

<210> 271
 <211> 23
 <212> DNA
 <213> Homo sapiens

<400> 271
 aactgatttg gttggtatag ctg 23

<210> 272

<211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 272
 caggggtccaa cccggacctg a 21

 <210> 273
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 273
 caggggtccaa tccggacctg a 21

 <210> 274
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 274
 ttgggaggct aaggcaggag aa 22

 <210> 275
 <211> 22
 <212> DNA
 <213> Homo sapiens

 <400> 275
 ttgggaggct gaggcaggag aa 22

 <210> 276
 <211> 15
 <212> DNA
 <213> Gallus gallus

 <400> 276
 accaggggaa tctcc 15

 <210> 277
 <211> 15
 <212> DNA
 <213> Gallus gallus

 <400> 277
 accagggaaa tctcc 15

 <210> 278
 <211> 45
 <212> DNA
 <213> Gallus gallus

<400> 278
cgctacccaa caccagggga atctcctggg attgttgga acttc

45

<210> 279
<211> 15
<212> PRT
<213> Homo sapiens

<400> 279
Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn Phe
1 5 10 15

<210> 280
<211> 15
<212> PRT
<213> Mus musculus

<400> 280
Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly Val Val Gly Asn Phe
1 5 10 15

<210> 281
<211> 15
<212> PRT
<213> Gallus gallus

<400> 281
Arg Tyr Pro Thr Pro Gly Glu Ser Pro Gly Ile Val Gly Asn Phe
1 5 10 15

<210> 282
<211> 15
<212> PRT
<213> Gallus gallus

<400> 282
Arg Tyr Pro Thr Pro Gly Lys Ser Pro Gly Ile Val Gly Asn Phe
1 5 10 15

<210> 283
<211> 45
<212> DNA
<213> Gallus gallus

<400> 283
cgctacccaa caccagggaa atctcctggg attgttgga acttc

45

<210> 284
<211> 19
<212> DNA
<213> Homo sapiens

<400> 284	
gcgtcagggg tggggacag	19
<210> 285	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 285	
gcgtcagggg ttggggacag	20
<210> 286	
<211> 17	
<212> DNA	
<213> Homo sapiens	
<400> 286	
ccacttcggt ctccatg	17
<210> 287	
<211> 17	
<212> DNA	
<213> Homo sapiens	
<400> 287	
ccacttcgat ctccatg	17